Proprietary  Name,Active Ingredient/Moiety,Applicant,NDA/BLA,Application Number(1),Application Number(2),Application Number(3),Dosage Form(1),Route of Administration(1),Dosage Form(2),Route of Administration(2),Dosage Form(3),Route of Administration(3),FDA Receipt Date,FDA Approval Date,Approval Year,Abbreviated Indication(s),Approved Use(s),Review Designation,Orphan Drug Designation,Accelerated Approval,Breakthrough Therapy Designation,Fast Track Designation,Qualified Infectious Disease Product,Issued a Priority Review Voucher,Redeemed a Priority Review Voucher,Notes,receipt_date,approval_date,review_time_days,log_review_time_days,regulatory_era
Lupron,leuprolide acetate,TAP Pharmaceuticals,NDA,19010,NA,NA,Injectable,Injection,NA,NA,NA,NA,12/28/1983,4/9/1985,1985,palliative treatment of advanced prostatic cancer,NA,Priority,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1983-12-28,1985-04-09,468,6.148468295917647,Pre-PDUFA
Seldane,terfenadine,Merrell-Dow,NDA,18949,NA,NA,Tablet,Oral,NA,NA,NA,NA,3/1/1983,5/8/1985,1985,"indicated for the relief of symptoms associated with seasonal allergic rhinitis such as sneezing, rhinorrhea, pruritus and lacrimation",NA,Priority,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1983-03-01,1985-05-08,799,6.683360945766275,Pre-PDUFA
Ridaura,auranofin,SmithKline & French,NDA,18689,NA,NA,Capsule,Oral,NA,NA,NA,NA,10/5/1981,5/24/1985,1985,"indicated in the management of adults with active, classical, or definite rheumatoid arthritis (ARA criteria) who have had an insufficient therapeutic response to, or are intolerant of, an adequate trial of full doses of one or more nonsteroidal anti-inflammatory drugs",NA,Priority,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1981-10-05,1985-05-24,1327,7.190676034332207,Pre-PDUFA
Marinol,dronabinol,Unimed,NDA,18651,NA,NA,Capsule,Oral,NA,NA,NA,NA,6/25/1981,5/31/1985,1985,treatment of the nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional anti-emetic treatment,NA,Priority,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1981-06-25,1985-05-31,1436,7.269616749608169,Pre-PDUFA
Fortaz,ceftazidime,Glaxo,NDA,50578,NA,NA,Injectable,Injection,NA,NA,NA,NA,5/23/1983,7/19/1985,1985,"treatment of patients with following infections caused by susceptible strains of designated organisms: lower respiratory infections including pneumonia, skin and skin structure infections, urinary tract infections, bacterial septicemia, bone and joint infections, gynecological infections, intra-abdominal infections including peritonitis, central nervous system infections including meningitis",NA,Priority,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1983-05-23,1985-07-19,788,6.669498089857879,Pre-PDUFA
Hexabrix,"ioxaglate meglumine, ioxaglate sodium",Mallinckrodt,NDA,18905,NA,NA,Injectable,Injection,NA,NA,NA,NA,11/19/1982,7/26/1985,1985,"indicated for cerebral angiography, peripheral arteriography, selective visceral arteriography and selective coronary arteriography with or without left ventriculography",NA,Standard,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1982-11-19,1985-07-26,980,6.887552571664617,Pre-PDUFA
Baros Effervescent,"tartaric acid, sodium bicarbonate",Mallinckrodt,NDA,18509,NA,NA,"Granule, Effervescent",Oral,NA,NA,NA,NA,6/9/1980,8/7/1985,1985,indictated for double-contrast radiographic imaging of the upper gastrointestinal tract,NA,Standard,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1980-06-09,1985-08-07,1885,7.541683099882111,Pre-PDUFA
Sulcosyn,sulconazole nitrate,Syntex,NDA,18738,NA,NA,Solution,Topical,NA,NA,NA,NA,6/15/1983,8/30/1985,1985,"treatment of tinea cruris tinea corporis caused by Trichophyton mentagrophytes, Epidermophyton floccosum, and Microeporam canis; and for the treatment of tinea versicolor",NA,Standard,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1983-06-15,1985-08-30,807,6.693323668269949,Pre-PDUFA
Betoptic,betaxolol hydrochloride,Alcon,NDA,19270,NA,NA,Solution/Drops,Ophthalmic,NA,NA,NA,NA,5/4/1984,8/30/1985,1985,"indicated in the treatment of patients with chronic open-angle glaucoma, patients with elevated intraocular pressure (ocular hypertensive patients), patients with glaucoma or ocular hypertension who have reactive airway disease, patients with glaucoma or ocular hypertension who are currently on multiple anti-glaucoma therapy",NA,Priority,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1984-05-04,1985-08-30,483,6.180016653652572,Pre-PDUFA
Protropin,somatrem,Genentech,NDA,19107,NA,NA,Injectable,Injection,NA,NA,NA,NA,9/1/1983,10/17/1985,1985,long-term treatment of children who have growth failure due to a lack of adequate endogenous growth hormone secretion,NA,Priority,Yes,N/A,N/A,N/A,N/A,N/A,N/A,NA,1983-09-01,1985-10-17,777,6.655440350367647,Pre-PDUFA
Moctanin,monooctanoin,Ascot Hospital,NDA,19368,NA,NA,Liquid,"Perfusion, Biliary",NA,NA,NA,NA,9/25/1984,10/29/1985,1985,"indicated as a solubilizing agent for cholesterol (radiolucent) gallstones retained in the biliary tract of patients following cholecystectomy, when other means of reducing cholesterol stones retained in the common bile duct have failed or cannot be undertaken",NA,Priority,Yes,N/A,N/A,N/A,N/A,N/A,N/A,NA,1984-09-25,1985-10-29,399,5.988961416889864,Pre-PDUFA
Tambocor,flecainide acetate,Riker,NDA,18830,NA,NA,Tablet,Oral,NA,NA,NA,NA,12/21/1982,10/31/1985,1985,"treatment of documented life-threatening ventricular arrhythmias, such as sustained ventricular tachycardia; symptomatic nonsustained ventricular tachycardia and frequent premature ventricular complexes",NA,Priority,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1982-12-21,1985-10-31,1045,6.951772164398911,Pre-PDUFA
Cuprid,trientine hydrochloride,Merck Sharp & Dohme,NDA,19194,NA,NA,Capsule,Oral,NA,NA,NA,NA,1/6/1984,11/8/1985,1985,treatment of patients with Wilson's disease who are intolerant of penicillamine,NA,Priority,Yes,N/A,N/A,N/A,N/A,N/A,N/A,NA,1984-01-06,1985-11-08,672,6.5102583405231496,Pre-PDUFA
Femstat,butoconazole nitrate,Syntex,NDA,19215,NA,NA,Cream,Vaginal,NA,NA,NA,NA,1/23/1984,11/25/1985,1985,indicated for local treatment of vulvovaginal mycotic infections caused by Candida species,NA,Standard,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1984-01-23,1985-11-25,672,6.5102583405231496,Pre-PDUFA
Primaxin,"cilastatin sodium, imipenem",Merck Sharp & Dohme,NDA,50587,NA,NA,Powder,Intravenous,NA,NA,NA,NA,5/3/1984,11/26/1985,1985,"treatment of patients with the following infections caused by susceptible strains of designated microorganisms in: lower respiratory tract infections, urinary tract infections, intra-abdominal infections, gynecological infections, bacterial septicemia, bone and joint infections, skin and skin structure infections, endocarditis, polymicrobic infections",NA,Priority,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1984-05-03,1985-11-26,572,6.349138991379798,Pre-PDUFA
Betagan,levobunolol hydrochloride,Allergan,NDA,19219,NA,NA,Solution/Drops,Ophthalmic,NA,NA,NA,NA,1/19/1984,12/19/1985,1985,has been shown to be effective in lowering intraocular pressure and may be used in patients with chronic open-angle glaucoma or ocular hypertension,NA,Standard,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1984-01-19,1985-12-19,700,6.551080335043404,Pre-PDUFA
Versed,midazolam hydrochloride,Hoffmann-La Roche,NDA,18654,NA,NA,Injectable,Injection,NA,NA,NA,NA,12/15/1982,12/20/1985,1985,"intramuscularly: for preoperative sedation and to impair memory of peri-operative events;  intravenously: as an agent for conscious sedation prior to short diagnostic or endoscopic procedures either alone or with a narcotic; intravenously: for induction of general anesthesia, before administration of other anesthetic agents",NA,Standard,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1982-12-15,1985-12-20,1101,7.00397413672268,Pre-PDUFA
Suprol,suprofen,Ortho,NDA,18217,NA,NA,Capsule,Oral,NA,NA,NA,NA,10/23/1978,12/24/1985,1985,relief of mild to moderate pain; treatment of primary dysmenorrhea,NA,Standard,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1978-10-23,1985-12-24,2619,7.870547844507712,Pre-PDUFA
[drug marketed without a proprietary name],indium In 111 oxyquinoline,Amersham,NDA,19044,NA,NA,Injectable,Injection,NA,NA,NA,NA,12/5/1983,12/24/1985,1985,"indicated for radiolabeling autologous leukocytes as an adjunct in the detection of inflammatory processes to which leukocytes migrate, such as those associated with abscesses or other infection, following reinjection and detection by appropriate imaging procedures",NA,Priority,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1983-12-05,1985-12-24,750,6.620073206530356,Pre-PDUFA
Cordarone,amiodarone hydrochloride,Ives,NDA,18972,NA,NA,Tablet,Oral,NA,NA,NA,NA,3/14/1983,12/24/1985,1985,"indicated for the treatment of the following documented, life-threatening recurrent ventricular arrhythmias: recurrent ventricular fibrillation or recurrent hemodynamically unstable ventricular tachycardia, when these have not responded to documented aggregate doses of other available antiarrhythmics or when alternative agents could not be tolerated",NA,Priority,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1983-03-14,1985-12-24,1016,6.923628628138427,Pre-PDUFA
Vasotec,enalapril maleate,Merck Sharp & Dohme,NDA,18998,NA,NA,Tablet,Oral,NA,NA,NA,NA,9/16/1983,12/24/1985,1985,treatment of hypertension,NA,Priority,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1983-09-16,1985-12-24,830,6.721425700790643,Pre-PDUFA
Cesamet,nabilone,Eli Lilly,NDA,18677,NA,NA,Capsule,Oral,NA,NA,NA,NA,2/17/1982,12/26/1985,1985,for use in the treatment of nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments,NA,Standard,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1982-02-17,1985-12-26,1408,7.249925536717988,Pre-PDUFA
Omnipaque,iohexol,Sterling,NDA,18956,NA,NA,Solution,"Injection, Oral, Rectal",NA,NA,NA,NA,3/1/1983,12/26/1985,1985,"indicated for intrathecal administration including angiocardiography, cerebral and peripheral arteriography, digital subtraction angiography, urography, phlebography and lumbar myelography",NA,Standard,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1983-03-01,1985-12-26,1031,6.93828448401696,Pre-PDUFA
Temovate,clobetasol propionate,Glaxo,NDA,19322,19323,NA,Cream,Topical,Ointment,Topical,NA,NA,8/30/1984,12/27/1985,1985,short term treatment of inflammatory and pruritic manifestations of moderate to severe corticosteroid-responsive dermatoses,NA,Standard,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1984-08-30,1985-12-27,484,6.182084906716632,Pre-PDUFA
Cefotan,cefotetan disodium,Stuart,NDA,50588,NA,NA,Injectable,Injection,NA,NA,NA,NA,1/20/1984,12/27/1985,1985,"indicated for the treatment of the following infections when caused by susceptible strains of designated organisms: urinary tract infections, lower respiratory infections, skin and skin structure infections; gynecologic infections, intra-abdominal infections, bone and joint infections",NA,Standard,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1984-01-20,1985-12-27,707,6.561030665896573,Pre-PDUFA
Dormalin,quazepam,Schering,NDA,18708,NA,NA,Tablet,Oral,NA,NA,NA,NA,4/9/1982,12/27/1985,1985,"treatment of insomnia characterized by difficulty in falling asleep, frequent nocturnal awakenings and/or early morning awakenings",NA,Standard,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1982-04-09,1985-12-27,1358,7.213768308118642,Pre-PDUFA
Carnitor,L-carnitine,Sigma-Tau,NDA,18948,NA,NA,Tablet,Oral,NA,NA,NA,NA,2/8/1983,12/27/1985,1985,treatment of primary systemic carnitine deficiency,NA,Priority,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1983-02-08,1985-12-27,1053,6.959398512133975,Pre-PDUFA
Mexitil,mexiletine hydrochloride,Boehringer Ingelheim Pharmaceuticals,NDA,18873,NA,NA,Capsule,Oral,NA,NA,NA,NA,10/1/1982,12/30/1985,1985,"for the suppression of symptomatic ventricular arrhythmias, including frequent premature ventricular contractions, unifocal or multifocal, couplets and ventricular tachycardia",NA,Priority,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1982-10-01,1985-12-30,1186,7.078341579557671,Pre-PDUFA
Wellbutrin,bupropion hydrochloride,Burroughs Wellcome,NDA,18644,NA,NA,Tablet,Oral,NA,NA,NA,NA,12/23/1981,12/30/1985,1985,"treatment of depression in patients who fail to respond adequately to, or who cannot tolerate, alternative antidepressant treatments",NA,Priority,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1981-12-23,1985-12-30,1468,7.291656209174461,Pre-PDUFA
Virazole,ribavirin,Viratek,NDA,18859,NA,NA,For Solution,Inhalation,NA,NA,NA,NA,9/21/1982,12/31/1985,1985,indicated in the treatment of carefully selected hospitalized infants and young children with severe lower respiratory tract infections due to respiratory syncytial virus (RSV),NA,Priority,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1982-09-21,1985-12-31,1197,7.087573705557973,Pre-PDUFA
Isovue,iopamidol,Squibb,NDA,18735,NA,NA,Injectable,Injection,NA,NA,NA,NA,3/4/1983,12/31/1985,1985,"indicated for lumbar, thoracic, cervical and total columnar myelography, coronary angiography and ventriculography, peripheral arteriography and ventriculography, peripheral arteriography, cerebral arteriography and CT scanning of the head and body",NA,Standard,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1983-03-04,1985-12-31,1033,6.940222469119639,Pre-PDUFA
Orudis,ketoprofen,Wyeth,NDA,18754,NA,NA,Capsule,Oral,NA,NA,NA,NA,3/16/1982,1/9/1986,1986,treatment of signs and symptoms of osteoarthritis and rheumatoid arthritis,NA,Standard,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1982-03-16,1986-01-09,1395,7.240649694255466,Pre-PDUFA
Nix,permethrin,Burroughs Wellcome,NDA,19435,NA,NA,Lotion,Topical,NA,NA,NA,NA,2/28/1985,3/31/1986,1986,single-application treatment of infestation with Pediculus humanus capitis (the head louse) and its nits (eggs),NA,Priority,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1985-02-28,1986-03-31,396,5.981414211254481,Pre-PDUFA
Intron-A,interferon alfa-2b,Schering,BLA,103132,NA,NA,Injectable,Injection,NA,NA,NA,NA,10/4/1983,6/4/1986,1986,treatment of patients 18 years of age or older with hairy cell leukemia,NA,Priority,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1983-10-04,1986-06-04,974,6.881411303642535,Pre-PDUFA
Roferon-A,interferon alfa-2a,Hoffmann-La Roche,BLA,103145,NA,NA,Injectable,Injection,NA,NA,NA,NA,10/24/1984,6/4/1986,1986,treatment of patients 18 years of age or older with hairy cell leukemia,NA,Priority,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1984-10-24,1986-06-04,588,6.376726947898627,Pre-PDUFA
Orthoclone OKT3,muromonab-CD3,Ortho Pharms,BLA,103135,NA,NA,Injectable,Injection,NA,NA,NA,NA,3/29/1984,6/19/1986,1986,treatment of acute allograft rejection in renal transplant patients,NA,Standard,No,N/A,N/A,N/A,N/A,N/A,N/A,Biologic product assigned new license number and now referenced by BLA 103463,1984-03-29,1986-06-19,812,6.699500340161678,Pre-PDUFA
Buspar,buspirone hydrochloride,Bristol-Myers,NDA,18731,NA,NA,Tablet,Oral,NA,NA,NA,NA,12/15/1982,9/29/1986,1986,management of anxiety disorders or the short term relief of the symptoms of anxiety,NA,Priority,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1982-12-15,1986-09-29,1384,7.232733136177615,Pre-PDUFA
Tegison,etretinate,Hoffmann-La Roche,NDA,19369,NA,NA,Capsule,Oral,NA,NA,NA,NA,12/19/1984,9/30/1986,1986,"treatment of severe recalcitrant psoriasis, including erythrodermic and generalized pustular types",NA,Priority,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1984-12-19,1986-09-30,650,6.476972362889683,Pre-PDUFA
Pepcid,famotidine,Merck Sharp & Dohme,NDA,19462,NA,NA,Tablet,Oral,NA,NA,NA,NA,6/24/1985,10/15/1986,1986,short term treatment of acute duodenal ulcer; maintenance therapy for duodenal ulcer patients at reduced dosage after healing of active ulcer; treatment of pathological hypersecretory conditions such as Zollinger-Ellison syndrome,NA,Standard,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1985-06-24,1986-10-15,478,6.169610732491456,Pre-PDUFA
Tenex,guanfacine hydrochloride,Robins,NDA,19032,NA,NA,Tablet,Oral,NA,NA,NA,NA,9/14/1983,10/27/1986,1986,indicated in the management of hypertension,NA,Standard,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1983-09-14,1986-10-27,1139,7.037905963447182,Pre-PDUFA
Provocholine,methacholine chloride,Hoffmann-La Roche,NDA,19193,NA,NA,For Solution,Inhalation,NA,NA,NA,NA,12/29/1983,10/31/1986,1986,indicated for the diagnosis of bronchial airway hyperreactivity in subjects who do not have clinically apparent asthma,NA,Priority,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1983-12-29,1986-10-31,1037,6.9440872082295275,Pre-PDUFA
Cibacalcin,calcitonin (human),Ciba-Geigy,NDA,18470,NA,NA,Injectable,Injection,NA,NA,NA,NA,12/8/1980,10/31/1986,1986,treatment of symptomatic Paget’s disease of the bone,NA,Priority,Yes,N/A,N/A,N/A,N/A,N/A,N/A,NA,1980-12-08,1986-10-31,2153,7.674617497364363,Pre-PDUFA
Technescan Hida,technetium Tc-99m lidofenin,Merck Sharp & Dohme,NDA,18489,NA,NA,Injectable,Injection,NA,NA,NA,NA,5/6/1980,10/31/1986,1986,indicated as a hepatobiliary imaging agent,NA,Standard,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1980-05-06,1986-10-31,2369,7.7702232041587855,Pre-PDUFA
Noroxin,norfloxacin,Merck Sharp & Dohme,NDA,19384,NA,NA,Tablet,Oral,NA,NA,NA,NA,1/14/1985,10/31/1986,1986,Treatment of adults with complicated and uncomplicated urinary tract infections caused by susceptible strains of microorganisms,NA,Priority,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1985-01-14,1986-10-31,655,6.484635235635252,Pre-PDUFA
Lamprene,clofazimine,Ciba-Geigy,NDA,19500,NA,NA,Capsule,Oral,NA,NA,NA,NA,7/1/1985,12/15/1986,1986,"indicated in the treatment of lepromatous leprosy, including dapsone-resistant lepromatous leprosy and lepromatous leprosy complicated by erythema nodosum leprosum",NA,Priority,Yes,N/A,N/A,N/A,N/A,N/A,N/A,NA,1985-07-01,1986-12-15,532,6.2766434893416445,Pre-PDUFA
Enkaid,encainide hydrochloride,Bristol-Myers,NDA,18981,NA,NA,Capsule,Oral,NA,NA,NA,NA,1/13/1984,12/24/1986,1986,for the treatment of documented life threatening arrhythmias such as sustained ventricular tachycardia; for the treatment of patients with symptomatic nonsustained ventricular tachycardia and frequent premature ventricular complexes,NA,Priority,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1984-01-13,1986-12-24,1076,6.98100574072173,Pre-PDUFA
Atrovent,ipratropium bromide,Boehringer Ingelheim Pharmaceuticals,NDA,19085,NA,NA,"Aerosol, Metered",Inhalation,NA,NA,NA,NA,8/1/1983,12/29/1986,1986,"indicated as a bronchodilator for maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease, including chronic bronchitis and emphysema",NA,Priority,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1983-08-01,1986-12-29,1246,7.1276936993473985,Pre-PDUFA
Alfenta,alfentanil hydrochloride,Janssen,NDA,19353,NA,NA,Injectable,Injection,NA,NA,NA,NA,12/26/1984,12/29/1986,1986,indicated as an analgesic adjunct given in incremental doses in the maintenance of anesthesia with barbituate/nitrous oxide/oxygen; as an analgesic administered by continuous infusion with nitrous oxide/oxygen in the maintenance of general anesthesia; as a primary anesthetic agent for the induction of anesthesia in patients undergoing general surgery in which endotracheal intubation and mechanical ventilation are required,NA,Standard,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1984-12-26,1986-12-29,733,6.597145701886651,Pre-PDUFA
Exirel,pirbuterol acetate,Pfizer,NDA,19009,NA,NA,"Aerosol, Metered",Inhalation,NA,NA,NA,NA,4/21/1983,12/30/1986,1986,"indicated for the relief of acute bronchospasm in patients with chronic reversible obstructive airway disease (extrinsic asthma, intrinsic asthma and chronic bronchitis/emphysema)",NA,Standard,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1983-04-21,1986-12-30,1349,7.207118856207756,Pre-PDUFA
Cyklokapron,tranexamic acid,KabiVitrum,NDA,19280,19281,NA,Tablet,Oral,Injectable,Injection,NA,NA,5/9/1984,12/30/1986,1986,indicated in patients with hemophilia for short term use (two to eight days) to reduce or prevent hemorrhage and reduce the need for replacement therapy during and following tooth extraction,NA,Standard,Yes,N/A,N/A,N/A,N/A,N/A,N/A,NA,1984-05-09,1986-12-30,965,6.872128101338986,Pre-PDUFA
Brevibloc,esmolol hydrochloride,DuPont,NDA,19386,NA,NA,Injectable,Injection,NA,NA,NA,NA,1/8/1985,12/31/1986,1986,"indicated for the rapid control of ventricular rate in patients with atrial fibrillation or atrial flutter in perioperative, postoperative, or other emergent circumstances where short term control of ventricular rate with a short-acting agent is desirable; also indicated in compensatory sinus tachycardia where, in the physician's judgment the rapid heart rate requires specific intervention",NA,Priority,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1985-01-08,1986-12-31,722,6.582025138892826,Pre-PDUFA
Azactam,aztreonam,Squibb,NDA,50580,NA,NA,Injectable,Injection,NA,NA,NA,NA,12/29/1983,12/31/1986,1986,"treatment of the following infections caused by susceptible gram-negative microorganisms: Urinary Tract Infections (complicated and uncomplicated), Lower Respiratory Tract Infections, Septicemia, Skin and Skin Structure Infections, Intra-abdominal Infections, Gynecologic Infections; indicated for adjunctive therapy to surgery in the management of infections caused by susceptible organisms including abscesses, infections complicating hollow viscous perforations, cutaneous infections and infections of serous surfaces",NA,Priority,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1983-12-29,1986-12-31,1098,7.001245622069476,Pre-PDUFA
Unasyn,"sulbactam sodium, ampicillin sodium",Pfizer,NDA,50608,NA,NA,Injectable,Injection,NA,NA,NA,NA,4/18/1985,12/31/1986,1986,treatment of infections due to susceptible of designated microorganisms for: Lower Respiratory Tract Infections; Skin and Skin Structure Infections; Urinary Tract Infections; Intra-Abdominal Infections; Gynecological Infections,NA,Standard,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1985-04-18,1986-12-31,622,6.432940092739179,Pre-PDUFA
Ocufen,flurbiprofen sodium,Allergan,NDA,19404,NA,NA,Solution/Drops,Ophthalmic,NA,NA,NA,NA,12/19/1984,12/31/1986,1986,inhibition of intraoperative miosis,NA,Priority,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1984-12-19,1986-12-31,742,6.60934924316738,Pre-PDUFA
Choletec,technetium Tc-99m mebrofenin,Squibb,NDA,18963,NA,NA,Injectable,Injection,NA,NA,NA,NA,3/4/1983,1/21/1987,1987,indicated as a hepatobiliary imaging agent,NA,Standard,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1983-03-04,1987-01-21,1419,7.257707677160043,Pre-PDUFA
Retrovir,zidovudine,Burroughs Wellcome,NDA,19655,NA,NA,Capsule,Oral,NA,NA,NA,NA,12/2/1986,3/19/1987,1987,for the management of certain adult patients with symptomatic HIV infection (AIDS and advanced ARC) who have a history of cytologically confirmed Pneumocystis carinii pneumonia (PCP) or an absolute CD4 (T4 helper/inducer) lymphocyte count of less than 200/mm in the peripheral blood before therapy is begun,NA,Priority,Yes,N/A,N/A,N/A,N/A,N/A,N/A,NA,1986-12-02,1987-03-19,107,4.672828834461906,Pre-PDUFA
Elocon,mometasone furoate,Schering,NDA,19543,NA,NA,Ointment,Topical,NA,NA,NA,NA,11/8/1985,4/30/1987,1987,indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses,NA,Standard,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1985-11-08,1987-04-30,538,6.2878585601617845,Pre-PDUFA
Hytrin,terazosin hydrochloride,Abbott Laboratories,NDA,19057,NA,NA,Tablet,Oral,NA,NA,NA,NA,10/3/1983,8/7/1987,1987,treatment of hypertension,NA,Standard,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1983-10-03,1987-08-07,1404,7.247080584585756,Pre-PDUFA
Mevacor,lovastatin,Merck Sharp & Dohme,NDA,19643,NA,NA,Tablet,Oral,NA,NA,NA,NA,11/14/1986,8/31/1987,1987,indicated as an adjunct to diet for the reduction of elevated total and LDL cholesterol levels in patients with primary hypercholesterolemia (Types IIa and IIb) when the response to diet and other nonpharmacological measures alone has been inadequate,NA,Priority,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1986-11-14,1987-08-31,290,5.66988092298052,Pre-PDUFA
Cipro,ciprofloxacin hydrochloride,Miles,NDA,19537,NA,NA,Tablet,Oral,NA,NA,NA,NA,3/25/1986,10/22/1987,1987,"indicated for treatment of infections caused by susceptible strains of designated microorganisms in the conditions listed: lower respiratory, skin and skin structure, bone and joint, and urinary tract infections; infectious diarrhea",NA,Priority,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1986-03-25,1987-10-22,576,6.3561076606958915,Pre-PDUFA
Activase,alteplase,Genentech,BLA,103172,NA,NA,Injectable,Injection,NA,NA,NA,NA,5/1/1986,11/13/1987,1987,"indicated for use in the management of acute myocardial infarction in adults for the lysis of thrombi obstructing coronary arteries, the improvement of ventricular function and reduction of the incidence of congestive heart failure",NA,Priority,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1986-05-01,1987-11-13,561,6.329720905522696,Pre-PDUFA
Novantrone,mitoxantrone hydrochloride,Lederle,NDA,19297,NA,NA,Injectable,Injection,NA,NA,NA,NA,5/24/1984,12/23/1987,1987,"indicated in the initial therapy of acute nonlymphocytic leukemia (ANLL) in adults.  This category includes myelogenous, promyelocytic, monocytic, and erythroid acute leukemias",NA,Standard,Yes,N/A,N/A,N/A,N/A,N/A,N/A,NA,1984-05-24,1987-12-23,1308,7.176254532017144,Pre-PDUFA
Parathar,teriparatide acetate,Rorer,NDA,19498,NA,NA,Injectable,Injection,NA,NA,NA,NA,6/28/1985,12/23/1987,1987,as a diagnostic agent to assist in establishing the diagnosis in patients presenting with evidence of hypocalcemia due to either hypoparathyroidism or pseudohypoparathyroidism,NA,Priority,Yes,N/A,N/A,N/A,N/A,N/A,N/A,NA,1985-06-28,1987-12-23,908,6.811244378601294,Pre-PDUFA
Ucephan,"sodium phenylacetate, sodium benzoate",Kendall McGaw,NDA,19530,NA,NA,Solution,Oral,NA,NA,NA,NA,10/2/1985,12/23/1987,1987,"indicated as adjunctive therapy for the prevention and treatment of hyperammonemia in chronic management of urea cycle enzymopathies involving partial or complete deficiencies of carbamylphosphate synthetase, ornithine transcarbmylase, or argininosuccinate synthetase",NA,Priority,Yes,N/A,N/A,N/A,N/A,N/A,N/A,NA,1985-10-02,1987-12-23,812,6.699500340161678,Pre-PDUFA
Rowasa,mesalamine,Reid-Rowell,NDA,19618,NA,NA,Enema,Rectal,NA,NA,NA,NA,6/13/1986,12/24/1987,1987,"treatment of active mild to moderate distal ulcerative colitis, proctosigmoiditis or proctitis",NA,Priority,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1986-06-13,1987-12-24,559,6.326149473155099,Pre-PDUFA
Spectamine,iofetamine hydrochloride  I 123,Medi-Physics,NDA,19432,NA,NA,Injectable,Injection,NA,NA,NA,NA,2/12/1985,12/24/1987,1987,evaluation of nonlucunar stroke especially when used within 96 hours of the first onset of neurological deficit,NA,Standard,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1985-02-12,1987-12-24,1045,6.951772164398911,Pre-PDUFA
Prozac,fluoxetine hydrochloride,Eli Lilly,NDA,18936,NA,NA,Capsule,Oral,NA,NA,NA,NA,9/6/1983,12/29/1987,1987,treatment of depression,NA,Priority,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1983-09-06,1987-12-29,1575,7.362010551259734,Pre-PDUFA
Prinivil,lisinopril,Merck Sharp & Dohme,NDA,19558,NA,NA,Tablet,Oral,NA,NA,NA,NA,4/17/1986,12/29/1987,1987,treatment of hypertension,NA,Standard,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1986-04-17,1987-12-29,621,6.431331081933479,Pre-PDUFA
Cefmax,cefmenoxime hydrochloride,TAP Pharmaceuticals,NDA,50571,NA,NA,Injectable,Injection,NA,NA,NA,NA,6/28/1983,12/30/1987,1987,"indicated for the treatment of infections caused by susceptible strains of designated microorganisms in:  Lower respiratory infections, urinary tract infections",NA,Standard,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1983-06-28,1987-12-30,1646,7.406103381237015,Pre-PDUFA
Levatol,penbutolol sulfate,Eli Lilly,NDA,18976,NA,NA,Tablet,Oral,NA,NA,NA,NA,9/6/1983,12/30/1987,1987,treatment of mild-to-moderate arterial hypertension,NA,Standard,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1983-09-06,1987-12-30,1576,7.362645270417825,Pre-PDUFA
Deursil,ursodiol,Gipharmex,NDA,19594,NA,NA,Capsule,Oral,NA,NA,NA,NA,2/24/1986,12/31/1987,1987,"patients with radiolucent, non-calcified, gallbladder stones <20mm in greatest diameter in whom elective cholecystectomy would be undertaken except for the presence of increased surgical risk due to systemic disease or age",NA,Priority,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1986-02-24,1987-12-31,675,6.51471269087253,Pre-PDUFA
Terazol 7,terconazole,Ortho,NDA,19579,NA,NA,Cream,Vaginal,NA,NA,NA,NA,5/22/1986,12/31/1987,1987,local treatment of vulvovaginal candidiasis (moniliasis),NA,Standard,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1986-05-22,1987-12-31,588,6.376726947898627,Pre-PDUFA
Corotrope,milrinone lactate,Sterling-Winthrop,NDA,19436,NA,NA,Injectable,Injection,NA,NA,NA,NA,6/27/1985,12/31/1987,1987,short-term  intravenous  treatment  of  patients  with  acute  decompensated  heart  failure,NA,Standard,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1985-06-27,1987-12-31,917,6.821107472256465,Pre-PDUFA
Bactroban,mupirocin,Beecham,NDA,50591,NA,NA,Ointment,Topical,NA,NA,NA,NA,3/26/1984,12/31/1987,1987,"indicated for the topical treatment of impetigo due to: Staphylococcus aureus, beta hemolytic Streptococcus, and Streptococcus pyogenes",NA,Standard,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1984-03-26,1987-12-31,1375,7.226209010100671,Pre-PDUFA
Iopidine,apraclonidine hydrochloride,Alcon,NDA,19779,NA,NA,Solution/Drops,Ophthalmic,NA,NA,NA,NA,10/5/1987,12/31/1987,1987,to control or prevent postsurgical elevations in intraocular pressure that occur in patients after argon laser trabeculoplasty or argon laser iridotomy,NA,Standard,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1987-10-05,1987-12-31,87,4.465908118654584,Pre-PDUFA
Rimadyl,carprofen,Hoffmann-La Roche,NDA,18550,NA,NA,Tablet,Oral,NA,NA,NA,NA,9/24/1980,12/31/1987,1987,"acute or long-term use for the relief of signs and symptoms of rheumatiod arthritis, osteoarthritis, and acute gouty arthritis",NA,Standard,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1980-09-24,1987-12-31,2654,7.8838232148921525,Pre-PDUFA
Naftin,naftifine hydrochloride,Herbert Labs,NDA,19599,NA,NA,Cream,Topical,NA,NA,NA,NA,3/18/1986,2/29/1988,1988,indicated for the topical treatment of tinea cruris and tinea corporis,NA,Standard,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1986-03-18,1988-02-29,713,6.569481420414296,Pre-PDUFA
Axid,nizatidine,Eli Lilly,NDA,19508,NA,NA,Capsule,Oral,NA,NA,NA,NA,5/15/1986,4/12/1988,1988,treatment of active duodenal ulcers for up to six weeks; maintenance therapy of duodenal ulcer patients at a reduced dosage after healing of an active duodenal ulcer,NA,Standard,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1986-05-15,1988-04-12,698,6.548219102762372,Pre-PDUFA
Magnevist,gadopentetate dimeglumine,Berlex,NDA,19596,NA,NA,Injectable,Injection,NA,NA,NA,NA,8/19/1986,6/2/1988,1988,"using magnetic resonance imaging in adult patients, gadopentetate dimeglumine provides contrast enhancement in those intracranial lesions with abnormal vascularity or those thought to cause an abnormal blood brain barrier",NA,Priority,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1986-08-19,1988-06-02,653,6.481577129276431,Pre-PDUFA
Voltaren,diclofenac sodium,Ciba,NDA,19201,NA,NA,"Tablet, Delayed Release",Oral,NA,NA,NA,NA,12/20/1983,7/28/1988,1988,"acute and chronic treatment of the signs and symptoms of rheumatoid arthritis, osteoarthritis, and ankylosing spondylitis",NA,Standard,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1983-12-20,1988-07-28,1682,7.427738840532894,Pre-PDUFA
Thiola,tiopronin,Mission Pharmacal,NDA,19569,NA,NA,Tablet,Oral,NA,NA,NA,NA,1/8/1986,8/11/1988,1988,"prevention of cystine (kidney) stone formation in patients with severe homozygous cystinuria with urinary cystine greater than 500 mg/day, who are resistant to treatment with conservative measures of high fluid intake, alkali and diet modification, or who have adverse reactions to d-penicillamine",NA,Priority,Yes,N/A,N/A,N/A,N/A,N/A,N/A,NA,1986-01-08,1988-08-11,946,6.852242569051878,Pre-PDUFA
Photoplex,"avobenzone, padimate-O",Herbert Labs,NDA,19459,NA,NA,Lotion,Topical,NA,NA,NA,NA,4/8/1985,9/30/1988,1988,protection from the acute and long-term risks associated with UVA and UVB light exposure,NA,Standard,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1985-04-08,1988-09-30,1271,7.147559271189454,Pre-PDUFA
Sandostatin,octreotide acetate,Sandoz,NDA,19667,NA,NA,Injectable,Injection,NA,NA,NA,NA,2/9/1987,10/21/1988,1988,treatment of chronic and severe diarrhea and flushing episodes associated with carcinoid tumors and vasoactive intestinal peptide-secreting tumors (VIPomas),NA,Priority,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1987-02-09,1988-10-21,620,6.429719478039138,Pre-PDUFA
Cardene,nicardipine hydrochloride,Syntex,NDA,19488,NA,NA,Capsule,Oral,NA,NA,NA,NA,11/20/1985,12/21/1988,1988,management of patients with chronic stable angina (effort-associated angina); management of hypertension,NA,Standard,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1985-11-20,1988-12-21,1127,7.027314514039777,Pre-PDUFA
Ethamolin,ethanolamine oleate,Glaxo,NDA,19357,NA,NA,Injectable,Injection,NA,NA,NA,NA,9/14/1984,12/22/1988,1988,"treatment of patients with esophageal varices that have recently bled, to prevent rebleeding",NA,Priority,Yes,N/A,N/A,N/A,N/A,N/A,N/A,NA,1984-09-14,1988-12-22,1560,7.352441100243583,Pre-PDUFA
Cytotec,misoprostol,Searle,NDA,19268,NA,NA,Tablet,Oral,NA,NA,NA,NA,5/23/1984,12/27/1988,1988,"prevention of NSAID (nonsteroidal anti-inflammatory drugs, including aspirin)- induced gastric ulcers in patients at high risk of complications from a gastric ulcer, e.g., the elderly and patients with concomitant disease, as well as patients at high risk of developing gastric ulceration, such as patients with a history of ulcer",NA,Priority,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1984-05-23,1988-12-27,1679,7.425953657077541,Pre-PDUFA
Nimotop,nimodipine,Miles,NDA,18869,NA,NA,Capsule,Oral,NA,NA,NA,NA,9/17/1982,12/28/1988,1988,for the improvement of neurological deficits due to spasm following subarachnoid hemorrhage from ruptured congenital intracranial aneurysms in patients who are in good neurological condition post-ictus (e.g. Hunt and Hess Grades I-III),NA,Priority,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1982-09-17,1988-12-28,2294,7.738052297689316,Pre-PDUFA
Cartrol,carteolol hydrochloride,Abbott Laboratories,NDA,19204,NA,NA,Tablet,Oral,NA,NA,NA,NA,10/3/1984,12/28/1988,1988,management of hypertension,NA,Standard,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1984-10-03,1988-12-28,1547,7.344072850573066,Pre-PDUFA
Hismanal,astemizole,Janssen,NDA,19402,NA,NA,Tablet,Oral,NA,NA,NA,NA,2/25/1985,12/29/1988,1988,relief of symptoms associated with seasonal allergic rhinitis and chronic idiopathic urticaria,NA,Standard,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1985-02-25,1988-12-29,1403,7.246368080102461,Pre-PDUFA
Oxistat,oxiconazole nitrate,Glaxo,NDA,19828,NA,NA,Cream,Topical,NA,NA,NA,NA,2/11/1988,12/30/1988,1988,"treatment of tinea pedis, tinea cruris and tinea corporis due to Trichophyton rubrum, Trichophyton mentagrophytes, or Epidermophyton floccosum",NA,Standard,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1988-02-11,1988-12-30,323,5.777652323222656,Pre-PDUFA
Optiray,ioversol,Mallinckrodt,NDA,19710,NA,NA,Injectable,Injection,NA,NA,NA,NA,6/26/1987,12/30/1988,1988,"Optiray-320 for angiography throughout the cardiovascular system including cerebral, coronary, peripheral, visceral and renal arteriography, aortography, and left ventriculography; contrast enhanced CT imaging of the head and body, and I.V. excretory urography. Optiray-240  indicated  for cerebral angiography and venography. Optiray-160 intra-arterial digital subtraction angiography",NA,Standard,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1987-06-26,1988-12-30,553,6.315358001522335,Pre-PDUFA
Ifex,ifosfamide,Bristol-Myers,NDA,19763,NA,NA,Injectable,Injection,NA,NA,NA,NA,12/10/1987,12/30/1988,1988,"used in combination with certain other approved antineoplastic agents is indicated for third-line chemotherapy of germ cell testicular cancer. It should ordinarily be used in combination with a prophylactic agent for hemorrhagic cystitis, such as mesna",NA,Priority,Yes,N/A,N/A,N/A,N/A,N/A,N/A,NA,1987-12-10,1988-12-30,386,5.955837369464831,Pre-PDUFA
Ceretec,technetium Tc-99m exametazime,Amersham,NDA,19829,NA,NA,Injectable,Injection,NA,NA,NA,NA,3/15/1988,12/30/1988,1988,use as an adjunct in the detection of altered regional cerebral perfusion in strokes,NA,Priority,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1988-03-15,1988-12-30,290,5.66988092298052,Pre-PDUFA
Mesnex,mesna,Asta,NDA,19884,NA,NA,Injectable,Intravenous,NA,NA,NA,NA,7/6/1988,12/30/1988,1988,prophylactic agent for reducing the incidence of ifosamide-induced hemorrhagic cystitis,NA,Priority,Yes,N/A,N/A,N/A,N/A,N/A,N/A,NA,1988-07-06,1988-12-30,177,5.176149732573829,Pre-PDUFA
Ceradon,cefotiam hydrochloride,Takeda,NDA,50601,NA,NA,Injectable,Injection,NA,NA,NA,NA,4/30/1985,12/30/1988,1988,"treatment of infections caused by susceptible strains of the designated microorganisms: lower respiratory tract infections, bronchitis, and pneumonia",NA,Standard,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1985-04-30,1988-12-30,1340,7.200424892944957,Pre-PDUFA
Permax,pergolide mesylate,Eli Lilly,NDA,19385,NA,NA,Tablet,Oral,NA,NA,NA,NA,9/13/1985,12/30/1988,1988,as adjunctive treatment to levodopa in the management of the signs and symptoms of Parkinson’s disease,NA,Priority,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1985-09-13,1988-12-30,1204,7.093404625868766,Pre-PDUFA
Eulexin,flutamide,Schering,NDA,18554,NA,NA,Capsule,Oral,NA,NA,NA,NA,9/30/1980,1/27/1989,1989,in combination with LHRH agonistic analogs (such as leuprolide acetate) for the treatment of metastatic prostatic carcinoma,NA,Priority,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1980-09-30,1989-01-27,3041,8.019941687677365,Pre-PDUFA
Cefpiramide,cefpiramide sodium,Wyeth-Ayerst,NDA,50633,NA,NA,Injectable,Injection,NA,NA,NA,NA,7/31/1987,1/31/1989,1989,"indicated for the treatment of the following infections when caused by susceptible strains of designated organisms:  lower respiratory infections including pneumonia, skin and skin structure infections",NA,Standard,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1987-07-31,1989-01-31,550,6.309918278226516,Pre-PDUFA
Paraplatin,carboplatin,Bristol-Myers,NDA,19880,NA,NA,Injectable,Injection,NA,NA,NA,NA,6/30/1988,3/3/1989,1989,"palliative treatment of patients with ovarian carcinoma recurrent after prior chemotherapy, including patients who have previously been treated with cisplatin",NA,Priority,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1988-06-30,1989-03-03,246,5.5053315359323625,Pre-PDUFA
Suprax,cefixime,Lederle,NDA,50621,50622,NA,Tablet,Oral,Suspension,Oral,NA,NA,6/27/1986,4/28/1989,1989,"indicated in the treatment of the following infections when caused by susceptible strains of the designated microorganisms: Uncomplicated Urinary Tract Infections, Otitis Media, Pharyngitis and tonsillitis, Acute Bronchitis and Acute Exacerbations of Chronic Bronchitis",NA,Standard,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1986-06-27,1989-04-28,1036,6.943122422819428,Pre-PDUFA
Lariam,mefloquine hydrochloride,Department of the Army,NDA,19578,NA,NA,Tablet,Oral,NA,NA,NA,NA,2/5/1986,5/2/1989,1989,"treatment of mild to moderate acute malaria caused by mefloquine-susceptible strains of P. falciparum (both chloroquine-susceptible and resistant strains) or by Plasmodium vivax; also indicated for the prophylaxis of P. falciparum and P. vivax malaria infections, including prophylaxis of chloroquine-resistant strains of P. falciparum.",NA,Priority,Yes,N/A,N/A,N/A,N/A,N/A,N/A,NA,1986-02-05,1989-05-02,1182,7.074963197966044,Pre-PDUFA
Epogen,epoetin alfa,Amgen,BLA,103234,NA,NA,Injectable,Injection,NA,NA,NA,NA,11/3/1987,6/1/1989,1989,"treatment of anemia associated with chronic renal failure, including patients on dialysis (end-stage renal disease) and patients not on dialysis",NA,Standard,Yes,N/A,N/A,N/A,N/A,N/A,N/A,NA,1987-11-03,1989-06-01,576,6.3561076606958915,Pre-PDUFA
Eldepryl,selegiline hydrochloride,Somerset,NDA,19334,NA,NA,Tablet,Oral,NA,NA,NA,NA,7/23/1984,6/5/1989,1989,indicated as an adjunct in the management of Parkinsonian patients being treated with levodopa/carbidopa who exhibit deterioration in the quality of their response to this therapy,NA,Priority,Yes,N/A,N/A,N/A,N/A,N/A,N/A,NA,1984-07-23,1989-06-05,1778,7.48324441607385,Pre-PDUFA
Cytovene,ganciclovir sodium,Syntex,NDA,19661,NA,NA,Injectable,Injection,NA,NA,NA,NA,12/29/1986,6/23/1989,1989,"treatment of CMV retinitis in immunocompromised 
patients, including patients with acquired immunodeficiency syndrome (AIDS)",NA,Priority,Yes,N/A,N/A,N/A,N/A,N/A,N/A,NA,1986-12-29,1989-06-23,907,6.810142450115136,Pre-PDUFA
Losec,omeprazole,Merck Sharp & Dohme,NDA,19810,NA,NA,"Capsule, Delayed Release Pellets",Oral,NA,NA,NA,NA,7/1/1988,9/14/1989,1989,"short-term treatment (four to eight weeks) of severe erosive esophagitis; short-term treatment of symptomatic gastroesophageal reflux disease (GERD) poorly responsive to customary medical treatment, usually including an adequate course of a histamine H2 receptor antagonist;  long-term treatment of Zollinger-Ellison syndrome",NA,Priority,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1988-07-01,1989-09-14,440,6.0867747269123065,Pre-PDUFA
Clozaril,clozapine,Sandoz,NDA,19758,NA,NA,Tablet,Oral,NA,NA,NA,NA,9/1/1987,9/26/1989,1989,treatment of severely ill schizophrenic patients who fail to respond to standard drug therapies,NA,Priority,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1987-09-01,1989-09-26,756,6.628041376179533,Pre-PDUFA
Diprivan,propofol,ICI,NDA,19627,NA,NA,Injectable,Injection,NA,NA,NA,NA,8/1/1986,10/2/1989,1989,induction and maintenance of anesthesia,NA,Standard,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1986-08-01,1989-10-02,1158,7.05444965813294,Pre-PDUFA
Alferon N,interferon alfa-n3,Interferon Sciences,BLA,103158,NA,NA,Injectable,Injection,NA,NA,NA,NA,12/16/1985,10/10/1989,1989,treatment of condyloma acuminata (genital warts),NA,Standard,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1985-12-16,1989-10-10,1394,7.2399325913204695,Pre-PDUFA
Adenocard,adenosine,Medco,NDA,19937,NA,NA,Injectable,Injection,NA,NA,NA,NA,12/28/1988,10/30/1989,1989,"indicated for conversion to sinus rhythm of paroxysmal supraventricular tachycardia (PSVT), including that associated with accessory bypass tracts (Wolff-Parkinson-White Syndrome)",NA,Priority,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1988-12-28,1989-10-30,306,5.723585101952381,Pre-PDUFA
Eminase,anistreplase,Beecham,BLA,103273,NA,NA,Injectable,Injection,NA,NA,NA,NA,6/8/1988,11/27/1989,1989,"indicated for use in the management of acute myocardial infarction (AMI) in adults, for the lysis of thrombi obstructing coronary arteries, the reduction of infarct size, the improvement of ventricular function following AMI, and the reduction of mortality associated with AMI",NA,Standard,No,N/A,N/A,N/A,N/A,N/A,N/A,Biologic product assigned new license number and now referenced by BLA 103674,1988-06-08,1989-11-27,537,6.285998094508865,Pre-PDUFA
Rythmol,propafenone hydrochloride,Knoll,NDA,19151,NA,NA,Tablet,Oral,NA,NA,NA,NA,10/26/1983,11/27/1989,1989,"treatment of documented ventricular arrhythmias, such as sustained ventricular tachycardia, that in the judgment of the physician, are life-threatening",NA,Standard,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1983-10-26,1989-11-27,2224,7.707062655370473,Pre-PDUFA
Toradol,ketorolac tromethamine,Syntex,NDA,19698,NA,NA,Injectable,Injection,NA,NA,NA,NA,6/22/1987,11/30/1989,1989,indicated for the short-term management of pain,NA,Priority,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1987-06-22,1989-11-30,892,6.79346613258001,Pre-PDUFA
Osmovist,iotrolan,Berlex,NDA,19580,NA,NA,Injectable,Intrathecal,NA,NA,NA,NA,2/10/1986,12/7/1989,1989,"indicated for lumbar, thoracic, cervical, and total columnar myelography, and computerized tomography (CT) of spinal and subarachnoid spaces, in adults",NA,Standard,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1986-02-10,1989-12-07,1396,7.241366283322318,Pre-PDUFA
Oculinum,botulinum toxin type A,Allergan,BLA,103000,NA,NA,Injectable,Injection,NA,NA,NA,NA,3/28/1985,12/9/1989,1989,"for the treatment of strabismus  in patients 12 years of age and above;
blepharospasm associated with dystonia, including benign essential blepharospasm or [seventh] nerve disorders in patients 12 years of age and above",NA,Standard,Yes,N/A,N/A,N/A,N/A,N/A,N/A,NA,1985-03-28,1989-12-09,1717,7.448333860897476,Pre-PDUFA
Zefazone,cefmetazole sodium,Upjohn,NDA,50637,NA,NA,Injectable,Injection,NA,NA,NA,NA,12/31/1987,12/11/1989,1989,"treatment of serious infections caused by susceptible strains of the designated microorganisms in the following diseases: Urinary Tract Infections; Lower Respiratory Tract Infections; Skin and Skin Structure Infections; Intraabdominal Infections; reduce the incidence of certain postoperative infections in patients who undergo caesarean section, abdominal or vaginal hysterectomy, cholecystectomy (high risk patients), and colorectal surgery",NA,Standard,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1987-12-31,1989-12-11,711,6.566672429803241,Pre-PDUFA
Pindac,pinacidil,Eli Lilly,NDA,19456,NA,NA,"Capsule, Extended Release",Oral,NA,NA,NA,NA,7/31/1985,12/28/1989,1989,treatment of hypertension,NA,Standard,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1985-07-31,1989-12-28,1611,7.384610383176974,Pre-PDUFA
Anafranil,clomipramine hydrochloride,Ciba-Geigy,NDA,19906,NA,NA,Capsule,Oral,NA,NA,NA,NA,6/16/1989,12/29/1989,1989,"treatment of obsessions and compulsions in patients with Obsessive Compulsive Disorder (OCD). The obsessions or compulsions must cause marked distress, be time-consuming, or significantly interfere with social or occupational functioning, in order to meet the DSM III-R (circa 1989) diagnosis of OCD",NA,Priority,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1989-06-16,1989-12-29,196,5.278114659230517,Pre-PDUFA
Zoladex,goserelin acetate,ICI,NDA,19726,NA,NA,Implant,Implantation,NA,NA,NA,NA,8/14/1987,12/29/1989,1989,palliative treatment of advanced carcinoma of the prostate,NA,Standard,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1987-08-14,1989-12-29,868,6.7661917146603505,Pre-PDUFA
Dalgan,dezocine,Wyeth-Ayerst,NDA,19082,NA,NA,Injectable,Injection,NA,NA,NA,NA,7/29/1983,12/29/1989,1989,indicated for the management of pain when the use of an opioid analgesic is appropriate,NA,Standard,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1983-07-29,1989-12-29,2345,7.76004068088038,Pre-PDUFA
Cardiogen-82,rubidium Rb 82 chloride,Bristol-Myers Squibb,NDA,19414,NA,NA,Injectable,Injection,NA,NA,NA,NA,12/28/1984,12/29/1989,1989,indicated for assessing regional myocardial perfusion in the diagnosis and localization of myocardial infarction,NA,Standard,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1984-12-28,1989-12-29,1827,7.510430556378006,Pre-PDUFA
Betamet,metipranolol hydrochloride,Bausch & Lomb,NDA,19907,NA,NA,Solution/Drops,Ophthalmic,NA,NA,NA,NA,10/21/1988,12/29/1989,1989,has been shown to be effective in lowering intraocular pressure and may be used in patients with chronic open-angle glaucoma or intraocular hypertension,NA,Standard,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1988-10-21,1989-12-29,434,6.073044534100405,Pre-PDUFA
Ortho Cyclen,"norgestimate, ethinyl estradiol",RW Johnson,NDA,19653,NA,NA,Tablet,Oral,NA,NA,NA,NA,3/24/1987,12/29/1989,1989,prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception,NA,Standard,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1987-03-24,1989-12-29,1011,6.918695219020472,Pre-PDUFA
Decabid,indecainide hydrochloride,Eli Lilly,NDA,19693,NA,NA,"Tablet, Extended Release",Oral,NA,NA,NA,NA,1/5/1988,12/29/1989,1989,"treatment of documented ventricular arrhythmias, such as sustained ventricular tachycardia, that in the judgment of the physician, are life-threatening",NA,Standard,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1988-01-05,1989-12-29,724,6.584791392385716,Pre-PDUFA
Diflucan,fluconazole,Pfizer,NDA,19949,19950,NA,Tablet,Oral,Injectable,Injection,NA,NA,3/2/1989,1/29/1990,1990,"treatment of oropharyngeal and esophageal candidiasis; serious systemic candidal infections, including urinary tract infection, peritonitis, and pneumonia; also indicated for treatment of cryptococcal meningitis",NA,Priority,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1989-03-02,1990-01-29,333,5.808142489980444,Pre-PDUFA
Synarel,nafarelin acetate,Syntex,NDA,19886,NA,NA,"Spray, Metered",Nasal,NA,NA,NA,NA,11/16/1988,2/13/1990,1990,"management of endometriosis, including pain relief and reduction of endometriotic lesions",NA,Standard,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1988-11-16,1990-02-13,454,6.118097198041348,Pre-PDUFA
Adagen,pegademase bovine,Enzon,BLA,19818,NA,NA,Injectable,Injection,NA,NA,NA,NA,1/13/1988,3/21/1990,1990,indicated for enzyme replacement therapy for adenosine deaminase (ADA) deficiency  in  patients  with  severe  combined  immunodeficiency  disease  (SCID)  who  are  not  suitable  candidates  for  –  or  who  have  failed  –  bone  marrow  transplantation,NA,Priority,Yes,N/A,N/A,N/A,N/A,N/A,N/A,Transition Product from NDA to BLA due to BPCI : Please see page 2 of data dictionary for more information.,1988-01-13,1990-03-21,798,6.682108597449809,Pre-PDUFA
TechneScan MAG3,technetium Tc-99m mertiatide,Mallinckrodt,NDA,19882,NA,NA,Injectable,Injection,NA,NA,NA,NA,10/18/1988,6/15/1990,1990,"indicated as a renal imaging agent for use in the diagnosis of congenital and acquired abnormalities, renal failure, urinary tract obstruction, and calculi",NA,Standard,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1988-10-18,1990-06-15,605,6.405228458030842,Pre-PDUFA
Ergamisol,levamisole hydrochloride,Janssen,NDA,20035,NA,NA,Tablet,Oral,NA,NA,NA,NA,11/1/1989,6/18/1990,1990,indicated as adjuvant treatment in combination with 5-fluorouracil after surgical resection in patients with Dukes' stage C colon cancer,NA,Priority,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1989-11-01,1990-06-18,229,5.43372200355424,Pre-PDUFA
Ethmozine,moricizine hydrochloride,DuPont,NDA,19753,NA,NA,Tablet,Oral,NA,NA,NA,NA,9/1/1987,6/19/1990,1990,"indicated for the treatment of documented ventricular arrhythmias, such as sustained ventricular tachycardia, that in the judgment of the physician are life-threatening",NA,Priority,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1987-09-01,1990-06-19,1022,6.92951677076365,Pre-PDUFA
Arduan,pipecuronium bromide,Organon,NDA,19638,NA,NA,Injectable,Injection,NA,NA,NA,NA,12/29/1987,6/26/1990,1990,"indicated as an adjunct to general anesthesia, to provide skeletal muscle relaxation during surgery; can also be used to provide skeletal muscle relaxation for endotracheal intubation",NA,Standard,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1987-12-29,1990-06-26,910,6.813444599510896,Pre-PDUFA
Dipentum,olsalazine sodium,Pharmacia,NDA,19715,NA,NA,Capsule,Oral,NA,NA,NA,NA,9/1/1987,7/31/1990,1990,indicated for the maintenance of remission of ulcerative colitis in patients who are intolerant of sulfasalazine,NA,Priority,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1987-09-01,1990-07-31,1064,6.96979066990159,Pre-PDUFA
Exosurf,"colfosceril palmitate, cetyl alcohol, tyloxapol",Burroughs Wellcome,NDA,20044,NA,NA,For Suspension,Intratracheal,NA,NA,NA,NA,2/16/1990,8/2/1990,1990,"indicated for prophylactic treatment of infants with birth weight less than 1350 grams who are at risk of developing RDS, prophylactic treatment of infants with birth weight greater than 1350 grams who have evidence of pulmonary immaturity, and rescue treatment of infants who have developed RDS",NA,Priority,Yes,N/A,N/A,N/A,N/A,N/A,N/A,NA,1990-02-16,1990-08-02,167,5.117993812416755,Pre-PDUFA
Idamycin,idarubicin hydrochloride,Adria,NDA,50661,NA,NA,Injectable,Injection,NA,NA,NA,NA,8/31/1989,9/27/1990,1990,in combination with other approved antileukemic drugs for the treatment of acute myeloid leukemia (AML) in adults,NA,Priority,Yes,N/A,N/A,N/A,N/A,N/A,N/A,NA,1989-08-31,1990-09-27,392,5.971261839790462,Pre-PDUFA
Cardura,doxazosin mesylate,Pfizer,NDA,19668,NA,NA,Tablet,Oral,NA,NA,NA,NA,3/11/1987,11/2/1990,1990,treatment of hypertension,NA,Standard,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1987-03-11,1990-11-02,1332,7.194436851100335,Pre-PDUFA
Ornidyl,eflornithine hydrochloride,Marion Merrell Dow,NDA,19879,NA,NA,Injectable,Injection,NA,NA,NA,NA,8/2/1988,11/28/1990,1990,treatment of meningoencephalitic stage of Trypanosoma brucei gambiense infection (sleeping sickness),NA,Priority,Yes,N/A,N/A,N/A,N/A,N/A,N/A,NA,1988-08-02,1990-11-28,848,6.742880635791903,Pre-PDUFA
Cutivate,fluticasone propionate,Glaxo,NDA,19957,NA,NA,Ointment,Topical,NA,NA,NA,NA,10/26/1989,12/14/1990,1990,indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses,NA,Standard,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1989-10-26,1990-12-14,414,6.025865973825314,Pre-PDUFA
Ultravate,halobetasol propionate,Bristol-Myers Squibb,NDA,19968,NA,NA,Ointment,Topical,NA,NA,NA,NA,4/3/1989,12/17/1990,1990,indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses,NA,Standard,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1989-04-03,1990-12-17,623,6.434546518787453,Pre-PDUFA
Cardiotec,technetium Tc-99m teboroxime,Squibb,NDA,19928,NA,NA,Injectable,Injection,NA,NA,NA,NA,12/23/1988,12/19/1990,1990,"indicated as a myocardial perfusion agent that is useful in distinguishing normal from abnormal myocardium in patients with suspected coronary artery disease, using rest and stress techniques",NA,Priority,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1988-12-23,1990-12-19,726,6.587550014824796,Pre-PDUFA
Dynacirc,isradipine,Sandoz,NDA,19546,NA,NA,Capsule,Oral,NA,NA,NA,NA,4/25/1986,12/20/1990,1990,indicated for the management of hypertension,NA,Standard,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1986-04-25,1990-12-20,1700,7.438383530044307,Pre-PDUFA
Actimmune,interferon gamma-1b,Genentech,BLA,103348,NA,NA,Injectable,Injection,NA,NA,NA,NA,12/22/1989,12/20/1990,1990,treatment of chronic granulomatous disease,NA,Priority,Yes,N/A,N/A,N/A,N/A,N/A,N/A,Biologic product assigned new license number and now referenced by BLA 103836,1989-12-22,1990-12-20,363,5.8944028342648505,Pre-PDUFA
Cardiolite,technetium Tc-99m sestamibi,DuPont,NDA,19785,NA,NA,Injectable,Injection,NA,NA,NA,NA,12/12/1988,12/21/1990,1990,"indicated as a myocardial perfusion agent that is useful in distinguishing normal from abnormal myocardium, and in the localization of the abnormality, in patients with suspected myocardial infarction",NA,Standard,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1988-12-12,1990-12-21,739,6.6052979209482015,Pre-PDUFA
Hexalen,altretamine,US Bioscience,NDA,19926,NA,NA,Capsule,Oral,NA,NA,NA,NA,12/19/1988,12/26/1990,1990,palliative treatment of patients with persistent or recurrent ovarian cancer following first-line therapy with cisplatin and/or alkylating agent based combination,NA,Priority,Yes,N/A,N/A,N/A,N/A,N/A,N/A,NA,1988-12-19,1990-12-26,737,6.602587892189336,Pre-PDUFA
ProSom,estazolam,Abbott Laboratories,NDA,19080,NA,NA,Tablet,Oral,NA,NA,NA,NA,12/19/1983,12/26/1990,1990,short term treatment of insomnia,NA,Standard,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1983-12-19,1990-12-26,2564,7.849323818040561,Pre-PDUFA
Geref,sermorelin acetate,Serono,NDA,19863,NA,NA,Injectable,Injection,NA,NA,NA,NA,5/5/1988,12/28/1990,1990,for evaluating the ability of the somatotroph of the pituitary gland to secrete growth hormone (GH),NA,Standard,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1988-05-05,1990-12-28,967,6.874198495453294,Pre-PDUFA
Vascor,bepridil hydrochloride,McNeil Laboratories,NDA,19002,NA,NA,Tablet,Oral,NA,NA,NA,NA,12/28/1983,12/28/1990,1990,treatment of chronic stable angina (classic effort-associated angina) in patients failing to respond adequately to other therapy,NA,Priority,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1983-12-28,1990-12-28,2557,7.846589975291186,Pre-PDUFA
Floxin,ofloxacin,RW Johnson,NDA,19735,NA,NA,Tablet,Oral,NA,NA,NA,NA,12/22/1987,12/28/1990,1990,"treatment for the following infections caused by susceptible strains of designated microorganisms; lower respiratory tract infections (acute bacterial exacerbations of chronic bronchitis and pneumonia); sexually transmitted diseases (acute, uncomplicated urethral and cervical gonorrhea, nongonococcal urethritis and cervicitis, and mixed infections of the urethra and cervix); skin and skin structure infections (mild to moderate skin and skin structure infections); urinary tract infections (uncomplicated cystitis, and complicated urinary tract infections); and prostatitis",NA,Standard,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1987-12-22,1990-12-28,1102,7.004881989712859,Pre-PDUFA
Rev-Eyes,dapiprazole hydrochloride,Angelini,NDA,19849,NA,NA,Solution/Drops,Ophthalmic,NA,NA,NA,NA,5/27/1988,12/31/1990,1990,treatment of iatrogenically induced mydriasis produced by adrenergic (phenylephrine) or parasmypatholytic (tropicamide) agents,NA,Priority,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1988-05-27,1990-12-31,948,6.854354502255021,Pre-PDUFA
Zofran,ondansetron hydrochloride,Glaxo,NDA,20007,NA,NA,Injectable,Injection,NA,NA,NA,NA,10/12/1989,1/4/1991,1991,prevention of nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy including high-dose cisplatin,NA,Priority,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1989-10-12,1991-01-04,449,6.1070228877422545,Pre-PDUFA
Ganite,gallium nitrate,Fujisawa,NDA,19961,NA,NA,Injectable,Injection,NA,NA,NA,NA,3/20/1989,1/17/1991,1991,for the treatment of clearly symptomatic cancer-related hypercalcemia that has not responded to adequate hydration,NA,Priority,Yes,N/A,N/A,N/A,N/A,N/A,N/A,NA,1989-03-20,1991-01-17,668,6.504288173536645,Pre-PDUFA
Altace,ramipril,Hoechst-Roussel,NDA,19901,NA,NA,Capsule,Oral,NA,NA,NA,NA,11/7/1988,1/28/1991,1991,for the treatment of hypertension,NA,Standard,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1988-11-07,1991-01-28,812,6.699500340161678,Pre-PDUFA
Chemet,succimer,McNeil,NDA,19998,NA,NA,Capsule,Oral,NA,NA,NA,NA,8/22/1989,1/30/1991,1991,treatment of lead poisoning in children with blood lead levels above 45 mug/dL,NA,Priority,Yes,N/A,N/A,N/A,N/A,N/A,N/A,NA,1989-08-22,1991-01-30,526,6.26530121273771,Pre-PDUFA
Lodine,etodolac,Wyeth-Ayerst,NDA,18922,NA,NA,Capsule,Oral,NA,NA,NA,NA,12/30/1982,1/31/1991,1991,indicated for the treatment of osteoarthritis; management of pain,NA,Standard,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1982-12-30,1991-01-31,2954,7.9909154630913255,Pre-PDUFA
Neupogen,filgrastim,Amgen,BLA,103353,NA,NA,Injectable,Injection,NA,NA,NA,NA,1/5/1990,2/20/1991,1991,"to decrease the incidence of infection, as manifested in febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a significant incidence of severe neutropenia with fever",NA,Priority,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1990-01-05,1991-02-20,411,6.018593214496234,Pre-PDUFA
Leukine,sargramostim,Immunex,BLA,103362,NA,NA,Injectable,Injection,NA,NA,NA,NA,2/24/1990,3/5/1991,1991,approved for use following induction chemotherapy in older adults with acute myelogenous leukemia (AML) to shorten the time to neutrophil recovery and reduce the incidence of severe and life-threatening infections and infections resulting in death,NA,Priority,Yes,N/A,N/A,N/A,N/A,N/A,N/A,NA,1990-02-24,1991-03-05,374,5.924255797414532,Pre-PDUFA
Nuromax,doxacurium chloride,Burroughs Wellcome,NDA,19946,NA,NA,Injectable,Injection,NA,NA,NA,NA,3/21/1989,3/7/1991,1991,"indicated as an adjunct to general anesthesia, to provide skeletal muscle relaxation during surgery; also be used to provide skeletal muscle relaxation for endotracheal intubation",NA,Standard,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1989-03-21,1991-03-07,716,6.573680166960646,Pre-PDUFA
Ceredase,alglucerase,Genzyme,NDA,20057,NA,NA,Injectable,Injection,NA,NA,NA,NA,4/24/1990,4/5/1991,1991,"indicated for use as long-term enzyme replacement therapy for patients with a confirmed diagnosis of Type 1 Gaucher disease who exhibit signs and symptoms that are severe enough to result in one of the following conditions:  moderate to severe anemia, thrombocytopenia with bleeding tendency, bone disease, significant hepatomegaly or splenomegaly",NA,Priority,Yes,N/A,N/A,N/A,N/A,N/A,N/A,NA,1990-04-24,1991-04-05,346,5.846438775057725,Pre-PDUFA
Fludara,fludarabine phosphate,Berlex,NDA,20038,NA,NA,Injectable,Injection,NA,NA,NA,NA,11/24/1989,4/18/1991,1991,treatment of patients with B-cell chronic lymphocytic leukemia (CLL) who have not responded to other treatments or whose disease has progressed during treatment with at least one standard alkylating agent-containing regimen,NA,Priority,Yes,N/A,N/A,N/A,N/A,N/A,N/A,NA,1989-11-24,1991-04-18,510,6.234410725718371,Pre-PDUFA
Monopril,fosinopril sodium,Bristol-Myers Squibb,NDA,19915,NA,NA,Tablet,Oral,NA,NA,NA,NA,11/15/1988,5/16/1991,1991,treatment of hypertension,NA,Standard,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1988-11-15,1991-05-16,912,6.815639990074331,Pre-PDUFA
Lotensin,benazepril hydrochloride,Ciba,NDA,19851,NA,NA,Tablet,Oral,NA,NA,NA,NA,7/6/1988,6/25/1991,1991,treatment of hypertension,NA,Standard,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1988-07-06,1991-06-25,1084,6.988413181999592,Pre-PDUFA
Survanta,beractant,Ross,BLA,20032,NA,NA,Suspension,Intratracheal,NA,NA,NA,NA,1/2/1990,7/1/1991,1991,"prevention of RDS (hyaline membrane disease) in premature infants less than 1250 grams birthweight or with evidence of surfactant deficiency; treatment of (""rescue"") of premature infants with RDS confirmed by x-ray and requiring mechanical ventilation",NA,Standard,Yes,N/A,N/A,N/A,N/A,N/A,N/A,Transition Product from NDA to BLA due to BPCI : Please see page 2 of data dictionary for more information.,1990-01-02,1991-07-01,545,6.300785794663244,Pre-PDUFA
Plendil,felodipine,Merck Sharp & Dohme,NDA,19834,NA,NA,"Tablet, Extended Release",Oral,NA,NA,NA,NA,2/26/1988,7/25/1991,1991,treatment of hypertension,NA,Standard,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1988-02-26,1991-07-25,1245,7.126890808898808,Pre-PDUFA
Foscavir,foscarnet sodium,Astra,NDA,20068,NA,NA,Injectable,Injection,NA,NA,NA,NA,9/20/1990,9/27/1991,1991,treatment of CMV retinitis in patients with acquired immunodeficiency syndrome (AIDS),NA,Priority,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1990-09-20,1991-09-27,372,5.918893854273146,Pre-PDUFA
Videx,didanosine,Bristol-Myers Squibb,NDA,20154,20155,20156,"Tablet, Chewable",Oral,Solution,Oral,Solution,Oral,4/2/1991,10/9/1991,1991,adult and pediatric patients over six months of age with advanced HIV infection who are intolerant of zidovudine [AZT] therapy or who have demonstrated significant clinical or immunologic deterioration during zidovudine therapy,NA,Priority,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1991-04-02,1991-10-09,190,5.247024072160486,Pre-PDUFA
Nipent,pentostatin,Parke-Davis,NDA,20122,NA,NA,Injectable,Injection,NA,NA,NA,NA,2/11/1991,10/11/1991,1991,treatment for adult patients with alpha-interferon-refractory hairy cell leukemia,NA,Priority,Yes,N/A,N/A,N/A,N/A,N/A,N/A,NA,1991-02-11,1991-10-11,242,5.488937726156687,Pre-PDUFA
Aredia,pamidronate disodium,Ciba-Geigy,NDA,20036,NA,NA,Injectable,Injection,NA,NA,NA,NA,12/21/1989,10/31/1991,1991,treatment of hypercalcemia associate with malignancy,NA,Priority,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1989-12-21,1991-10-31,679,6.520621127558696,Pre-PDUFA
Pravachol,pravastatin sodium,Bristol-Myers Squibb,NDA,19898,NA,NA,Tablet,Oral,NA,NA,NA,NA,1/31/1989,10/31/1991,1991,as an adjunct to diet for the reduction of elevated total and LDL-cholesterol levels in patients with primary hypercholesterolemia (Type IIa and IIb) when the response to a diet restricted in saturated fat and cholesterol has not been adequate,NA,Standard,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1989-01-31,1991-10-31,1003,6.910750787961936,Pre-PDUFA
Ticlid,ticlopidine hydrochloride,Syntex,NDA,19979,NA,NA,Tablet,Oral,NA,NA,NA,NA,11/15/1989,10/31/1991,1991,"indicated to reduce the risk of thrombotic stroke (fatal 
or nonfatal) in patients who have experienced stroke precursors,
and in patients who have had a completed thrombotic stroke",NA,Priority,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1989-11-15,1991-10-31,715,6.5722825426940075,Pre-PDUFA
Biaxin,clarithromycin,Abbott Laboratories,NDA,50662,NA,NA,Tablet,Oral,NA,NA,NA,NA,12/20/1989,10/31/1991,1991,indicated for the treatment of mild to moderate infections caused by susceptible strains of designated microorganisms in the conditions listed below:  pharyngitis/tonsillitis; sinusitis; acute bacterial exacerbations of chronic bronchitis; pneumonia; uncomplicated skin and skin structure infections,NA,Priority,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1989-12-20,1991-10-31,680,6.522092798170152,Pre-PDUFA
Zithromax,azithromycin,Pfizer,NDA,50670,NA,NA,Capsule,Oral,NA,NA,NA,NA,4/11/1990,11/1/1991,1991,"indicated for the treatment of individuals 16 years of age and older with mild to moderate infections caused by susceptible strains of designated microorganisms in the conditions listed below: acute bacterial exacerbations of chronic obstructive pulmonary disease; pneumonia; streptococcal pharyngitis/tonsillitis, as an alternative to first line therapy in individuals who cannot use first line therapy; uncomplicated skin and skin structure infections; non-gonococal urethritis and cervicitis",NA,Priority,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1990-04-11,1991-11-01,569,6.343880434126331,Pre-PDUFA
Accupril,quinapril hydrochloride,Parke-Davis,NDA,19885,NA,NA,Tablet,Oral,NA,NA,NA,NA,1/26/1989,11/19/1991,1991,treatment of hypertension,NA,Standard,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1989-01-26,1991-11-19,1027,6.934397209928558,Pre-PDUFA
Romazicon,flumazenil,Roche,NDA,20073,NA,NA,Injectable,Injection,NA,NA,NA,NA,12/10/1990,12/20/1991,1991,"the complete or partial reversal of the sedative effects of benzodiazepines in cases where general anesthesia has been induced and/or maintained with benzodiazepines, where sedation has been produced with benzodiazepines for diagnostic and therapeutic procedures, and for the management of benzodiazepine overdose",NA,Priority,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1990-12-10,1991-12-20,375,5.926926025970411,Pre-PDUFA
Zocor,simvastatin,Merck Sharp & Dohme,NDA,19766,NA,NA,Tablet,Oral,NA,NA,NA,NA,10/16/1987,12/23/1991,1991,as an adjunct to diet for the reduction of elevated total and LDL cholesterol levels in patients with primary hypercholesterolemia (Types IIa and IIb) when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacological measures alone has not been adequate,NA,Standard,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1987-10-16,1991-12-23,1529,7.332369205929062,Pre-PDUFA
Cefzil,cefprozil,Bristol-Myers Squibb,NDA,50664,50665,NA,Tablet,Oral,Suspension,Oral,NA,NA,3/30/1990,12/23/1991,1991,indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of designated microorganisms in the conditions listed below: pharyngitis/tonsillitis; otitis media; secondary bacterial infection of acute bronchitis and acute bacterial exacerbations of chronic bronchitis; uncomplicated skin and skin structure infections,NA,Standard,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1990-03-30,1991-12-23,633,6.450470422144176,Pre-PDUFA
Supprelin,histrelin acetate,Johnson & Johnson,NDA,19836,NA,NA,Injectable,Injection,NA,NA,NA,NA,5/22/1989,12/24/1991,1991,treatment of central precocious puberty,NA,Priority,Yes,N/A,N/A,N/A,N/A,N/A,N/A,NA,1989-05-22,1991-12-24,946,6.852242569051878,Pre-PDUFA
Relafen,nabumetone,SmithKline Beecham,NDA,19583,NA,NA,Tablet,Oral,NA,NA,NA,NA,2/10/1986,12/24/1991,1991,acute and chronic treatment of signs and symptoms of osteoarthritis and rheumatoid arthritis,NA,Standard,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1986-02-10,1991-12-24,2143,7.669961995473577,Pre-PDUFA
Ismo,isosorbide mononitrate,Wyeth,NDA,19091,NA,NA,Tablet,Oral,NA,NA,NA,NA,12/30/1983,12/30/1991,1991,prevention and control of stable angina pectoris due to coronary artery disease,NA,Standard,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1983-12-30,1991-12-30,2922,7.980023592310645,Pre-PDUFA
Zoloft,sertraline hydrochloride,Pfizer,NDA,19839,NA,NA,Tablet,Oral,NA,NA,NA,NA,4/13/1988,12/30/1991,1991,treatment of depression,NA,Standard,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1988-04-13,1991-12-30,1356,7.212294468500341,Pre-PDUFA
Lorabid,loracarbef,Eli Lilly,NDA,50667,50668,NA,For Suspension,Oral,Capsule,Oral,NA,NA,8/27/1990,12/31/1991,1991,indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of designated microorganisms in the conditions listed: Secondary Bacterial Infection of Acute Bronchitis; Acute Bacterial Exacerbations of Chronic Bronchitis; Pneumonia; Acute Otitis Media; Acute Maxillary Sinusitis; Pharyngitis and Tonsillitis; Uncomplicated Skin and Skin Structure Infections; Uncomplicated Urinary Tract Infections; Uncomplicated Pyelonephritis,NA,Standard,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1990-08-27,1991-12-31,491,6.19644412779452,Pre-PDUFA
Penetrex,enoxacin,Warner-Lambert,NDA,19616,NA,NA,Tablet,Oral,NA,NA,NA,NA,10/24/1986,12/31/1991,1991,"indicated for the treatment of infections caused by susceptible strains of designated microorganisms in the infections listed: urinary tract infections (uncomplicated and complicated), uncomplicated urethritis or endocervicitis due to susceptible strains of Neisseria gonorrhoea, including non-penicillinase- and penicillinase-producing strains",NA,Standard,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1986-10-24,1991-12-31,1894,7.546446273746024,Pre-PDUFA
Mivacron,mivacurium chloride,Burroughs Wellcome,NDA,20098,NA,NA,Solution,Intravenous,NA,NA,NA,NA,8/30/1990,1/22/1992,1992,"for inpatients and outpatients, as an adjunct to general anesthesia, to facilitate tracheal intubation and to provide skeletal muscle relaxation during surgery or mechanical ventilation",NA,Priority,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1990-08-30,1992-01-22,510,6.234410725718371,Pre-PDUFA
Omniflox,temafloxacin hydrochloride,Abbott Laboratories,NDA,20043,NA,NA,Tablet,Oral,NA,NA,NA,NA,11/30/1989,1/30/1992,1992,"treatment of adults with mild to moderate infections caused by susceptible strains of designated microorganisms in the conditions listed: Lower Respiratory Tract Infections (acute bacterial exacerbation of chronic bronchitis and pneumonia), uncomplicated skin and skin structure infections, prostatitis, uncomplicated and complicated urinary tract infections",NA,Standard,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1989-11-30,1992-01-30,791,6.673297967767654,Pre-PDUFA
Maxaquin,lomefloxacin hydrochloride,Searle,NDA,20013,NA,NA,Tablet,Oral,NA,NA,NA,NA,7/31/1990,2/21/1992,1992,indicated  for  the  treatment  of  adults  with  mild  to moderate  infections  caused  by  susceptible  strains  of  the  designated  microorganisms  in  the  conditions listed: complicated and uncomplicated urinary tract infections; acute bacterial exacerbations of chronic bronchitis; indicated pre-operatively to reduce the incidence of urinary tract infections in the early postoperative period in patients undergoing transurethral surgical procedures,NA,Standard,No,N/A,N/A,N/A,N/A,N/A,N/A,NA,1990-07-31,1992-02-21,570,6.345636360828596,Pre-PDUFA
Proleukin,aldesleukin,Chiron,BLA,103293,NA,NA,Injectable,Injection,NA,NA,NA,NA,12/1/1988,5/5/1992,1992,treatment of adults (>18 years old) with metastatic renal cell carcinoma,NA,Standard,Yes,No,N/A,N/A,N/A,N/A,N/A,NA,1988-12-01,1992-05-05,1251,7.1316985104669115,Pre-PDUFA
Proscar,finasteride,Merck Sharp & Dohme,NDA,20180,NA,NA,Tablet,Oral,NA,NA,NA,NA,4/15/1991,6/19/1992,1992,treatment of symptomatic benign prostatic hyperplasia,NA,Priority,No,No,N/A,N/A,N/A,N/A,N/A,NA,1991-04-15,1992-06-19,431,6.066108090103747,Pre-PDUFA
Hivid,zalcitabine,Roche,NDA,20199,NA,NA,Tablet,Oral,NA,NA,NA,NA,10/31/1991,6/19/1992,1992,indicated for the treatment of adult patients with advanced HIV infection who have demonstrated significant clinical or immunological deterioration,NA,Priority,Yes,Yes,N/A,N/A,N/A,N/A,N/A,NA,1991-10-31,1992-06-19,232,5.44673737166631,Pre-PDUFA
Vumon,teniposide,Bristol-Myers Squibb,NDA,20119,NA,NA,Injectable,Injection,NA,NA,NA,NA,9/28/1990,7/14/1992,1992,indicated for induction therapy in patients with refractory childhood acute lymphoblastic leukemia,NA,Priority,Yes,No,N/A,N/A,N/A,N/A,N/A,NA,1990-09-28,1992-07-14,655,6.484635235635252,Pre-PDUFA
Halfan,halofantrine hydrochloride,SmithKline Beecham,NDA,20250,NA,NA,Tablet,Oral,NA,NA,NA,NA,1/7/1992,7/24/1992,1992,treatment of adults who can tolerate oral medication and who have mild to moderate malaria caused by Plasmodium falciparum or Plasmodium vivax,NA,Priority,Yes,No,N/A,N/A,N/A,N/A,N/A,NA,1992-01-07,1992-07-24,199,5.293304824724492,Pre-PDUFA
Norvasc,amlodipine besylate,Pfizer,NDA,19787,NA,NA,Tablet,Oral,NA,NA,NA,NA,12/23/1987,7/31/1992,1992,"treatment of hypertension, alone or in combination with other antihypertensive agents, treatment of chronic stable angina alone or in combination with other antianginal agents, treatment of confirmed or suspected vasospastic angina, as monotherapy or in combination with other antianginal drugs",NA,Standard,No,No,N/A,N/A,N/A,N/A,N/A,NA,1987-12-23,1992-07-31,1682,7.427738840532894,Pre-PDUFA
Zebeta,bisoprolol fumarate,Lederle,NDA,19982,NA,NA,Tablet,Oral,NA,NA,NA,NA,8/1/1989,7/31/1992,1992,management of hypertension,NA,Standard,No,No,N/A,N/A,N/A,N/A,N/A,NA,1989-08-01,1992-07-31,1095,6.9985096422506015,Pre-PDUFA
Vantin,cefpodoxime proxetil,Upjohn,NDA,50674,50675,NA,Tablet,Oral,Suspension,Oral,NA,NA,3/29/1991,8/7/1992,1992,"treatment of patients with mild to moderate infections caused by susceptible strains of designated microorganisms in the conditions listed:  Acute, community-acquired pneumonia; acute, uncomplicated urethral and cervical gonorrhea; acute, uncomplicated ano-rectal infections in women due to Neisseria gonorrhoeae; uncomplicated skin and skin structure infections; acute otitis media; pharyngitis/tonsillitis; uncomplicated urinary tract infections",NA,Standard,No,No,N/A,N/A,N/A,N/A,N/A,NA,1991-03-29,1992-08-07,497,6.208590026096629,Pre-PDUFA
Actinex,masoprocol,Block,NDA,19940,NA,NA,Cream,Topical,NA,NA,NA,NA,4/10/1989,9/4/1992,1992,topical treatment of actinic (solar) keratoses,NA,Standard,No,No,N/A,N/A,N/A,N/A,N/A,NA,1989-04-10,1992-09-04,1243,7.1252830915107115,Pre-PDUFA
Sporanox,itraconazole,Janssen,NDA,20083,NA,NA,Capsule,Oral,NA,NA,NA,NA,5/31/1990,9/11/1992,1992,"treatment of the following fungal infections in immunocompromised and non-immunocompromised patients: blastomycosis, pulmonary and extrapulmonary; histoplasmosis, including chronic cavitary pulmonary disease and disseminated, non-meningeal histoplasmosis",NA,Priority,No,No,N/A,N/A,N/A,N/A,N/A,NA,1990-05-31,1992-09-11,834,6.726233402358747,Pre-PDUFA
Suprane,desflurane,Anaquest,NDA,20118,NA,NA,Liquid,Inhalation,NA,NA,NA,NA,1/30/1991,9/18/1992,1992,indicated as an inhalation agent for induction and/or maintenance of anesthesia for inpatient and outpatient surgery in adults,NA,Standard,No,No,N/A,N/A,N/A,N/A,N/A,NA,1991-01-30,1992-09-18,597,6.391917113392602,Pre-PDUFA
Betapace,sotalol hydrochloride,Bristol-Myers Squibb,NDA,19865,NA,NA,Tablet,Oral,NA,NA,NA,NA,6/30/1988,10/30/1992,1992,"treatment of documented ventricular arrhythmias, such as sustained ventricular tachycardia, that in the judgment of the physician are life-threatening",NA,Priority,Yes,No,N/A,N/A,N/A,N/A,N/A,NA,1988-06-30,1992-10-30,1583,7.367077059881012,Pre-PDUFA
ProHance,gadoteridol,Squibb,NDA,20131,NA,NA,Injectable,Injection,NA,NA,NA,NA,1/23/1991,11/16/1992,1992,"provides contrast enhancement of the brain, spine, and surrounding tissues resulting in improved visualization of lesions with abnormal vascularity or those thought to cause a disruption of the normal blood-brain barrier",NA,Standard,No,No,N/A,N/A,N/A,N/A,N/A,NA,1991-01-23,1992-11-16,663,6.4967749901858625,Pre-PDUFA
Mepron,atovaquone,Burroughs Wellcome,NDA,20259,NA,NA,Tablet,Oral,NA,NA,NA,NA,4/24/1992,11/25/1992,1992,treatment of mild to moderate Pneumocystis carinii pneumonia in patients who are intolerant to trimethoprim-sulfamethoxazole,NA,Priority,Yes,No,N/A,N/A,N/A,N/A,N/A,NA,1992-04-24,1992-11-25,215,5.3706380281276624,Pre-PDUFA
Desogen,"desogestrel, ethinyl estradiol",Organon,NDA,20071,NA,NA,Tablet,Oral,NA,NA,NA,NA,12/31/1990,12/10/1992,1992,prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception,NA,Standard,No,No,N/A,N/A,N/A,N/A,N/A,NA,1990-12-31,1992-12-10,710,6.565264970035361,Pre-PDUFA
Ambien,zolpidem tartrate,Lorex,NDA,19908,NA,NA,Tablet,Oral,NA,NA,NA,NA,1/30/1989,12/16/1992,1992,short-term treatment of insomnia,NA,Standard,No,No,N/A,N/A,N/A,N/A,N/A,NA,1989-01-30,1992-12-16,1416,7.255591274253665,Pre-PDUFA
Mycobutin,rifabutin,Adria,NDA,50689,NA,NA,Capsule,Oral,NA,NA,NA,NA,1/17/1992,12/23/1992,1992,prevention of disseminated Mycobacterium avium complex (MAC) disease in patients with advanced HIV infection,NA,Priority,Yes,No,N/A,N/A,N/A,N/A,N/A,NA,1992-01-17,1992-12-23,341,5.831882477283517,Pre-PDUFA
Imitrex,sumatriptan succinate,Glaxo,NDA,20080,NA,NA,Injectable,Subcutaneous,NA,NA,NA,NA,7/2/1990,12/28/1992,1992,acute treatment of migraine attacks with or without aura,NA,Priority,No,No,N/A,N/A,N/A,N/A,N/A,NA,1990-07-02,1992-12-28,910,6.813444599510896,Pre-PDUFA
Indiclor,indium In 111 chloride,Amersham,NDA,19862,NA,NA,Injectable,Injection,NA,NA,NA,NA,5/2/1988,12/29/1992,1992,indicated for radiolabeling of monoclonal antibodies in preparations used for in vivo diagnostic imaging procedures,NA,Standard,No,No,N/A,N/A,N/A,N/A,N/A,NA,1988-05-02,1992-12-29,1702,7.43955930913332,Pre-PDUFA
Taxol,paclitaxel,Bristol-Myers Squibb,NDA,20262,NA,NA,Injectable,Injection,NA,NA,NA,NA,7/22/1992,12/29/1992,1992,treatment of patients with metastatic carcinoma of the ovary after failure of first-line or subsequent chemotherapy,NA,Priority,No,No,N/A,N/A,N/A,N/A,N/A,NA,1992-07-22,1992-12-29,160,5.075173815233827,Pre-PDUFA
OncoScint,satumomab pendetide,Cytogen,BLA,103336,NA,NA,Injectable,Injection,NA,NA,NA,NA,9/28/1989,12/29/1992,1992,"indicated for determining the extent and location of extrahepatic malignant disease in the following:
[A] in patients with known colorectal cancer 
[B] in patients with known ovarian cancer",NA,Standard,Yes (indication [B] only),No,N/A,N/A,N/A,N/A,N/A,Biologic product assigned new license number and now referenced by BLA 103673,1989-09-28,1992-12-29,1188,7.080026499922591,Pre-PDUFA
Paxil,paroxetine hydrochloride,SmithKline Beecham,NDA,20031,NA,NA,Tablet,Oral,NA,NA,NA,NA,11/21/1989,12/29/1992,1992,treatment of depression,NA,Standard,No,No,N/A,N/A,N/A,N/A,N/A,NA,1989-11-21,1992-12-29,1134,7.033506484287697,Pre-PDUFA
Tilade,nedocromil sodium,Fisons,NDA,19660,NA,NA,"Aerosol, Metered",Inhalation,NA,NA,NA,NA,3/3/1987,12/30/1992,1992,indicated for maintenance therapy in the management of patients with mild to moderate bronchial asthma,NA,Standard,No,No,N/A,N/A,N/A,N/A,N/A,NA,1987-03-03,1992-12-30,2129,7.663407664893479,Pre-PDUFA
Lamisil,terbinafine hydrochloride,Sandoz,NDA,20192,NA,NA,Cream,Topical,NA,NA,NA,NA,7/3/1991,12/30/1992,1992,"treatment of the following dermatologic infections: interdigital tinea pedis, tinea cruris, or tinea corporis due to Epidermophyton floccosum, Trichophyton mentagrophytes, or Trichophyton rubrum",NA,Standard,No,No,N/A,N/A,N/A,N/A,N/A,NA,1991-07-03,1992-12-30,546,6.302618975744905,Pre-PDUFA
Manoplax,flosequinan,Boots,NDA,19960,NA,NA,Tablet,Oral,NA,NA,NA,NA,10/1/1990,12/30/1992,1992,management of congestive heart failure in patients not responding adequately to diuretics,NA,Standard,No,No,N/A,N/A,N/A,N/A,N/A,NA,1990-10-01,1992-12-30,821,6.710523109452428,Pre-PDUFA
Omniscan,gadodiamide,Sterling-Winthrop,NDA,20123,NA,NA,Injectable,Injection,NA,NA,NA,NA,10/12/1990,1/8/1993,1993,intravenous administration with magnetic resonance imaging in adult patients to provide contrast enhancement in those central nervous system lesions with abnormal vascularity or those thought to cause abnormalities in the blood brain barrier,NA,Standard,No,No,N/A,N/A,N/A,N/A,N/A,NA,1990-10-12,1993-01-08,819,6.70808408385307,Early-PDUFA
Leustatin,cladribine,Johnson & Johnson,NDA,20229,NA,NA,Injectable,Injection,NA,NA,NA,NA,12/31/1991,2/26/1993,1993,treatment of active hairy cell leukemia,NA,Priority,Yes,No,N/A,N/A,N/A,N/A,N/A,NA,1991-12-31,1993-02-26,423,6.0473721790462776,Early-PDUFA
Lovenox,enoxaparin sodium,Rhone-Poulenc Rorer,NDA,20164,NA,NA,Injectable,Subcutaneous,NA,NA,NA,NA,12/31/1991,3/29/1993,1993,"prevention of deep vein thrombosis (DVT), which may lead to pulmonary embolism, following hip replacement surgery",NA,Priority,No,No,N/A,N/A,N/A,N/A,N/A,NA,1991-12-31,1993-03-29,454,6.118097198041348,Early-PDUFA
Claritin,loratadine,Schering,NDA,19658,NA,NA,Tablet,Oral,NA,NA,NA,NA,10/31/1986,4/12/1993,1993,for the relief of nasal and non-nasal symptoms of seasonal allergic rhinitis,NA,Standard,No,No,N/A,N/A,N/A,N/A,N/A,NA,1986-10-31,1993-04-12,2355,7.764296006450518,Early-PDUFA
Metastron,strontium 89 chloride,Medi Physics,NDA,20134,NA,NA,Injectable,Injection,NA,NA,NA,NA,10/2/1992,6/18/1993,1993,for the relief of bone pain in patients with painful skeletal metastases,NA,Priority,No,No,N/A,N/A,N/A,N/A,N/A,NA,1992-10-02,1993-06-18,259,5.556828061699537,Early-PDUFA
Orlaam,levomethadyl acetate hydrochloride,Biometric Res,NDA,20315,NA,NA,Concentrate,Oral,NA,NA,NA,NA,6/21/1993,7/9/1993,1993,indicated for the management of opiate dependence,NA,Priority,Yes,No,N/A,N/A,N/A,N/A,N/A,NA,1993-06-21,1993-07-09,18,2.8903717578961645,Early-PDUFA
Betaseron,interferon beta-1b,Chiron,BLA,103471,NA,NA,Injectable,Injection,NA,NA,NA,NA,6/18/1992,7/23/1993,1993,for use in ambulatory patients with relapse-remitting multiple sclerosis (MS) to reduce the frequency of clinical exacerbations,NA,Priority,Yes,Yes,N/A,N/A,N/A,N/A,N/A,NA,1992-06-18,1993-07-23,400,5.991464547107982,Early-PDUFA
Felbatol,felbamate,Wallace,NDA,20189,NA,NA,Suspension,Oral,NA,NA,NA,NA,9/30/1991,7/29/1993,1993,"[A] as monotherapy and adjunctive therapy in the treatment of partial seizures with and without generalization in adults with epilepsy
[B] as adjunctive therapy in the treatment of partial and generalized seizures associated with the Lennox-Gastaut syndrome in children",NA,Priority,Yes (indication [B] only),No,N/A,N/A,N/A,N/A,N/A,NA,1991-09-30,1993-07-29,668,6.504288173536645,Early-PDUFA
Propulsid,cisapride monohydrate,Janssen,NDA,20210,NA,NA,Tablet,Oral,NA,NA,NA,NA,8/29/1991,7/29/1993,1993,symptomatic treatment of patients with nocturnal heartburn due to gastroesophageal reflux disease,NA,Standard,No,No,N/A,N/A,N/A,N/A,N/A,NA,1991-08-29,1993-07-29,700,6.551080335043404,Early-PDUFA
Imagent GI,perflubron,Alliance,NDA,20091,NA,NA,Liquid,Oral,NA,NA,NA,NA,10/25/1990,8/13/1993,1993,Indicated for use with magnetic resonance imaging to enhance the delineation of the bowel in order to distinguish it from adjacent organs and areas of suspected pathology,NA,Priority,No,No,N/A,N/A,N/A,N/A,N/A,NA,1990-10-25,1993-08-13,1023,6.930494765951626,Early-PDUFA
Demadex,torsemide,Boehringer Mannheim,NDA,20136,20137,NA,Tablet,Oral,Injectable,Injection,NA,NA,2/28/1991,8/23/1993,1993,"treatment of edema associated with congestive heart failure (CHF), renal disease, or hepatic disease; treatment of hypertension",NA,Standard,No,No,N/A,N/A,N/A,N/A,N/A,NA,1991-02-28,1993-08-23,907,6.810142450115136,Early-PDUFA
Cognex,tacrine hydrochloride,Parke-Davis,NDA,20070,NA,NA,Capsule,Oral,NA,NA,NA,NA,6/4/1990,9/9/1993,1993,treatment of mild to moderate dementia of the Alzheimer's type,NA,Priority,No,No,N/A,N/A,N/A,N/A,N/A,NA,1990-06-04,1993-09-09,1193,7.084226422097916,Early-PDUFA
Flumadine,rimantadine hydrochloride,Forest,NDA,19649,19650,NA,Tablet,Oral,Syrup,Oral,NA,NA,11/14/1986,9/17/1993,1993,prophylaxis and treatment of illness caused by various strains of influenza A virus in adults; indicated for prophylaxis against influenza A virus in children,NA,Priority,No,No,N/A,N/A,N/A,N/A,N/A,NA,1986-11-14,1993-09-17,2499,7.823645930834952,Early-PDUFA
Alomide,lodoxamide tromethamine,Alcon,NDA,20191,NA,NA,Solution/Drops,Ophthalmic,NA,NA,NA,NA,6/10/1991,9/23/1993,1993,"treatment of the ocular disorders referred to by the terms vernal keratoconjunctivitis, vernal conjunctivitis, and vernal keratitis",NA,Standard,Yes,No,N/A,N/A,N/A,N/A,N/A,NA,1991-06-10,1993-09-23,836,6.728628613084702,Early-PDUFA
Zosyn,"tazobactam sodium, pipercillin sodium",Lederle,NDA,50684,NA,NA,Injectable,Injection,NA,NA,NA,NA,9/3/1991,10/22/1993,1993,"treatment of moderate to severe infections cased by piperacillin-resistant, piperacillin/tazobactam-susceptible, beta-lactamase producing strains of designated microorganisms in: appendicitis and peritonitis; uncomplicated and complicated skin and skin structures infections; postpartum endometritis or pelvic inflammatory disease; community-acquired pneumonia (moderate severity only)",NA,Standard,No,No,N/A,N/A,N/A,N/A,N/A,NA,1991-09-03,1993-10-22,780,6.659293919683638,Early-PDUFA
Livostin,levocabastine hydrochloride,Iolab,NDA,20219,NA,NA,Suspension/Drops,Ophthalmic,NA,NA,NA,NA,9/24/1991,11/10/1993,1993,temporary relief of the signs and symptoms of seasonal allergic conjunctivitis,NA,Priority,No,No,N/A,N/A,N/A,N/A,N/A,NA,1991-09-24,1993-11-10,778,6.656726524178391,Early-PDUFA
Neutrexin,trimetrexate glucuronate,US BioScience,NDA,20326,NA,NA,Injectable,Injection,NA,NA,NA,NA,2/1/1993,12/17/1993,1993,"for use with concurrent leucovorin administration is indicated as an alternative therapy for the treatment of moderate-to-severe Pneumocystis carnii pneumonia (PCP) in immunocompromised patients, including patients with acquired immunodeficiency syndrome (AIDS), who are intolerant of, or are refractory to, trimethoprim-sulfamethoxazole (TMP/SMX) therapy or for whom TMP/SMX is contraindicated",NA,Priority,Yes,No,N/A,N/A,N/A,N/A,N/A,NA,1993-02-01,1993-12-17,319,5.765191102784844,Early-PDUFA
Effexor,venlafaxine hydrochloride,Wyeth-Ayerst,NDA,20151,NA,NA,Tablet,Oral,NA,NA,NA,NA,4/26/1991,12/28/1993,1993,treatment of depression,NA,Standard,No,No,N/A,N/A,N/A,N/A,N/A,NA,1991-04-26,1993-12-28,977,6.884486652042782,Early-PDUFA
Kytril,granisetron hydrochloride,SmithKline Beecham,NDA,20239,NA,NA,Injectable,Injection,NA,NA,NA,NA,4/14/1992,12/29/1993,1993,"prevention of nausea and/or vomiting associated with initial and repeat courses of emetogenic cancer therapy, including high-dose cisplatin",NA,Standard,No,No,N/A,N/A,N/A,N/A,N/A,NA,1992-04-14,1993-12-29,624,6.436150368369428,Early-PDUFA
Trasylol,aprotinin,Miles,BLA,20304,NA,NA,Injectable,Injection,NA,NA,NA,NA,11/24/1992,12/29/1993,1993,"prophylactic use to reduce perioperative blood loss and the homologous blood transfusion requirement in patients undergoing cardiopulmonary bypass surgery in the course of repeat coronary artery bypass graft surgery, and in selected cases
of primary coronary artery bypass graft surgery where the risk of bleeding is especially high (impaired hemostasis) or where transfusion is unavailable or unacceptable",NA,Priority,Yes,No,N/A,N/A,N/A,N/A,N/A,Transition Product from NDA to BLA due to BPCI : Please see page 2 of data dictionary for more information.,1992-11-24,1993-12-29,400,5.991464547107982,Early-PDUFA
Dovonex,calcipotriene,Bristol-Myers,NDA,20273,NA,NA,Ointment,Topical,NA,NA,NA,NA,3/31/1992,12/29/1993,1993,treatment of moderate plaque psoriasis,NA,Standard,No,No,N/A,N/A,N/A,N/A,N/A,NA,1992-03-31,1993-12-29,638,6.45833828334479,Early-PDUFA
Risperdal,risperidone,Janssen,NDA,20272,NA,NA,Tablet,Oral,NA,NA,NA,NA,4/15/1992,12/29/1993,1993,management of the manifestations of psychotic disorders,NA,Priority,No,No,N/A,N/A,N/A,N/A,N/A,NA,1992-04-15,1993-12-29,623,6.434546518787453,Early-PDUFA
Pulmozyme,dornase alfa,Genentech,BLA,103532,NA,NA,"Aerosol, Metered",Inhalation,NA,NA,NA,NA,3/29/1993,12/30/1993,1993,management of cystic fibrosis patients to reduce the frequency of respiratory infections requiring parenteral antibiotics and to improve pulmonary function,NA,Priority,Yes,No,N/A,N/A,N/A,N/A,N/A,NA,1993-03-29,1993-12-30,276,5.62040086571715,Early-PDUFA
Neurontin,gabapentin,Parke-Davis,NDA,20235,NA,NA,Capsule,Oral,NA,NA,NA,NA,1/31/1992,12/30/1993,1993,indicated as adjunctive therapy in the treatment of partial seizures with and without secondary generalization in adults with epilepsy,NA,Priority,No,No,N/A,N/A,N/A,N/A,N/A,NA,1992-01-31,1993-12-30,699,6.54965074223381,Early-PDUFA
Aceon,perindopril erbumine,RW Johnson Pharmaceutical Development,NDA,20184,NA,NA,Tablet,Oral,NA,NA,NA,NA,6/28/1991,12/30/1993,1993,treatment of patients with essential hypertension,NA,Standard,No,No,N/A,N/A,N/A,N/A,N/A,NA,1991-06-28,1993-12-30,916,6.82001636467413,Early-PDUFA
Lipidil,fenofibrate,Fournier,NDA,19304,NA,NA,Capsule,Oral,NA,NA,NA,NA,6/4/1984,12/31/1993,1993,adjunctive therapy to diet for treatment of adult patients with very high elevations of serum triglyceride levels (types IV and V hyperlipidemia) who are at risk of pancreatitis and who do not respond adequately to a determined dietary effort to control them,NA,Standard,No,No,N/A,N/A,N/A,N/A,N/A,NA,1984-06-04,1993-12-31,3497,8.159660737063376,Early-PDUFA
Lescol,fluvastatin sodium,Sandoz,NDA,20261,NA,NA,Capsule,Oral,NA,NA,NA,NA,3/31/1992,12/31/1993,1993,as an adjunct to diet in the treatment of elevated total cholesterol (total-C) and LDL-C levels in patients with primary hypercholesteremia (type IIa and IIb) whose response to dietary restriction of saturated fat and cholesterol and other non-pharmacological measures has not been adequate,NA,Standard,No,No,N/A,N/A,N/A,N/A,N/A,NA,1992-03-31,1993-12-31,640,6.461468176353717,Early-PDUFA
Oncaspar,pegaspargase,Enzon,BLA,103411,NA,NA,Injectable,Injection,NA,NA,NA,NA,1/15/1991,2/1/1994,1994,Treatment of acute lymphocytic leukemia (ALL) in patients who require L-asparaginase in their treatment regimen but have developed hypersensitivity to the native forms of L-asparaginase,NA,Standard,Yes,No,N/A,N/A,N/A,N/A,N/A,NA,1991-01-15,1994-02-01,1113,7.014814351275545,Early-PDUFA
Serevent,salmeterol xinafoate,Glaxo,NDA,20236,NA,NA,"Aerosol, Metered",Inhalation,NA,NA,NA,NA,12/20/1991,2/4/1994,1994,maintenance treatment of asthma and prevention of bronchospasm in patients 12 years old and above,NA,Priority,No,No,N/A,N/A,N/A,N/A,N/A,NA,1991-12-20,1994-02-04,777,6.655440350367647,Early-PDUFA
Rhinocort,budesonide,GH Besselaar,NDA,20233,NA,NA,"Aerosol, Metered",Nasal,NA,NA,NA,NA,12/31/1992,2/14/1994,1994,management of symptoms of seasonal or perennial allergic rhinitis in adults and children and nonallergic perennial rhinitis in adults,NA,Standard,No,No,N/A,N/A,N/A,N/A,N/A,NA,1992-12-31,1994-02-14,410,6.016157159698354,Early-PDUFA
Zemuron,rocuronium bromide,Organon,NDA,20214,NA,NA,Injectable,Injection,NA,NA,NA,NA,6/29/1993,3/17/1994,1994,"indicated for inpatients and outpatients as an adjunct to general anesthesia to facilitate both rapid sequence and routine tracheal intubation, and to provide skeletal muscle relaxation during surgery or mechanical ventilation",NA,Standard,No,No,N/A,N/A,N/A,N/A,N/A,NA,1993-06-29,1994-03-17,261,5.564520407322694,Early-PDUFA
Semprex-D,"acrivastine, pseudoephedrine hydrochloride",Burroughs Wellcome,NDA,19806,NA,NA,Capsule,Oral,NA,NA,NA,NA,12/29/1987,3/25/1994,1994,"indicated for relief of symptoms associated with seasonal allergic rhinitis such as sneezing, rhinorrhea, pruritus, lacrimation, and nasal congestion",NA,Standard,No,No,N/A,N/A,N/A,N/A,N/A,NA,1987-12-29,1994-03-25,2278,7.731053144007127,Early-PDUFA
[drug marketed without a proprietary name],iobenguane sulfate I 131,CIS US,NDA,20084,NA,NA,Injectable,Injection,NA,NA,NA,NA,11/15/1991,3/25/1994,1994,indicated as an adjunctive diagnostic agent in the localization of primary or metastatic pheochromocytomas and neuroblastomas,NA,Priority,No,No,N/A,N/A,N/A,N/A,N/A,NA,1991-11-15,1994-03-25,861,6.7580945044277305,Early-PDUFA
Prograf,tacrolimus,Fujisawa,NDA,50708,50709,NA,Capsule,Oral,Injectable,Injection,NA,NA,7/26/1993,4/8/1994,1994,indicated for the prophylaxis of organ rejection in patients receiving allogeneic liver transplants,NA,Priority,No,No,N/A,N/A,N/A,N/A,N/A,NA,1993-07-26,1994-04-08,256,5.545177444479562,Early-PDUFA
Cerezyme,imiglucerase,Genzyme,BLA,20367,NA,NA,Injectable,Injection,NA,NA,NA,NA,5/21/1993,5/23/1994,1994,"indicated for long-term enzyme replacement therapy for patients with a confirmed diagnosis of Type 1 Gaucher disease that results in one or more of the following conditions: anemia, thrombocytopenia, bone disease, hepatomegaly, or splenomegaly",NA,Priority,Yes,No,N/A,N/A,N/A,N/A,N/A,Transition Product from NDA to BLA due to BPCI : Please see page 2 of data dictionary for more information.,1993-05-21,1994-05-23,367,5.905361848054571,Early-PDUFA
Octreoscan,indium In 111 pentetreotide,Mallinckrodt Medical,NDA,20314,NA,NA,Injectable,Injection,NA,NA,NA,NA,10/23/1992,6/2/1994,1994,for the scintigraphic localization of primary and metastatic neuroendocrine tumors bearing somatostatin receptors,NA,Priority,No,No,N/A,N/A,N/A,N/A,N/A,NA,1992-10-23,1994-06-02,587,6.375024819828097,Early-PDUFA
Zerit,stavudine,Bristol-Myers Squibb,NDA,20412,NA,NA,Capsule,Oral,NA,NA,NA,NA,12/28/1993,6/24/1994,1994,indicated for the treatment of adults with advanced HIV infection who are intolerant of approved therapies with proven clinical benefit or who have experienced significant clinical or immunologic deterioration while receiving these therapies or for whom such therapies are contraindicated,NA,Priority,No,Yes,N/A,N/A,N/A,N/A,N/A,NA,1993-12-28,1994-06-24,178,5.181783550292085,Early-PDUFA
Famvir,famciclovir,SmithKline Beecham,NDA,20363,NA,NA,Tablet,Oral,NA,NA,NA,NA,6/30/1993,6/29/1994,1994,management of acute herpes zoster (shingles),NA,Standard,No,No,N/A,N/A,N/A,N/A,N/A,NA,1993-06-30,1994-06-29,364,5.8971538676367405,Early-PDUFA
Cystagon,cysteamine bitartrate,Mylan,NDA,20392,NA,NA,Capsule,Oral,NA,NA,NA,NA,11/23/1993,8/15/1994,1994,indicated for the management of nephropathic cystinosis in children and adults,NA,Priority,Yes,No,N/A,N/A,N/A,N/A,N/A,NA,1993-11-23,1994-08-15,265,5.579729825986222,Early-PDUFA
[drug marketed without a proprietary name],fludeoxyglucose F 18,Downstate Clinical Center,NDA,20306,NA,NA,Injectable,Injection,NA,NA,NA,NA,1/19/1993,8/19/1994,1994,indicated in positron emission tomography for the identification of regions of abnormal glucose metabolism associated with foci of epileptic seizures,NA,Priority,No,No,N/A,N/A,N/A,N/A,N/A,NA,1993-01-19,1994-08-19,577,6.3578422665081,Early-PDUFA
Neurolite,technetium Tc-99m bicisate,Dupont Merck,NDA,20256,NA,NA,Injectable,Injection,NA,NA,NA,NA,3/6/1992,11/23/1994,1994,indicated as an adjunct to conventional CT or MRI imaging in the localization of stroke in patients in whom stroke has already been diagnosed,NA,Standard,No,No,N/A,N/A,N/A,N/A,N/A,NA,1992-03-06,1994-11-23,992,6.899723107284872,Early-PDUFA
Luvox,fluvoxamine maleate,Solvay,NDA,20243,NA,NA,Tablet,Oral,NA,NA,NA,NA,12/30/1991,12/5/1994,1994,treatment of obsessions and compulsions in patients with obsessive-compulsive disorder,NA,Standard,No,No,N/A,N/A,N/A,N/A,N/A,NA,1991-12-30,1994-12-05,1071,6.976348070447749,Early-PDUFA
Trusopt,dorzolamide hydrochloride,Merck,NDA,20408,NA,NA,Solution/Drops,Ophthalmic,NA,NA,NA,NA,12/10/1993,12/9/1994,1994,treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma,NA,Priority,No,No,N/A,N/A,N/A,N/A,N/A,NA,1993-12-10,1994-12-09,364,5.8971538676367405,Early-PDUFA
Fragmin,dalteparin sodium,Pharmacia,NDA,20287,NA,NA,Injectable,Subcutaneous,NA,NA,NA,NA,12/30/1992,12/22/1994,1994,prophylaxis against deep vein thrombosis (DVT) which may lead to pulmonary embolism (PE) in patients undergoing abdominal surgery who are at risk for thromboembolic complications,NA,Standard,No,No,N/A,N/A,N/A,N/A,N/A,NA,1992-12-30,1994-12-22,722,6.582025138892826,Early-PDUFA
ReoPro,abciximab,Centocor,BLA,103575,NA,NA,Injectable,Injection,NA,NA,NA,NA,12/16/1993,12/22/1994,1994,indicated as an adjunct to percutaneous transluminal coronary angioplasty or atherectomy (PTCA) for the prevention of acute cardiac ischemic complications in patients at high risk for abrupt closure of the treated coronary vessel,NA,Priority,No,No,N/A,N/A,N/A,N/A,N/A,NA,1993-12-16,1994-12-22,371,5.916202062607435,Early-PDUFA
Serzone,nefazodone hydrochloride,Bristol-Myers,NDA,20152,NA,NA,Tablet,Oral,NA,NA,NA,NA,9/6/1991,12/22/1994,1994,treatment of depression,NA,Standard,No,No,N/A,N/A,N/A,N/A,N/A,NA,1991-09-06,1994-12-22,1203,7.0925737159746784,Early-PDUFA
Navelbine,vinorelbine tartrate,Burroughs Wellcome,NDA,20388,NA,NA,Injectable,Injection,NA,NA,NA,NA,8/27/1993,12/23/1994,1994,"as a single agent or in combination with cisplatin for the first-line treatment of ambulatory patients with unresectable, advanced non-small cell lung cancer (NSCLC)",NA,Priority,No,No,N/A,N/A,N/A,N/A,N/A,NA,1993-08-27,1994-12-23,483,6.180016653652572,Early-PDUFA
Lamictal,lamotrigine,Burroughs Wellcome,NDA,20241,NA,NA,Tablet,Oral,NA,NA,NA,NA,3/23/1992,12/27/1994,1994,indicated as adjunctive therapy in the treatment of partial seizures in adults with epilepsy,NA,Priority,No,No,N/A,N/A,N/A,N/A,N/A,NA,1992-03-23,1994-12-27,1009,6.9167150203536085,Early-PDUFA
Renormax,spirapril hydrochloride,Sandoz,NDA,20240,NA,NA,Tablet,Oral,NA,NA,NA,NA,12/31/1991,12/29/1994,1994,treatment of hypertension,NA,Standard,No,No,N/A,N/A,N/A,N/A,N/A,NA,1991-12-31,1994-12-29,1094,6.9975959829819265,Early-PDUFA
Vexol,rimexalone,Alcon,NDA,20474,NA,NA,Suspension/Drops,Ophthalmic,NA,NA,NA,NA,6/1/1994,12/30/1994,1994,treatment of postoperative inflammation following ocular surgery and in the treatment of anterior uveitis,NA,Priority,No,No,N/A,N/A,N/A,N/A,N/A,NA,1994-06-01,1994-12-30,212,5.356586274672012,Early-PDUFA
Sular,nisoldipine,Miles,NDA,20356,NA,NA,"Tablet, Extended Release",Oral,NA,NA,NA,NA,4/1/1993,2/2/1995,1995,treatment of hypertension,NA,Standard,No,No,N/A,N/A,N/A,N/A,N/A,NA,1993-04-01,1995-02-02,672,6.5102583405231496,Early-PDUFA
Ultram,tramadol hydrochloride,RW Johnson,NDA,20281,NA,NA,Tablet,Oral,NA,NA,NA,NA,11/18/1993,3/3/1995,1995,management of moderate to moderately severe pain,NA,Standard,No,No,N/A,N/A,N/A,N/A,N/A,NA,1993-11-18,1995-03-03,470,6.152732694704104,Early-PDUFA
Glucophage,metformin hydrochloride,Lipha,NDA,20357,NA,NA,Tablet,Oral,NA,NA,NA,NA,9/29/1993,3/3/1995,1995,indicated as an adjunct to diet to lower blood glucose in patients with non-insulin-dependent diabetes mellitus whose hyperglycemia cannot be satisfactorily managed on diet alone,NA,Priority,No,No,N/A,N/A,N/A,N/A,N/A,NA,1993-09-29,1995-03-03,520,6.253828811575473,Early-PDUFA
Cozaar,losartan potassium,Merck,NDA,20386,NA,NA,Tablet,Oral,NA,NA,NA,NA,12/3/1993,4/14/1995,1995,treatment of hypertension,NA,Standard,No,No,N/A,N/A,N/A,N/A,N/A,NA,1993-12-03,1995-04-14,497,6.208590026096629,Early-PDUFA
Revex,nalmefene hydrochloride,Ohmeda,NDA,20459,NA,NA,Injectable,Injection,NA,NA,NA,NA,4/29/1994,4/17/1995,1995,"indicated for the complete or partial reversal of opioid drug effects, including respiratory depression, induced by either natural or synthetic opioids, and in the management of known or suspected opioid overdose",NA,Standard,No,No,N/A,N/A,N/A,N/A,N/A,NA,1994-04-29,1995-04-17,353,5.8664680569332965,Early-PDUFA
Univasc,moexipril hydrochloride,Schwarz Pharma,NDA,20312,NA,NA,Tablet,Oral,NA,NA,NA,NA,12/18/1992,4/19/1995,1995,treatment of hypertension,NA,Standard,No,No,N/A,N/A,N/A,N/A,N/A,NA,1992-12-18,1995-04-19,852,6.747586526829315,Early-PDUFA
Cellcept,mycophenolate mofetil,Syntex,NDA,50722,NA,NA,Capsule,Oral,NA,NA,NA,NA,11/10/1994,5/3/1995,1995,prophylaxis of organ rejection in patients receiving allogeneic renal transplants,NA,Priority,No,No,N/A,N/A,N/A,N/A,N/A,NA,1994-11-10,1995-05-03,174,5.159055299214529,Early-PDUFA
Prevacid,lansoprazole,TAP Holdings,NDA,20406,NA,NA,"Capsule, Delayed Release Pellets",Oral,NA,NA,NA,NA,11/15/1993,5/10/1995,1995,short-term treatment (up to four weeks) for healing and symptom relief of active duodenal ulcer; short-term treatment (up to eight weeks) for healing and symptom relief of all grades of erosive esophagitis; long-term treatment of pathological hypersecretory conditions including Zollinger-Ellison syndrome,NA,Standard,No,No,N/A,N/A,N/A,N/A,N/A,NA,1993-11-15,1995-05-10,541,6.293419278846481,Early-PDUFA
Ultravist,iopromide,Berlex Laboratories,NDA,20220,NA,NA,Injectable,Injection,NA,NA,NA,NA,3/2/1992,5/10/1995,1995,"intra-arterial Ultravist is indicated for intra-arterial digital subtraction angiography, cerebral arteriography, and peripheral arteriography, and coronary arteriography and left ventriculography, visceral angiography, and aortography; intravenous Ultravist is indicated for peripheral venography and for contrast enhanced computed tomographic (CECT) imaging of the head and body, and excretory urography",NA,Standard,No,No,N/A,N/A,N/A,N/A,N/A,NA,1992-03-02,1995-05-10,1164,7.059617628291383,Early-PDUFA
Zinecard,dexrazoxane,Pharmacia,NDA,20212,NA,NA,Injectable,Injection,NA,NA,NA,NA,2/10/1992,5/26/1995,1995,"for reducing the incidence and severity of cardiomyopathy associated with doxorubicin administration in women with metastatic breast cancer who have received a cumulative dose of 300 mg/m2 and who, in their physician's opinion, would benefit from continuing therapy with doxorubicin",NA,Priority,Yes,Yes,N/A,N/A,N/A,N/A,N/A,NA,1992-02-10,1995-05-26,1201,7.0909098220799835,Early-PDUFA
Ultane,sevoflurane,Abbott Laboratories,NDA,20478,NA,NA,Liquid,Inhalation,NA,NA,NA,NA,7/11/1994,6/7/1995,1995,induction and maintenance of general anesthesia in adult and pediatric patients for inpatient and outpatient surgery,NA,Standard,No,No,N/A,N/A,N/A,N/A,N/A,NA,1994-07-11,1995-06-07,331,5.802118375377063,Early-PDUFA
Dynabac,dirithromycin,Lilly,NDA,50678,NA,NA,"Tablet, Delayed Release",Oral,NA,NA,NA,NA,4/29/1993,6/19/1995,1995,"treatment of individuals 12 years of age or older with mild-to-moderate infections caused by susceptible strains of designated microorganisms in the following specific conditions: acute bacterial exacerbation of chronic bronchitis, secondary bacterial infection of acute bronchitis, community-acquired pneumonia, pharyngitis/tonsillitis, uncomplicated skin and skin structure infections,",NA,Standard,No,No,N/A,N/A,N/A,N/A,N/A,NA,1993-04-29,1995-06-19,781,6.660575149839686,Early-PDUFA
Precose,acarbose,Bayer,NDA,20482,NA,NA,Tablet,Oral,NA,NA,NA,NA,9/6/1994,9/6/1995,1995,adjunct to diet to lower blood glucose in patients with non-insulin-dependent diabetes mellitus whose hyperglycemia cannot be managed alone.  It may also be used in combination with a sulfonylurea when diet plus Precose or a sulfonurea do not result in adequate glycemic control,NA,Standard,No,No,N/A,N/A,N/A,N/A,N/A,NA,1994-09-06,1995-09-06,365,5.8998973535824915,Early-PDUFA
Azelex,azelaic acid,Allergan,NDA,20428,NA,NA,Cream,Topical,NA,NA,NA,NA,2/28/1994,9/13/1995,1995,treatment of mild-to-moderate inflammatory acne vulgaris,NA,Standard,No,No,N/A,N/A,N/A,N/A,N/A,NA,1994-02-28,1995-09-13,562,6.331501849893691,Early-PDUFA
Coreg,carvedilol,SmithKline Beecham,NDA,20297,NA,NA,Tablet,Oral,NA,NA,NA,NA,3/31/1993,9/14/1995,1995,treatment of hypertension,NA,Standard,No,No,N/A,N/A,N/A,N/A,N/A,NA,1993-03-31,1995-09-14,897,6.799055862058796,Early-PDUFA
Flolan,epoprostenol sodium,Burroughs Wellcome,NDA,20444,NA,NA,Injectable,Injection,NA,NA,NA,NA,2/28/1994,9/20/1995,1995,long-term intravenous treatment of primary pulmonary hypertension and pulmonary hypertension in NYHA Class III and Class IV patients,NA,Priority,Yes,No,N/A,N/A,N/A,N/A,N/A,NA,1994-02-28,1995-09-20,569,6.343880434126331,Early-PDUFA
Eprex,epoetin alfa,Johnson & Johnson,BLA,103310,NA,NA,Injectable,Injection,NA,NA,NA,NA,2/28/1989,9/29/1995,1995,"indicated for the treatment of anemia associated with chronic renal  failure, including patients on dialysis (ESRD) and patients not on dialysis",NA,Priority,No,No,N/A,N/A,N/A,N/A,N/A,Biologic product assigned new license number and now referenced by BLA 103839,1989-02-28,1995-09-29,2404,7.784889295655098,Early-PDUFA
Fosamax,alendronate sodium,Merck,NDA,20560,NA,NA,Tablet,Oral,NA,NA,NA,NA,3/31/1995,9/29/1995,1995,treatment of osteoporosis in postmenopausal women; treatment of Paget's disease of the bone.,NA,Priority,No,No,N/A,N/A,N/A,N/A,N/A,NA,1995-03-31,1995-09-29,182,5.204006687076795,Early-PDUFA
Casodex,bicalutamide,Zeneca,NDA,20498,NA,NA,Tablet,Oral,NA,NA,NA,NA,9/14/1994,10/4/1995,1995,use in combination therapy with a luteinizing-hormone releasing hormone (LHRH) analogue for the treatment of advanced prostate cancer,NA,Standard,No,Yes,N/A,N/A,N/A,N/A,N/A,NA,1994-09-14,1995-10-04,385,5.953243334287785,Early-PDUFA
Epivir,lamivudine,Glaxo Wellcome,NDA,20564,20596,NA,Tablet,Oral,Solution,Oral,NA,NA,7/7/1995,11/17/1995,1995,in combination with Retrovir (zidovudine) for the treatment of HIV infection when therapy is warranted based on clinical and/or immunological evidence of disease progression,NA,Priority,No,Yes,N/A,N/A,N/A,N/A,N/A,NA,1995-07-07,1995-11-17,133,4.890349128221754,Early-PDUFA
Amaryl,glimepiride,Hoechst-Roussel,NDA,20496,NA,NA,Tablet,Oral,NA,NA,NA,NA,8/30/1994,11/30/1995,1995,indicated as an adjunct to diet and exercise to lower blood glucose levels in patients with noninsulin-dependent (Type 2) diabetes mellitus (NIDDM) whose hyperglycemia cannot be controlled by diet and exercise alone; in combination with insulin to lower the blood glucose in patients whose hyperglycemia cannot be controlled by diet and exercise in conjunction with an oral hypoglycemic agent,NA,Standard,No,No,N/A,N/A,N/A,N/A,N/A,NA,1994-08-30,1995-11-30,457,6.124683390894205,Early-PDUFA
Invirase,saquinavir,Roche,NDA,20628,NA,NA,Capsule,Oral,NA,NA,NA,NA,8/31/1995,12/6/1995,1995,in combination with nucleoside analogues for the treatment of advanced HIV infection in selected patients,NA,Priority,No,Yes,N/A,N/A,N/A,N/A,N/A,NA,1995-08-31,1995-12-06,97,4.574710978503383,Early-PDUFA
Ethyol,amifostine,US Bioscience,NDA,20221,NA,NA,Injectable,Injection,NA,NA,NA,NA,9/30/1991,12/8/1995,1995,indicated to reduce the cumulative renal toxicity associated with repeated administration of cisplatin in patients with advanced ovarian cancer,NA,Priority,Yes,No,N/A,N/A,N/A,N/A,N/A,NA,1991-09-30,1995-12-08,1530,7.333023014386481,Early-PDUFA
Zyrtec,cetirizine,Pfizer,NDA,19835,NA,NA,Tablet,Oral,NA,NA,NA,NA,7/1/1988,12/8/1995,1995,"relief of symptoms associated with seasonal allergic rhinitis, perennial allergic rhinitis, and chronic urticaria",NA,Standard,No,No,N/A,N/A,N/A,N/A,N/A,NA,1988-07-01,1995-12-08,2716,7.906915488678587,Early-PDUFA
Rilutek,riluzole,Rhone-Poulenc,NDA,20599,NA,NA,Tablet,Oral,NA,NA,NA,NA,6/29/1995,12/12/1995,1995,treatment of patients with amyotrophic lateral sclerosis (ALS),NA,Priority,Yes,No,N/A,N/A,N/A,N/A,N/A,NA,1995-06-29,1995-12-12,166,5.111987788356544,Early-PDUFA
Cedax,ceftibuten,Schering Plough,NDA,50685,50686,NA,Capsule,Oral,Suspension,Oral,NA,NA,12/20/1991,12/20/1995,1995,"indicated for the treatment of individuals with mild-to-moderate infections caused by susceptible strains of designated microorganisms in the following conditions: acute bacterial exacerbations of chronic bronchitis, acute bacterial otitis media, pharyngitis and tonsillitis",NA,Standard,No,No,N/A,N/A,N/A,N/A,N/A,NA,1991-12-20,1995-12-20,1461,7.2868764117507,Early-PDUFA
Oxilan,ioxilan,Cook Imaging,NDA,20316,NA,NA,Injectable,Injection,NA,NA,NA,NA,12/4/1992,12/21/1995,1995,"indicated for intra-arterial use in cerebral arteriography, coronary arteriography and left ventriculography, visceral angiography, aortography and peripheral arteriography;  indicated for intravenous use in excretory urography and contrast enhanced computed tomographic imaging of the head and body",NA,Standard,No,No,N/A,N/A,N/A,N/A,N/A,NA,1992-12-04,1995-12-21,1112,7.013915474810528,Early-PDUFA
Photofrin,porfimer sodium,QLT Phototherapeutics,NDA,20451,NA,NA,Injectable,Injection,NA,NA,NA,NA,4/13/1994,12/27/1995,1995,"palliation of patients with completely obstructing esophageal cancer, or of patients with partially obstructing esophageal cancer who, in the opinion of their physician, cannot be satisfactorily treated with Nd:YAG laser therapy",NA,Priority,Yes,No,N/A,N/A,N/A,N/A,N/A,NA,1994-04-13,1995-12-27,623,6.434546518787453,Early-PDUFA
Arimidex,anastrozole,Zeneca,NDA,20541,NA,NA,Tablet,Oral,NA,NA,NA,NA,3/29/1995,12/27/1995,1995,treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy,NA,Standard,No,No,N/A,N/A,N/A,N/A,N/A,NA,1995-03-29,1995-12-27,273,5.60947179518496,Early-PDUFA
Corvert,ibutilide fumurate,Upjohn,NDA,20491,NA,NA,Injectable,Injection,NA,NA,NA,NA,10/28/1994,12/28/1995,1995,indicated for the rapid conversion of atrial fibrillation or atrial flutter of recent onset to sinus rhythm,NA,Standard,No,No,N/A,N/A,N/A,N/A,N/A,NA,1994-10-28,1995-12-28,426,6.054439346269371,Early-PDUFA
Maxipime,cefepime hydrochloride,Bristol-Myers Squibb,NDA,50679,NA,NA,Injectable,Injection,NA,NA,NA,NA,7/1/1992,1/18/1996,1996,"indicated in the treatment of the following infections when caused by susceptible strains of designated microorganisms: uncomplicated and complicated urinary tract infections, including pyelonephritis; uncomplicated skin and skin structure infections; pneumonia",NA,Standard,No,No,N/A,N/A,N/A,N/A,N/A,NA,1992-07-01,1996-01-18,1296,7.16703787691222,Early-PDUFA
Myoview,technetium Tc-99m tetrofosmin,Medi Physics,NDA,20372,NA,NA,Injectable,Injection,NA,NA,NA,NA,6/7/1993,2/9/1996,1996,indicated for scientific imaging of the myocardium following separate administrations under exercise and resting conditions to enhance the delineation of regions of reversible myocardial ischemia in the presence or absence of infarcted myocardium,NA,Standard,No,No,N/A,N/A,N/A,N/A,N/A,NA,1993-06-07,1996-02-09,977,6.884486652042782,Early-PDUFA
Norvir,ritonavir,Abbott Laboratories,NDA,20659,20680,NA,Solution,Oral,Capsule,Oral,NA,NA,12/21/1995,3/1/1996,1996,in combination with nucleoside analogues or as monotherapy for the treatment of HIV infection when therapy is warranted,NA,Priority,No,Yes,N/A,N/A,N/A,N/A,N/A,NA,1995-12-21,1996-03-01,71,4.2626798770413155,Early-PDUFA
Crixivan,indinavir sulfate,Merck,NDA,20685,NA,NA,Capsule,Oral,NA,NA,NA,NA,1/31/1996,3/13/1996,1996,treatment of HIV infection in adults when antiretroviral therapy is warranted,NA,Priority,No,Yes,N/A,N/A,N/A,N/A,N/A,NA,1996-01-31,1996-03-13,42,3.7376696182833684,Early-PDUFA
Visipaque,iodixanol,Nycomed,NDA,20351,NA,NA,Injectable,Injection,NA,NA,NA,NA,3/5/1993,3/22/1996,1996,"indicated for intra-arterial use in visceral intra-arterial digital subtraction angiography, angiocardiography (left ventriculography and selective coronary arteriography), peripheral arteriography, visceral arteriography, cerebral arteriography; indicated for intravenous use in contrast enhancement computed tomography imaging of the head and body, excretory urography, and peripheral venography",NA,Standard,No,No,N/A,N/A,N/A,N/A,N/A,NA,1993-03-05,1996-03-22,1113,7.014814351275545,Early-PDUFA
Mavik,trandolapril,Knoll,NDA,20528,NA,NA,Tablet,Oral,NA,NA,NA,NA,9/29/1994,4/26/1996,1996,treatment of hypertension,NA,Standard,No,No,N/A,N/A,N/A,N/A,N/A,NA,1994-09-29,1996-04-26,575,6.354370040797351,Early-PDUFA
Buphenyl,sodium phenylbutyrate,Ucyclyd,NDA,20573,NA,NA,Powder,Oral,NA,NA,NA,NA,2/17/1995,4/30/1996,1996,"indicated as adjunctive therapy in the chronic management of patients with urea cycle disorders involving deficiencies of carbamylphosphate synthetase, ornithine transcarbamylase or argininosuccinic acid synthetase",NA,Priority,Yes,No,N/A,N/A,N/A,N/A,N/A,NA,1995-02-17,1996-04-30,438,6.082218910376446,Early-PDUFA
Taxotere,docetaxel,Rhone-Poulenc,NDA,20449,NA,NA,Injectable,Injection,NA,NA,NA,NA,7/27/1994,5/14/1996,1996,treatment of patients with locally advanced or metastatic breast cancer who have progressed during anthracycline-based therapy or have relapsed during anthracycline-based adjuvant therapy,NA,Priority,No,Yes,N/A,N/A,N/A,N/A,N/A,NA,1994-07-27,1996-05-14,657,6.48768401848461,Early-PDUFA
Gemzar,gemcitabine hydrochloride,Lilly,NDA,20509,NA,NA,Injectable,Injection,NA,NA,NA,NA,2/2/1995,5/15/1996,1996,first-line treatment for patients with locally advanced (nonresectable stage II or III) or metastatic (stage IV) adenocarcinoma of the pancreas; also indicated for patients previously treated with 5-fluorouracil,NA,Priority,No,No,N/A,N/A,N/A,N/A,N/A,NA,1995-02-02,1996-05-15,468,6.148468295917647,Early-PDUFA
Avonex,interferon beta-1a,Biogen,BLA,103628,NA,NA,Injectable,Injection,NA,NA,NA,NA,5/22/1995,5/17/1996,1996,indicated for the treatment of relapsing forms of multiple sclerosis to slow the accumulation of physical disability and decrease the frequency of clinical exacerbations,NA,Priority,Yes,No,N/A,N/A,N/A,N/A,N/A,NA,1995-05-22,1996-05-17,361,5.8888779583328805,Early-PDUFA
Acthrel,corticorelin ovine triflutate,Ferring Pharmaceuticals,BLA,20162,NA,NA,Injectable,Injection,NA,NA,NA,NA,2/19/1991,5/23/1996,1996,indicated for use in differentiating pituitary and ectopic production of ACTH in patients with ACTH-dependent Cushing’s syndrome,NA,Priority,Yes,No,N/A,N/A,N/A,N/A,N/A,Transition Product from NDA to BLA due to BPCI : Please see page 2 of data dictionary for more information.,1991-02-19,1996-05-23,1920,7.560080465021827,Early-PDUFA
Hycamtin,topotecan hydrochloride,SmithKline Beecham,NDA,20671,NA,NA,Injectable,Injection,NA,NA,NA,NA,12/22/1995,5/28/1996,1996,treatment of patients with metastatic carcinoma of the ovary after failure of initial or subsequent chemotherapy,NA,Priority,No,No,N/A,N/A,N/A,N/A,N/A,NA,1995-12-22,1996-05-28,158,5.062595033026967,Early-PDUFA
Differin,adapalene,Galderma,NDA,20338,20380,NA,Solution,Topical,Gel,Topical,NA,NA,3/26/1993,5/31/1996,1996,indicated for the topical treatment of acne vulgaris,NA,Standard,No,No,N/A,N/A,N/A,N/A,N/A,NA,1993-03-26,1996-05-31,1162,7.057897937411856,Early-PDUFA
Xalatan,latanoprost,Pharmacia and Upjohn,NDA,20597,NA,NA,Solution/Drops,Ophthalmic,NA,NA,NA,NA,6/16/1995,6/5/1996,1996,indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma and/or ocular hypertension who were intolerant of other IOP-lowering medications or insufficiently responsive (failed to achieve target IOP determined after multiple measurements over time) to another IOP-lowering medication,NA,Priority,No,No,N/A,N/A,N/A,N/A,N/A,NA,1995-06-16,1996-06-05,355,5.872117789475416,Early-PDUFA
Albenza,albendazole,SmithKline Beecham,NDA,20666,NA,NA,Tablet,Oral,NA,NA,NA,NA,12/11/1995,6/11/1996,1996,"indicated for the treatment of parenchymal neurocysticercosis due to active lesions caused by larval forms of the pork tapeworm, Taenia solium; also indicated for the treatment of cystic hydatid disease of the liver, lung, and peritoneum, caused by the larval form of the dog tapeworm, Echinococcus granulosus",NA,Priority,Yes,No,N/A,N/A,N/A,N/A,N/A,NA,1995-12-11,1996-06-11,183,5.209486152841421,Early-PDUFA
Humalog,lispro insulin,Lilly,BLA,20563,NA,NA,Injectable,Injection,NA,NA,NA,NA,3/14/1995,6/14/1996,1996,treatment of diabetes mellitus in patients requiring insulin,NA,Standard,No,No,N/A,N/A,N/A,N/A,N/A,Transition Product from NDA to BLA due to BPCI : Please see page 2 of data dictionary for more information.,1995-03-14,1996-06-14,458,6.126869184114185,Early-PDUFA
Camptosar,irinotecan hydrochloride,Pharmacia and Upjohn,NDA,20571,NA,NA,Injectable,Injection,NA,NA,NA,NA,12/28/1995,6/14/1996,1996,treatment of patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following 5-FU-based therapy,NA,Priority,No,Yes,N/A,N/A,N/A,N/A,N/A,NA,1995-12-28,1996-06-14,169,5.1298987149230735,Early-PDUFA
Remeron,mirtazapine,Organon,NDA,20415,NA,NA,Tablet,Oral,NA,NA,NA,NA,1/30/1995,6/14/1996,1996,treatment of depression,NA,Standard,No,No,N/A,N/A,N/A,N/A,N/A,NA,1995-01-30,1996-06-14,501,6.2166061010848646,Early-PDUFA
Merrem,meropenem,Zeneca,NDA,50706,NA,NA,Injectable,Injection,NA,NA,NA,NA,11/30/1993,6/21/1996,1996,indicated as single agent therapy for the treatment of the following infections when caused by susceptible strains of the designated microorganisms: complicated intra-abdominal infections (appendicitis and peritonitis); pediatric bacterial meningitis,NA,Standard,No,No,N/A,N/A,N/A,N/A,N/A,NA,1993-11-30,1996-06-21,934,6.839476438228843,Early-PDUFA
Viramune,nevirapine,Boehringer Ingelheim Pharmaceuticals,NDA,20636,NA,NA,Tablet,Oral,NA,NA,NA,NA,2/23/1996,6/21/1996,1996,indicated for use in combination with nucleoside analogues to treat adults with HIV infection who have experienced clinical and/or immunological deterioration,NA,Priority,No,Yes,N/A,N/A,N/A,N/A,N/A,NA,1996-02-23,1996-06-21,119,4.77912349311153,Early-PDUFA
Vistide,cidofovir,Gilead Sciences,NDA,20638,NA,NA,Injectable,Injection,NA,NA,NA,NA,10/4/1995,6/26/1996,1996,treatment of cytomegalovirus (CMV) retinitis in patients with acquired immunodeficiency syndrome (AIDS),NA,Standard,No,No,N/A,N/A,N/A,N/A,N/A,NA,1995-10-04,1996-06-26,266,5.583496308781699,Early-PDUFA
CEA-Scan,arcitumomab,Immunomedics,BLA,103425,NA,NA,Injectable,Injection,NA,NA,NA,NA,4/15/1991,6/28/1996,1996,for use in conjunction with computerized tomography scans to detect recurrent or metastatic colorectal cancer,NA,Standard,No,No,N/A,N/A,N/A,N/A,N/A,NA,1991-04-15,1996-06-28,1901,7.550135342488429,Early-PDUFA
Myoscint,imciromab pentetate,Centocor,BLA,103634,NA,NA,Injectable,Injection,NA,NA,NA,NA,7/7/1995,7/3/1996,1996,indicated for the preparation of Indium In 111 Imciromab pentetate to be used as a cardiac imaging agent for detecting the presence and/or identifying the location of myocardial injury in patients with suspected myocardial infarction,NA,Priority,No,No,N/A,N/A,N/A,N/A,N/A,NA,1995-07-07,1996-07-03,362,5.8916442118257715,Early-PDUFA
Ultiva,remifentanil hydrochloride,Glaxo Wellcome,NDA,20630,NA,NA,Injectable,Injection,NA,NA,NA,NA,9/15/1995,7/12/1996,1996,"indicated for induction and maintenance of general anesthesia for inpatient and outpatient procedures, and for continuation as an analgesic into the immediate postoperative period under the direct supervision of an anesthesia practitioner in a postoperative anesthesia care unit or intensive care setting; also provides an analgesic component of monitored anesthesia care",NA,Standard,No,No,N/A,N/A,N/A,N/A,N/A,NA,1995-09-15,1996-07-12,301,5.707110264748875,Early-PDUFA
Allegra,fexofenadine hydrochloride,Hoechst Marion Roussel,NDA,20625,NA,NA,Capsule,Oral,NA,NA,NA,NA,7/31/1995,7/25/1996,1996,relief of symptoms associated with seasonal allergic rhinitis in adults and children 12 years of age and older,NA,Standard,No,No,N/A,N/A,N/A,N/A,N/A,NA,1995-07-31,1996-07-25,360,5.886104031450156,Early-PDUFA
Cerebyx,fosphenytoin sodium,Parke-Davis,NDA,20450,NA,NA,Injectable,Injection,NA,NA,NA,NA,2/23/1995,8/5/1996,1996,"for short-term parenteral administration when other means of phenytoin administration are unavailable, inappropriate or deemed less advantageous, indicated for the following:
[A] control of generalized convulsive status epilepticus
[B] prevention and treatment of seizures occurring during neuorsurgery
[C] as a substitute, short-term, for oral phenytoin",NA,Standard,Yes (indication [A] only),No,N/A,N/A,N/A,N/A,N/A,NA,1995-02-23,1996-08-05,529,6.270988431858299,Early-PDUFA
Verluma,nofetumomab,Boehringer Ingelheim Pharmaceuticals,BLA,103582,NA,NA,Injectable,Injection,NA,NA,NA,NA,3/30/1994,8/20/1996,1996,"detection of extensive stage disease in patients with biopsy-confirmed, previously untreated, small cell lung cancer",NA,Standard,No,No,N/A,N/A,N/A,N/A,N/A,Biologic product assigned new license number and now referenced by  BLA 103769,1994-03-30,1996-08-20,874,6.773080375655535,Early-PDUFA
Ivy Block,bentoquatam,Enviroderm,NDA,20532,NA,NA,Lotion,Topical,NA,NA,NA,NA,9/29/1994,8/26/1996,1996,"indicated as a skin protectant against poison ivy, poison oak, poison sumac",NA,Priority,No,No,N/A,N/A,N/A,N/A,N/A,NA,1994-09-29,1996-08-26,697,6.546785410760524,Early-PDUFA
Feridex,ferumoxides,Advanced Magnetics,NDA,20416,NA,NA,Injectable,Injection,NA,NA,NA,NA,2/7/1994,8/30/1996,1996,"indicated for detection of lesions of the liver and spleen manifested by an alteration in RES distribution, to facilitate visualization and detection of hepatosplenic lesions, including, but not limited to, tumors",NA,Standard,No,No,N/A,N/A,N/A,N/A,N/A,NA,1994-02-07,1996-08-30,935,6.840546529288687,Early-PDUFA
Alphagan,brimonidine tartrate,Allergan,NDA,20613,NA,NA,Solution/Drops,Ophthalmic,NA,NA,NA,NA,9/7/1995,9/6/1996,1996,indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension,NA,Standard,No,No,N/A,N/A,N/A,N/A,N/A,NA,1995-09-07,1996-09-06,365,5.8998973535824915,Early-PDUFA
ProAmatine,midodrine hydrochloride,Roberts,NDA,19815,NA,NA,Tablet,Oral,NA,NA,NA,NA,4/28/1988,9/6/1996,1996,treatment of symptomatic or orthostatic hypotension,NA,Priority,Yes,Yes,N/A,N/A,N/A,N/A,N/A,NA,1988-04-28,1996-09-06,3053,8.023879992734878,Early-PDUFA
Meretek UBT,13 C Urea,Meretek,NDA,20586,NA,NA,For Solution,Oral,NA,NA,NA,NA,5/11/1995,9/17/1996,1996,for the detection of the presence of absence of active Helicobactor pylori infection of the stomach,NA,Standard,No,No,N/A,N/A,N/A,N/A,N/A,NA,1995-05-11,1996-09-17,495,6.20455776256869,Early-PDUFA
Nilandron,nilutamide,Roussel UCLAF,NDA,20169,NA,NA,Tablet,Oral,NA,NA,NA,NA,3/7/1994,9/19/1996,1996,in combination with surgical castration for the treatment of stage D2 metastatic carcinoma of the prostate,NA,Standard,No,No,N/A,N/A,N/A,N/A,N/A,NA,1994-03-07,1996-09-19,927,6.831953565565855,Early-PDUFA
Denavir,penciclovir,SmithKline Beecham,NDA,20629,NA,NA,Cream,Topical,NA,NA,NA,NA,10/16/1995,9/24/1996,1996,treatment of recurrent herpes labialis (cold sores) in adults,NA,Standard,No,No,N/A,N/A,N/A,N/A,N/A,NA,1995-10-16,1996-09-24,344,5.840641657373398,Early-PDUFA
Naropin,ropivacaine hydrochloride monohydrate,Astra,NDA,20533,NA,NA,Solution,Injection,NA,NA,NA,NA,3/31/1995,9/24/1996,1996,"production of local or regional anesthesia for surgery, for postoperative pain management and for obstetrical procedures",NA,Standard,No,No,N/A,N/A,N/A,N/A,N/A,NA,1995-03-31,1996-09-24,543,6.297109319933935,Early-PDUFA
Elmiron,pentosan polysulfate sodium,Baker Norton,NDA,20193,NA,NA,Capsule,Oral,NA,NA,NA,NA,6/19/1991,9/26/1996,1996,indicated for the relief of bladder pain or discomfort associated with interstitial cystitis,NA,Standard,Yes,No,N/A,N/A,N/A,N/A,N/A,NA,1991-06-19,1996-09-26,1926,7.563200592358071,Early-PDUFA
Accolate,zafirlukast,Zeneca,NDA,20547,NA,NA,Tablet,Oral,NA,NA,NA,NA,6/26/1995,9/26/1996,1996,prophylaxis and chronic treatment of asthma in adults and children 12 years of age and older,NA,Standard,No,No,N/A,N/A,N/A,N/A,N/A,NA,1995-06-26,1996-09-26,458,6.126869184114185,Early-PDUFA
Zyprexa,olanzapine,Lilly,NDA,20592,NA,NA,Tablet,Oral,NA,NA,NA,NA,9/22/1995,9/30/1996,1996,treatment of the manifestations of psychotic disorders,NA,Standard,No,No,N/A,N/A,N/A,N/A,N/A,NA,1995-09-22,1996-09-30,374,5.924255797414532,Early-PDUFA
Mentax,butenafine hydrochloride,Penederm,NDA,20524,NA,NA,Cream,Topical,NA,NA,NA,NA,4/5/1995,10/18/1996,1996,treatment of interdigital tinea pedis,NA,Standard,No,No,N/A,N/A,N/A,N/A,N/A,NA,1995-04-05,1996-10-18,562,6.331501849893691,Early-PDUFA
Cystadane,betaine anhydrous,Orphan Medical,NDA,20576,NA,NA,For Solution,Oral,NA,NA,NA,NA,10/25/1995,10/25/1996,1996,treatment of homocystinuria to decrease elevated homocysteine blood levels,NA,Priority,Yes,No,N/A,N/A,N/A,N/A,N/A,NA,1995-10-25,1996-10-25,366,5.902633333401366,Early-PDUFA
ProstaScint,capromab pendetide,Cytogen,BLA,103608,NA,NA,Injectable,Injection,NA,NA,NA,NA,1/13/1995,10/28/1996,1996,"indicated for the preparation of lndium In 111 Capromab Pendetide to be used as a diagnostic imaging agent in newly diagnosed patients with biopsy-proven prostate cancer, thought to be clinically localized after standard diagnostic evaluation, who are at high risk for pelvic lymph node metastases, and in post-prostatectomy patients with a rising PSA and a negative or equivocal standard metastatic evaluation in whom there is a high clinical suspicion of occult metastatic disease",NA,Priority,No,No,N/A,N/A,N/A,N/A,N/A,NA,1995-01-13,1996-10-28,654,6.483107351457199,Early-PDUFA
Retavase,reteplase,Boehringer Mannheim,BLA,103632,NA,NA,Injectable,Injection,NA,NA,NA,NA,6/30/1995,10/30/1996,1996,"indicated in the management of acute myocardial infarction (AMI) in adults for the improvement of ventricular function following AMI, the reduction of the incidence of congestive heart failure and the reduction of mortality associated with AMI",NA,Standard,No,No,N/A,N/A,N/A,N/A,N/A,Biologic product assigned new license number and now referenced by BLA 103786,1995-06-30,1996-10-30,488,6.1903154058531475,Early-PDUFA
Astelin,azelastine hydrochloride,Wallace Lab,NDA,20114,NA,NA,"Spray, Metered",Nasal,NA,NA,NA,NA,3/26/1991,11/1/1996,1996,"treatment of the symptoms of seasonal allergic rhinitis such as rhinorrhea, sneezing, and nasal pruritus in adults and children 12 years and older",NA,Standard,No,No,N/A,N/A,N/A,N/A,N/A,NA,1991-03-26,1996-11-01,2047,7.624130585661289,Early-PDUFA
Stromectol,ivermectin,Merck,NDA,50742,NA,NA,Tablet,Oral,NA,NA,NA,NA,4/1/1996,11/22/1996,1996,indicated for the treatment of intestinal strongyloidiasis due to the nematode parasite Strongyloides stercoralis; also indicated for the treatment of onchocerciasis due to the nematode parasite Onchocerca volvulus,NA,Priority,No,No,N/A,N/A,N/A,N/A,N/A,NA,1996-04-01,1996-11-22,235,5.459585514144159,Early-PDUFA
Aricept,donepezil hydrochloride,Eisai,NDA,20690,NA,NA,Tablet,Oral,NA,NA,NA,NA,4/5/1996,11/25/1996,1996,treatment of mild to moderate dementia of the Alzheimer's type,NA,Priority,No,No,N/A,N/A,N/A,N/A,N/A,NA,1996-04-05,1996-11-25,234,5.455321115357702,Early-PDUFA
Zanaflex,tizanidine hydrochloride,Athena Neuroscience,NDA,20397,NA,NA,Tablet,Oral,NA,NA,NA,NA,12/6/1993,11/27/1996,1996,acute and intermittent management of increased muscle tone associated with spasticity,NA,Standard,No,No,N/A,N/A,N/A,N/A,N/A,NA,1993-12-06,1996-11-27,1087,6.99117688712121,Early-PDUFA
Gastromark,ferumoxsil,Advanced Magnetics,NDA,20410,NA,NA,Suspension,Oral,NA,NA,NA,NA,11/23/1993,12/6/1996,1996,for oral use with magnetic resonance imaging to enhance the delineation of the bowel to distinguish it from organs and tissues that are adjacent to the upper regions of the gastrointestinal tract,NA,Standard,No,No,N/A,N/A,N/A,N/A,N/A,NA,1993-11-23,1996-12-06,1109,7.011213987350367,Early-PDUFA
Zyflo,zileuton,Abbott Laboratories,NDA,20471,NA,NA,Tablet,Oral,NA,NA,NA,NA,7/19/1994,12/9/1996,1996,prophylaxis and chronic treatment of asthma in adults and children 12 years of age and older,NA,Standard,No,No,N/A,N/A,N/A,N/A,N/A,NA,1994-07-19,1996-12-09,874,6.773080375655535,Early-PDUFA
Aphthasol,amlexanox,Block Drug,NDA,20511,NA,NA,Paste,Oral,NA,NA,NA,NA,4/19/1995,12/17/1996,1996,the treatment of aphthous ulcers in people with normal immune systems,NA,Priority,No,No,N/A,N/A,N/A,N/A,N/A,NA,1995-04-19,1996-12-17,608,6.410174881966167,Early-PDUFA
Lipitor,atorvastatin calcium,Parke-Davis,NDA,20702,NA,NA,Tablet,Oral,NA,NA,NA,NA,6/17/1996,12/17/1996,1996,"indicated as an adjunct to diet to reduce elevated total-C, LDL-C, apo B, and TG levels in patients with primary hypercholesterolemia (heterozygous familial and non familial) and mixed dyslipidemia (Fredrickson Types IIa and IIb); to reduce total-C and LDL-C in patients with homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) or if such treatments are unavailable",NA,Priority,No,No,N/A,N/A,N/A,N/A,N/A,NA,1996-06-17,1996-12-17,183,5.209486152841421,Early-PDUFA
Patanol,olopatadine hydrochloride,Alcon,NDA,20688,NA,NA,Solution/Drops,Ophthalmic,NA,NA,NA,NA,1/29/1996,12/18/1996,1996,For the temporary prevention of itching of the eye due to allergic conjunctivitis,NA,Standard,No,No,N/A,N/A,N/A,N/A,N/A,NA,1996-01-29,1996-12-18,324,5.780743515792329,Early-PDUFA
Glyset,miglitol,Bayer,NDA,20682,NA,NA,Tablet,Oral,NA,NA,NA,NA,12/29/1995,12/18/1996,1996,indicated as adjunct to diet or diet plus sulfonylurea therapy to improve glycemic control in patients with non-insulin-dependent diabetes mellitus,NA,Standard,No,No,N/A,N/A,N/A,N/A,N/A,NA,1995-12-29,1996-12-18,355,5.872117789475416,Early-PDUFA
Monurol,fosfomycin tromethamine,Zambon,NDA,50717,NA,NA,For Solution,Oral,NA,NA,NA,NA,9/29/1994,12/19/1996,1996,treatment of uncomplicated urinary tract infections(acute cystitis) in women due to susceptible strains of Escherichia coli and Enterococcus faecalis,NA,Standard,No,No,N/A,N/A,N/A,N/A,N/A,NA,1994-09-29,1996-12-19,812,6.699500340161678,Early-PDUFA
Zagam,sparfloxacin,Rhone-Poulenc Rorer,NDA,20677,NA,NA,Tablet,Oral,NA,NA,NA,NA,12/27/1995,12/19/1996,1996,indicated for the treatment of adults with the following infections caused by susceptible strains of designated organisms: community-acquired pneumonia; acute bacterial exacerbations of chronic bronchitis,NA,Standard,No,No,N/A,N/A,N/A,N/A,N/A,NA,1995-12-27,1996-12-19,358,5.8805329864007,Early-PDUFA
Copaxone,glatiramer acetate,Teva,NDA,20622,NA,NA,For Solution,Subcutaneous,NA,NA,NA,NA,10/11/1995,12/20/1996,1996,indicated for the reduction of the frequency of relapses in patients with relapsing-remitting multiple sclerosis,NA,Standard,Yes,No,N/A,N/A,N/A,N/A,N/A,NA,1995-10-11,1996-12-20,436,6.077642243349034,Early-PDUFA
Diovan,valsartan,Ciba-Geigy,NDA,20665,NA,NA,Capsule,Oral,NA,NA,NA,NA,12/28/1995,12/23/1996,1996,treatment of hypertension,NA,Standard,No,No,N/A,N/A,N/A,N/A,N/A,NA,1995-12-28,1996-12-23,361,5.8888779583328805,Early-PDUFA
Dostinex,cabergoline,Pharmacia and Upjohn,NDA,20664,NA,NA,Tablet,Oral,NA,NA,NA,NA,12/27/1995,12/23/1996,1996,"treatment of hyperprolactinemic disorders, either idiopathic or due to pituitary adenomas",NA,Standard,No,No,N/A,N/A,N/A,N/A,N/A,NA,1995-12-27,1996-12-23,362,5.8916442118257715,Early-PDUFA
Orgaran,danaparoid sodium,Organon,NDA,20430,NA,NA,Injectable,Injection,NA,NA,NA,NA,12/30/1994,12/24/1996,1996,indicated for the prophylaxis of post-operative deep venous thrombosis (DVT) which may lead to pulmonary embolism (PE) in patients undergoing elective hip replacement surgery,NA,Standard,No,No,N/A,N/A,N/A,N/A,N/A,NA,1994-12-30,1996-12-24,725,6.586171654854675,Early-PDUFA
Topamax,topiramate,RW Johnson,NDA,20505,NA,NA,Tablet,Oral,NA,NA,NA,NA,12/30/1994,12/24/1996,1996,adjunctive therapy for the treatment of adults with partial onset seizures,NA,Standard,No,No,N/A,N/A,N/A,N/A,N/A,NA,1994-12-30,1996-12-24,725,6.586171654854675,Early-PDUFA
Rezulin,troglitazone,Parke-Davis,NDA,20720,NA,NA,Tablet,Oral,NA,NA,NA,NA,8/1/1996,1/29/1997,1997,indicated for use in Type II diabetes patients whose hyperglycemia is inadequately controlled despite insulin therapy,NA,Priority,No,No,N/A,N/A,N/A,N/A,N/A,NA,1996-08-01,1997-01-29,181,5.198497031265826,Early-PDUFA
Aldara,imiquimod,3M,NDA,20723,NA,NA,Cream,Topical,NA,NA,NA,NA,7/26/1996,2/27/1997,1997,treatment of external genital and perianal warts/condyloma acuminata in adults,NA,Standard,No,No,N/A,N/A,N/A,N/A,N/A,NA,1996-07-26,1997-02-27,216,5.375278407684165,Early-PDUFA
Skelid,tiludronate disodium,Sanofi Winthrop,NDA,20707,NA,NA,Tablet,Oral,NA,NA,NA,NA,2/28/1996,3/7/1997,1997,treatment of Paget's disease of bone,NA,Standard,No,No,N/A,N/A,N/A,N/A,N/A,NA,1996-02-28,1997-03-07,373,5.921578419643816,Early-PDUFA
Agrylin,anagrelide hydrochloride,Roberts,NDA,20333,NA,NA,Capsule,Oral,NA,NA,NA,NA,1/31/1996,3/14/1997,1997,treatment of patients with essential thrombocythemia to reduce the elevated platelet count and the risk of thrombosis and ameliorate associated systems,NA,Priority,Yes,No,N/A,N/A,N/A,N/A,N/A,NA,1996-01-31,1997-03-14,408,6.0112671744041615,Early-PDUFA
Viracept,nelfinavir mesylate,Agouron,NDA,20779,20778,NA,Tablet,Oral,Powder,Oral,NA,NA,12/23/1996,3/14/1997,1997,treatment of HIV infection when therapy is warranted,NA,Priority,No,Yes,N/A,N/A,N/A,N/A,N/A,NA,1996-12-23,1997-03-14,81,4.394449154672439,Early-PDUFA
Quadramet,samarium Sm 153 lexidronam,Cytogen,NDA,20570,NA,NA,Injectable,Injection,NA,NA,NA,NA,6/13/1995,3/28/1997,1997,indicated for the relief of pain in patients with confirmed osteoblastic metastatic bone lesions that enhance on radionuclide bone scan,NA,Standard,No,No,N/A,N/A,N/A,N/A,N/A,NA,1995-06-13,1997-03-28,654,6.483107351457199,Early-PDUFA
Rescriptor,delavirdine mesylate,Pharmacia and Upjohn,NDA,20705,NA,NA,Tablet,Oral,NA,NA,NA,NA,7/15/1996,4/4/1997,1997,treatment of HIV-1 infection in combination with appropriate antiretroviral agents when therapy is warranted,NA,Priority,No,Yes,N/A,N/A,N/A,N/A,N/A,NA,1996-07-15,1997-04-04,263,5.572154032177765,Early-PDUFA
Flomax,tamsulosin hydrochloride,Boehringer Ingelheim Pharmaceuticals,NDA,20579,NA,NA,Capsule,Oral,NA,NA,NA,NA,4/15/1996,4/15/1997,1997,indicated for the treatment of the signs and symptoms of benign prostatic hyperplasia,NA,Standard,No,No,N/A,N/A,N/A,N/A,N/A,NA,1996-04-15,1997-04-15,365,5.8998973535824915,Early-PDUFA
Pytest Kit,14 C Urea,TriMed,NDA,20617,NA,NA,Capsule,Oral,NA,NA,NA,NA,5/22/1995,5/9/1997,1997,indicated for the diagnosis of Helicobacter pylori infection of the stomach,NA,Priority,No,No,N/A,N/A,N/A,N/A,N/A,NA,1995-05-22,1997-05-09,718,6.576469569048224,Early-PDUFA
Normiflo,ardeparin sodium,Wyeth-Ayerst,NDA,20227,NA,NA,Injectable,Injection,NA,NA,NA,NA,12/16/1992,5/23/1997,1997,prevention of deep venous thrombosis which may lead to pulmonary embolism following knee replacement surgery,NA,Standard,No,No,N/A,N/A,N/A,N/A,N/A,NA,1992-12-16,1997-05-23,1619,7.389563953677635,Early-PDUFA
Fareston,toremifene citrate,Orion,NDA,20497,NA,NA,Tablet,Oral,NA,NA,NA,NA,1/3/1995,5/29/1997,1997,treatment of metastatic breast cancer in postmenopausal women with estrogen receptor positive or receptor unknown tumors,NA,Standard,Yes,No,N/A,N/A,N/A,N/A,N/A,NA,1995-01-03,1997-05-29,877,6.776506992372183,Early-PDUFA
Tazorac,tazarotene,Allergan,NDA,20600,NA,NA,Gel,Topical,NA,NA,NA,NA,6/19/1995,6/13/1997,1997,indicated for the topical treatment of patients with stable plaque psoriasis of up to 20% body surface area involvement and topical treatment of patients with facial acne vulgaris of mild to moderate severity,NA,Standard,No,No,N/A,N/A,N/A,N/A,N/A,NA,1995-06-19,1997-06-13,725,6.586171654854675,Early-PDUFA
Posicor,mibefradil dihydrochloride,Roche,NDA,20689,NA,NA,Tablet,Oral,NA,NA,NA,NA,3/11/1996,6/20/1997,1997,treatment of hypertension and chronic stable angina pectoris,NA,Standard,No,No,N/A,N/A,N/A,N/A,N/A,NA,1996-03-11,1997-06-20,466,6.1441856341256456,Early-PDUFA
Baycol,cerivastatin sodium,Bayer,NDA,20740,NA,NA,Tablet,Oral,NA,NA,NA,NA,6/26/1996,6/26/1997,1997,indicated as an adjunct to diet for the reduction of elevated total and LDL cholesterol levels in patients with primary hypercholesterolemia and mixed dyslipidemia (Frederickson Types IIa and IIb) when the response to dietary restriction of saturated fat and cholesterol and other non-pharmacological measures alone has been inadequate,NA,Standard,No,No,N/A,N/A,N/A,N/A,N/A,NA,1996-06-26,1997-06-26,365,5.8998973535824915,Early-PDUFA
Mirapex,pramipexole dihydrochloride,Pharmacia and Upjohn,NDA,20667,NA,NA,Tablet,Oral,NA,NA,NA,NA,12/28/1995,7/1/1997,1997,treatment of the signs and symptoms of idiopathic Parkinson's disease,NA,Standard,No,No,N/A,N/A,N/A,N/A,N/A,NA,1995-12-28,1997-07-01,551,6.311734809152915,Early-PDUFA
Duract,bromfenac sodium,Wyeth-Ayerst,NDA,20535,NA,NA,Capsule,Oral,NA,NA,NA,NA,12/30/1994,7/15/1997,1997,indicated for the short-term (generally less than 10 days) management of pain,NA,Standard,No,No,N/A,N/A,N/A,N/A,N/A,NA,1994-12-30,1997-07-15,928,6.833031732786201,Early-PDUFA
Femara,letrozole,Novartis Pharmaceuticals,NDA,20726,NA,NA,Tablet,Oral,NA,NA,NA,NA,7/25/1996,7/25/1997,1997,indicated for the treatment of advanced breast cancer in postmenopausal women,NA,Standard,No,No,N/A,N/A,N/A,N/A,N/A,NA,1996-07-25,1997-07-25,365,5.8998973535824915,Early-PDUFA
Anzemet,dolasetron mesylate,Hoechst Marion Roussel,NDA,20623,20624,NA,Tablet,Oral,Injectable,Injection,NA,NA,9/29/1995,9/11/1997,1997,prevention of chemotherapy-induced nausea and vomiting; prevention of postoperative nausea and vomiting,NA,Standard,No,No,N/A,N/A,N/A,N/A,N/A,NA,1995-09-29,1997-09-11,713,6.569481420414296,Early-PDUFA
Genesa,arbutamine hydrochloride,Gensia,NDA,20420,NA,NA,Injectable,Injection,NA,NA,NA,NA,1/6/1994,9/12/1997,1997,indicated for us as an aid in diagnosing the presence or absence of coronary artery disease in patients who cannot exercise adequately when used in conjunction with radionuclide myocardial perfusion imaging or echocardiography,NA,Standard,No,No,N/A,N/A,N/A,N/A,N/A,NA,1994-01-06,1997-09-12,1345,7.20414929203594,Early-PDUFA
Requip,ropinirole hydrochloride,SmithKline Beecham,NDA,20658,NA,NA,Tablet,Oral,NA,NA,NA,NA,1/2/1996,9/19/1997,1997,treatment of the signs and symptoms of idiopathic Parkinson's disease,NA,Standard,No,No,N/A,N/A,N/A,N/A,N/A,NA,1996-01-02,1997-09-19,626,6.439350371100098,Early-PDUFA
Corlopam,fenoldopam mesylate,Neurex,NDA,19922,NA,NA,Injectable,Injection,NA,NA,NA,NA,12/12/1988,9/23/1997,1997,"indicated for the in-hospital, short-term (up to 48 hours) use in the management of severe hypertension when rapid, but quickly reversible, emergency reduction of blood pressure is clinically indicated, including malignant hypertension with deteriorating end-organ function",NA,Standard,No,No,N/A,N/A,N/A,N/A,N/A,NA,1988-12-12,1997-09-23,3207,8.073091199693154,Early-PDUFA
Seroquel,quetiapine fumarate,Zeneca,NDA,20639,NA,NA,Tablet,Oral,NA,NA,NA,NA,7/29/1996,9/26/1997,1997,treatment of the manifestations of psychotic disorders,NA,Standard,No,No,N/A,N/A,N/A,N/A,N/A,NA,1996-07-29,1997-09-26,424,6.049733455231958,Early-PDUFA
Gabitril,tiagabine hydrochloride,Abbott Laboratories,NDA,20646,NA,NA,Tablet,Oral,NA,NA,NA,NA,11/6/1995,9/30/1997,1997,indicated as adjunctive therapy in adults and children 12 years and older in the treatment of partial seizures,NA,Standard,No,No,N/A,N/A,N/A,N/A,N/A,NA,1995-11-06,1997-09-30,694,6.542471960506805,Early-PDUFA
Avapro,irbesartan,Sanofi,NDA,20757,NA,NA,Tablet,Oral,NA,NA,NA,NA,9/26/1996,9/30/1997,1997,treatment of hypertension,NA,Standard,No,No,N/A,N/A,N/A,N/A,N/A,NA,1996-09-26,1997-09-30,369,5.910796644040527,Early-PDUFA
Infergen,interferon alfacon-1,Amgen,BLA,103663,NA,NA,Injectable,Injection,NA,NA,NA,NA,4/11/1996,10/6/1997,1997,treatment of chronic hepatitis C virus (HCV) infection in patients 18 years of age or older with compensated liver disease who have anti-HCV serum antibodies and/or the presence of HCV RNA,NA,Standard,No,No,N/A,N/A,N/A,N/A,N/A,NA,1996-04-11,1997-10-06,543,6.297109319933935,Early-PDUFA
Raxar,grepafloxacin hydrochloride,Glaxo Wellcome,NDA,20695,NA,NA,Tablet,Oral,NA,NA,NA,NA,11/8/1996,11/6/1997,1997,"treatment of adults with acute bacterial exacerbations of chronic bronchitis, community-acquired pneumonia, uncomplicated gonorrhea, and nongonococcal urethritis and cervicitis",NA,Standard,No,No,N/A,N/A,N/A,N/A,N/A,NA,1996-11-08,1997-11-06,363,5.8944028342648505,Early-PDUFA
Plavix,clopidogrel bisulfate,Sanofi,NDA,20839,NA,NA,Tablet,Oral,NA,NA,NA,NA,4/28/1997,11/17/1997,1997,"indicated for the reduction of atherosclerotic events (myocardial infarction, stroke, and vascular death) in patients with atherosclerosis documented by recent stroke, recent myocardial infarction, or established peripheral arterial disease",NA,Priority,No,No,N/A,N/A,N/A,N/A,N/A,NA,1997-04-28,1997-11-17,203,5.313205979041787,Early-PDUFA
Meridia,sibutramine hydrochloride,Knoll  Pharmacuticals,NDA,20632,NA,NA,Capsule,Oral,NA,NA,NA,NA,8/9/1995,11/22/1997,1997,"indicated for the management of obesity, including weight loss and maintenance of weight loss, and should be used in conjunction with a reduced calorie diet",NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,1995-08-09,1997-11-22,836,6.728628613084702,Early-PDUFA
Neumega,oprelvekin,Genetics Institute,BLA,103694,NA,NA,Injectable,Injection,NA,NA,NA,NA,12/23/1996,11/25/1997,1997,indicated for the prevention of severe thrombocytopenia and the reduction of the need for platelet transfusions following myelosuppressive chemotherapy in patients with nonmyeloid malignancies who are at high risk of severe thrombocytopenia,NA,Standard,Yes,No,N/A,No,N/A,N/A,N/A,NA,1996-12-23,1997-11-25,337,5.820082930352362,Early-PDUFA
Zomig,zolmitriptan,Zeneca,NDA,20768,NA,NA,Tablet,Oral,NA,NA,NA,NA,11/26/1996,11/25/1997,1997,treatment of acute migraine,NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,1996-11-26,1997-11-25,364,5.8971538676367405,Early-PDUFA
Teslascan,mangafodipir trisodium,Nycomed,NDA,20652,NA,NA,Injectable,Injection,NA,NA,NA,NA,9/15/1995,11/26/1997,1997,"indicated as an adjunct to MRI to enhance the T1-weighted images used in the detection, localization, characterization, and evaluation of lesions of the liver",NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,1995-09-15,1997-11-26,803,6.688354713946762,Early-PDUFA
Rituxan,rituximab,Genentech,BLA,103705,NA,NA,Injectable,Injection,NA,NA,NA,NA,2/28/1997,11/26/1997,1997,"treatment of patients with relapsed or refractory low-grade or follicular, CD20 positive, B-cell non-Hodgkin’s lymphoma",NA,Priority,Yes,No,N/A,No,N/A,N/A,N/A,NA,1997-02-28,1997-11-26,271,5.602118820879701,Early-PDUFA
Antizol,fomepizole,Orphan Medical,NDA,20696,NA,NA,Injectable,Injection,NA,NA,NA,NA,12/6/1996,12/4/1997,1997,"indicated as an antidote to ethylene glycol (antifreeze) poisoning in patients who have ingested, or are suspected of having ingested ethylene glycol",NA,Standard,Yes,No,N/A,No,N/A,N/A,N/A,NA,1996-12-06,1997-12-04,363,5.8944028342648505,Early-PDUFA
Omnicef,cefdinir,Parke-Davis,NDA,50739,50749,NA,Capsule,Oral,Suspension,Oral,NA,NA,9/4/1996,12/4/1997,1997,"indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of designated microorganisms in the following conditions:  community-acquired pneumonia, acute exacerbations of chronic bronchitis, acute bacterial otitis media, acute maxillary sinusitis, pharyngitis/tonsillitis and uncomplicated skin and skin structure infections",NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,1996-09-04,1997-12-04,456,6.1224928095143865,Early-PDUFA
Evista,raloxifene hydrochloride,Lilly,NDA,20815,NA,NA,Tablet,Oral,NA,NA,NA,NA,6/9/1997,12/9/1997,1997,prevention of osteoporosis in postmenopausal women,NA,Priority,No,No,N/A,No,N/A,N/A,N/A,NA,1997-06-09,1997-12-09,183,5.209486152841421,Early-PDUFA
Zenapax,daclizumab,Roche,BLA,103749,NA,NA,Injectable,Injection,NA,NA,NA,NA,6/10/1997,12/10/1997,1997,"indicated for the prophylaxis of acute organ rejection in patients receiving renal transplants, to be used as a part of an immunosuppressive regimen that includes cyclosporine and corticosteroids",NA,Priority,Yes,No,N/A,No,N/A,N/A,N/A,NA,1997-06-10,1997-12-10,183,5.209486152841421,Early-PDUFA
Regranex,becaplermin,Johnson & Johnson,BLA,103691,NA,NA,Injectable,Injection,NA,NA,NA,NA,12/16/1996,12/16/1997,1997,"indicated for treatment of lower extremity diabetic neuropathic ulcers that extend into the subcutaneous tissue or beyond, and have adequate blood supply",NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,1996-12-16,1997-12-16,365,5.8998973535824915,Early-PDUFA
Trovan,alatrofloxacin mesylate,Pfizer,NDA,20760,NA,NA,Injectable,Injection,NA,NA,NA,NA,12/30/1996,12/18/1997,1997,"indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of designated microorganisms in the following conditions: nosocomial pneumonia, community acquired pneumonia, acute bacterial exacerbation of chronic bronchitis, acute sinusitis, complicated intra-abdominal infections including post-surgical infections, gynecologic and pelvic infections including endomyometritis, parametritis, septic abortion and post-partum infections, prophylaxis of infection associated with elective colorectal surgery, vaginal and abdominal hysterectomy, uncomplicated skin and skin structure infection including diabetic foot infections, uncomplicated urinary tract infections, chronic bacterial prostatitis, uncomplicate urethral gonorrhea in males and endocervical and rectal gonorrhea in females, pelvic inflammatory disease",NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,1996-12-30,1997-12-18,353,5.8664680569332965,Early-PDUFA
Trovan,trovafloxacin mesylate,Pfizer,NDA,20759,NA,NA,Tablet,Oral,NA,NA,NA,NA,12/30/1996,12/18/1997,1997,indicated for the treatment of infections caused by susceptible strains of designated microorganisms in the following conditions:,NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,1996-12-30,1997-12-18,353,5.8664680569332965,Early-PDUFA
Teveten,eprosartan mesylate,SmithKline Beecham,NDA,20738,NA,NA,Tablet,Oral,NA,NA,NA,NA,10/11/1996,12/22/1997,1997,treatment of hypertension,NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,1996-10-11,1997-12-22,437,6.07993319509559,Early-PDUFA
Prandin,repaglinide,Novo Nordisk,NDA,20741,NA,NA,Tablet,Oral,NA,NA,NA,NA,7/1/1997,12/22/1997,1997,"indicated as an adjunct to diet and exercise to lower blood glucose in patients with non-insulin dependent (type 2) diabetes whose hyperglycemia cannot be controlled satisfactorily by diet and exercise alone; in combination with metformin to lower blood glucose in patients whose hyperglycemia cannot be controlled satisfactorily by exercise, diet, and either repaglinide or metformin alone",NA,Priority,No,No,N/A,No,N/A,N/A,N/A,NA,1997-07-01,1997-12-22,174,5.159055299214529,Early-PDUFA
Sclerosol,talc,Bryan,NDA,20587,NA,NA,"Aerosol, Metered",Inhalation,NA,NA,NA,NA,8/15/1995,12/24/1997,1997,for the prevention of the recurrence of malignant pleural effusions in symptomatic patients,NA,Priority,Yes,No,N/A,No,N/A,N/A,N/A,NA,1995-08-15,1997-12-24,862,6.759255270663693,Early-PDUFA
Emadine,emedastine difumarate,Alcon,NDA,20706,NA,NA,Solution/Drops,Ophthalmic,NA,NA,NA,NA,3/26/1996,12/29/1997,1997,for the temporary relief of the signs and symptoms of allergic conjunctivitis,NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,1996-03-26,1997-12-29,643,6.466144724237619,Early-PDUFA
Tasmar,tolcapone,Roche,NDA,20697,NA,NA,Tablet,Oral,NA,NA,NA,NA,6/5/1996,1/29/1998,1998,indicated as an adjunct to levodopa and carbidopa for the treatment of the signs and symptoms of idiopathic Parkinson’s disease,NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,1996-06-05,1998-01-29,603,6.401917196727186,Early-PDUFA
Amerge,naratriptan,Glaxo Wellcome,NDA,20763,NA,NA,Tablet,Oral,NA,NA,NA,NA,12/4/1996,2/10/1998,1998,acute treatment of migraine headache,NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,1996-12-04,1998-02-10,433,6.07073772800249,Early-PDUFA
Singulair,montelukast sodium,Merck,NDA,20829,20830,NA,Tablet,Oral,Tablet,Oral,NA,NA,2/21/1997,2/20/1998,1998,prophylaxis and chronic treatment of asthma in patients 15 years and older,NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,1997-02-21,1998-02-20,364,5.8971538676367405,Early-PDUFA
Refludan,lepirudin,Hoechst Marion Roussel,NDA,20807,NA,NA,Injectable,Injection,NA,NA,NA,NA,12/31/1996,3/6/1998,1998,anticoagulation in patients with heparin-induced thrombocytopenia (HIT) and thromboembolic disease in order to prevent further thromboembolic complications,NA,Priority,Yes,No,N/A,No,N/A,N/A,N/A,NA,1996-12-31,1998-03-06,430,6.063785208687608,Early-PDUFA
Lotemax; Alrex,loteprednol etabonate,Bausch & Lomb,NDA,20583,20841,20803,Suspension,Ophthalmic,Suspension,Ophthalmic,Suspension,Ophthalmic,3/31/1995,3/9/1998,1998,"Lotemax is indicated for treatment of steroid response inflammatory conditions of the palepebral and bulbar conjunctiva, cornea, and anterior segment of the eye; Lotemax is also indicated for treatment of post-operative inflammation following ocular surgery; Alrex is indicated for temporary relief of signs and symptoms of seasonal allergic conjunctivitis",NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,1995-03-31,1998-03-09,1074,6.97914527506881,Early-PDUFA
Detrol,tolterodine tartrate,Pharmacia and Upjohn,NDA,20771,NA,NA,Tablet,Oral,NA,NA,NA,NA,3/25/1997,3/25/1998,1998,"treatment of patients with an overactive bladder with symptoms of urinary frequency, urgency, or urge incontinence",NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,1997-03-25,1998-03-25,365,5.8998973535824915,Early-PDUFA
Actonel,risedronate sodium,Procter & Gamble,NDA,20835,NA,NA,Tablet,Oral,NA,NA,NA,NA,4/1/1997,3/27/1998,1998,treatment of Paget's disease of the bone,NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,1997-04-01,1998-03-27,360,5.886104031450156,Early-PDUFA
Viagra,sildenafil citrate,Pfizer,NDA,20895,NA,NA,Tablet,Oral,NA,NA,NA,NA,9/29/1997,3/27/1998,1998,treatment of erectile dysfunction,NA,Priority,No,No,N/A,No,N/A,N/A,N/A,NA,1997-09-29,1998-03-27,179,5.187385805840755,Early-PDUFA
Azopt,brinzolamide,Alcon,NDA,20816,NA,NA,Suspension/Drops,Ophthalmic,NA,NA,NA,NA,1/28/1997,4/1/1998,1998,treatment of elevated intraocular pressure in patients with ocular hypertension or open angle glaucoma,NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,1997-01-28,1998-04-01,428,6.059123195581797,Early-PDUFA
Sucraid,sacrosidase,Orphan Medical,BLA,20772,NA,NA,Solution,Oral,NA,NA,NA,NA,5/7/1997,4/9/1998,1998,"treatment of the genetically determined sucrase deficiency, which is part of congenital sucrase-isomaltase deficiency (CSID)",NA,Priority,Yes,No,N/A,No,N/A,N/A,N/A,Transition Product from NDA to BLA due to BPCI : Please see page 2 of data dictionary for more information.,1997-05-07,1998-04-09,337,5.820082930352362,Early-PDUFA
Zemplar,paricalcitol,Abbott Laboratories,NDA,20819,NA,NA,Solution,Intravenous,NA,NA,NA,NA,1/17/1997,4/17/1998,1998,prevention and treatment of secondary hyperparathyroidism encountered with chronic renal failure,NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,1997-01-17,1998-04-17,455,6.12029741895095,Early-PDUFA
Xeloda,capecitabine,Roche,NDA,20896,NA,NA,Tablet,Oral,NA,NA,NA,NA,10/31/1997,4/30/1998,1998,"treatment of patients with metastatic breast cancer resistant to both paclitaxel and an anthracycline-containing chemotherapy regimen or resistant to paclitaxel and for whom further anthracycline therapy may be contraindicated, e.g., patients who have received cumulative doses of 400 mg/m2 of doxorubicin or doxorubicin equivalents",NA,Priority,No,Yes,N/A,No,N/A,N/A,N/A,NA,1997-10-31,1998-04-30,181,5.198497031265826,Early-PDUFA
Simulect,basiliximab,Novartis Pharmaceuticals,BLA,103764,NA,NA,Injectable,Injection,NA,NA,NA,NA,11/12/1997,5/12/1998,1998,indicated for the prophylaxis of acute organ rejection in patients receiving renal transplantation when used as part of an immunosuppressive regimen that includes cyclosporine and corticosteroids,NA,Priority,Yes,No,N/A,No,N/A,N/A,N/A,NA,1997-11-12,1998-05-12,181,5.198497031265826,Early-PDUFA
Aggrastat,tirofiban hydrochloride,Merck,NDA,20912,20913,NA,Injectable,Injection,Injectable,Injection,NA,NA,10/31/1997,5/14/1998,1998,"in combination with heparin, for the treatment of acute coronary syndrome, including patients who are to be managed medically and those undergoing PTCA or atherectomy",NA,Priority,No,No,N/A,No,N/A,N/A,N/A,NA,1997-10-31,1998-05-14,195,5.272999558563747,Early-PDUFA
Integrilin,eptifibatide,COR Therapeutics,NDA,20718,NA,NA,Injectable,Injection,NA,NA,NA,NA,4/2/1996,5/18/1998,1998,"treatment of patients with acute coronary syndrome (UA/NQMI), including patients who are to be managed medically and those undergoing percutaneous coronary intervention (PCI). In this setting, INTEGRILIN has been shown to decrease the rate of a combined endpoint of death or new myocardial infarction;  also indicated for treatment of patients undergoing PCI. In this setting, INTEGRILIN has been shown to decrease the rate of a combined endpoint of death, new myocardial infarction, or need for urgent intervention",NA,Priority,No,No,N/A,No,N/A,N/A,N/A,NA,1996-04-02,1998-05-18,776,6.654152520183219,Early-PDUFA
Atacand,candesartan cilexetil,Astra Merck,NDA,20838,NA,NA,Tablet,Oral,NA,NA,NA,NA,4/30/1997,6/4/1998,1998,treatment of hypertension,NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,1997-04-30,1998-06-04,400,5.991464547107982,Early-PDUFA
Synagis,palivizumab,MedImmune,BLA,103770,NA,NA,Injectable,Injection,NA,NA,NA,NA,12/19/1997,6/19/1998,1998,"prophylaxis of serious lower respiratory tract disease, caused by respiratory syncytial virus, in pediatric patients at high risk of RSV disease",NA,Priority,No,No,N/A,No,N/A,N/A,N/A,NA,1997-12-19,1998-06-19,182,5.204006687076795,Early-PDUFA
Priftin,rifapentine,Hoechst Marion Roussel,NDA,21024,NA,NA,Tablet,Oral,NA,NA,NA,NA,12/22/1997,6/22/1998,1998,treatment of pulmonary tuberculosis,NA,Priority,Yes,Yes,N/A,No,N/A,N/A,N/A,NA,1997-12-22,1998-06-22,182,5.204006687076795,Early-PDUFA
Maxalt; Maxalt-MLT,rizatriptan benzoate,Merck,NDA,20864,20865,NA,Tablet,Oral,Tablet,Oral,NA,NA,6/30/1997,6/29/1998,1998,acute treatment of migraine headache,NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,1997-06-30,1998-06-29,364,5.8971538676367405,Early-PDUFA
Infasurf,calfactant,Ony,BLA,20521,NA,NA,Suspension,Intratracheal,NA,NA,NA,NA,7/31/1995,7/1/1998,1998,prevention and treatment of Respiratory Distress Syndrome (RDS) in neonates,NA,Standard,Yes,No,N/A,No,N/A,N/A,N/A,Transition Product from NDA to BLA due to BPCI : Please see page 2 of data dictionary for more information.,1995-07-31,1998-07-01,1066,6.97166860472579,Early-PDUFA
Thalomid,thalidomide,Celgene,NDA,20785,NA,NA,Capsule,Oral,NA,NA,NA,NA,12/20/1996,7/16/1998,1998,acute treatment of the cutaneous manifestations of moderate to severe erythema nodosum leprosum (ENL) and as maintenance therapy for prevention and suppression of the cutaneous manifestations of ENL recurrences,NA,Priority,Yes,No,N/A,No,N/A,N/A,N/A,NA,1996-12-20,1998-07-16,573,6.35088571671474,Early-PDUFA
Celexa,citalopram hydrobromide,Forest Laboratories,NDA,20822,NA,NA,Tablet,Oral,NA,NA,NA,NA,5/12/1997,7/17/1998,1998,treatment of depression,NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,1997-05-12,1998-07-17,431,6.066108090103747,Early-PDUFA
Remicade,infliximab,Centocor,BLA,103772,NA,NA,Injectable,Injection,NA,NA,NA,NA,12/30/1997,8/24/1998,1998,"indicated for the treatment of moderately to severely active Crohn’s disease for the reduction of the signs and symptoms, in patients who have an inadequate response to conventional therapies; and treatment of patients with fistulizing Crohn’s disease for the reduction in the number of draining enterocutaneous fistula(s)",NA,Priority,Yes,Yes,N/A,No,N/A,N/A,N/A,NA,1997-12-30,1998-08-24,237,5.4680601411351315,Early-PDUFA
Vitravene,fomivirsen sodium,Isis Pharm,NDA,20961,NA,NA,Injectable,Injection,NA,NA,NA,NA,4/9/1998,8/26/1998,1998,local treatment of cytomegalovirus (CMV) retinitis in patients with acquired immunodeficiency syndrome (AIDS) who are intolerant or have a contraindication to other treatments for CMV retinitis or who were insufficiently responsive to previous treatment(s) for CMV retinitis,NA,Priority,No,No,N/A,No,N/A,N/A,N/A,NA,1998-04-09,1998-08-26,139,4.9344739331306915,Early-PDUFA
Arava,leflunomide,Quintiles,NDA,20905,NA,NA,Tablet,Oral,NA,NA,NA,NA,3/10/1998,9/10/1998,1998,treatment of active rheumatoid arthritis (RA) to reduce signs and symptoms and to retard structural damage as evidenced by X-ray erosions and joint space narrowing,NA,Priority,No,No,N/A,No,N/A,N/A,N/A,NA,1998-03-10,1998-09-10,184,5.214935757608986,Early-PDUFA
AcuTect,technetium Tc-99m apcitide,Diatide,NDA,20887,NA,NA,Injectable,Injection,NA,NA,NA,NA,8/20/1997,9/14/1998,1998,for scintigraphic imaging of acute venous thrombosis in the lower extremities of patients who have signs and symptoms of acute venous thrombosis,NA,Priority,No,No,N/A,No,N/A,N/A,N/A,NA,1997-08-20,1998-09-14,390,5.966146739123692,Early-PDUFA
Sustiva,efavirenz,Dupont Pharmaceuticals,NDA,20972,NA,NA,Capsule,Oral,NA,NA,NA,NA,6/11/1998,9/17/1998,1998,provides for the use of efavirenz in combination with other antiretroviral agents for the treatment of HIV-1 infection,NA,Priority,No,Yes,N/A,Yes,N/A,N/A,N/A,NA,1998-06-11,1998-09-17,98,4.584967478670572,Early-PDUFA
Herceptin,trastuzumab,Genentech,BLA,103792,NA,NA,Injectable,Injection,NA,NA,NA,NA,5/4/1998,9/25/1998,1998,treatment of patients with metastatic breast cancer whose tumors overexpress the HER2 protein and who have received one or more chemotherapy regimens for their metastatic disease; also indicated in combination with paclitaxel for treatment of patients with metastatic breast cancer whose tumors overexpress HER2 protein and who have not received chemotherapy for their metastatic disease,NA,Priority,No,No,N/A,Yes,N/A,N/A,N/A,NA,1998-05-04,1998-09-25,144,4.969813299576001,Early-PDUFA
Valstar,valrubicin,Anthra Pharm,NDA,20892,NA,NA,Solution,Intravesical,NA,NA,NA,NA,12/31/1997,9/25/1998,1998,indicated for intravesical therapy of BCG-refractory carcinoma in situ (CIS) of the urinary bladder in patients for whom immediate cystectomy would be associated with unacceptable morbidity or mortality,NA,Priority,Yes,No,N/A,No,N/A,N/A,N/A,NA,1997-12-31,1998-09-25,268,5.5909869805108565,Early-PDUFA
Renagel,sevelamer hydrochloride,GelTex Pharm,NDA,20926,NA,NA,Capsule,Oral,NA,NA,NA,NA,11/3/1997,10/30/1998,1998,indicated for the reduction of serum phosphorus in patients with end stage renal disease who are on hemodialysis,NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,1997-11-03,1998-10-30,361,5.8888779583328805,Early-PDUFA
Enbrel,etanercept,Immunex,BLA,103795,NA,NA,Injectable,Injection,NA,NA,NA,NA,5/8/1998,11/2/1998,1998,indicated for reduction in signs and symptoms of moderately to severely active rheumatoid arthritis in patients who have had an inadequate response to one or more disease-modifying antirheumatic drugs (DMARDS); Etanercept can be used in combination with methotrexate in patients who do not respond adequately to methotrexate alone,NA,Priority,No,No,N/A,Yes,N/A,N/A,N/A,NA,1998-05-08,1998-11-02,178,5.181783550292085,Early-PDUFA
Micardis,telmisartan,Boehringer Ingelheim Pharmaceuticals,NDA,20850,NA,NA,Tablet,Oral,NA,NA,NA,NA,9/26/1997,11/10/1998,1998,treatment of hypertension,NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,1997-09-26,1998-11-10,410,6.016157159698354,Early-PDUFA
Thyrogen,thyrotropin alfa,Genzyme,BLA,20898,NA,NA,Injectable,Injection,NA,NA,NA,NA,12/15/1997,11/30/1998,1998,indicated for use as an adjunctive diagnostic tool for serum thyroglobulin (Tg) testing with or without radioiodine imaging in the follow-up of patients with well-differentiated thyroid cancer,NA,Priority,Yes,No,N/A,No,N/A,N/A,N/A,Transition Product from NDA to BLA due to BPCI : Please see page 2 of data dictionary for more information.,1997-12-15,1998-11-30,350,5.857933154483459,Early-PDUFA
Ziagen,abacavir sulfate,Glaxo Wellcome,NDA,20977,20978,NA,Tablet,Oral,Solution,Oral,NA,NA,6/24/1998,12/17/1998,1998,"in combination with other antiretroviral agents, for the treatment of HIV-1 infection",NA,Priority,No,Yes,N/A,Yes,N/A,N/A,N/A,NA,1998-06-24,1998-12-17,176,5.170483995038151,Early-PDUFA
Provigil,modafinil,Cephalon,NDA,20717,NA,NA,Tablet,Oral,NA,NA,NA,NA,12/30/1996,12/24/1998,1998,indicated  to  improve  wakefulness  in  patients  with  excessive  daytime sleepiness associated with narcolepsy,NA,Standard,Yes,No,N/A,No,N/A,N/A,N/A,NA,1996-12-30,1998-12-24,724,6.584791392385716,Early-PDUFA
Celebrex,celecoxib,Searle,NDA,20998,NA,NA,Capsule,Oral,NA,NA,NA,NA,6/30/1998,12/31/1998,1998,indicated for relief of the signs and symptoms of osteoarthritis; also indicated for relief of signs and symptoms of rheumatoid arthritis in adults,NA,Priority,No,No,N/A,No,N/A,N/A,N/A,NA,1998-06-30,1998-12-31,184,5.214935757608986,Early-PDUFA
Pletal,cilostazol,Otsuka Pharmaceutical,NDA,20863,NA,NA,Tablet,Oral,NA,NA,NA,NA,9/19/1997,1/15/1999,1999,indicated for the reduction of symptoms of intermittent claudication,NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,1997-09-19,1999-01-15,483,6.180016653652572,Early-PDUFA
Panretin,alitretinoin,Ligand Pharm,NDA,20886,NA,NA,Gel,Topical,NA,NA,NA,NA,5/27/1998,2/2/1999,1999,topical treatment of cutaneous lesions in patients with AIDS-related Kaposi’s sarcoma,NA,Priority,Yes,No,N/A,No,N/A,N/A,N/A,NA,1998-05-27,1999-02-02,251,5.5254529391317835,Early-PDUFA
Ontak,denileukin diftitox,Seragen,BLA,103767,NA,NA,Injectable,Injection,NA,NA,NA,NA,12/9/1997,2/5/1999,1999,treatment of patients with persistent or recurrent cutaneous T-cell lymphoma whose malignant cells express the CD25 component of the IL-2 receptor,NA,Priority,Yes,Yes,N/A,No,N/A,N/A,N/A,NA,1997-12-09,1999-02-05,423,6.0473721790462776,Early-PDUFA
Ferrlecit,sodium ferric gluconate complex,Makoff R&D Labs,NDA,20955,NA,NA,Injectable,Injection,NA,NA,NA,NA,12/30/1997,2/18/1999,1999,treatment of iron deficiency anemia in patients undergoing chronic hemodialysis who are receiving supplemental erythropoietin therapy,NA,Priority,No,No,N/A,No,N/A,N/A,N/A,NA,1997-12-30,1999-02-18,415,6.028278520230698,Early-PDUFA
Wellferon,interferon alfa-n1,Glaxo Wellcome,BLA,103760,NA,NA,Injectable,Injection,NA,NA,NA,NA,9/30/1997,3/25/1999,1999,treatment of chronic hepatitis C in patients 18 years of age or older without decompensated liver disease,NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,1997-09-30,1999-03-25,541,6.293419278846481,Early-PDUFA
Agenerase,amprenavir,Glaxo Wellcome,NDA,21007,21039,NA,Capsule,Oral,Solution,Oral,NA,NA,10/16/1998,4/15/1999,1999,"in combination with other antiretroviral agents, for the treatment of HIV-1 infection",NA,Priority,No,Yes,N/A,Yes,N/A,N/A,N/A,NA,1998-10-16,1999-04-15,181,5.198497031265826,Early-PDUFA
Xenical,orlistat,Roche,NDA,20766,NA,NA,Capsule,Oral,NA,NA,NA,NA,11/27/1996,4/23/1999,1999,indicated for obesity management including weight loss and weight maintenance when used in conjunction with a reduced-calorie diet;  also indicated to reduce the risk for weight re-gain after prior loss,NA,Priority,No,No,N/A,No,N/A,N/A,N/A,NA,1996-11-27,1999-04-23,877,6.776506992372183,Early-PDUFA
Vioxx,rofecoxib,Merck Research Laboratories,NDA,21042,21052,NA,Tablet,Oral,Suspension,Oral,NA,NA,11/23/1998,5/20/1999,1999,"indicated for the relief of the signs and symptoms of osteoarthritis, for the management of acute pain, and for the treatment of primary dysmenorrhea",NA,Priority,No,No,N/A,No,N/A,N/A,N/A,NA,1998-11-23,1999-05-20,178,5.181783550292085,Early-PDUFA
Avandia,rosiglitazone maleate,SKB Pharms,NDA,21071,NA,NA,Tablet,Oral,NA,NA,NA,NA,11/25/1998,5/25/1999,1999,indicated as an adjunct to diet and exercise to improve glycemic control in patients with Type 2 diabetes mellitus as monotherapy or in combination with metformin,NA,Priority,No,No,N/A,No,N/A,N/A,N/A,NA,1998-11-25,1999-05-25,181,5.198497031265826,Early-PDUFA
Hectorol,doxercalciferol,Bone Care,NDA,20862,NA,NA,Capsule,Oral,NA,NA,NA,NA,3/9/1998,6/9/1999,1999,indicated for the reduction of elevated iPTH levels in the management of secondary hyperparathyroidism in patients undergoing chronic renal dialysis,NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,1998-03-09,1999-06-09,457,6.124683390894205,Early-PDUFA
Zaditor,ketotifen fumarate,Ciba Vision,NDA,21066,NA,NA,Solution/Drops,Ophthalmic,NA,NA,NA,NA,1/4/1999,7/2/1999,1999,prevention of itching of the eye due to allergic conjunctivitis,NA,Priority,No,No,N/A,No,N/A,N/A,N/A,NA,1999-01-04,1999-07-02,179,5.187385805840755,Early-PDUFA
Actos,pioglitazone hydrochloride,Takeda America,NDA,21073,NA,NA,Tablet,Oral,NA,NA,NA,NA,1/15/1999,7/15/1999,1999,"indicated for the improvement of glycemic control in patients with type 2 diabetes as monotherapy, or in combination with a sulfonylurea, metformin or insulin when diet and the single agent does not result in adequate glycemic control",NA,Priority,No,No,N/A,No,N/A,N/A,N/A,NA,1999-01-15,1999-07-15,181,5.198497031265826,Early-PDUFA
Relenza,zanamivir,Glaxo Wellcome,NDA,21036,NA,NA,Powder,Inhalation,NA,NA,NA,NA,10/27/1998,7/26/1999,1999,treatment of uncomplicated acute illness due to influenza virus in adults and adolescents twelve years and older who have been symptomatic for no more than two days,NA,Priority,No,No,N/A,No,N/A,N/A,N/A,NA,1998-10-27,1999-07-26,272,5.605802066295998,Early-PDUFA
Antagon,ganirelix acetate,Organon,NDA,21057,NA,NA,Injectable,Injection,NA,NA,NA,NA,1/29/1999,7/29/1999,1999,indicated for the inhibition of premature LH surges in women undergoing controlled ovarian hyperstimulation,NA,Priority,No,No,N/A,No,N/A,N/A,N/A,NA,1999-01-29,1999-07-29,181,5.198497031265826,Early-PDUFA
NeoTect,technetium Tc 99m depreotide,Diatide,NDA,21012,NA,NA,Injectable,Injection,NA,NA,NA,NA,6/16/1998,8/3/1999,1999,indicated as a scintigraphic imaging agent that identifies somatostatin receptor-bearing pulmonary masses in patients presenting with pulmonary lesions on computed tomography and/or chest x-ray who have known malignancy or who are highly suspect for malignancy,NA,Priority,No,No,N/A,No,N/A,N/A,N/A,NA,1998-06-16,1999-08-03,413,6.023447592961033,Early-PDUFA
Temodar,temozolomide,Schering,NDA,21029,NA,NA,Capsule,Oral,NA,NA,NA,NA,8/13/1998,8/11/1999,1999,"treatment of adult patients with refractory anaplastic astrocytoma, i.e., patients at first relapse who have experienced disease progression on a drug regimen containing a nitrosourea and procarbazine",NA,Priority,Yes,Yes,N/A,No,N/A,N/A,N/A,NA,1998-08-13,1999-08-11,363,5.8944028342648505,Early-PDUFA
Sonata,zaleplon,Wyeth-Ayerst,NDA,20859,NA,NA,Capsule,Oral,NA,NA,NA,NA,1/6/1998,8/13/1999,1999,short-term treatment of insomnia,NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,1998-01-06,1999-08-13,584,6.369900982828227,Early-PDUFA
Raplon,rapacuronium bromide,Organon,NDA,20984,NA,NA,Injectable,Injection,NA,NA,NA,NA,6/25/1998,8/18/1999,1999,"indicated for outpatients and inpatients as an adjunct to general anesthesia to facilitate tracheal intubation, and to provide skeletal muscle relaxation during surgical procedures",NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,1998-06-25,1999-08-18,419,6.037870919922137,Early-PDUFA
Aciphex,rabeprazole sodium,Eisai,NDA,20973,NA,NA,"Tablet, Delayed Release",Oral,NA,NA,NA,NA,3/31/1998,8/19/1999,1999,"indicated for: healing of erosive or ulcerative gastroesophageal reflux disease (GERD); maintenance of healing of erosive or ulcerative GERD; healing of duodenal ulcer; treatment of pathological hypersecretory conditions, including Zollinger-Ellison Syndrome",NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,1998-03-31,1999-08-19,506,6.226536669287466,Early-PDUFA
Ellence,epirubicin hydrochloride,Pharmacia and Upjohn,NDA,50778,NA,NA,Injectable,Injection,NA,NA,NA,NA,12/15/1998,9/15/1999,1999,indicated as a component of adjuvant therapy in patients with evidence of axillary node tumor involvement following resection of primary breast cancer,NA,Priority,Yes,No,N/A,No,N/A,N/A,N/A,NA,1998-12-15,1999-09-15,274,5.6131281063880705,Early-PDUFA
Rapamune,sirolimus,Wyeth Ayerst Research,NDA,21083,NA,NA,Solution,Oral,NA,NA,NA,NA,12/15/1998,9/15/1999,1999,prophylaxis of organ rejection in patients receiving renal transplants,NA,Priority,No,No,N/A,No,N/A,N/A,N/A,NA,1998-12-15,1999-09-15,274,5.6131281063880705,Early-PDUFA
Synercid,"dalfopristin, quinupristin",Rhone-Poulenc Rorer,NDA,50747,50748,NA,Injectable,Injection,Injectable,Injection,NA,NA,9/5/1997,9/21/1999,1999,"[A] treatment of vancomycin resistant Enterococcus faecium
[B] treatment of complicated skin and skin structure infections",NA,Priority (indication [A] only),No,Yes (indication [A] only),N/A,No,N/A,N/A,N/A,NA,1997-09-05,1999-09-21,746,6.61472560020376,Early-PDUFA
Alamast,pemirolast potassium,Santen,NDA,21079,NA,NA,Solution/Drops,Ophthalmic,NA,NA,NA,NA,3/26/1999,9/24/1999,1999,prevention of itching of the eye due to allergic conjunctivitis,NA,Priority,No,No,N/A,No,N/A,N/A,N/A,NA,1999-03-26,1999-09-24,182,5.204006687076795,Early-PDUFA
Tikosyn,dofetilide,Pfizer,NDA,20931,NA,NA,Capsule,Oral,NA,NA,NA,NA,3/9/1998,10/1/1999,1999,indicated for the maintenance of normal sinus rhythm (delay in time to recurrence of atrial fibrillation/atrial flutter) in patients with atrial fibrillation /atrial flutter of greater than one week duration who have been converted to normal sinus rhythm,NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,1998-03-09,1999-10-01,571,6.3473892096560105,Early-PDUFA
Comtan,entacapone,Orion,NDA,20796,NA,NA,Tablet,Oral,NA,NA,NA,NA,1/2/1998,10/19/1999,1999,"indicated as an adjunct to levodopa/carbidopa to treat patients with idiopathic Parkinson’s Disease who experience the signs and symptoms of end-of-dose ""wearing-off"" (so called ""fluctuating"" patients)",NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,1998-01-02,1999-10-19,655,6.484635235635252,Early-PDUFA
Aromasin,exemestane,Pharmacia and Upjohn,NDA,20753,NA,NA,Tablet,Oral,NA,NA,NA,NA,12/21/1998,10/21/1999,1999,treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy,NA,Standard,Yes,No,N/A,No,N/A,N/A,N/A,NA,1998-12-21,1999-10-21,304,5.717027701406222,Early-PDUFA
Tamiflu,oseltamivir phosphate,Roche,NDA,21087,NA,NA,Capsule,Oral,NA,NA,NA,NA,4/29/1999,10/27/1999,1999,"treatment of uncomplicated acute illness due to influenza infections in adults who have been symptomatic for no more than
two days",NA,Priority,No,No,N/A,No,N/A,N/A,N/A,NA,1999-04-29,1999-10-27,181,5.198497031265826,Early-PDUFA
Curosurf,poractant,Dey Laboratories,BLA,20744,NA,NA,Suspension,Intratracheal,NA,NA,NA,NA,7/3/1996,11/18/1999,1999,treatment (rescue) of Respiratory Distress Syndrome (RDS) in premature infants,NA,Standard,Yes,No,N/A,No,N/A,N/A,N/A,Transition Product from NDA to BLA due to BPCI : Please see page 2 of data dictionary for more information.,1996-07-03,1999-11-18,1233,7.117205503164344,Early-PDUFA
Keppra,levetiracetam,UCP Pharma,NDA,21035,NA,NA,Tablet,Oral,NA,NA,NA,NA,2/1/1999,11/30/1999,1999,indicated as an adjunctive therapy in the treatment of partial onset seizures in adults with epilepsy,NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,1999-02-01,1999-11-30,302,5.71042701737487,Early-PDUFA
Levulan Kerastick,aminolevulinic acid hydrochloride,Dusa,NDA,20965,NA,NA,Solution,Topical,NA,NA,NA,NA,7/1/1998,12/3/1999,1999,Levulan Kerastick plus blue light illumination using the BLU-U Blue Light Photodynamic Therapy Illuminator is indicated for the treatment of non-hyperkeratotic actinic keratoses of the face and scalp,NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,1998-07-01,1999-12-03,520,6.253828811575473,Early-PDUFA
Optimark,gadoversetamide,Mallinckrodt,NDA,20937,20975,20976,Injectable,Injection,Injectable,Injection,Injectable,Injection,3/2/1998,12/8/1999,1999,"indicated for the use with magnetic resonance imaging (MRI) in patients with an abnormal blood barrier or abnormal vascularity of the brain, spine and associated tissues; and with MRI to provide contrast enhancement and facilitate visualization of lesions with abnormal vascularity in the liver in patients who are highly suspect for liver structural abnormalities identified on computerized tomography",NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,1998-03-02,1999-12-08,646,6.470799503782602,Early-PDUFA
Solage,"mequinol, tretinoin",Bristol-Myers Squibb,NDA,20922,NA,NA,Solution,Topical,NA,NA,NA,NA,12/30/1997,12/10/1999,1999,treatment of solar lentigines,NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,1997-12-30,1999-12-10,710,6.565264970035361,Early-PDUFA
Avelox,moxifloxacin hydrochloride,Bayer,NDA,21085,NA,NA,Tablet,Oral,NA,NA,NA,NA,12/10/1998,12/10/1999,1999,"indicated for the treatment of adults with infections caused by susceptible strains of  designated microorganisms in the
following conditions: acute bacterial sinusitis, acute bacterial exacerbation of chronic bronchitis, community-acquired pneumonia",NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,1998-12-10,1999-12-10,365,5.8998973535824915,Early-PDUFA
Precedex,dexmedetomidine hydrochloride,Abbott Laboratories,NDA,21038,NA,NA,Injectable,Injection,NA,NA,NA,NA,12/18/1998,12/17/1999,1999,indicated for the sedation of initially intubated and mechanically ventilated adult patients in an intensive care unit setting,NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,1998-12-18,1999-12-17,364,5.8971538676367405,Early-PDUFA
Tequin,gatifloxacin,Bristol-Myers Squibb,NDA,21061,21062,NA,Tablet,Oral,Injectable,Injection,NA,NA,12/28/1998,12/17/1999,1999,"indicated for the treatment of infections caused by susceptible strains of designated microorganisms in the
following conditions: acute bacterial exacerbation of chronic bronchitis, acute sinusitis, community-acquired pneumonia, uncomplicated and complicated urinary tract infections, pyelonephritis, and uncomplicated gonorrhea",NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,1998-12-28,1999-12-17,354,5.869296913133774,Early-PDUFA
Inomax,nitric oxide,Ino Therapeutics,NDA,20845,NA,NA,Gas,Inhalation,NA,NA,NA,NA,6/16/1997,12/23/1999,1999,"indicated in conjunction with ventilatory support and other appropriate agents, is indicated for the treatment of term and near-term (>34 weeks) neonates with hypoxic respiratory failure associated with clinical or echocardiographic evidence or pulmonary hypertension, where it improves oxygenation and reduces the need for extracorporeal membrane oxygenation",NA,Priority,Yes,No,N/A,No,N/A,N/A,N/A,NA,1997-06-16,1999-12-23,920,6.824373670043086,Early-PDUFA
Targretin,bexarotene,Ligand Pharms,NDA,21055,NA,NA,Capsule,Oral,NA,NA,NA,NA,6/23/1999,12/29/1999,1999,treatment of cutaneous manifestations of cutaneous T-cell lymphoma in patients who are refractory to at least one prior systemic therapy,NA,Priority,Yes,No,N/A,No,N/A,N/A,N/A,NA,1999-06-23,1999-12-29,189,5.241747015059643,Early-PDUFA
Evoxac,cevimeline hydrochloride,Snowbrand Pharmaceuticals,NDA,20989,NA,NA,Capsule,Oral,NA,NA,NA,NA,8/27/1998,1/11/2000,2000,treatment of symptoms of dry mouth in patients with Sjögren's Syndrome,NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,1998-08-27,2000-01-11,502,6.218600119691729,Early-PDUFA
Trileptal,oxcarbazepine,Novartis Pharmaceuticals,NDA,21014,NA,NA,Tablet,Oral,NA,NA,NA,NA,9/25/1998,1/14/2000,2000,indicated for use as monotherapy or adjunctive therapy in the treatment of partial seizures in adults with epilepsy and as adjunctive therapy in the treatment of partial seizures in children ages 4-16 with epilepsy,NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,1998-09-25,2000-01-14,476,6.16541785423142,Early-PDUFA
Protonix,pantoprazole sodium,Wyeth-Ayerst Laboratories,NDA,20987,NA,NA,"Tablet, Delayed Release",Oral,NA,NA,NA,NA,6/30/1998,2/2/2000,2000,short-term treatment (up to 8 weeks) in the healing and symptomatic relief of erosive esophagitis,NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,1998-06-30,2000-02-02,582,6.366470447731438,Early-PDUFA
Lotronex,alosetron hydrochloride,Glaxo Wellcome,NDA,21107,NA,NA,Tablet,Oral,NA,NA,NA,NA,6/30/1999,2/9/2000,2000,treatment of irritable bowel syndrome (IBS) in female patients whose predominant bowel symptom is diarrhea,NA,Priority,No,No,N/A,No,N/A,N/A,N/A,NA,1999-06-30,2000-02-09,224,5.4116460518550396,Early-PDUFA
Skin Exposure Reduction Paste Against Chemical Warfare Agents (SERPACWA),"perfluoroalkylpolyether, polytetrafluoroethylene",US Army Medical Research and Materiel Command,NDA,21084,NA,NA,Paste,Topical,NA,NA,NA,NA,8/19/1999,2/17/2000,2000,in conjunction with Mission Oriented Protective Posture (MOPP) gear to reduce or delay the absorption of chemical warfare agents through the skin when applied prior to exposure,NA,Priority,No,No,N/A,No,N/A,N/A,N/A,NA,1999-08-19,2000-02-17,182,5.204006687076795,Early-PDUFA
Zonegran,zonisamide,Elan Pharmaceuticals,NDA,20789,NA,NA,Capsule,Oral,NA,NA,NA,NA,3/19/1997,3/27/2000,2000,indicated as an adjunctive therapy in the treatment of partial seizures in adults with epilepsy,NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,1997-03-19,2000-03-27,1104,7.00669522683704,Early-PDUFA
Septocaine,"articaine hydrochloride, ephinephrine",Deproco,NDA,20971,NA,NA,Injectable,Injection,NA,NA,NA,NA,3/30/1998,4/3/2000,2000,"indicated for local, infiltrative, or conductive anesthesia in both simple and complex dental and periodontal procedures",NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,1998-03-30,2000-04-03,735,6.5998704992128365,Early-PDUFA
Visudyne,verteporfin,QLT Phototherapeutics,NDA,21119,NA,NA,Injectable,Injection,NA,NA,NA,NA,8/16/1999,4/12/2000,2000,treatment of age-related macular degeneration in patients with predominantly classic subfoveal choroidal neovascularization,NA,Priority,No,No,N/A,No,N/A,N/A,N/A,NA,1999-08-16,2000-04-12,240,5.480638923341991,Early-PDUFA
Mobic,meloxicam,Boehringer Ingelheim Pharmaceuticals,NDA,20938,NA,NA,Tablet,Oral,NA,NA,NA,NA,12/16/1998,4/13/2000,2000,indicated for the relief of the signs and symptoms of osteoarthritis,NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,1998-12-16,2000-04-13,484,6.182084906716632,Early-PDUFA
Zyvox,linezolid,Pharmacia and Upjohn,NDA,21130,21131,21132,Tablet,Oral,Injectable,Injection,Suspension,Oral,10/18/1999,4/18/2000,2000,"treatment of adult patients with vancomycin-resistant Enterococcus faecium infections, nosocomial pneumonia, complicated and uncomplicated skin and skin structure infections, and community-acquired pneumonia",NA,Priority,No,No,N/A,No,N/A,N/A,N/A,NA,1999-10-18,2000-04-18,183,5.209486152841421,Early-PDUFA
Lantus,insulin glargine,Aventis Pharmaceuticals,BLA,21081,NA,NA,Injectable,Injection,NA,NA,NA,NA,4/23/1999,4/20/2000,2000,treatment of adult and pediatric patients with type 1 diabetes mellitus or adult patients with type 2 diabetes mellitus who require basal (long-acting) insulin for the control of hyperglycemia,NA,Standard,No,No,N/A,No,N/A,N/A,N/A,Transition Product from NDA to BLA due to BPCI : Please see page 2 of data dictionary for more information.,1999-04-23,2000-04-20,363,5.8944028342648505,Early-PDUFA
Exelon,rivastigmine tartrate,Novartis Pharmaceuticals,NDA,20823,21025,NA,Capsule,Oral,Solution,Oral,NA,NA,4/7/1997,4/21/2000,2000,treatment of mild to moderate dementia of the Alzheimer’s type,NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,1997-04-07,2000-04-21,1110,7.01211529430638,Early-PDUFA
Mylotarg,gemtuzumab ozogamicin,Wyeth-Ayerst,NDA,21174,NA,NA,Injectable,Injection,NA,NA,NA,NA,10/29/1999,5/17/2000,2000,treatment of patients with CD33 positive acute myeloid leukemia in first relapse who are 60 years of age or older and who are not considered candidates for cytotoxic chemotherapy,NA,Priority,Yes,Yes,N/A,No,N/A,N/A,N/A,NA,1999-10-29,2000-05-17,201,5.303304908059076,Early-PDUFA
Welchol,colesevelam hydrochloride,GelTex,NDA,21176,21141,NA,Tablet,Oral,Capsule,Oral,NA,NA,7/30/1999,5/26/2000,2000,"alone or in combination with an HMG-CoA reductase inhibitor, for the reduction of elevated LDL-cholesterol in patients with primary hypercholesterolemia (Frederickson Type IIa)",NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,1999-07-30,2000-05-26,301,5.707110264748875,Early-PDUFA
TNKase,tenecteplase,Genentech,BLA,103909,NA,NA,Injectable,Injection,NA,NA,NA,NA,8/2/1999,6/2/2000,2000,indicated for reduction of mortality associated with acute myocardial infarction (AMI),NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,1999-08-02,2000-06-02,305,5.720311776607412,Early-PDUFA
Novolog,insulin aspart recombinant,Novo Nordisk,BLA,20986,NA,NA,Injectable,Subcutaneous,NA,NA,NA,NA,9/16/1998,6/7/2000,2000,"treatment of adult patients with diabetes mellitus, for the control of hyperglycemia",NA,Standard,No,No,N/A,No,N/A,N/A,N/A,Transition Product from NDA to BLA due to BPCI : Please see page 2 of data dictionary for more information.,1998-09-16,2000-06-07,630,6.4457198193855785,Early-PDUFA
Trelstar Depot,triptorelin pamoate,Debio Recherche,NDA,20715,NA,NA,Injectable,Intramuscular,NA,NA,NA,NA,6/26/1996,6/15/2000,2000,palliative treatment of advanced prostate cancer,NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,1996-06-26,2000-06-15,1450,7.27931883541462,Early-PDUFA
Acova,argatroban,Texas Biotechnology Corporation,NDA,20883,NA,NA,Injectable,Injection,NA,NA,NA,NA,8/15/1997,6/30/2000,2000,indicated as an anticoagulant for prophylaxis or treatment of thrombosis in patients with heparin-induced thrombocytopenia,NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,1997-08-15,2000-06-30,1050,6.956545443151569,Early-PDUFA
Innohep,tinzaparin sodium,Dupont Pharmaceuticals,NDA,20484,NA,NA,Injectable,Injection,NA,NA,NA,NA,6/30/1999,7/14/2000,2000,treatment of acute symptomatic deep vein thrombosis with or without pulmonary embolism when administered in conjunction with warfarin sodium,NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,1999-06-30,2000-07-14,380,5.940171252720432,Early-PDUFA
Colazal,balsalazide disodium,Salix Pharmaceuticals,NDA,20610,NA,NA,Capsule,Oral,NA,NA,NA,NA,6/23/1997,7/18/2000,2000,treatment of mildly to moderate active ulcerative colitis,NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,1997-06-23,2000-07-18,1121,7.02197642307216,Early-PDUFA
Abreva,docosanol,Avanir Pharmaceuticals,NDA,20941,NA,NA,Cream,Topical,NA,NA,NA,NA,12/22/1997,7/25/2000,2000,treatment of cold sores and fever blisters,NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,1997-12-22,2000-07-25,946,6.852242569051878,Early-PDUFA
Rescula,unoprostone isopropyl,Ciba Vision,NDA,21214,NA,NA,Solution/Drops,Ophthalmic,NA,NA,NA,NA,2/15/2000,8/3/2000,2000,indicated for the lowering of intraocular pressure in patients with open-angel glaucoma or ocular hypertension who are intolerant of other intraocular pressure lowering medications or insufficiently responsive (failed to achieve target IOP determined after multiple measurements over time) to another intraocular pressure lowering medication,NA,Priority,No,No,N/A,No,N/A,N/A,N/A,NA,2000-02-15,2000-08-03,170,5.135798437050262,Early-PDUFA
Cetrotide,cetrorelix acetate,Asta Medica,NDA,21197,NA,NA,Injectable,Injection,NA,NA,NA,NA,10/29/1999,8/11/2000,2000,prevention of premature LH surges in women undergoing controlled ovarian stimulation,NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,1999-10-29,2000-08-11,287,5.659482215759621,Early-PDUFA
Kaletra,"lopinavir, ritonavir",Abbott Laboratories,NDA,21226,21251,NA,Capsule,Oral,Solution,Oral,NA,NA,6/1/2000,9/15/2000,2000,in combination with other antiretroviral agents for the treatment of HIV-1 infections in adults and pediatric patients age six months and older,NA,Priority,No,Yes,N/A,Yes,N/A,N/A,N/A,NA,2000-06-01,2000-09-15,106,4.663439094112067,Early-PDUFA
Trisenox,arsenic trioxide,Cell Therapeutics,NDA,21248,NA,NA,Injectable,Injection,NA,NA,NA,NA,3/28/2000,9/25/2000,2000,"indicated for induction of remission and consolidation in patients with acute promyelocytic leukemia (APL) who are refractory to, or have relapsed from, retinoid and anthracycline chemotherapy, and whose APL is characterized by the presence of the t(15;17) translocation or PML/RAR-alpha gene expression",NA,Priority,Yes,No,N/A,Yes,N/A,N/A,N/A,NA,2000-03-28,2000-09-25,181,5.198497031265826,Early-PDUFA
Mifeprex,mifepristone,Population Council,NDA,20687,NA,NA,Tablet,Oral,NA,NA,NA,NA,3/18/1996,9/28/2000,2000,indicated for medical termination of intrauterine pregnancy through 49 days’ pregnancy,NA,Priority,No,No,N/A,No,N/A,N/A,N/A,NA,1996-03-18,2000-09-28,1655,7.411556287811163,Early-PDUFA
Myobloc,botulinum toxin type B,Elan Pharmaceuticals,BLA,103846,NA,NA,Injectable,Injection,NA,NA,NA,NA,12/22/1998,12/8/2000,2000,treatment of patients with cervical dystonia to reduce the severity of abnormal head position and neck pain associated with cervical dystonia,NA,Standard,Yes,No,N/A,No,N/A,N/A,N/A,NA,1998-12-22,2000-12-08,717,6.57507584059962,Early-PDUFA
Angiomax,bivalirudin,The Medicines Company,NDA,20873,NA,NA,Injectable,Intravenous,NA,NA,NA,NA,12/23/1997,12/15/2000,2000,indicated for use as an anticoagulant in conjunction with aspirin in patients with unstable angina undergoing percutaneous transluminal coronary angioplasty (PTCA),NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,1997-12-23,2000-12-15,1088,6.992096427415888,Early-PDUFA
Starlix,nateglinide,Novartis Pharmaceuticals,NDA,21204,NA,NA,Tablet,Oral,NA,NA,NA,NA,12/17/1999,12/22/2000,2000,"indicated  as  monotherapy  to  lower  blood  glucose  in  patients  with  Type  2  diabetes (non-insulin   dependent   diabetes   mellitus,   NIDDM)   whose   hyperglycemia   cannot   be adequately controlled by diet and physical exercise and who have not been chronically treated with other anti-diabetic agents; also indicated   for   use   in   combination   with   metformin in  patients   whose hyperglycemia  is  inadequately  controlled  with  metformin,  Starlix    may  be  added  to,  but  not substituted for, metformin",NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,1999-12-17,2000-12-22,371,5.916202062607435,Early-PDUFA
Peg-Intron,peginterferon alfa-2b,Schering,BLA,103949,NA,NA,Injectable,Injection,NA,NA,NA,NA,12/23/1999,1/19/2001,2001,treatment of chronic hepatitis C in patients not previously treated with interferon alfa who have compensated liver disease and are at least 18 years of age,NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,1999-12-23,2001-01-19,393,5.973809611869261,Early-PDUFA
Cancidas,caspofungin acetate,Merck Research Laboratories,NDA,21227,NA,NA,Powder,Intravenous,NA,NA,NA,NA,7/28/2000,1/26/2001,2001,treatment of invasive aspergillosis in patients who are refractory to or intolerant of other therapies,NA,Priority,No,No,N/A,Yes,N/A,N/A,N/A,NA,2000-07-28,2001-01-26,182,5.204006687076795,Early-PDUFA
Geodon,ziprasidone hydrochloride,Pfizer Central Research,NDA,20825,NA,NA,Capsule,Oral,NA,NA,NA,NA,3/17/1997,2/5/2001,2001,treatment of schizophrenia,NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,1997-03-17,2001-02-05,1421,7.259116128097101,Early-PDUFA
Foradil,formoterol fumarate,Novartis Pharmaceuticals,NDA,20831,NA,NA,Powder,Inhalation,NA,NA,NA,NA,6/26/1997,2/16/2001,2001,"indicated for the long-term, administration in the maintenance treatment of asthma and in the prevention of bronchospasm in adults and children 5 years of age and older with reversible obstructive airways disease, including patients with symptoms of nocturnal asthma; also indicated for the acute prevention of exercise-induced bronchospasm (EIB) in adults and children 12 years of age and older, when administered on an occasional, as-needed basis",NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,1997-06-26,2001-02-16,1331,7.193685818395112,Early-PDUFA
Reminyl,galantamine hydrobromide,Janssen Research Foundation,NDA,21169,NA,NA,Tablet,Oral,NA,NA,NA,NA,9/29/1999,2/28/2001,2001,treatment of mild to moderate dementia of the Alzheimer's type,NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,1999-09-29,2001-02-28,518,6.249975242259483,Early-PDUFA
Travatan,travoprost,Alcon Research,NDA,21257,NA,NA,Solution/Drops,Ophthalmic,NA,NA,NA,NA,7/7/2000,3/16/2001,2001,indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension who are intolerant of other intraocular pressure lowering medications or insufficiently responsive (failed to achieve target IOP determined after multiple measurements over time) to another intraocular pressure lowering medication,NA,Priority,No,No,N/A,No,N/A,N/A,N/A,NA,2000-07-07,2001-03-16,252,5.529429087511423,Early-PDUFA
Lumigan,bimatoprost,Allergan,NDA,21275,NA,NA,Solution/Drops,Ophthalmic,NA,NA,NA,NA,9/18/2000,3/16/2001,2001,indicated for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension who are intolerant of other intraocular pressure lowering medications or insufficiently responsive (failed to achieve target IOP determined after multiple measurements over time) to another intraocular pressure lowering medication,NA,Priority,No,No,N/A,No,N/A,N/A,N/A,NA,2000-09-18,2001-03-16,179,5.187385805840755,Early-PDUFA
Campath,alemtuzumab,Millennium and ILEX Partners,BLA,103948,NA,NA,Injectable,Injection,NA,NA,NA,NA,12/23/1999,5/7/2001,2001,treatment of patients with B-cell chronic lymphocytic leukemia who have been treated with alkylating agents and who have failed fludarabine therapy,NA,Priority,Yes,Yes,N/A,Yes,N/A,N/A,N/A,NA,1999-12-23,2001-05-07,501,6.2166061010848646,Early-PDUFA
Axert,almotriptan malate,Pharmacia and Upjohn,NDA,21001,NA,NA,Tablet,Oral,NA,NA,NA,NA,12/20/1999,5/7/2001,2001,indicated for the acute treatment of migraine with or without aura in adults,NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,1999-12-20,2001-05-07,504,6.222576268071369,Early-PDUFA
Gleevec,imatinib mesylate,Novartis Pharmaceuticals,NDA,21335,NA,NA,Capsule,Oral,NA,NA,NA,NA,2/27/2001,5/10/2001,2001,"indicated for the treatment of patients with chronic myeloid leukemia (CML) in blast crisis, accelerated phase, or in chronic phase after failure of interferon-alpha therapy",NA,Priority,Yes,Yes,N/A,Yes,N/A,N/A,N/A,NA,2001-02-27,2001-05-10,72,4.276666119016055,Early-PDUFA
Yasmin,"drospirenone,ethinyl estradiol",Berlex Laboratories,NDA,21098,NA,NA,Tablet,Oral,NA,NA,NA,NA,5/17/1999,5/11/2001,2001,indicated for the prevention of pregnancy in women who elect to use an oral contraceptive,NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,1999-05-17,2001-05-11,725,6.586171654854675,Early-PDUFA
Definity,perflutren lipid microsphere,Dupont Pharmaceuticals,NDA,21064,NA,NA,Injectable,Intravenous,NA,NA,NA,NA,12/9/1998,7/31/2001,2001,indicated for use in patients with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border,NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,1998-12-09,2001-07-31,965,6.872128101338986,Early-PDUFA
Natrecor,nesiritide,Scios,NDA,20920,NA,NA,For Solution,Intravenous,NA,NA,NA,NA,4/27/1998,8/10/2001,2001,treatment of patients with acutely decompensated congestive heart failure who have dyspnea at rest or with minimal activity,NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,1998-04-27,2001-08-10,1201,7.0909098220799835,Early-PDUFA
Zometa,zoledronic acid,Novartis Pharmaceuticals,NDA,21223,NA,NA,Injectable,Intravenous,NA,NA,NA,NA,12/21/1999,8/20/2001,2001,treatment of hypercalcemia of malignancy,NA,Priority,Yes,No,N/A,No,N/A,N/A,N/A,NA,1999-12-21,2001-08-20,608,6.410174881966167,Early-PDUFA
Spectracef,cefditoren pivoxil,TAP Pharmaceutical Products,NDA,21222,NA,NA,Tablet,Oral,NA,NA,NA,NA,12/29/1999,8/29/2001,2001,"treatment of acute bacterial exacerbation of chronic bronchitis, pharyngitis/tonsillitis, and uncomplicated skin and skin structure infections",NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,1999-12-29,2001-08-29,609,6.411818267709897,Early-PDUFA
Aranesp,darbepoetin alfa,Amgen,BLA,103951,NA,NA,Injectable,Injection,NA,NA,NA,NA,12/28/1999,9/17/2001,2001,"treatment of anemia associated with chronic renal failure, including patients on dialysis and patients not on dialysis",NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,1999-12-28,2001-09-17,629,6.444131256700441,Early-PDUFA
NuvaRing,"etonogestrel, ethinyl estradiol",Organon,NDA,21187,NA,NA,Ring,Vaginal,NA,NA,NA,NA,12/28/1999,10/3/2001,2001,indicated for the prevention of pregnancy in women who elect to use this product as a method of contraception,NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,1999-12-28,2001-10-03,645,6.4692503167957724,Early-PDUFA
Viread,tenofovir disoproxil fumarate,Gilead Sciences,NDA,21356,NA,NA,Tablet,Oral,NA,NA,NA,NA,5/1/2001,10/26/2001,2001,in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults,NA,Priority,No,Yes,N/A,Yes,N/A,N/A,N/A,NA,2001-05-01,2001-10-26,178,5.181783550292085,Early-PDUFA
Frova,frovatriptan,Elan Pharmaceuticals,NDA,21006,NA,NA,Tablet,Oral,NA,NA,NA,NA,1/29/1999,11/8/2001,2001,acute treatment of migraine,NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,1999-01-29,2001-11-08,1014,6.921658184151129,Early-PDUFA
Kineret,anakinra,Amgen,BLA,103950,NA,NA,Injectable,Injection,NA,NA,NA,NA,12/28/1999,11/14/2001,2001,"indicated for the reduction in signs and symptoms of moderately to severely active rheumatoid arthritis, in patients 18 years of age or older who have failed one or more disease modifying antirheumatic drugs (DMARDs)",NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,1999-12-28,2001-11-14,687,6.532334292222349,Early-PDUFA
Bextra,valdecoxib,GD Searle,NDA,21341,NA,NA,Tablet,Oral,NA,NA,NA,NA,1/16/2001,11/16/2001,2001,indicated for the relief of signs and symptoms of osteoarthritis and adult rheumatoid arthritis and for the treatment of primary dysmenorrhea,NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,2001-01-16,2001-11-16,304,5.717027701406222,Early-PDUFA
Avodart,dutasteride,GlaxoSmithKline,NDA,21319,NA,NA,Capsule,Oral,NA,NA,NA,NA,12/21/2000,11/20/2001,2001,treatment of symptomatic benign prostatic hyperplasia in men with an enlarged prostate gland,NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,2000-12-21,2001-11-20,334,5.811140992976701,Early-PDUFA
Ortho Evra,"norelgestromin, ethinyl estradiol",RW Johnson Pharmaceutical Research,NDA,21180,NA,NA,"Film, Extended Release",Transdermal,NA,NA,NA,NA,12/21/2000,11/20/2001,2001,indicated for the prevention of pregnancy,NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,2000-12-21,2001-11-20,334,5.811140992976701,Early-PDUFA
Tracleer,bosentan,Actelion Pharmaceuticals,NDA,21290,NA,NA,Tablet,Oral,NA,NA,NA,NA,11/17/2000,11/20/2001,2001,indicated for the treatment of pulmonary arterial hypertension,NA,Standard,Yes,No,N/A,No,N/A,N/A,N/A,NA,2000-11-17,2001-11-20,368,5.908082938168931,Early-PDUFA
Invanz,ertapenem sodium,Merck,NDA,21337,NA,NA,Injectable,"Intramuscular, Intravenous",NA,NA,NA,NA,11/30/2000,11/21/2001,2001,"treatment of complicated intra-abdominal infections; complicated skin and skin structure infections; community acquired pneumonia; complicated urinary tract infections including pyelonephritis; acute pelvic infections including postpartum endomyometritis, septic abortion and post surgical gynecologic infections",NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,2000-11-30,2001-11-21,356,5.87493073085203,Early-PDUFA
Xigris,drotrecogin alfa,Eli Lilly,BLA,125029,NA,NA,Injectable,Injection,NA,NA,NA,NA,1/26/2001,11/21/2001,2001,indicated for the reduction of mortality in adult patients with severe sepsis (sepsis associated with acute organ dysfunction) who have a high risk of death,NA,Priority,No,No,N/A,No,N/A,N/A,N/A,NA,2001-01-26,2001-11-21,299,5.700443573390687,Early-PDUFA
Arixtra,fondaparinux sodium,Fonda BV,NDA,21345,NA,NA,Injectable,Subcutaneous,NA,NA,NA,NA,2/15/2001,12/7/2001,2001,"indicated for the prophylaxis of deep vein thrombosis, which may lead to pulmonary embolism, in patients undergoing hip fracture surgery, hip replacement surgery, or knee replacement surgery",NA,Priority,No,No,N/A,No,N/A,N/A,N/A,NA,2001-02-15,2001-12-07,295,5.68697535633982,Early-PDUFA
Elidel,pimecrolimus,Novartis Pharmaceuticals,NDA,21302,NA,NA,Cream,Topical,NA,NA,NA,NA,12/15/2000,12/13/2001,2001,"short-term and intermittent long-term therapy in the treatment of mild to moderate atopic dermatitis in non-immunocompromised patients 2 years of age and older, in whom the use of alternative, conventional therapies is deemed inadvisable because of potential risks, or in the treatment of patients who are not adequately responsive to or intolerant of alternative, conventional therapies",NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,2000-12-15,2001-12-13,363,5.8944028342648505,Early-PDUFA
Clarinex,desloratadine,Schering,NDA,21165,NA,NA,Tablet,Oral,NA,NA,NA,NA,10/21/1999,12/21/2001,2001,indicated for the relief of the nasal and non-nasal symptoms of seasonal allergic rhinitis in patients 12 years of age and older,NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,1999-10-21,2001-12-21,792,6.674561391814426,Early-PDUFA
Orfadin,nitisinone,Swedish Orphan,NDA,21232,NA,NA,Capsule,Oral,NA,NA,NA,NA,9/8/2000,1/18/2002,2002,indicated as adjunctive therapy to dietary restriction of tyrosine and phenylalanine in the treatment of hereditary tyrosinemia type 1,NA,Priority,Yes,No,N/A,Yes,N/A,N/A,N/A,NA,2000-09-08,2002-01-18,497,6.208590026096629,Early-PDUFA
Neulasta,pegfilgrastim,Amgen,BLA,125031,NA,NA,Injectable,Injection,NA,NA,NA,NA,4/2/2001,1/31/2002,2002,"indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia",NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,2001-04-02,2002-01-31,304,5.717027701406222,Early-PDUFA
Zevalin,ibritumomab tiuxetan,Idec Pharmaceuticals,BLA,125019,NA,NA,Injectable,Injection,NA,NA,NA,NA,11/1/2000,2/19/2002,2002,"as part of a specific therapeutic regimen including Rituximab, Indium-111, Ibritumomab Tiuxetan, and Yttrium-90 Ibritumomab Tiuxetan, is indicated for the treatment of patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma, including patients with Rituximab (Rituxan) refractory follicular non-Hodgkin’s lymphoma",NA,Priority,Yes,Yes,N/A,Yes,N/A,N/A,N/A,NA,2000-11-01,2002-02-19,475,6.163314804034641,Early-PDUFA
Rebif,interferon beta-1a,Serono,BLA,103780,NA,NA,Injectable,Injection,NA,NA,NA,NA,2/27/1998,3/7/2002,2002,treatment of patients with relapsing forms of multiple sclerosis to decrease the frequency of clinical exacerbations and delay the accumulation of physical disability,NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,1998-02-27,2002-03-07,1469,7.292337176173877,Early-PDUFA
Faslodex,fulvestrant,AstraZeneca Pharmaceuticals,NDA,21344,NA,NA,Injectable,Intramuscular,NA,NA,NA,NA,3/28/2001,4/25/2002,2002,treatment of hormone receptor positive metastatic breast cancer in postmenopausal women with disease progression following antiestrogen therapy,NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,2001-03-28,2002-04-25,393,5.973809611869261,Early-PDUFA
Benicar,olmesartan medoxomil,Sankyo,NDA,21286,NA,NA,Tablet,Oral,NA,NA,NA,NA,7/25/2000,4/25/2002,2002,treatment of hypertension,NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,2000-07-25,2002-04-25,639,6.459904454377535,Early-PDUFA
Remodulin,treprostinil sodium,United Therapeutics,NDA,21272,NA,NA,Injectable,"Iv (Infusion), Subcutaneous",NA,NA,NA,NA,10/16/2000,5/21/2002,2002,treatment of pulmonary arterial hypertension,NA,Priority,Yes,Yes,N/A,No,N/A,N/A,N/A,NA,2000-10-16,2002-05-21,582,6.366470447731438,Early-PDUFA
Vfend,voriconazole,Pfizer,NDA,21266,21267,NA,Tablet,Oral,Injectable,Injection,NA,NA,11/17/2000,5/24/2002,2002,"treatment of invasive aspergillosis and serious fungal infections caused by Scedosporium apiospermum and Fusarium spp., including Fusarium solani, in patients intolerant of, or refractory to, other therapy",NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,2000-11-17,2002-05-24,553,6.315358001522335,Early-PDUFA
Imagent,"dimyristoylphosphatidylcholine, perflexane",Alliance Pharmaceuticals,NDA,21191,NA,NA,Injectable,Intravenous,NA,NA,NA,NA,10/14/1999,5/31/2002,2002,indicated for the use in patients with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border,NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,1999-10-14,2002-05-31,960,6.866933284461882,Early-PDUFA
Elitek,rasburicase,Sanofi-Synthelabo,BLA,103946,NA,NA,Injectable,Injection,NA,NA,NA,NA,12/16/1999,7/12/2002,2002,"indicated for the initial management of plasma uric acid levels in pediatric patients with leukemia, lymphoma, and solid tumor malignancies who are receiving anti-cancer therapy expected to result in tumor lysis and subsequent elevation of plasma uric acid",NA,Standard,Yes,No,N/A,No,N/A,N/A,N/A,NA,1999-12-16,2002-07-12,939,6.844815479208263,Early-PDUFA
Xyrem,sodium oxybate,Orphan Medical,NDA,21196,NA,NA,Solution,Oral,NA,NA,NA,NA,10/2/2000,7/17/2002,2002,treatment of cataplexy associated with narcolepsy,NA,Priority,Yes,No,N/A,No,N/A,N/A,N/A,NA,2000-10-02,2002-07-17,653,6.481577129276431,Early-PDUFA
Zelnorm,tegaserod maleate,Novartis Pharmaceuticals,NDA,21200,NA,NA,Tablet,Oral,NA,NA,NA,NA,2/11/2000,7/24/2002,2002,short-term treatment of women with irritable bowel syndrome whose primary bowel symptom is constipation,NA,Priority,No,No,N/A,No,N/A,N/A,N/A,NA,2000-02-11,2002-07-24,894,6.795705775173514,Early-PDUFA
Eloxatin,oxaliplatin,Sanofi-Synthelabo,NDA,21492,NA,NA,Injectable,Intravenous,NA,NA,NA,NA,6/24/2002,8/9/2002,2002,in combination with infusional 5-FU/LV for the treatment of patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed during or within 6 months of completion of first line therapy with the combination of bolus 5-FU/LV and irinotecan,NA,Priority,No,Yes,N/A,Yes,N/A,N/A,N/A,NA,2002-06-24,2002-08-09,46,3.828641396489095,Early-PDUFA
Hepsera,adefovir dipivoxil,Gilead Sciences,NDA,21449,NA,NA,Tablet,Oral,NA,NA,NA,NA,3/21/2002,9/20/2002,2002,treatment of chronic hepatitis B in adults with evidence of active viral replication and either evidence of persistent elevations in serum alanine aminotransferase (ALT)/aspartate aminotransferase (AST) or histologically active disease,NA,Priority,No,No,N/A,No,N/A,N/A,N/A,NA,2002-03-21,2002-09-20,183,5.209486152841421,Early-PDUFA
Inspra,eplerenone,GD Searle,NDA,21437,NA,NA,Tablet,Oral,NA,NA,NA,NA,11/29/2001,9/27/2002,2002,"treatment of hypertension, alone or in combination with other agents",NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,2001-11-29,2002-09-27,302,5.71042701737487,Early-PDUFA
Pegasys,peginterferon alfa-2a,Hoffmann-La Roche,BLA,103964,NA,NA,Injectable,Injection,NA,NA,NA,NA,5/22/2000,10/16/2002,2002,treatment of adults with chronic hepatitis C who have compensated liver disease and who have not been previously treated with interferon alfa,NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,2000-05-22,2002-10-16,877,6.776506992372183,Early-PDUFA
Zetia,ezetimibe,Schering,NDA,21445,NA,NA,Tablet,Oral,NA,NA,NA,NA,12/27/2001,10/25/2002,2002,"indicated as adjunctive therapy to diet for reduction of elevated total-C, LDL-C and Apo B in patients with primary (heterozygous familial and non-familial) hypercholesterolemia either alone or with an HMG-Co A reductase inhibitor; treatment of homozygous familial hypercholesterolemia in combination with either atorvastatin or simvastatin, as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) or, if such treatments are unavailable, in combination with either atorvastatin or simvastatin alone; treatment of homozygous familial sitosterolemia as adjunctive therapy to diet for the reduction of elevated sitosterol and campesterol levels",NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,2001-12-27,2002-10-25,302,5.71042701737487,Early-PDUFA
Abilify,aripiprazole,Otsuka Pharmaceutical,NDA,21436,NA,NA,Tablet,Oral,NA,NA,NA,NA,10/31/2001,11/15/2002,2002,treatment of schizophrenia,NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,2001-10-31,2002-11-15,380,5.940171252720432,Early-PDUFA
Alinia,nitazoxanide,Romark Laboratories,NDA,21498,NA,NA,For Suspension,Oral,NA,NA,NA,NA,5/29/2002,11/22/2002,2002,treatment of diarrhea caused by Cryptosporidium parvum and Giardia lamblia,NA,Priority,Yes,No,N/A,No,N/A,N/A,N/A,NA,2002-05-29,2002-11-22,177,5.176149732573829,Early-PDUFA
Strattera,atomoxetine hydrochloride,Eli Lilly,NDA,21411,NA,NA,Capsule,Oral,NA,NA,NA,NA,10/12/2001,11/26/2002,2002,treatment of Attention-Deficit Hyperactivity Disorder (ADHD) for children and adolescents ages 6-18 and adults,NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,2001-10-12,2002-11-26,410,6.016157159698354,Early-PDUFA
Extraneal,icodextrin,Baxter Healthcare,NDA,21321,NA,NA,Solution,Intraperitoneal,NA,NA,NA,NA,12/22/2000,12/20/2002,2002,indicated for a single daily exchange for the long (8-16-hour) dwell during continuous ambulatory peritoneal dialysis (CAPD) or automated peritoneal dialysis (APD) for the management of chronic renal failure,NA,Standard,Yes,No,N/A,No,N/A,N/A,N/A,NA,2000-12-22,2002-12-20,728,6.590301048196686,Early-PDUFA
Relpax,eletriptan hydrobromide,Pfizer,NDA,21016,NA,NA,Tablet,Oral,NA,NA,NA,NA,10/27/1998,12/26/2002,2002,acute treatment of migraine,NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,1998-10-27,2002-12-26,1521,7.327123292259293,Early-PDUFA
Humira,adalimumab,Abbott Laboratories,BLA,125057,NA,NA,Injectable,Injection,NA,NA,NA,NA,3/29/2002,12/31/2002,2002,indicated for reducing signs and symptoms and inhibiting the progression of structural damage in adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs (DMARDs),NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,2002-03-29,2002-12-31,277,5.6240175061873385,Early-PDUFA
Amevive,alefacept,Biogen,BLA,125036,NA,NA,Injectable,Injection,NA,NA,NA,NA,8/6/2001,1/30/2003,2003,treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy,NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,2001-08-06,2003-01-30,542,6.295266001439646,Mid-PDUFA
Fuzeon,enfuvirtide,Hoffmann-La Roche,NDA,21481,NA,NA,Injectable,Subcutaneous,NA,NA,NA,NA,9/16/2002,3/13/2003,2003,"in combination with other antiretroviral agents, for the treatment of HIV-1 infection in treatment experienced patients with evidence of HIV-1 replication despite ongoing antiretroviral therapy",NA,Priority,No,Yes,N/A,Yes,N/A,N/A,N/A,NA,2002-09-16,2003-03-13,178,5.181783550292085,Mid-PDUFA
Somavert,pegvisomant,Pharmacia and Upjohn,BLA,21106,NA,NA,Injectable,Subcutaneous,NA,NA,NA,NA,12/26/2000,3/25/2003,2003,"treatment of acromegaly in patients who have an inadequate response to surgery and/or radiation therapy and/or other medical therapies, or for whom these therapies are not appropriate",NA,Priority,Yes,No,N/A,Yes,N/A,N/A,N/A,Transition Product from NDA to BLA due to BPCI : Please see page 2 of data dictionary for more information.,2000-12-26,2003-03-25,819,6.70808408385307,Mid-PDUFA
Emend,aprepitant,Merck,NDA,21549,NA,NA,Capsule,Oral,NA,NA,NA,NA,9/27/2002,3/26/2003,2003,"in combination with other antiemetic agents, for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy, including high-dose cisplatin",NA,Priority,No,No,N/A,No,N/A,N/A,N/A,NA,2002-09-27,2003-03-26,180,5.19295685089021,Mid-PDUFA
Factive,gemifloxacin mesylate,LG Life Sciences,NDA,21158,NA,NA,Tablet,Oral,NA,NA,NA,NA,12/16/1999,4/4/2003,2003,treatment of community-acquired pneumonia and acute bacterial exacerbation of chronic bronchitis,NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,1999-12-16,2003-04-04,1205,7.094234845924755,Mid-PDUFA
Fabrazyme,agalsidase beta,Genzyme,BLA,103979,NA,NA,Injectable,Injection,NA,NA,NA,NA,6/23/2000,4/24/2003,2003,indicated for use in patients with Fabry disease to reduce globotriaosylceramide (GL-3) deposition in capillary endothelium of the kidney and certain other cell types,NA,Priority,Yes,Yes,N/A,Yes,N/A,N/A,N/A,NA,2000-06-23,2003-04-24,1035,6.942156705699469,Mid-PDUFA
Aldurazyme,laronidase,Biomarin Pharmaceutical,BLA,125058,NA,NA,Injectable,Injection,NA,NA,NA,NA,7/29/2002,4/30/2003,2003,indicated for patients with Hurler and Hurler-Scheie forms of Mucopolysaccharidosis I (MPS I) and for patients with the Scheie form who have moderate to severe symptoms,NA,Priority,Yes,No,N/A,Yes,N/A,N/A,N/A,NA,2002-07-29,2003-04-30,275,5.616771097666572,Mid-PDUFA
Iressa,gefitinib,AstraZeneca Pharmaceuticals,NDA,21399,NA,NA,Tablet,Oral,NA,NA,NA,NA,8/5/2002,5/5/2003,2003,indicated as monotherapy for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of both platinum-based and docetaxel chemotherapies,NA,Priority,No,Yes,N/A,Yes,N/A,N/A,N/A,NA,2002-08-05,2003-05-05,273,5.60947179518496,Mid-PDUFA
Velcade,bortezomib,Millennium Pharmaceuticals,NDA,21602,NA,NA,Injectable,"Intravenous, Subcutaneous",NA,NA,NA,NA,1/21/2003,5/13/2003,2003,treatment of multiple myeloma patients who have received at least two prior therapies and have demonstrated disease progression on the last therapy,NA,Priority,Yes,Yes,N/A,Yes,N/A,N/A,N/A,NA,2003-01-21,2003-05-13,112,4.718498871295094,Mid-PDUFA
Boniva,ibandronate sodium,Hoffmann-La Roche,NDA,21455,NA,NA,Tablet,Oral,NA,NA,NA,NA,7/16/2002,5/16/2003,2003,treatment and prevention of postmenopausal osteoporosis,NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,2002-07-16,2003-05-16,304,5.717027701406222,Mid-PDUFA
Uroxatral,alfuzosin hydrochloride,Sanofi-Synthelabo,NDA,21287,NA,NA,"Tablet, Extended Release",Oral,NA,NA,NA,NA,12/8/2000,6/12/2003,2003,treatment of the signs and symptoms of benign prostatic hyperplasia (BPH),NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,2000-12-08,2003-06-12,916,6.82001636467413,Mid-PDUFA
Reyataz,atazanavir sulfate,Bristol-Myers Squibb,NDA,21567,NA,NA,Capsule,Oral,NA,NA,NA,NA,12/20/2002,6/20/2003,2003,in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults,NA,Priority,No,No,N/A,No,N/A,N/A,N/A,NA,2002-12-20,2003-06-20,182,5.204006687076795,Mid-PDUFA
Xolair,omalizumab,Genentech,BLA,103976,NA,NA,Injectable,Injection,NA,NA,NA,NA,6/5/2000,6/20/2003,2003,indicated for adults and adolescents (12 years of age and above) with moderate to severe persistent asthma who have a positive skin test or in vitro reactivity to a perennial aeroallergen and whose symptoms are inadequately controlled with inhaled corticosteroids,NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,2000-06-05,2003-06-20,1110,7.01211529430638,Mid-PDUFA
Bexxar,"tositumomab, iodine I 131 tositumomab",Corixa,BLA,125011,NA,NA,Injectable,Injection,NA,NA,NA,NA,9/15/2000,6/27/2003,2003,"indicated for the treatment of patients with CD20 positive, follicular, non-Hodgkin's lymphoma, with and without transformation, whose disease is refractory to Rituximab and has relapsed following chemotherapy",NA,Priority,Yes,No,N/A,Yes,N/A,N/A,N/A,NA,2000-09-15,2003-06-27,1015,6.922643891475888,Mid-PDUFA
Emtriva,emtricitabine,Gilead Sciences,NDA,21500,NA,NA,Capsule,Oral,NA,NA,NA,NA,9/3/2002,7/2/2003,2003,indicated for the treatment of HIV infection in adults,NA,Standard,No,No,N/A,Yes,N/A,N/A,N/A,NA,2002-09-03,2003-07-02,302,5.71042701737487,Mid-PDUFA
Aloxi,palonosetron hydrochloride,Helsinn Healthcare,NDA,21372,NA,NA,Injectable,Intravenous,NA,NA,NA,NA,9/27/2002,7/25/2003,2003,prevention of acute nausea and vomiting associated with initial and repeat courses of moderately and highly emetogenic cancer chemotherapy; prevention of delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy,NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,2002-09-27,2003-07-25,301,5.707110264748875,Mid-PDUFA
Zavesca,miglustat,Actelion Pharmaceuticals,NDA,21348,NA,NA,Capsule,Oral,NA,NA,NA,NA,8/21/2001,7/31/2003,2003,"treatment of mild to moderate Type I Gaucher disease in adults for whom enzyme replacement therapy is not a therapeutic option (e.g., due to constraints such as allergy, hypersensitivity, or poor venous access)",NA,Standard,Yes,No,N/A,Yes,N/A,N/A,N/A,NA,2001-08-21,2003-07-31,709,6.5638555265321274,Mid-PDUFA
Crestor,rosuvastatin calcium,AstraZeneca Pharmaceuticals,NDA,21366,NA,NA,Tablet,Oral,NA,NA,NA,NA,6/26/2001,8/12/2003,2003,"indicated as an adjunct to diet to reduce elevated total-C in patients with primary hypercholesterolemia (heterozygous familial and nonfamilial) and mixed dyslipidemia (Frederickson Type IIa and IIb);  as an adjunct to diet for the treatment of patients with elevated serum TG levels (Frederickson Type IV); indicated to reduce LDL-C, total-C, and ApoB in patients with homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) or if such treatments are unavailable)",NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,2001-06-26,2003-08-12,777,6.655440350367647,Mid-PDUFA
Levitra,vardenafil hydrochloride,Bayer,NDA,21400,NA,NA,Tablet,Oral,NA,NA,NA,NA,9/24/2001,8/19/2003,2003,treatment of erectile dysfunction,NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,2001-09-24,2003-08-19,694,6.542471960506805,Mid-PDUFA
Cubicin,daptomycin,Cubist Pharmaceuticals,NDA,21572,NA,NA,Powder,Intravenous,NA,NA,NA,NA,12/20/2002,9/12/2003,2003,treatment of complicated skin and skin structure infections caused by susceptible strains of Gram-positive microorganisms,NA,Priority,No,No,N/A,No,N/A,N/A,N/A,NA,2002-12-20,2003-09-12,266,5.583496308781699,Mid-PDUFA
Radiogardase,prussian blue,Heyl Chemisch-pharmazeutische Fabrik GmbH,NDA,21626,NA,NA,Capsule,Oral,NA,NA,NA,NA,3/13/2003,10/2/2003,2003,treatment of patients with known or suspected internal contamination with radioactive cesium and/or radioactive or non-radioactive thallium to increase their rates of elimination,NA,Priority,Yes,No,N/A,No,N/A,N/A,N/A,NA,2003-03-13,2003-10-02,203,5.313205979041787,Mid-PDUFA
Elestat,epinastine hydrochloride,Allergan,NDA,21565,NA,NA,Solution/Drops,Ophthalmic,NA,NA,NA,NA,12/20/2002,10/16/2003,2003,prevention of itching associated with allergic conjunctivitis,NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,2002-12-20,2003-10-16,300,5.703782474656201,Mid-PDUFA
Namenda,memantine hydrochloride,Forest Laboratories,NDA,21487,NA,NA,Tablet,Oral,NA,NA,NA,NA,12/19/2002,10/16/2003,2003,treatment of moderate to severe dementia of the Alzheimer's type,NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,2002-12-19,2003-10-16,301,5.707110264748875,Mid-PDUFA
Raptiva,efalizumab,Genentech,BLA,125075,NA,NA,Injectable,Injection,NA,NA,NA,NA,12/27/2002,10/27/2003,2003,treatment of adult patients (18 years or older) with chronic moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy,NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,2002-12-27,2003-10-27,304,5.717027701406222,Mid-PDUFA
Cialis,tadalafil,Lilly Icos,NDA,21368,NA,NA,Tablet,Oral,NA,NA,NA,NA,6/29/2001,11/21/2003,2003,treatment of erectile dysfunction,NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,2001-06-29,2003-11-21,875,6.774223886357614,Mid-PDUFA
Plenaxis,abarelix,Praecis Pharmaceuticals,NDA,21320,NA,NA,Injectable,Intramuscular,NA,NA,NA,NA,12/12/2000,11/25/2003,2003,"palliative treatment of men with advanced symptomatic prostate cancer, in whom LHRH agonist therapy is not appropriate and who refuse surgical castration, and have one or more of the following:  risk of neurological compromise due to metastases, ureteral or bladder outlet obstruction due to local encroachment or metastatic disease, or severe bone pain from skeletal metastases persisting on narcotic analgesia",NA,Priority,No,No,N/A,No,N/A,N/A,N/A,NA,2000-12-12,2003-11-25,1078,6.982862751468942,Mid-PDUFA
Ertaczo,sertaconazole nitrate,Mylan Pharmaceuticals,NDA,21385,NA,NA,Cream,Topical,NA,NA,NA,NA,9/28/2001,12/10/2003,2003,"treatment of interdigital tinea pedis in immunocompetent patients 12 years of age and older, caused by Trichophyton rubrum, Trichophyton mentagrophytes, and Epidermophyton floccosum",NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,2001-09-28,2003-12-10,803,6.688354713946762,Mid-PDUFA
Spiriva Handihaler,tiotropium bromide,Boehringer Ingelheim Pharmaceuticals,NDA,21395,NA,NA,Powder,Inhalation,NA,NA,NA,NA,12/13/2001,1/30/2004,2004,"long-term, once-daily, maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema",NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,2001-12-13,2004-01-30,778,6.656726524178391,Mid-PDUFA
Alimta,pemetrexed disodium,Eli Lilly,NDA,21462,NA,NA,Powder,Intravenous,NA,NA,NA,NA,9/30/2003,2/4/2004,2004,treatment of patients with malignant pleural mesothelioma whose disease is either unresectable or who are otherwise not candidates for curative surgery,NA,Priority,Yes,No,N/A,Yes,N/A,N/A,N/A,NA,2003-09-30,2004-02-04,127,4.844187086458591,Mid-PDUFA
Erbitux,cetuximab,ImClone Systems,BLA,125084,NA,NA,Injectable,Injection,NA,NA,NA,NA,8/14/2003,2/12/2004,2004,"in combination with irinotecan for treatment of EGFR-expressing, metastatic colorectal carcinoma in patients who are refractory to irinotecan-based chemotherapy; as a single agent for treatment of EGFR-expressing, metastatic colorectal carcinoma in patients who are intolerant to irinotecan-based chemotherapy",NA,Priority,No,Yes,N/A,Yes,N/A,N/A,N/A,NA,2003-08-14,2004-02-12,182,5.204006687076795,Mid-PDUFA
Avastin,bevacizumab,Genentech,BLA,125085,NA,NA,Injectable,Injection,NA,NA,NA,NA,9/30/2003,2/26/2004,2004,in combination with intravenous 5-fluorouracil-based chemotherapy is indicated for the first-line treatment of patients with metastatic carcinoma of the colon and rectum,NA,Priority,No,No,N/A,Yes,N/A,N/A,N/A,NA,2003-09-30,2004-02-26,149,5.003946305945459,Mid-PDUFA
Sensipar,cinacalcet hydrochloride,Amgen,NDA,21688,NA,NA,Tablet,Oral,NA,NA,NA,NA,9/8/2003,3/8/2004,2004,"[A] treatment of secondary hyperparathyroidism in patients with chronic kidney disease on dialysis
[B] treatment of hypercalcemia in patients with parathyroid carcinoma",NA,Priority,Yes (indication [B] only),No,N/A,No,N/A,N/A,N/A,NA,2003-09-08,2004-03-08,182,5.204006687076795,Mid-PDUFA
Ketek,telithromycin,Aventis Pharmaceuticals,NDA,21144,NA,NA,Tablet,Oral,NA,NA,NA,NA,3/1/2000,4/1/2004,2004,"treatment of infections caused by susceptible strains of  designated microorganisms in the conditions listed below, for patients 18 years old and above:  acute bacterial exacerbation of chronic bronchitis,  acute bacterial sinusitis, community-acquired pneumonia (of mild to moderate severity)",NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,2000-03-01,2004-04-01,1492,7.307872780763706,Mid-PDUFA
ChiRhoStim,human secretin,ChiRhoClin,NDA,21256,NA,NA,For Solution,Intravenous,NA,NA,NA,NA,6/14/2001,4/9/2004,2004,"indicated for stimulation of pancreatic secretions, including bicarbonate, to aid in the diagnosis of pancreatic exocrine dysfunction; also indicated for stimulation of gastrin secretion to aid in the diagnosis of gastrinoma; also indicated for stimulation of pancreatic secretions to facilitate the identification of the ampulla of Vater and accessory papilla during endoscopic retrograde cholangiopancreatography (ERCP)",NA,Priority,Yes,No,N/A,No,N/A,N/A,N/A,NA,2001-06-14,2004-04-09,1030,6.937314081223682,Mid-PDUFA
Apidra,insulin glulisine,Aventis Pharmaceuticals,BLA,21629,NA,NA,Injectable,"Intravenous, Subcutaneous",NA,NA,NA,NA,6/18/2003,4/16/2004,2004,treatment of adult patients with diabetes mellitus for the control of hyperglycemia,NA,Standard,No,No,N/A,No,N/A,N/A,N/A,Transition Product from NDA to BLA due to BPCI : Please see page 2 of data dictionary for more information.,2003-06-18,2004-04-16,303,5.713732805509369,Mid-PDUFA
Apokyn,apomorphine hydrochloride,Bertek Pharmaceuticals,NDA,21264,NA,NA,Injectable,Subcutaneous,NA,NA,NA,NA,1/2/2003,4/20/2004,2004,"indicated for the acute, intermittent treatment of hypomobility, ""off"" episodes (""end-of-dose wearing off"" and unpredictable ""on/off"" episodes) associated with advanced Parkinson's disease",NA,Priority,Yes,No,N/A,Yes,N/A,N/A,N/A,NA,2003-01-02,2004-04-20,474,6.161207321695077,Mid-PDUFA
Vitrase,hyaluronidase (ovine),Ista Pharmaceuticals,BLA,21640,NA,NA,Injectable,Injection,NA,NA,NA,NA,8/5/2003,5/5/2004,2004,indicated as an adjuvant to increase the absorption and dispersion of other injected drugs; for hypodermoclysis; and as an adjunct in subcutaneous urography for improving resorption of radiopaque agents,NA,Priority,No,No,N/A,No,N/A,N/A,N/A,Transition Product from NDA to BLA due to BPCI : Please see page 2 of data dictionary for more information.,2003-08-05,2004-05-05,274,5.6131281063880705,Mid-PDUFA
Tindamax,tinidazole,Presutti Laboratories,NDA,21618,21681,21682,Tablet,Oral,Tablet,Oral,Tablet,Oral,7/17/2003,5/17/2004,2004,"[A] treatment of trichomoniasis
[B] treatment of giardiasis
[C] treatment of amebiasis and amebic liver abscess",NA,Standard,Yes (indication [B] and [C] only),No,N/A,No,N/A,N/A,N/A,NA,2003-07-17,2004-05-17,305,5.720311776607412,Mid-PDUFA
Vidaza,azacitidine,Pharmion,NDA,50794,NA,NA,Powder,"Intravenous, Subcutaneous",NA,NA,NA,NA,12/29/2003,5/19/2004,2004,"treatment of patients with the following myelodysplastic syndrome subtypes: refractory anemia or refractory anemia with ringed sideroblasts (if accompanied by neutropenia or thrombocytopenia and requiring transfusions), refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia",NA,Priority,Yes,No,N/A,Yes,N/A,N/A,N/A,NA,2003-12-29,2004-05-19,142,4.955827057601261,Mid-PDUFA
Xifaxan,rifaximin,Salix Pharmaceuticals,NDA,21361,NA,NA,Tablet,Oral,NA,NA,NA,NA,12/26/2001,5/25/2004,2004,treatment of patients (> 12 years of age) with travelers' diarrhea caused by noninvasive strains of Escherichia coli,NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,2001-12-26,2004-05-25,881,6.78105762593618,Mid-PDUFA
Sanctura,trospium chloride,Indevus Pharmaceuticals,NDA,21595,NA,NA,Tablet,Oral,NA,NA,NA,NA,4/29/2003,5/28/2004,2004,"treatment of overactive bladder associated with symptoms of urge urinary incontinence, urgency, and urinary frequency",NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,2003-04-29,2004-05-28,395,5.978885764901122,Mid-PDUFA
NutreStore,l-glutamine,Nutritional Restart Pharmaceutical,NDA,21667,NA,NA,For Solution,Oral,NA,NA,NA,NA,8/11/2003,6/10/2004,2004,treatment of short bowel syndrome in patients receiving specialized nutritional support when used in conjunction with a recombinant human growth that is approved for this indication,NA,Standard,Yes,No,N/A,No,N/A,N/A,N/A,NA,2003-08-11,2004-06-10,304,5.717027701406222,Mid-PDUFA
NeutroSpec,technetium Tc 99m fanolesomab,Palatin Technologies,BLA,103928,NA,NA,Injectable,Injection,NA,NA,NA,NA,11/22/1999,7/2/2004,2004,indicated for scintigraphic imaging of patients with equivocal signs and symptoms of appendicitis who are five years of age or older,NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,1999-11-22,2004-07-02,1684,7.428927194802272,Mid-PDUFA
Campral,acamprosate calcium,Lipha Pharmaceuticals,NDA,21431,NA,NA,"Tablet, Delayed Release",Oral,NA,NA,NA,NA,12/27/2001,7/29/2004,2004,indicated for the maintenance of abstinence from alcohol in patients with alcohol dependence who are abstinent at treatment initiation,NA,Priority,No,No,N/A,No,N/A,N/A,N/A,NA,2001-12-27,2004-07-29,945,6.851184927493743,Mid-PDUFA
Cymbalta,duloxetine hydrochloride,Eli Lilly,NDA,21427,NA,NA,"Capsule, Delayed Release Pellets",Oral,NA,NA,NA,NA,11/13/2001,8/3/2004,2004,treatment of major depressive disorder (MDD),NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,2001-11-13,2004-08-03,994,6.901737206656574,Mid-PDUFA
[drug marketed without a proprietary name],pentetate calcium trisodium,Hameln Pharmaceuticals GmbH,NDA,21749,NA,NA,Solution,"Inhalation, Intravenous",NA,NA,NA,NA,4/28/2004,8/11/2004,2004,"treatment of internal contamination with plutonium, americium or curium to increase the rates of elimination",NA,Priority,Yes,No,N/A,No,N/A,N/A,N/A,NA,2004-04-28,2004-08-11,105,4.653960350157523,Mid-PDUFA
[drug marketed without a proprietary name],pentetate zinc trisodium,Hameln Pharmaceuticals GmbH,NDA,21751,NA,NA,Solution,"Inhalation, Intravenous",NA,NA,NA,NA,4/28/2004,8/11/2004,2004,"treatment of internal contamination with plutonium, americium or curium to increase the rates of elimination",NA,Priority,Yes,No,N/A,No,N/A,N/A,N/A,NA,2004-04-28,2004-08-11,105,4.653960350157523,Mid-PDUFA
Amphadase,hyaluronidase (bovine),Amphastar Pharmaceuticals,BLA,21665,NA,NA,Injectable,Injection,NA,NA,NA,NA,7/7/2003,10/26/2004,2004,indicated as an adjuvant to increase the absorption and dispersion of other injected drugs; for hypodermoclysis; and as an adjunct in subcutaneous urography for improving resorption of radiopaque agents,NA,Priority,No,No,N/A,No,N/A,N/A,N/A,Transition Product from NDA to BLA due to BPCI : Please see page 2 of data dictionary for more information.,2003-07-07,2004-10-26,477,6.1675164908883415,Mid-PDUFA
Fosrenol,lanthanum carbonate hydrate,Shire Pharmaceutical Development,NDA,21468,NA,NA,"Tablet, Chewable",Oral,NA,NA,NA,NA,4/30/2002,10/26/2004,2004,indicated to reduce serum phosphate in patients with end stage renal disease,NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,2002-04-30,2004-10-26,910,6.813444599510896,Mid-PDUFA
Omacor,omega-3-acid ethyl esters,Abbott Laboratories,NDA,21654,NA,NA,Capsule,Oral,NA,NA,NA,NA,1/12/2004,11/10/2004,2004,indicated as an adjunct to diet to reduce triglyceride (TG) levels in adult patients with TG levels > 500 mg/dL,NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,2004-01-12,2004-11-10,303,5.713732805509369,Mid-PDUFA
Tarceva,erlotinib hydrochloride,OSI Pharmaceuticals,NDA,21743,NA,NA,Tablet,Oral,NA,NA,NA,NA,7/30/2004,11/18/2004,2004,treatment of locally advanced or metastatic Non Small-Cell Lung Cancer (NSCLC) after failure of at least one prior chemotherapy regimen,NA,Priority,No,No,N/A,Yes,N/A,N/A,N/A,NA,2004-07-30,2004-11-18,111,4.709530201312334,Mid-PDUFA
Vesicare,solifenacin succinate,Yamanouchi Pharma America,NDA,21518,NA,NA,Tablet,Oral,NA,NA,NA,NA,12/19/2002,11/19/2004,2004,"treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency",NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,2002-12-19,2004-11-19,701,6.55250788703459,Mid-PDUFA
Multihance,gadobenate dimeglumine,Bracco Diagnostics,NDA,21357,21358,NA,Injectable,Intravenous,Injectable,Injection,NA,NA,4/27/2001,11/23/2004,2004,"indicated for intravenous use in magnetic resonance imaging (MRI) of the central nervous system in adults to visualize lesions with abnormal blood brain barrier or abnormal vascularity of the brain, spine, and associated tissues",NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,2001-04-27,2004-11-23,1306,7.174724309836376,Mid-PDUFA
Tysabri,natalizumab,Biogen Idec,BLA,125104,NA,NA,Injectable,Injection,NA,NA,NA,NA,5/24/2004,11/23/2004,2004,treatment of patients with relapsing forms of multiple sclerosis (MS) to reduce the frequency of clinical exacerbations,NA,Priority,No,Yes,N/A,No,N/A,N/A,N/A,NA,2004-05-24,2004-11-23,183,5.209486152841421,Mid-PDUFA
Kepivance,palifermin,Amgen,BLA,125103,NA,NA,Injectable,Injection,NA,NA,NA,NA,6/15/2004,12/15/2004,2004,indicated to decrease the incidence and duration of severe oral mucositis in patients with hematologic malignancies receiving myelotoxic therapy requiring hematopoietic stem cell support,NA,Priority,No,No,N/A,Yes,N/A,N/A,N/A,NA,2004-06-15,2004-12-15,183,5.209486152841421,Mid-PDUFA
Lunesta,eszopiclone,Sepracor,NDA,21476,NA,NA,Tablet,Oral,NA,NA,NA,NA,1/31/2003,12/15/2004,2004,treatment of insomnia,NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,2003-01-31,2004-12-15,684,6.52795791762255,Mid-PDUFA
VisionBlue,trypan blue,Dutch Ophthalmic USA,NDA,21670,NA,NA,Solution,Ophthalmic,NA,NA,NA,NA,10/27/2003,12/16/2004,2004,indicated as an aid in ophthalmic surgery by staining the anterior capsule of the lens,NA,Priority,No,No,N/A,No,N/A,N/A,N/A,NA,2003-10-27,2004-12-16,416,6.030685260261263,Mid-PDUFA
Macugen,pegaptanib sodium,Eyetech Pharmaceuticals,NDA,21756,NA,NA,Injectable,Intravitreal,NA,NA,NA,NA,6/17/2004,12/17/2004,2004,treatment of neovascular (wet) age-related macular degeneration,NA,Priority,No,No,N/A,Yes,N/A,N/A,N/A,NA,2004-06-17,2004-12-17,183,5.209486152841421,Mid-PDUFA
Enablex,darifenacin hydrobromide,Novartis Pharmaceuticals,NDA,21513,NA,NA,"Tablet, Extended Release",Oral,NA,NA,NA,NA,12/3/2002,12/22/2004,2004,treatment of overactive bladder,NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,2002-12-03,2004-12-22,750,6.620073206530356,Mid-PDUFA
Prialt,ziconotide,Elan Pharmaceuticals,NDA,21060,NA,NA,Injectable,Intrathecal,NA,NA,NA,NA,12/28/1999,12/28/2004,2004,"management of severe chronic pain in patients for whom intrathecal (IT) therapy is warranted and who are intolerant of or refractory to other treatment, such as systemic analgesics, adjunctive therapies, or IT morphine",NA,Priority,No,No,N/A,No,N/A,N/A,N/A,NA,1999-12-28,2004-12-28,1827,7.510430556378006,Mid-PDUFA
Clolar,clofarbine,Genzyme,NDA,21673,NA,NA,Solution,Intravenous,NA,NA,NA,NA,3/30/2004,12/28/2004,2004,treatment of pediatric patients 1 to 21 years old with relapsed or refractory acute lymphoblastic leukemia after at least two prior regimens,NA,Priority,Yes,Yes,N/A,Yes,N/A,N/A,N/A,NA,2004-03-30,2004-12-28,273,5.60947179518496,Mid-PDUFA
Ventavis,iloprost,CoTherix,NDA,21779,NA,NA,Solution,Inhalation,NA,NA,NA,NA,6/30/2004,12/29/2004,2004,treatment of pulmonary arterial hypertension (WHO Group I) in patients with NYHA Class III or IV symptoms,NA,Priority,Yes,No,N/A,No,N/A,N/A,N/A,NA,2004-06-30,2004-12-29,182,5.204006687076795,Mid-PDUFA
Lyrica,pregabalin,Pfizer,NDA,21446,21723,NA,Capsule,Oral,Capsule,Oral,NA,NA,10/31/2003,12/30/2004,2004,"[A] management of neuropathic pain associated with diabetic peripheral neuropathy
[B] management of postherpetic neuralgia",NA,Priority (indication [A] only),No,No,N/A,No,N/A,N/A,N/A,NA,2003-10-31,2004-12-30,426,6.054439346269371,Mid-PDUFA
Symlin,pramlintide acetate,Amylin Pharmaceuticals,NDA,21332,NA,NA,Injectable,Subcutaneous,NA,NA,NA,NA,12/8/2000,3/16/2005,2005,"indicated for type 1 diabetes, as an adjunct treatment in patients who use mealtime insulin therapy and who have failed to achieve desired glucose control despite optimal insulin therapy; indicated for type 2 diabetes, as an adjunct treatment in patients who use mealtime insulin therapy and who have failed to achieve desired glucose control despite optimal insulin therapy, with or without a concurrent sulfonylurea agent and/or metformin",NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,2000-12-08,2005-03-16,1559,7.351799869057777,Mid-PDUFA
Mycamine,micafungin sodium,Fujisawa Healthcare,NDA,21506,21754,NA,Injectable,Intravenous,Injectable,Injection,NA,NA,4/29/2002,3/16/2005,2005,"[A] prophylaxis of Candida infections in patients undergoing hematopoietic stem cell transplantation
[B] treatment of esophageal candidiasis",NA,Priority (indication [A] only),No,No,N/A,No,N/A,N/A,N/A,NA,2002-04-29,2005-03-16,1052,6.9584483932976555,Mid-PDUFA
Baraclude,entecavir,Bristol-Myers Squibb,NDA,21797,21798,NA,Tablet,Oral,Solution,Oral,NA,NA,9/29/2004,3/29/2005,2005,treatment of chronic hepatitis B virus infection in adults with evidence of active viral replication and either evidence of persistent elevations in serum aminotransferases (ALT or AST) or histologically active disease,NA,Priority,No,No,N/A,No,N/A,N/A,N/A,NA,2004-09-29,2005-03-29,181,5.198497031265826,Mid-PDUFA
Byetta,exenatide,Amylin Pharmaceuticals,NDA,21773,NA,NA,Injectable,Subcutaneous,NA,NA,NA,NA,6/30/2004,4/28/2005,2005,"indicated to improve glycemic control in patients with type 2 diabetes mellitus who have not achieved adequate glycemic control on metformin, a sulfonylurea, or a combination of metformin and a sulfonylurea",NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,2004-06-30,2005-04-28,302,5.71042701737487,Mid-PDUFA
Naglazyme,galsulfase,Biomarin Pharmaceutical,BLA,125117,NA,NA,Injectable,Injection,NA,NA,NA,NA,11/29/2004,5/31/2005,2005,treatment of patients with Mucopolysaccharidosis VI (MPS VI),NA,Priority,Yes,No,N/A,Yes,N/A,N/A,N/A,NA,2004-11-29,2005-05-31,183,5.209486152841421,Mid-PDUFA
Tygacil,tigecycline,Wyeth Pharmaceuticals,NDA,21821,NA,NA,Powder,Intravenous,NA,NA,NA,NA,12/15/2004,6/15/2005,2005,treatment of Complicated Skin and Skin Structure Infections (cSSSI) and Complicated Intra-abdominal Infections (cIAI),NA,Priority,No,No,N/A,No,N/A,N/A,N/A,NA,2004-12-15,2005-06-15,182,5.204006687076795,Mid-PDUFA
Levemir,insulin detemir,Novo Nordisk,BLA,21536,NA,NA,Injectable,Subcutaneous,NA,NA,NA,NA,12/5/2002,6/16/2005,2005,treatment of adult patients with Type 1 or Type 2 diabetes mellitus who require basal (long-acting) insulin for the control of hyperglycemia,NA,Standard,No,No,N/A,No,N/A,N/A,N/A,Transition Product from NDA to BLA due to BPCI : Please see page 2 of data dictionary for more information.,2002-12-05,2005-06-16,924,6.828712071641684,Mid-PDUFA
Aptivus,tipranavir,Boehringer Ingelheim Pharmaceuticals,NDA,21814,NA,NA,Capsule,Oral,NA,NA,NA,NA,12/22/2004,6/22/2005,2005,"co-administered with ritonavir, is indicated for combination antiretroviral treatment of HIV-1 infected adult patients with evidence of viral replication, who are highly treatment-experienced or have HIV-1 strains resistant to multiple protease inhibitors",NA,Priority,No,Yes,N/A,No,N/A,N/A,N/A,NA,2004-12-22,2005-06-22,182,5.204006687076795,Mid-PDUFA
Rozerem,ramelteon,Takeda Global Research & Development Center,NDA,21782,NA,NA,Tablet,Oral,NA,NA,NA,NA,9/22/2004,7/22/2005,2005,treatment of insomnia characterized by difficulty with sleep onset,NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,2004-09-22,2005-07-22,303,5.713732805509369,Mid-PDUFA
Nevanac,nepafenac,Alcon,NDA,21862,NA,NA,Suspension/Drops,Ophthalmic,NA,NA,NA,NA,2/28/2005,8/19/2005,2005,treatment of pain and inflammation associated with cataract surgery,NA,Priority,No,No,N/A,No,N/A,N/A,N/A,NA,2005-02-28,2005-08-19,172,5.147494476813453,Mid-PDUFA
Increlex,mecasermin (rDNA origin),Tercica,BLA,21839,NA,NA,Injectable,Subcutaneous,NA,NA,NA,NA,2/28/2005,8/30/2005,2005,long-term treatment of growth failure in children with severe primary IGF-1 deficiency (Primary IGFD) or with growth hormone (GH) gene deletion who have developed neutralizing antibodies to growth hormone,NA,Priority,Yes,No,N/A,No,N/A,N/A,N/A,Transition Product from NDA to BLA due to BPCI : Please see page 2 of data dictionary for more information.,2005-02-28,2005-08-30,183,5.209486152841421,Mid-PDUFA
Hydase,hyaluronidase (bovine),PrimaPharm,BLA,21716,NA,NA,Injectable,Injection,NA,NA,NA,NA,10/20/2003,10/25/2005,2005,indicated as an adjuvant to increase the absorption and dispersion of other injected drugs; for hypodermoclysis; and as an adjunct in subcutaneous urography for improving resorption of radiopaque agents,NA,Priority,No,No,N/A,No,N/A,N/A,N/A,Transition Product from NDA to BLA due to BPCI : Please see page 2 of data dictionary for more information.,2003-10-20,2005-10-25,736,6.601230118728877,Mid-PDUFA
Arranon,nelarabine,GlaxoSmithKline,NDA,21877,NA,NA,Injectable,Intravenous,NA,NA,NA,NA,4/29/2005,10/28/2005,2005,treatment of patients with T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma whose disease has not responded to or has relapsed following treatment with at least two chemotherapy regimens,NA,Priority,Yes,Yes,N/A,Yes,N/A,N/A,N/A,NA,2005-04-29,2005-10-28,182,5.204006687076795,Mid-PDUFA
Exjade,deferasirox,Novartis Pharmaceuticals,NDA,21882,NA,NA,"Tablet, For Suspension",Oral,NA,NA,NA,NA,5/2/2005,11/2/2005,2005,treatment of chronic iron overload due to blood transfusions (transfusional hemosiderosis) in patients 2 years of age and older,NA,Priority,Yes,Yes,N/A,Yes,N/A,N/A,N/A,NA,2005-05-02,2005-11-02,184,5.214935757608986,Mid-PDUFA
Hylenex,hyaluronidase (human),Halozyme Therapeutics,BLA,21859,NA,NA,Injectable,Injection,NA,NA,NA,NA,3/23/2005,12/2/2005,2005,indicated as an adjuvant to increase the absorption and dispersion of other injected drugs; for hypodermoclysis; and as an adjunct in subcutaneous urography for improving resorption of radiopaque agents,NA,Priority,No,No,N/A,No,N/A,N/A,N/A,Transition Product from NDA to BLA due to BPCI : Please see page 2 of data dictionary for more information.,2005-03-23,2005-12-02,254,5.537334267018537,Mid-PDUFA
Iplex,mecasermin rinfabate (rDNA origin),Insmed,BLA,21884,NA,NA,Injectable,Subcutaneous,NA,NA,NA,NA,1/3/2005,12/12/2005,2005,treatment of growth failure in children with severe primary IGF-1 deficiency (Primary IGFD) or with growth hormone (GH) gene deletion who have developed neutralizing antibodies to growth hormone,NA,Priority,Yes,No,N/A,No,N/A,N/A,N/A,Transition Product from NDA to BLA due to BPCI : Please see page 2 of data dictionary for more information.,2005-01-03,2005-12-12,343,5.8377304471659395,Mid-PDUFA
Nexavar,sorafenib tosylate,Bayer Pharmaceuticals,NDA,21923,NA,NA,Tablet,Oral,NA,NA,NA,NA,7/8/2005,12/20/2005,2005,treatment of patients with advanced renal cell carcinoma,NA,Priority,Yes,No,N/A,Yes,N/A,N/A,N/A,NA,2005-07-08,2005-12-20,165,5.10594547390058,Mid-PDUFA
Orencia,abatacept,Bristol-Myers Squibb,BLA,125118,NA,NA,Injectable,Injection,NA,NA,NA,NA,4/1/2005,12/23/2005,2005,"indicated for reducing signs and symptoms, inducing major clinical response, slowing the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more Disease Modifying Anti-Rheumatoid Drugs (DMARDs), such as methotrexate or TNF antagonists.  Abatacept may be used as monotherapy or concomitantly with DMARDs other than TNF antagonists",NA,Priority,No,No,N/A,Yes,N/A,N/A,N/A,NA,2005-04-01,2005-12-23,266,5.583496308781699,Mid-PDUFA
Revlimid,lenalidomide,Celgene,NDA,21880,NA,NA,Capsule,Oral,NA,NA,NA,NA,4/7/2005,12/27/2005,2005,treatment of patients with transfusion dependent anemia due to low or intermediate-1 risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities,NA,Priority,Yes,No,N/A,Yes,N/A,N/A,N/A,NA,2005-04-07,2005-12-27,264,5.575949103146316,Mid-PDUFA
Vaprisol,conivaptan hydrochloride,Astellas Pharma,NDA,21697,NA,NA,Injectable,Intravenous,NA,NA,NA,NA,1/30/2004,12/29/2005,2005,treatment of euvolemic hyponatremia in hospitalized patients,NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,2004-01-30,2005-12-29,699,6.54965074223381,Mid-PDUFA
Sutent,sunitinib malate,Pfizer,NDA,21938,21968,NA,Capsule,Oral,Capsule,Oral,NA,NA,8/11/2005,1/26/2006,2006,"[A] treatment of gastrointestinal stromal tumor after disease progression on or intolerance to imatinib mesylate
[B] treatment of advanced renal cell carcinoma",NA,Priority,No,Yes (indication [B] only),N/A,Yes,N/A,N/A,N/A,NA,2005-08-11,2006-01-26,168,5.123963979403259,Mid-PDUFA
Ranexa,ranolazine,CV Therapeutics,NDA,21526,NA,NA,"Tablet, Extended Release",Oral,NA,NA,NA,NA,12/30/2002,1/27/2006,2006,treatment of chronic angina,NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,2002-12-30,2006-01-27,1124,7.024649030453636,Mid-PDUFA
Amitiza,lubiprostone,Sucampo Pharmaceuticals,NDA,21908,NA,NA,Capsule,Oral,NA,NA,NA,NA,3/31/2005,1/31/2006,2006,treatment of chronic idiopathic constipation in the adult population,NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,2005-03-31,2006-01-31,306,5.723585101952381,Mid-PDUFA
Eraxis,anidulafungin,Pfizer,NDA,21632,21948,NA,Powder,Intravenous,Injectable,Injection,NA,NA,4/25/2003,2/17/2006,2006,"[A] treatment of patients with esophageal candidiasis
[B] treatment of patients with candidemia and other forms of Candida infections (intra-abdominal abscess and peritonitis)",NA,Priority (indication [B] only),No,No,N/A,No,N/A,N/A,N/A,NA,2003-04-25,2006-02-17,1029,6.9363427358340495,Mid-PDUFA
Myozyme,alglucosidase alfa,Genzyme,BLA,125141,NA,NA,Injectable,Injection,NA,NA,NA,NA,7/28/2005,4/28/2006,2006,treatment of Pompe disease (GAA deficiency),NA,Priority,Yes,No,N/A,Yes,N/A,N/A,N/A,NA,2005-07-28,2006-04-28,274,5.6131281063880705,Mid-PDUFA
Dacogen,decitabine,MGI Pharma,NDA,21790,NA,NA,Injectable,Intravenous,NA,NA,NA,NA,11/1/2004,5/2/2006,2006,treatment of myelodysplastic syndrome (MDS),NA,Standard,Yes,No,N/A,Yes,N/A,N/A,N/A,NA,2004-11-01,2006-05-02,547,6.304448802421981,Mid-PDUFA
Chantix,varenicline,Pfizer,NDA,21928,NA,NA,Tablet,Oral,NA,NA,NA,NA,11/10/2005,5/10/2006,2006,indicated as an aid to smoking cessation treatment,NA,Priority,No,No,N/A,No,N/A,N/A,N/A,NA,2005-11-10,2006-05-10,181,5.198497031265826,Mid-PDUFA
Azilect,rasagiline mesylate,Teva Pharmaceuticals,NDA,21641,NA,NA,Tablet,Oral,NA,NA,NA,NA,9/5/2003,5/16/2006,2006,indicated for the treatment of the signs and symptoms of idiopathic Parkinson's disease as initial monotherapy and as adjunct therapy to levodopa,NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,2003-09-05,2006-05-16,984,6.891625897052253,Mid-PDUFA
Prezista,darunavir,Tibotec,NDA,21976,NA,NA,Tablet,Oral,NA,NA,NA,NA,12/23/2005,6/23/2006,2006,"coadministered with ritonavir, indicated for the treatment of human immunodeficiency virus (HIV) infection in antiretroviral treatment-experienced adult patients, such as those with HIV-1 strains resistant to more than one protease inhibitor",NA,Priority,No,Yes,N/A,Yes,N/A,N/A,N/A,NA,2005-12-23,2006-06-23,182,5.204006687076795,Mid-PDUFA
Sprycel,dasatinib,Bristol-Myers Squibb,NDA,21986,22072,NA,Tablet,Oral,Tablet,Oral,NA,NA,12/28/2005,6/28/2006,2006,"[A] treatment of adults with chronic myeloid leukemia with resistance or intolerance to prior therapy including imatinib
[B] treatment of adults with Philadelphia chromosome-positive acute lymphoblastic leukemia with resistance or intolerance to prior therapy",NA,Priority,Yes,Yes (indication [A] only),N/A,Yes (indication [A] only),N/A,N/A,N/A,NA,2005-12-28,2006-06-28,182,5.204006687076795,Mid-PDUFA
Lucentis,ranibizumab,Genentech,BLA,125156,NA,NA,Injectable,Injection,NA,NA,NA,NA,12/30/2005,6/30/2006,2006,treatment of patients with neovascular (wet) age-related macular degeneration,NA,Priority,No,No,N/A,No,N/A,N/A,N/A,NA,2005-12-30,2006-06-30,182,5.204006687076795,Mid-PDUFA
Anthelios SX,"avobenzone, ecamsule, octocrylene",L'Oreal USA Products,NDA,21502,NA,NA,Cream,Topical,NA,NA,NA,NA,5/12/2005,7/21/2006,2006,prevention of sunburn and to help provide protection from UVA and UVB rays,NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,2005-05-12,2006-07-21,435,6.075346031088684,Mid-PDUFA
Elaprase,idursulfase,Shire Human Genetic Therapies,BLA,125151,NA,NA,Injectable,Injection,NA,NA,NA,NA,11/23/2005,7/24/2006,2006,"treatment of patients with Hunter syndrome (Mucopolysaccharidosis II, MPS II)",NA,Priority,Yes,No,N/A,Yes,N/A,N/A,N/A,NA,2005-11-23,2006-07-24,243,5.493061443340548,Mid-PDUFA
Noxafil,posaconazole,Schering,NDA,22003,NA,NA,Suspension,Oral,NA,NA,NA,NA,12/22/2005,9/15/2006,2006,"prophylaxis of invasive Aspergillus and Candida infections in patients, 13 years of age and older, who are at high risk of developing these infections due to being severely immunocompromised, such as hematopoietic stem cell transplant (HSCT) recipients with Graft versus Host Disease (GVHD) or those with hematologic malignancies with prolonged neutropenia from chemotherapy",NA,Priority,No,No,N/A,No,N/A,N/A,N/A,NA,2005-12-22,2006-09-15,267,5.58724865840025,Mid-PDUFA
Vectibix,panitumumab,Amgen,BLA,125147,NA,NA,Injectable,Injection,NA,NA,NA,NA,3/29/2006,9/27/2006,2006,"treatment of EGFR-expressing metastatic colorectal carcinoma with disease progression on or following fluoropyrimidine, oxaliplatin, and irinotecan-containing chemotherapy regimens",NA,Priority,No,Yes,N/A,Yes,N/A,N/A,N/A,NA,2006-03-29,2006-09-27,182,5.204006687076795,Mid-PDUFA
Pylera,"biskalcitrate, metronidazole, tetracycline hydrochloride",Axcan Scandipharm,NDA,50786,NA,NA,Capsule,Oral,NA,NA,NA,NA,10/23/2001,9/28/2006,2006,"in combination with omeprazole, for the treatment of patients with Helicobacter pylori infection and duodenal ulcer disease (active or history of within the past 5 years) to eradicate H. pylori",NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,2001-10-23,2006-09-28,1801,7.496097345175956,Mid-PDUFA
Zolinza,vorinostat,Merck,NDA,21991,NA,NA,Capsule,Oral,NA,NA,NA,NA,4/7/2006,10/6/2006,2006,"treatment of cutaneous manifestations in patients with cutaneous T-cell lymphoma (CTCL) who have progressive, persistent or recurrent disease on or following two systemic therapies",NA,Priority,Yes,No,N/A,Yes,N/A,N/A,N/A,NA,2006-04-07,2006-10-06,182,5.204006687076795,Mid-PDUFA
Januvia,sitagliptin phosphate,Merck,NDA,21995,NA,NA,Tablet,Oral,NA,NA,NA,NA,12/16/2005,10/16/2006,2006,"indicated as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus as monotherapy and in combination with metformin or a PPAR? agonist (e.g., thiazolidinediones) when diet and exercise plus the single agent do not provide adequate glycemic control",NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,2005-12-16,2006-10-16,304,5.717027701406222,Mid-PDUFA
Omnaris,ciclesonide,Altana Pharma,NDA,22004,NA,NA,"Spray, Metered",Nasal,NA,NA,NA,NA,12/22/2005,10/20/2006,2006,treatment of seasonal and allergic rhinitis in patients 12 years of age and older,NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,2005-12-22,2006-10-20,302,5.71042701737487,Mid-PDUFA
Tyzeka,telbivudine,Idenix Pharmaceuticals,NDA,22011,NA,NA,Tablet,Oral,NA,NA,NA,NA,12/30/2005,10/25/2006,2006,treatment of chronic hepatitis B (CHB) in patients with evidence of viral replication and active liver inflammation,NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,2005-12-30,2006-10-25,299,5.700443573390687,Mid-PDUFA
Veregen,kunecatechins,Medigene,NDA,21902,NA,NA,Ointment,Topical,NA,NA,NA,NA,9/30/2005,10/31/2006,2006,treatment of external genital and perianal warts (Condylomata acuminata) in immunocompetent patients 18 years and older,NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,2005-09-30,2006-10-31,396,5.981414211254481,Mid-PDUFA
Invega,paliperidone,Johnson & Johnson,NDA,21999,NA,NA,"Tablet, Extended Release",Oral,NA,NA,NA,NA,11/30/2005,12/19/2006,2006,treatment of schizophrenia,NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,2005-11-30,2006-12-19,384,5.950642552587727,Mid-PDUFA
Vyvanse,lisdexamfetamine dimesylate,New River Pharmaceuticals,NDA,21977,NA,NA,Capsule,Oral,NA,NA,NA,NA,12/6/2005,2/23/2007,2007,treatment of Attention-Deficit Hyperactivity Disorder (ADHD) in children 6-12 years of age,NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,2005-12-06,2007-02-23,444,6.095824562432225,Mid-PDUFA
Tekturna,aliskiren,Novartis Pharmaceuticals,NDA,21985,NA,NA,Tablet,Oral,NA,NA,NA,NA,2/13/2006,3/5/2007,2007,treatment of hypertension,NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,2006-02-13,2007-03-05,385,5.953243334287785,Mid-PDUFA
Tykerb,lapatinib,GlaxoSmithKline,NDA,22059,NA,NA,Tablet,Oral,NA,NA,NA,NA,9/13/2006,3/13/2007,2007,"in combination with capecitabine for the treatment of patients with advanced or metastatic breast cancer whose tumors over-express HER2 (ErbB2) and who have received prior therapy including and anthracycline, a taxane and trastuzumab",NA,Priority,No,No,N/A,Yes,N/A,N/A,N/A,NA,2006-09-13,2007-03-13,181,5.198497031265826,Mid-PDUFA
Soliris,eculizumab,Alexion Pharmaceuticals,BLA,125166,NA,NA,Injectable,Injection,NA,NA,NA,NA,9/15/2006,3/16/2007,2007,treatment of paroxysmal nocturnal hemoglobinuria to reduce hemolysis,NA,Priority,Yes,No,N/A,No,N/A,N/A,N/A,NA,2006-09-15,2007-03-16,182,5.204006687076795,Mid-PDUFA
Altabax,retapamulin,GlaxoSmithKline,NDA,22055,NA,NA,Ointment,Topical,NA,NA,NA,NA,6/12/2006,4/12/2007,2007,treatment of impetigo,NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,2006-06-12,2007-04-12,304,5.717027701406222,Mid-PDUFA
Neupro,rotigotine,Schwarz BioSciences,NDA,21829,NA,NA,"Film, Extended Release",Transdermal,NA,NA,NA,NA,1/28/2005,5/9/2007,2007,treatment of the signs and symptoms of early-stage idiopathic Parkinson’s disease,NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,2005-01-28,2007-05-09,831,6.7226297948554485,Mid-PDUFA
Torisel,temsirolimus,Wyeth,NDA,22088,NA,NA,Solution,Intravenous,NA,NA,NA,NA,10/5/2006,5/30/2007,2007,treatment of advanced renal cell carcinoma,NA,Priority,Yes,No,N/A,Yes,N/A,N/A,N/A,NA,2006-10-05,2007-05-30,237,5.4680601411351315,Mid-PDUFA
Letairis,ambrisentan,Gilead Sciences,NDA,22081,NA,NA,Tablet,Oral,NA,NA,NA,NA,12/18/2006,6/15/2007,2007,treatment of pulmonary arterial hypertension (WHO Group I) in patients with WHO class II or III symptoms to improve exercise capacity and delay clinical worsening,NA,Priority,Yes,No,N/A,Yes,N/A,N/A,N/A,NA,2006-12-18,2007-06-15,179,5.187385805840755,Mid-PDUFA
Selzentry,maraviroc,Pfizer,NDA,22128,NA,NA,Tablet,Oral,NA,NA,NA,NA,12/20/2006,8/6/2007,2007,treatment of patients infected with CCR5-tropic HIV-1,NA,Priority,No,Yes,N/A,Yes,N/A,N/A,N/A,NA,2006-12-20,2007-08-06,229,5.43372200355424,Mid-PDUFA
[drug marketed without a proprietary name],ammonia N 13,Feinstein Institute for Medical Research,NDA,22119,NA,NA,Injectable,Intravenous,NA,NA,NA,NA,10/25/2006,8/23/2007,2007,indicated for diagnostic Positron Emission Tomography (PET) imaging of the myocardium under rest or pharmacologic stress conditions to evaluate myocardial perfusion in patients with suspected or existing coronary artery disease,NA,Standard,No,No,N/A,No,N/A,N/A,N/A,NA,2006-10-25,2007-08-23,302,5.71042701737487,Mid-PDUFA
Somatuline Depot,lanreotide,Beaufour Ipsen Pharma,NDA,22074,NA,NA,Solution,Subcutaneous,NA,NA,NA,NA,10/30/2006,8/30/2007,2007,long-term treatment of acromegalic patients who have had an inadequate response to or cannot be treated with surgery and/or radiotherapy,NA,Standard,Yes,No,N/A,No,N/A,N/A,N/A,NA,2006-10-30,2007-08-30,304,5.717027701406222,Mid-PDUFA
Doribax,doripenem,Johnson & Johnson,NDA,22106,NA,NA,Injectable,Intravenous,NA,NA,NA,NA,12/13/2006,10/12/2007,2007,NA,"Doribax is indicated to reduce the development of drug-resistant bacteria and maintain the effectiveness of DORIBAX and other antibacterial drugs, DORIBAX should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting and modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. 
DORIBAX (doripenem for injection) is indicated as a single agent for the treatment of complicated intra-abdominal infections caused by Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Bacteroides caccae, Bacteroides fragilis, Bacteroides thetaiotaomicron, Bacteroides uniformis, Bacteroides vulgatus, Streptococcus intermedius, Streptococcus constellatus and Peptostreptococcus micros. 
DORIBAX (doripenem for injection) is indicated as a single agent for the treatment of complicated urinary tract infections, including pyelonephritis caused by Escherichia coli including cases with concurrent bacteremia, Klebsiella pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa, and Acinetobacter baumannii.",Standard,No,No,N/A,No,N/A,No,No,NA,2006-12-13,2007-10-12,303,5.713732805509369,Mid-PDUFA
Isentress,raltegravir,Merck,NDA,22145,NA,NA,Tablet,Oral,NA,NA,NA,NA,4/13/2007,10/12/2007,2007,NA,"ISENTRESS in combination with other antiretroviral agents is indicated for the treatment of HIV-1 infection in treatment-experienced adult patients who have evidence of viral replication and HIV-1 strains resistant to multiple antiretroviral agents. 
This indication is based on analyses of plasma HIV-1 RNA levels up through 24 weeks in two controlled studies of ISENTRESS. These studies were conducted in clinically advanced, 3-class antiretroviral (NNRTI, NRTI, PI) treatment-experienced adults. 
The use of other active agents with ISENTRESS is associated with a greater likelihood of treatment response.
The safety and efficacy of ISENTRESS have not been established in treatment-naïve adult patients or pediatric patients.  
There are no study results demonstrating the effect of ISENTRESS on clinical progression of HIV-1 infection.",Priority,No,Yes,N/A,Yes,N/A,No,No,NA,2007-04-13,2007-10-12,182,5.204006687076795,Mid-PDUFA
Ixempra,ixabepilone,Bristol-Myers Squibb,NDA,22065,NA,NA,Injectable,Intravenous,NA,NA,NA,NA,4/16/2007,10/16/2007,2007,NA,"IXEMPRA is indicated in combination with capecitabine for the treatment of patients with metastatic or locally advanced breast cancer resistant to treatment with an anthracycline and a taxane, or whose cancer is taxane resistant and for whom further anthracycline therapy is contraindicated. Anthracycline resistance is defined as progression while on therapy or within 6 months in the adjuvant setting or 3 months in the metastatic setting. Taxane resistance is defined as progression while on therapy or within 12 months in the adjuvant setting or 4 months in the metastatic setting. 
IXEMPRA is indicated as monotherapy for the treatment of metastatic or locally advanced breast cancer in patients whose tumors are resistant or refractory to anthracyclines, taxanes, and capecitabine.",Priority,No,No,N/A,No,N/A,No,No,NA,2007-04-16,2007-10-16,183,5.209486152841421,Mid-PDUFA
Tasigna,nilotinib,Novartis Pharmaceuticals,NDA,22068,NA,NA,Capsule,Oral,NA,NA,NA,NA,9/29/2006,10/29/2007,2007,NA,"Tasigna (nilotinib) is indicated for the treatment of chronic phase and accelerated phase Philadelphia chromosome positive chronic myelogenous leukemia (CML) in adult patients resistant or intolerant to  prior therapy that included imatinib. The effectiveness of Tasigna is based on hematologic and cytogenetic response rates. There are no controlled trials demonstrating a clinical benefit, such as improvement in disease-related symptoms or increased survival.",Standard,Yes,Yes,N/A,Yes,N/A,No,No,NA,2006-09-29,2007-10-29,395,5.978885764901122,Mid-PDUFA
Mircera,methoxy polyethylene glycol-epoetin beta,Hoffmann-La Roche,BLA,125164,NA,NA,Injectable,Injection,NA,NA,NA,NA,4/19/2006,11/14/2007,2007,NA,"Mircera is indicated for the treatment of anemia associated with chronic renal failure (CRF) in adults, including patients on dialysis and not on dialysis.
Mircera is not indicated for the treatment of anemia due to cancer chemotherapy.",Standard,No,No,N/A,No,N/A,No,No,NA,2006-04-19,2007-11-14,574,6.352629396319567,Mid-PDUFA
Kuvan,sapropterin dihydrochloride,Biomarin Pharmaceutical,NDA,22181,NA,NA,Tablet,Oral,NA,NA,NA,NA,5/25/2007,12/13/2007,2007,NA,Kuvan is indicated to reduce blood phenylalanine (Phe) levels in patients with hyperphenylalaninemia (HPA) due to tetrahydrobiopterin- (BH4-) responsive Phenylketonuria (PKU). Kuvan is to be used in conjunction with a Phe-restricted diet.,Priority,Yes,No,N/A,Yes,N/A,No,No,NA,2007-05-25,2007-12-13,202,5.308267697401205,Mid-PDUFA
Bystolic,nebivolol,Mylan Bertek Pharmaceuticals,NDA,21742,NA,NA,Tablet,Oral,NA,NA,NA,NA,4/30/2004,12/17/2007,2007,NA,BYSTOLIC is indicated for the treatment of hypertension. BYSTOLIC may be used alone or in combination with other antihypertensive agents.,Standard,No,No,N/A,No,N/A,No,No,NA,2004-04-30,2007-12-17,1326,7.189922170745808,Mid-PDUFA
Intelence,etravirine,Tibotec,NDA,22187,NA,NA,Tablet,Oral,NA,NA,NA,NA,7/18/2007,1/18/2008,2008,NA,"INTELENCE, in combination with other antiretroviral agents, is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in antiretroviral treatment-experienced adult patients, who have evidence of viral replication and HIV-1 strains resistant to a non-nucleoside reverse transcriptase inhibitor (NNRTI) and other antiretroviral agents.
This indication is based on Week 24 analyses from 2 randomized, double-blind, placebo-controlled trials of INTELENCE. Both studies were conducted in clinically advanced, 3-class antiretroviral (NNRTI, N[t]RTI, PI) treatment-experienced adults. 
The following points should be considered when initiating therapy with INTELENCE: 
- Treatment history and, when available, resistance testing, should guide the use of INTELENCE. 
- The use of other active antiretroviral agents with INTELENCE is associated with an increased likelihood of treatment response. 
- In patients who have experienced virologic failure on an NNRTI-containing regimen, do not use INTELENCE in combination with only N[t]RTIs. 
- The risks and benefits of INTELENCE have not been established in pediatric patients or in treatment-naïve adult patients.",Priority,No,Yes,N/A,Yes,N/A,No,No,NA,2007-07-18,2008-01-18,184,5.214935757608986,Mid-PDUFA
Emend,fosaprepitant dimeglumine,Merck,NDA,22023,NA,NA,Powder,Intravenous,NA,NA,NA,NA,4/3/2006,1/25/2008,2008,NA,"EMEND for Injection, in combination with other antiemetic agents, is indicated for the: 
- prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy including high-dose cisplatin 
- prevention of nausea and vomiting associated with initial and repeated courses of moderately emetogenic cancer chemotherapy.",Standard,No,No,N/A,No,N/A,No,No,NA,2006-04-03,2008-01-25,662,6.495265555937008,Mid-PDUFA
Arcalyst,rilonacept,Regeneron Pharmaceuticals,BLA,125249,NA,NA,Injectable,Injection,NA,NA,NA,NA,5/29/2007,2/27/2008,2008,NA,"ARCALYST (rilonacept) is an interleukin-1 blocker indicated for the treatment of Cryopyrin-Associated Periodic Syndomes (CAPS), including Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS) in adults and children 12 and older.",Priority,Yes,No,N/A,Yes,N/A,No,No,NA,2007-05-29,2008-02-27,274,5.6131281063880705,Mid-PDUFA
Pristiq,desvenlafaxine,Wyeth Pharmaceuticals,NDA,21992,NA,NA,"Tablet, Extended Release",Oral,NA,NA,NA,NA,12/22/2005,2/29/2008,2008,NA,"Pristiq, a selective serotonin and norepinephrine reuptake inhibitor (SNRI), is indicated for the treatment of major depressive disorder (MDD). The efficacy of Pristiq has been established in four 8-week, placebo-controlled studies of outpatients who met DSM-IV criteria for major depressive disorder. 
A major depressive episode (DSM-IV) implies a prominent and relatively persistent (nearly every day for at least 2 weeks) depressed or dysphoric mood that usually interferes with daily functioning, and includes at least 5 of the following 9 symptoms: depressed mood, loss of interest in usual activities, significant change in weight and/or appetite, insomnia or hypersomnia, psychomotor agitation or retardation, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, or a suicide attempt or suicidal ideation.",Standard,No,No,N/A,No,N/A,No,No,NA,2005-12-22,2008-02-29,799,6.683360945766275,Mid-PDUFA
Treanda,bendamustine hydrochloride,Cephalon,NDA,22249,NA,NA,Powder,Iv (Infusion),NA,NA,NA,NA,9/20/2007,3/20/2008,2008,NA,TREANDA (bendamustine hydrochloride) for Injection is indicated for the treatment of patients with chronic lymphocytic leukemia (CLL). Efficacy relative to first line therapies other than chlorambucil has not been established.,Priority,Yes,No,N/A,No,N/A,No,No,NA,2007-09-20,2008-03-20,182,5.204006687076795,Mid-PDUFA
Lexiscan,regadenoson,CV Therapeutics,NDA,22161,NA,NA,Solution,Intravenous,NA,NA,NA,NA,5/14/2007,4/10/2008,2008,NA,Lexiscan (regadenoson) injection is a pharmacologic stress agent indicated for radionuclide myocardial perfusion imaging (MPI) in patients unable to undergo adequate exercise stress.,Standard,No,No,N/A,No,N/A,No,No,NA,2007-05-14,2008-04-10,332,5.805134968916488,Mid-PDUFA
Cimzia,certolizumab pegol,UCB,BLA,125160,NA,NA,Injectable,Injection,NA,NA,NA,NA,3/1/2006,4/22/2008,2008,NA,CIMZIA is indicated for reducing signs and symptoms of Crohn's disease and maintaining clinical response in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy.,Standard,No,No,N/A,No,N/A,No,No,NA,2006-03-01,2008-04-22,783,6.663132695990803,Mid-PDUFA
Relistor,methylnaltrexone bromide,Progenics Pharmaceuticals,NDA,21964,NA,NA,Solution,Subcutaneous,NA,NA,NA,NA,3/30/2007,4/24/2008,2008,NA,"RELISTOR is indicated for the treatment of opioid-induced constipation in patients with advanced illness who are receiving palliative care, when response to laxative therapy has not been sufficient. Use of RELISTOR beyond four months has not been studied.",Standard,No,No,N/A,No,N/A,No,No,NA,2007-03-30,2008-04-24,391,5.968707559985366,Mid-PDUFA
Entereg,alvimopan,Adolor,NDA,21775,NA,NA,Capsule,Oral,NA,NA,NA,NA,6/25/2004,5/20/2008,2008,NA,ENTEREG is indicated to accelerate the time to upper and lower gastrointestinal recovery following partial large or small bowel resection surgery with primary anastomosis.,Standard,No,No,N/A,Yes,N/A,No,No,NA,2004-06-25,2008-05-20,1425,7.261927092702751,Mid-PDUFA
Durezol,difluprednate,Sirion Therapeutics,NDA,22212,NA,NA,Emulsion,Ophthalmic,NA,NA,NA,NA,12/26/2007,6/23/2008,2008,NA,"Durezol (difluprednate ophthalmic emulsion) 0.05%, a topical corticosteroid, is indicated for the treatment of inflammation and pain associated with ocular surgery.",Priority,No,No,N/A,No,N/A,No,No,NA,2007-12-26,2008-06-23,180,5.19295685089021,Mid-PDUFA
Eovist,gadoxetate disodium,Bayer Healthcare Pharmaceuticals,NDA,22090,NA,NA,Solution,Intravenous,NA,NA,NA,NA,7/2/2007,7/3/2008,2008,NA,EOVIST Injection is a gadolinium-based contrast agent indicated for intravenous use in T1-weighted magnetic resonance imaging (MRI) of the liver to detect and characterize lesions in adults with known or suspected focal liver disease.,Standard,No,No,N/A,No,N/A,No,No,NA,2007-07-02,2008-07-03,367,5.905361848054571,Mid-PDUFA
Cleviprex,clevidipine,The Medicines Company,NDA,22156,NA,NA,Emulsion,Intravenous,NA,NA,NA,NA,7/2/2007,8/1/2008,2008,NA,Cleviprex is indicated for the reduction of blood pressure when oral therapy is not feasible or not desirable.,Standard,No,No,N/A,No,N/A,No,No,NA,2007-07-02,2008-08-01,396,5.981414211254481,Mid-PDUFA
Xenazine,tetrabenazine,Prestwick Pharmaceuticals,NDA,21894,NA,NA,Tablet,Oral,NA,NA,NA,NA,9/26/2005,8/15/2008,2008,NA,XENAZINE is indicated for the treatment of chorea associated with Huntington's disease.,Priority,Yes,No,N/A,Yes,N/A,No,No,NA,2005-09-26,2008-08-15,1054,6.960347729101308,Mid-PDUFA
Nplate,romiplostim,Amgen,BLA,125268,NA,NA,Injectable,Injection,NA,NA,NA,NA,10/23/2007,8/22/2008,2008,NA,"Nplate is indicated for the treatment of thrombocytopenia in patients with chronic immune (idiopathic) thrombocytopenic purpura (ITP) who have had an insufficient response to corticosteroids, immunoglobulins or splenectomy. Nplate should be used only in patients with ITP whose degree of thrombocytopenia and clinical condition increases the risk for bleeding. Nplate should not be used in an attempt to normalize platelet counts.",Priority,Yes,No,N/A,Yes,N/A,No,No,NA,2007-10-23,2008-08-22,304,5.717027701406222,Mid-PDUFA
AdreView,iobenguane I 123,GE Healthcare,NDA,22290,NA,NA,Solution,Intravenous,NA,NA,NA,NA,3/21/2008,9/19/2008,2008,NA,AdreView is a radiopharmaceutical indicated for use in the detection of primary or metastatic pheochromocytoma or neuroblastoma as an adjunct to other diagnostic tests.,Priority,Yes,No,N/A,No,N/A,No,No,NA,2008-03-21,2008-09-19,182,5.204006687076795,Mid-PDUFA
Rapaflo,silodosin,Watson Laboratories,NDA,22206,NA,NA,Capsule,Oral,NA,NA,NA,NA,12/13/2007,10/8/2008,2008,NA,"RAPAFLO, a selective alpha-1 adrenergic receptor antagonist, is indicated for the treatment of the signs and symptoms of benign prostatic hyperplasia (BPH). RAPAFLO is not indicated for the treatment of hypertension.",Standard,No,No,N/A,No,N/A,No,No,NA,2007-12-13,2008-10-08,300,5.703782474656201,Mid-PDUFA
Vimpat,lacosamide,Schwarz Biosciences,NDA,22253,22254,NA,Tablet,Oral,Injectable,Injection,NA,NA,9/28/2007,10/28/2008,2008,NA,"VIMPAT (lacosamide) tablets are indicated as adjunctive therapy in the treatment of partial-onset seizures in patients with epilepsy aged 17 years and older. 
VIMPAT (lacosamide) injection for intravenous use is indicated as adjunctive therapy in the treatment of partial-onset seizures in patients with epilepsy aged 17 years and older when oral administration is temporarily not feasible.",Standard,No,No,N/A,No,N/A,No,No,NA,2007-09-28,2008-10-28,396,5.981414211254481,Mid-PDUFA
Toviaz,fesoterodine fumarate,Pfizer,NDA,22030,NA,NA,"Tablet, Extended Release",Oral,NA,NA,NA,NA,3/27/2006,10/31/2008,2008,NA,"Toviaz is indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency.",Standard,No,No,N/A,No,N/A,No,No,NA,2006-03-27,2008-10-31,949,6.855408798609928,Mid-PDUFA
Banzel,rufinamide,Eisai Medical Research,NDA,21911,NA,NA,Tablet,Oral,NA,NA,NA,NA,11/17/2005,11/14/2008,2008,NA,BANZEL (rufinamide) is indicated for adjunctive treatment of seizures associated with Lennox-Gastaut syndrome in children 4 years and older and adults.,Standard,Yes,No,N/A,No,N/A,No,No,NA,2005-11-17,2008-11-14,1093,6.996681488176539,Mid-PDUFA
Promacta,eltrombopag,GlaxoSmithKline,NDA,22291,NA,NA,Tablet,Oral,NA,NA,NA,NA,12/19/2007,11/20/2008,2008,NA,"PROMACTA is indicated for the treatment of thrombocytopenia in patients with chronic immune (idiopathic) thrombocytopenic purpura (ITP) who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy. PROMACTA should be used only in patients with ITP whose degree of thrombocytopenia and clinical condition increases the risk for bleeding. PROMACTA should not be used in an attempt to normalize platelet counts.",Priority,Yes,Yes,N/A,No,N/A,No,No,NA,2007-12-19,2008-11-20,337,5.820082930352362,Mid-PDUFA
Nucynta,tapentadol,Johnson & Johnson,NDA,22304,NA,NA,Tablet,Oral,NA,NA,NA,NA,1/23/2008,11/20/2008,2008,NA,tapentadol is indicated for the relief of moderate to severe acute pain in patients 18 years of age or older.,Standard,No,No,N/A,No,N/A,No,No,NA,2008-01-23,2008-11-20,302,5.71042701737487,Mid-PDUFA
Lusedra,fospropofol disodium,Eisai Medical Research,NDA,22244,NA,NA,Solution,Intravenous,NA,NA,NA,NA,9/27/2007,12/12/2008,2008,NA,LUSEDRA (fospropofol disodium) injection is an intravenous sedative-hypnotic agent indicated for monitored anesthesia care (MAC) sedation in adult patients undergoing diagnostic or therapeutic procedures.,Standard,No,No,N/A,No,N/A,No,No,NA,2007-09-27,2008-12-12,442,6.091309882077698,Mid-PDUFA
Mozobil,plerixafor,Genzyme,NDA,22311,NA,NA,Solution,Subcutaneous,NA,NA,NA,NA,6/16/2008,12/15/2008,2008,NA,Mozobil (plerixafor injection) is indicated in combination with granulocyte-colony stimulating factor (G-CSF) to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkin’s lymphoma (NHL) and multiple myeloma (MM).,Priority,Yes,No,N/A,No,N/A,No,No,NA,2008-06-16,2008-12-15,182,5.204006687076795,Mid-PDUFA
Vasovist,gadofosveset trisodium,Epix Pharmaceuticals,NDA,21711,NA,NA,Solution,Intravenous,NA,NA,NA,NA,12/15/2003,12/22/2008,2008,NA,VASOVIST is indicated for use as a contrast agent in magnetic resonance angiography (MRA) to evaluate aortoiliac occlusive disease (AIOD) in adults with known or suspected peripheral vascular disease.,Standard,No,No,N/A,No,N/A,No,No,NA,2003-12-15,2008-12-22,1834,7.51425465281641,Mid-PDUFA
Firmagon,degarelix,Ferring Pharmaceuticals,NDA,22201,NA,NA,Powder,Subcutaneous,NA,NA,NA,NA,2/28/2008,12/24/2008,2008,NA,degarelix is a GnRH receptor antagonist indicated for treatment of patients with advanced prostate cancer.,Standard,No,No,N/A,No,N/A,No,No,NA,2008-02-28,2008-12-24,300,5.703782474656201,Mid-PDUFA
Savella,milnacipran hydrochloride,Cypress Bioscience,NDA,22256,NA,NA,Tablet,Oral,NA,NA,NA,NA,12/18/2007,1/14/2009,2009,NA,"Savella is indicated for the management of fibromyalgia. 
Savella is not approved for use in pediatric patients.",Standard,No,No,N/A,No,N/A,No,No,NA,2007-12-18,2009-01-14,393,5.973809611869261,Mid-PDUFA
Uloric,febuxostat,Takeda Pharmaceuticals,NDA,21856,NA,NA,Tablet,Oral,NA,NA,NA,NA,12/15/2004,2/13/2009,2009,NA,"ULORIC is a xanthine oxidase (XO) inhibitor indicated for the chronic management of hyperuricemia in patients with gout. 
ULORIC is not recommended for the treatment of asymptomatic hyperuricemia.",Standard,No,No,N/A,No,N/A,No,No,NA,2004-12-15,2009-02-13,1521,7.327123292259293,Mid-PDUFA
Afinitor,everolimus,Novartis Pharmaceuticals,NDA,22334,NA,NA,Tablet,Oral,NA,NA,NA,NA,6/30/2008,3/30/2009,2009,NA,AFINITOR is indicated for the treatment of patients with advanced renal cell carcinoma after failure of treatment with sunitinib or sorafenib.,Priority,No,No,N/A,No,N/A,No,No,NA,2008-06-30,2009-03-30,273,5.60947179518496,Mid-PDUFA
Coartem,"artemether, lumefantrine",Novartis Pharmaceuticals,NDA,22268,NA,NA,Tablet,Oral,NA,NA,NA,NA,6/27/2008,4/7/2009,2009,NA,"Coartem (artemether/lumefantrine) Tablets are indicated for treatment of acute, uncomplicated malaria infections due to Plasmodium falciparum in patients of 5 kg bodyweight and above. Coartem Tablets have been shown to be effective in geographical regions where resistance to chloroquine has been reported. 
Limitations of Use: 
- Coartem Tablets are not approved for patients with severe or complicated P. falciparum malaria. 
- Coartem Tablets are not approved for the prevention of malaria.",Priority,Yes,No,N/A,Yes,N/A,TD,No,NA,2008-06-27,2009-04-07,284,5.648974238161206,Mid-PDUFA
Ulesfia,benzyl alcohol,Sciele Pharma,NDA,22129,NA,NA,Lotion,Topical,NA,NA,NA,NA,6/15/2007,4/9/2009,2009,NA,"benzyl alcohol Lotion is indicated for the topical treatment of head lice infestation in patients 6 months of age and older. 
Limitation of Use:
benzyl alcohol Lotion does not have ovocidal activity. 
Adjunctive Measures: 
benzyl alcohol Lotion should be used in the context of an overall lice management program: 
- Wash (in hot water) or dry-clean all recently worn clothing, hats, used bedding, and towels. 
- Wash personal care items such as combs, brushes and hair clips in hot water. 
- A fine-tooth comb or special nit comb may be used to remove dead lice and nits.",Standard,No,No,N/A,No,N/A,No,No,NA,2007-06-15,2009-04-09,664,6.498282149476434,Mid-PDUFA
Simponi,golimumab,Centocor Ortho Biotech,BLA,125289,NA,NA,Injectable,Injection,NA,NA,NA,NA,6/24/2008,4/24/2009,2009,NA,"SIMPONI, in combination with methotrexate, is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis. 
SIMPONI, alone or in combination with methotrexate, is indicated for the treatment of adult patients with active psoriatic arthritis.
SIMPONI is indicated for the treatment of adult patients with active ankylosing spondylitis.",Standard,No,No,N/A,No,N/A,No,No,NA,2008-06-24,2009-04-24,304,5.717027701406222,Mid-PDUFA
Dysport,abobotulinumtoxinA,Ipsen Biopharm,BLA,125274,NA,NA,Injectable,Injection,NA,NA,NA,NA,11/29/2007,4/29/2009,2009,NA,"[A] DYSPORT (abobotulinumtoxinA) is an acetylcholine release inhibitor and a neuromuscular blocking agent indicated for the treatment of adults with cervical dystonia to reduce the severity of abnormal head position and neck pain in both toxin-naïve and previously treated patients. 
[B] DYSPORT (abobotulinumtoxinA) is an acetylcholine release inhibitor and a neuromuscular blocking agent indicated for the temporary improvement in the appearance of moderate to severe glabellar lines associated with procerus and corrugator muscle activity in adult patients < 65 years of age.",Standard,Yes (indication [A] only),No,N/A,No,N/A,No,No,NA,2007-11-29,2009-04-29,517,6.248042874508429,Mid-PDUFA
Fanapt,iloperidone,Vanda Pharmaceuticals,NDA,22192,NA,NA,Tablet,Oral,NA,NA,NA,NA,9/27/2007,5/6/2009,2009,NA,"FANAPT tablets are indicated for the acute treatment of adults with schizophrenia. 
When deciding among the alternative treatments available for this condition, the prescriber should consider the finding that FANAPT is associated with prolongation of the QTc interval. Prolongation of the QTc interval is associated in some other drugs with the ability to cause torsade de pointes-type arrhythmia, a potentially fatal polymorphic ventricular tachycardia which can result in sudden death. In many cases this would lead to the conclusion that other drugs should be tried first. Whether FANAPT will cause torsade de pointes or increase the rate of sudden death is not yet known. 
Patients must be titrated to an effective dose of FANAPT. Thus, control of symptoms may be delayed during the first 1 to 2 weeks of treatment compared to some other antipsychotic drugs that do not require a similar titration. Prescribers should be mindful of this delay when selecting an antipsychotic drug for the acute treatment of schizophrenia. 
The effectiveness of FANAPT in long-term use, that is, for more than 6 weeks, has not been systematically evaluated in controlled trials. Therefore, the physician who elects to use FANAPT for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient.",Standard,No,No,N/A,No,N/A,No,No,NA,2007-09-27,2009-05-06,587,6.375024819828097,Mid-PDUFA
Samsca,tolvaptan,Otsuka Pharmaceutical,NDA,22275,NA,NA,Tablet,Oral,NA,NA,NA,NA,10/23/2007,5/19/2009,2009,NA,"SAMSCA is indicated for the treatment of clinically significant hypervolemic and euvolemic hyponatremia (serum sodium < 125 mEq/L or less marked hyponatremia that is symptomatic and has resisted correction with fluid restriction), including patients with heart failure, cirrhosis, and Syndrome of Inappropriate Antidiuretic Hormone (SIADH). Important Limitations: Patients requiring intervention to raise serum sodium urgently to prevent or to treat serious neurological symptoms should not be treated with SAMSCA. It has not been established that raising serum sodium with SAMSCA provides a symptomatic benefit to patients.",Standard,No,No,N/A,No,N/A,No,No,NA,2007-10-23,2009-05-19,574,6.352629396319567,Mid-PDUFA
Besivance,besifloxacin,Bausch & Lomb,NDA,22308,NA,NA,Suspension/Drops,Ophthalmic,NA,NA,NA,NA,6/2/2008,5/28/2009,2009,NA,"Besivance (besifloxacin ophthalmic suspension) 0.6%, is indicated for the treatment of bacterial conjunctivitis caused by susceptible isolates of the following bacteria: 
CDC coryneform group G 
Corynebacterium pseudodiphtheriticum*
Corynebacterium striatum*
Haemophilus influenzae
Moraxella lacunata*
Staphylococcus aureus
Staphylococcus epidermidis
Staphylococcus hominis*
Staphylococcus lugdunensis*
Streptococcus mitis group
Streptococcus oralis
Streptococcus pneumoniae
Streptococcus salivarius*
*Efficacy for this organism was studied in fewer than 10 infections.",Standard,No,No,N/A,No,N/A,No,No,NA,2008-06-02,2009-05-28,360,5.886104031450156,Mid-PDUFA
Ilaris,canakinumab,Novartis Pharmaceuticals,BLA,125319,NA,NA,Injectable,Injection,NA,NA,NA,NA,12/17/2008,6/17/2009,2009,NA,"ILARIS (canakinumab) is an interleukin-1beta blocker indicated for the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), in adults and children 4 years of age and older including: 
- Familial Cold Autoinflammatory Syndrom (FCAS) 
- Muckle-Wells Syndrome (MWS)",Priority,Yes,No,N/A,Yes,N/A,No,No,NA,2008-12-17,2009-06-17,182,5.204006687076795,Mid-PDUFA
Multaq,dronedarone,Sanofi-Aventis,NDA,22425,NA,NA,Tablet,Oral,NA,NA,NA,NA,7/31/2008,7/1/2009,2009,NA,"MULTAQ is indicated to reduce the risk of cardiovascular hospitalization in patients with paroxysmal or persistent atrial fibrillation (AF) or atrial flutter (AFL), with a recent episode of AF/AFL and associated cardiovascular risk factors (i.e., age >70, hypertension, diabetes, prior cerebrovascular accident, left atrial diameter >= 50 mm or left ventricular ejection fraction [LVEF] < 40%), who are in sinus rhythm or who will be cardioverted.",Priority,No,No,N/A,No,N/A,No,No,NA,2008-07-31,2009-07-01,335,5.814130531825066,Mid-PDUFA
Effient,prasugrel,Eli Lilly,NDA,22307,NA,NA,Tablet,Oral,NA,NA,NA,NA,12/26/2007,7/10/2009,2009,NA,"Effient is indicated to reduce the rate of thrombotic cardiovascular (CV) events (including stent thrombosis) in patients with acute coronary syndrome (ACS) who are to be managed with percutaneous coronary intervention (PCI) as follows:  
- Patients with unstable angina (UA) or non-ST-elevation myocardial infarction (NSTEMI).  
- Patients with ST-elevation myocardial infarction (STEMI) when managed with either primary or delayed PCI. 
Effient has been shown to reduce the rate of a combined endpoint of cardiovascular death, nonfatal myocardial infarction (MI), or nonfatal stroke compared to clopidogrel. The difference between treatments was driven predominantly by MI, with no difference on strokes and little difference on CV death. 
It is generally recommended that antiplatelet therapy be administered promptly in the management of ACS because many cardiovascular events occur within hours of initial presentation. In the clinical trial that established the efficacy of Effient, Effient and the control drug were not administered to UA/NSTEMI patients until coronary anatomy was established. For the small fraction of patients that required urgent CABG after treatment with Effient, the risk of significant bleeding was substantial. Because the large majority of patients are managed without CABG, however, treatment can be considered before determining coronary anatomy if need for CABG is considered unlikely. The advantages of earlier treatment with Effient must then be balanced against the increased rate of bleeding in patients who do need to undergo urgent CABG.",Priority,No,No,N/A,No,N/A,No,No,NA,2007-12-26,2009-07-10,562,6.331501849893691,Mid-PDUFA
Onglyza,saxagliptin,Bristol-Myers Squibb,NDA,22350,NA,NA,Tablet,Oral,NA,NA,NA,NA,6/30/2008,7/31/2009,2009,NA,"Monotherapy and Combination Therapy:
ONGLYZA is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. 
Important Limitations of Use: 
ONGLYZA should not be used for the treatment of type 1 diabetes mellitus or diabetic ketoacidosis, as it would not be effective in these settings. 
ONGLYZA has not been studied in combination with insulin.",Standard,No,No,N/A,No,N/A,No,No,NA,2008-06-30,2009-07-31,396,5.981414211254481,Mid-PDUFA
Livalo,pitavastatin,Kowa Research Institute,NDA,22363,NA,NA,Tablet,Oral,NA,NA,NA,NA,10/3/2008,8/3/2009,2009,NA,"Drug therapy should be one component of multiple-risk-factor intervention in individuals who require modifications of their lipid profile. Lipid-altering agents should be used in addition to a diet restricted in saturated fat and cholesterol only when the response to diet and other nonpharmacological measures has been inadequate. 
LIVALO is indicated as an adjunctive therapy to diet to reduce elevated total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), apolipoprotein B (Apo B), triglycerides (TG), and to increase HDL-C in adult patients with primary hyperlipidemia or mixed dyslipidemia. 
Limitations of Use: 
Doses of LIVALO greater than 4 mg once daily were associated with an increased risk for severe myopathy in premarketing clinical studies. Do not exceed 4 mg once daily dosing of LIVALO. 
The effect of LIVALO on cardiovascular morbidity and mortality has not been determined. 
LIVALO has not been studied in patients with severe renal impairment (glomerular filtration rate < 30 mL/min/1.73 m2) not on hemodialysis. LIVALO should not be used in this patient population. 
LIVALO has not been studied with the protease inhibitor combination lopinavir/ritonavir. LIVALO should not be used with this combination of protease inhibitors. 
LIVALO has not been studied in Fredrickson Type I, III, and V dyslipidemias.",Standard,No,No,N/A,No,N/A,No,No,NA,2008-10-03,2009-08-03,304,5.717027701406222,Mid-PDUFA
Saphris,asenapine,Organon,NDA,22117,NA,NA,Tablet,Oral,NA,NA,NA,NA,8/31/2007,8/13/2009,2009,NA,"SAPHRIS is indicated for the acute treatment of schizophrenia in adults. The physician who elects to use SAPHRIS for extended periods in schizophrenia should periodically re-evaluate the long-term risks and benefits of the drug for the individual patient. 
SAPHRIS is indicated for the acute treatment of manic or mixed episodes associated with bipolar I disorder with or without psychotic features in adults. If SAPHRIS is used for extended periods in bipolar disorder, the physician should periodically re-evaluate the long-term risks and benefits of the drug for the individual patient.",Standard,No,No,N/A,No,N/A,No,No,NA,2007-08-31,2009-08-13,713,6.569481420414296,Mid-PDUFA
Bepreve,bepotastine besilate,Ista Pharmaceuticals,NDA,22288,NA,NA,Solution/Drops,Ophthalmic,NA,NA,NA,NA,11/12/2008,9/8/2009,2009,NA,Bepreve (bepotastine besilate ophthalmic solution) 1.5% is a histamine H1 receptor antagonist indicated for the treatment of itching associated with signs and symptoms of allergic conjunctivitis.,Standard,No,No,N/A,No,N/A,No,No,NA,2008-11-12,2009-09-08,300,5.703782474656201,Mid-PDUFA
Vibativ,telavancin,Theravance,NDA,22110,NA,NA,Powder,Intravenous,NA,NA,NA,NA,12/19/2006,9/11/2009,2009,NA,"To reduce the development of drug-resistant bacteria and maintain the effectiveness of VIBATIV and other antibacterial drugs, VIBATIV should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. 
VIBATIV is indicated for the treatment of adult patients with complicated skin and skin structure infections (cSSSI) caused by susceptible isolates of the following Gram-positive microorganisms: Staphylococcus aureus (including methicillin-susceptible and -resistant isolates), Streptococcus pyogenes, Streptococcus agalactiae, Streptococcus anginosus group (includes S. anginosus, S. intermedius, and S. constellatus), or Enterococcus faecalis (vancomycin-susceptible isolates only). 
Combination therapy may be clinically indicated if the documented or presumed pathogens include Gram-negative organisms. 
Appropriate specimens for bacteriological examination should be obtained in order to isolate and identify the causative pathogens and to determine their susceptibility to telavancin. VIBATIV may be initiated as empiric therapy before results of these tests are known.",Standard,No,No,N/A,Yes,N/A,No,No,NA,2006-12-19,2009-09-11,997,6.904750769961838,Mid-PDUFA
Folotyn,pralatrexate,Allos Therapeutics,NDA,22468,NA,NA,Solution,Intravenous,NA,NA,NA,NA,3/24/2009,9/24/2009,2009,NA,FOLOTYN is indicated for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). This indication is based on overall response rate. Clinical benefit such as improvement in progression free survival or overall survival has not been demonstrated.,Priority,Yes,Yes,N/A,Yes,N/A,No,No,NA,2009-03-24,2009-09-24,184,5.214935757608986,Mid-PDUFA
Stelara,ustekinumab,Centocor Ortho Biotech,BLA,125261,NA,NA,Injectable,Injection,NA,NA,NA,NA,11/29/2007,9/25/2009,2009,NA,STELARA is indicated for the treatment of adult patients (18 years or older) with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy.,Standard,No,No,N/A,No,N/A,No,No,NA,2007-11-29,2009-09-25,666,6.501289670540389,Mid-PDUFA
Votrient,pazopanib,GlaxoSmithKline,NDA,22465,NA,NA,Tablet,Oral,NA,NA,NA,NA,12/19/2008,10/19/2009,2009,NA,VOTRIENT is indicated for the treatment of patients with advanced renal cell carcinoma (RCC).,Standard,No,No,N/A,No,N/A,No,No,NA,2008-12-19,2009-10-19,304,5.717027701406222,Mid-PDUFA
Arzerra,ofatumumab,GlaxoSmithKline,BLA,125326,NA,NA,Injectable,Injection,NA,NA,NA,NA,1/30/2009,10/26/2009,2009,NA,"ARZERRA (ofatumumab) is indicated for the treatment of patients with chronic lymphocytic leukemia (CLL) refractory to fludarabine and alemtuzumab. 
The effectiveness of ARZERRA is based on the demonstration of durable objective responses. No data demonstrate an improvement in disease related symptoms or increased survival with ARZERRA.",Priority,Yes,Yes,N/A,Yes,N/A,No,No,NA,2009-01-30,2009-10-26,269,5.594711379601839,Mid-PDUFA
Istodax,romidepsin,Gloucester Pharmaceuticals,NDA,22393,NA,NA,Powder,Intravenous,NA,NA,NA,NA,1/12/2009,11/5/2009,2009,NA,ISTODAX is indicated for treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy.,Standard,Yes,No,N/A,Yes,N/A,No,No,NA,2009-01-12,2009-11-05,297,5.6937321388027,Mid-PDUFA
Qutenza,capsaicin,Neurogesx,NDA,22395,NA,NA,Patch,Topical,NA,NA,NA,NA,10/16/2008,11/16/2009,2009,NA,Qutenza is indicated for the management of neuropathic pain associated with postherpetic neuralgia.,Standard,Yes,No,N/A,No,N/A,No,No,NA,2008-10-16,2009-11-16,396,5.981414211254481,Mid-PDUFA
Kalbitor,ecallantide,Dyax,BLA,125277,NA,NA,Injectable,Injection,NA,NA,NA,NA,9/23/2008,12/1/2009,2009,NA,KALBITOR (ecallantide) is indicated for treatment of acute attacks of hereditary angioedema (HAE) in patients 16 years of age and older.,Priority,Yes,No,N/A,Yes,N/A,No,No,NA,2008-09-23,2009-12-01,434,6.073044534100405,Mid-PDUFA
Actemra,tocilizumab,Genentech,BLA,125276,NA,NA,Injectable,Injection,NA,NA,NA,NA,11/19/2007,1/8/2010,2010,NA,ACTEMRA (tocilizumab) is indicated for treatment of adult patients with moderately- to severely-active rheumatoid arthritis who have had an inadequate response to one or more TNF antagonist therapies.,Standard,No,No,N/A,No,N/A,No,No,NA,2007-11-19,2010-01-08,781,6.660575149839686,Mid-PDUFA
Ampyra,dalfampridine,Acorda Therapeutics,NDA,22250,NA,NA,"Tablet, Extended Release",Oral,NA,NA,NA,NA,4/22/2009,1/22/2010,2010,NA,AMPYRA (dalfampridine) is indicated as a treatment to improve walking in patients with multiple sclerosis (MS). This was demonstrated by an increase in walking speed.,Priority,Yes,No,N/A,No,N/A,No,No,NA,2009-04-22,2010-01-22,275,5.616771097666572,Mid-PDUFA
Victoza,liraglutide,Novo Nordisk,NDA,22341,NA,NA,Solution,Subcutaneous,NA,NA,NA,NA,5/23/2008,1/25/2010,2010,NA,Victoza is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.,Standard,No,No,N/A,No,N/A,No,No,NA,2008-05-23,2010-01-25,612,6.416732282512326,Mid-PDUFA
Xiaflex,clostridial collagenase histolyticum,Auxilium Pharmaceuticals,BLA,125338,NA,NA,Injectable,Injection,NA,NA,NA,NA,2/27/2009,2/2/2010,2010,NA,XIAFLEX is indicated for the treatment of adult patients with Dupuytren's contracture with a palpable cord.,Priority,Yes,No,N/A,No,N/A,No,No,NA,2009-02-27,2010-02-02,340,5.8289456176102075,Mid-PDUFA
Vpriv,velaglucerase alfa,Shire Human Genetic Therapies,BLA,22575,NA,NA,Powder,Intravenous,NA,NA,NA,NA,8/31/2009,2/26/2010,2010,NA,VPRIV (velaglucerase alfa for injection) is a hydrolytic lysosomal glucocerebroside-specific enzyme indicated for long-term enzyme replacement therapy (ERT) for pediatric and adult patients with type 1 Gaucher disease.,Priority,Yes,No,N/A,Yes,N/A,No,No,Transition Product from NDA to BLA due to BPCI : Please see page 2 of data dictionary for more information.,2009-08-31,2010-02-26,179,5.187385805840755,Mid-PDUFA
Carbaglu,carglumic acid,Orphan Europe,NDA,22562,NA,NA,Tablet,Oral,NA,NA,NA,NA,6/18/2009,3/18/2010,2010,NA,"Carbaglu is indicated as an adjunctive therapy in pediatric and adult patients for the treatment of acute hyperammonemia due to the deficiency of the hepatic enzyme N-acetylglutamate synthase (NAGS). During acute hyperammonemic episodes concomitant administration of Carbaglu with other ammonia lowering therapies such as alternate pathway medications, hemodialysis, and dietary protein restriction are recommended. 
Carbaglu is indicated for maintenance therapy in pediatric and adult patients for chronic hyperammonemia due to the deficiency of the hepatic enzyme N-acetylglutamate synthase (NAGS). During maintenance therapy, the concomitant use of other ammonia lowering therapies and protein restriction may be reduced or discontinued based on plasma ammonia levels.",Priority,Yes,No,N/A,Yes,N/A,No,No,NA,2009-06-18,2010-03-18,273,5.60947179518496,Mid-PDUFA
Natazia,estradiol valerate; estradiol valerate and dienogest,Bayer HealthCare Pharmaceuticals,NDA,22252,NA,NA,Tablet,Oral,NA,NA,NA,NA,7/6/2009,5/6/2010,2010,NA,"Natazia is indicated for use by women to prevent pregnancy. 
The efficacy of Natazia in women with a body mass index (BMI) of >30 kg/m2 has not been evaluated.",Standard,No,No,N/A,No,N/A,No,No,NA,2009-07-06,2010-05-06,304,5.717027701406222,Mid-PDUFA
Lumizyme,alglucosidase alfa,Genzyme,BLA,125291,NA,NA,Injectable,Injection,NA,NA,NA,NA,5/30/2008,5/24/2010,2010,NA,"LUMIZYME (alglucosidase alfa) is a lysosomal glycogen-specific enzyme indicated for patients 8 years and older with late (non-infantile) onset Pompe disease (acid alpha-glucosidase(GAA) deficiency) who do not have evidence of cardiac hypertrophy. The safety and efficacy of LUMIZYME have not been evaluated in controlled clinical trials in infantile-onset patients, or in late (non-infantile) onset patients less than 8 years of age.",Priority,Yes,No,N/A,Yes,N/A,No,No,NA,2008-05-30,2010-05-24,724,6.584791392385716,Mid-PDUFA
Prolia,denosumab,Amgen,BLA,125320,NA,NA,Injectable,Injection,NA,NA,NA,NA,12/19/2008,6/1/2010,2010,NA,"Prolia is indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture, defined as history of osteoporotic fracture, or multiple risk factors for fracture; or in patients who have failed or are intolerant to other available osteoporosis therapy. In postmenopausal women with osteoporosis, Prolia reduces the incidence of vertebral, nonvertebral, and hip fractures.",Standard,No,No,N/A,No,N/A,No,No,NA,2008-12-19,2010-06-01,529,6.270988431858299,Mid-PDUFA
Jevtana,cabazitaxel,Sanofi-Aventis,NDA,201023,NA,NA,Solution,Intravenous,NA,NA,NA,NA,3/31/2010,6/17/2010,2010,NA,JEVTANA is a microtubule inhibitor indicated in combination with prednisone for the treatment of patients with hormone-refractory metastatic prostate cancer previously treated with a docetaxel-containing treatment regimen.,Priority,No,No,N/A,Yes,N/A,No,No,NA,2010-03-31,2010-06-17,78,4.356708826689592,Mid-PDUFA
Lastacaft,alcaftadine,Vistakon Pharmaceuticals,NDA,22134,NA,NA,Solution/Drops,Ophthalmic,NA,NA,NA,NA,9/29/2009,7/28/2010,2010,NA,LASTACAFT is a H1 histamine receptor antagonist indicated for the prevention of itching associated with allergic conjunctivitis.,Standard,No,No,N/A,No,N/A,No,No,NA,2009-09-29,2010-07-28,302,5.71042701737487,Mid-PDUFA
Xeomin,incobotulinumtoxinA,Merz Pharmaceuticals,BLA,125360,NA,NA,Injectable,Injection,NA,NA,NA,NA,7/2/2009,7/30/2010,2010,NA,Xeomin (incobotulinumtoxinA) is indicated for the treatment of adults with cervical dystonia to decrease the severity of abnormal head position and neck pain in both botulinum toxin-naïve and previously treated patients. XEOMIN (incobotulinumtoxinA) is indicated for the treatment of adults with blepharospasm who were previously treated with onabotulinumtoxinA (Botox).,Standard,No,No,N/A,No,N/A,No,No,NA,2009-07-02,2010-07-30,393,5.973809611869261,Mid-PDUFA
Ella,ulipristal acetate,Laboratoire HRA Pharma,NDA,22474,NA,NA,Tablet,Oral,NA,NA,NA,NA,10/15/2009,8/13/2010,2010,NA,Ella is a progesterone agonist/antagonist emergency contraceptive indicated for prevention of pregnancy following unprotected intercourse or a known or suspected contraceptive failure. ella is not intended for routine use as a contraceptive.,Standard,No,No,N/A,No,N/A,No,No,NA,2009-10-15,2010-08-13,302,5.71042701737487,Mid-PDUFA
Krystexxa,pegloticase,Savient Pharmaceuticals,BLA,125293,NA,NA,Injectable,Injection,NA,NA,NA,NA,10/31/2008,9/14/2010,2010,NA,"KRYSTEXXA (pegloticase) is a PEGylated uric acid specific enzyme indicated for the treatment  of chronic gout in adult patients refractory to conventional therapy. 
Gout refractory to conventional therapy occurs in patients who have failed to normalize serum uric acid and whose signs and symptoms are inadequately controlled with xanthine oxidase inhibitors at the maximum medically appropriate dose or for whom these drugs are contraindicated. 
Important limitations of use: 
KRSTEXXA is not recommended for the treatment of asymptomatic hyperuricemia.",Priority,Yes,No,N/A,No,N/A,No,No,NA,2008-10-31,2010-09-14,683,6.52649485957079,Mid-PDUFA
Gilenya,fingolimod,Novartis Pharmaceuticals,NDA,22527,NA,NA,Capsule,Oral,NA,NA,NA,NA,12/21/2009,9/21/2010,2010,NA,GILENYA is indicated for the treatment of patients with relapsing forms of multiple sclerosis (MS) to reduce the frequency of clinical exacerbations and to delay the accumulation of physical disability.,Priority,No,No,N/A,Yes,N/A,No,No,NA,2009-12-21,2010-09-21,274,5.6131281063880705,Mid-PDUFA
Pradaxa,dabigatran etexilate mesylate,Boehringer Ingelheim Pharmaceuticals,NDA,22512,NA,NA,Capsule,Oral,NA,NA,NA,NA,4/19/2010,10/19/2010,2010,NA,PRADAXA is indicated to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation.,Priority,No,No,N/A,No,N/A,No,No,NA,2010-04-19,2010-10-19,183,5.209486152841421,Mid-PDUFA
Latuda,lurasidone hydrochloride,Sunovion Pharmaceuticals,NDA,200603,NA,NA,Tablet,Oral,NA,NA,NA,NA,12/30/2009,10/28/2010,2010,NA,"LATUDA is indicated for the treatment of patients with schizophrenia. 
The efficacy of LATUDA in schizophrenia was established in four 6-week controlled studies of adult patients with schizophrenia. 
The effectiveness of LATUDA for longer-term use, that is, for more than 6 weeks, has not been established in controlled studies. Therefore, the physician who elects to use LATUDA for extended periods should periodically re-evaluate the long-term usefulness of the drug in the individual patient.",Standard,No,No,N/A,No,N/A,No,No,NA,2009-12-30,2010-10-28,302,5.71042701737487,Mid-PDUFA
Teflaro,ceftaroline fosamil,Cerexa,NDA,200327,NA,NA,Powder,Intravenous,NA,NA,NA,NA,12/30/2009,10/29/2010,2010,NA,"Teflaro (ceftaroline fosamil) is indicated for the treatment of patients with the following infections caused by susceptible isolates of the designated microorganisms. 
[A] Teflaro is indicated for the treatment of actute bacterial skin and skin structure infections (ABSSSI) caused by susceptible isolates of the following Gram-positive and Gram-negative microorganisms: Staphylococcus aureus (including methicillin-susceptible and -resistant isolates), Streptococcus pyogenes, Streptococcus agalactiae, Escherichia coli, Klebsiella pneumoniae, and Klebsiella oxytoca.  
[B] Teflaro is indicated for the treatment of community-acquired bacterial pneumonia (CABP) caused by susceptible isolates of the following Gram-positive and Gram-negative microorganisms: Streptococcus pneumonia (including cases with concurrent bacteremia), Staphylococcus aureus (methicillin-susceptible isolates only), Haemophilus influenzae, Klebsiella pneumoniae, Klebsiella oxytoca, and Escherichia coli. 
Usage: To reduce the development of drug-resistant bacteria and maintain the effectiveness of Teflaro and other antibacterial drugs, Teflaro should be used to treat only ABSSSI or CABP that are proven or strongly suspected to be caused by susceptible bacteria.  Appropriate specimens for microbiological examination should be obtained in order to isolate and identify the causative pathogens and to determine their susceptibility to ceftaroline.  When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.",Standard,No,No,N/A,Yes (indication [A] only),N/A,No,No,NA,2009-12-30,2010-10-29,303,5.713732805509369,Mid-PDUFA
Egrifta,tesamorelin,Kendle International,BLA,22505,NA,NA,Powder,Subcutaneous,NA,NA,NA,NA,5/29/2009,11/10/2010,2010,NA,"EGRIFTA (tesamorelin for injection) is indicated for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy.  
Limitations of Use: 
- Since the long-term cardiovascular safety and potential long-term cardiovascular benefit of EGRIFTA treatment have not been studied and are not known, careful consideration should be given whether to continue EGRIFTA treatment in patients who do not show a clear efficacy response as judged by the degree of reduction in visceral adipose tissue measured by waist circumference or CT scan. 
- EGRIFTA is not indicated for weight loss management (weight neutral effect).  
- There are no data to support improved compliance with anti-retroviral therapies in HIV-positive patients taking EGRIFTA.",Standard,No,No,N/A,No,N/A,No,No,Transition Product from NDA to BLA due to BPCI : Please see page 2 of data dictionary for more information.,2009-05-29,2010-11-10,530,6.272877006546167,Mid-PDUFA
Halaven,eribulin mesylate,Eisai,NDA,201532,NA,NA,Solution,Intravenous,NA,NA,NA,NA,3/30/2010,11/15/2010,2010,NA,HALAVEN is indicated for the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease.  Prior therapy should have included an anthracycline and a taxane in either the adjuvant or metastatic setting.,Priority,No,No,N/A,Yes,N/A,No,No,NA,2010-03-30,2010-11-15,230,5.438079308923196,Mid-PDUFA
DaTscan,ioflupane I 123,GE Healthcare,NDA,22454,NA,NA,Solution,Intravenous,NA,NA,NA,NA,3/9/2009,1/14/2011,2011,NA,"DaTscan is a radiopharmaceutical indicated for striatal dopamine transporter visualization using single photon emission computed tomography (SPECT) brain imaging to assist in the evaluation of adult patients with suspected Parkinsonian syndromes (PS).  In these patients, DaTscan may be used to help differentiate essential tremor from tremor due to PS (idiopathic Parkinson’s disease, multiple system atrophy and progressive supranuclear palsy). DaTscan is an adjunct to other diagnostic evaluations.",Priority,No,No,N/A,No,N/A,No,No,NA,2009-03-09,2011-01-14,676,6.516193076042964,Mid-PDUFA
Natroba,spinosad,Parapro,NDA,22408,NA,NA,Suspension,Topical,NA,NA,NA,NA,1/22/2009,1/18/2011,2011,NA,"NATROBA (spinosad) Topical Suspension is indicated for the topical treatment of head lice infestation in patients four (4) years of age and older.  
Adjunctive Measures:
NATROBA Topical Suspension should be used in the context of an overall lice management program:  
- Wash (in hot water) or dry-clean all recently worn clothing, hats, used bedding and towels.  
- Wash personal care items such as combs, brushes and hair clips in hot water.  
- A fine-tooth comb or special nit comb may be used to remove dead lice and nits.",Standard,No,No,N/A,No,N/A,No,No,NA,2009-01-22,2011-01-18,726,6.587550014824796,Mid-PDUFA
Viibryd,vilazodone hydrochloride,Trovis Pharmaceuticals,NDA,22567,NA,NA,Tablet,Oral,NA,NA,NA,NA,3/22/2010,1/21/2011,2011,NA,"VIIBRYD is indicated for the treatment of major depressive disorder (MDD). The efficacy of VIIBRYD was established in two 8-week, randomized, double-blind, placebo-controlled trials in adult patients with a diagnosis of MDD. 
Major depressive disorder consists of one or more major depressive episodes. A major depressive episode (DSM-IV-TR) implies a prominent and relatively persistent (nearly every day for at least 2 weeks) depressed or dysphoric mood that usually interferes with daily functioning, and includes at least 5 of the following 9 symptoms: depressed mood, loss of interest in usual activities, significant change in weight and/or appetite, insomnia or hypersomnia, psychomotor agitation or retardation, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, or a suicide attempt or suicidal ideation.",Standard,No,No,N/A,No,N/A,No,No,NA,2010-03-22,2011-01-21,305,5.720311776607412,Mid-PDUFA
Edarbi,azilsartan medoxomil,Takeda Pharmaceuticals,NDA,200796,NA,NA,Tablet,Oral,NA,NA,NA,NA,4/27/2010,2/25/2011,2011,NA,Edarbi is an angiotensin II receptor blocker (ARB) indicated for the treatment of hypertension.  It may be used alone or in combination with other antihypertensive agents.,Standard,No,No,N/A,No,N/A,No,No,NA,2010-04-27,2011-02-25,304,5.717027701406222,Mid-PDUFA
Daliresp,roflumilast,Forest Research Institute,NDA,22522,NA,NA,Tablet,Oral,NA,NA,NA,NA,7/17/2009,2/28/2011,2011,NA,"DALIRESP is indicated as a treatment to reduce the risk of COPD exacerbations in patients with severe COPD associated with chronic bronchitis and a history of exacerbations.  
Limitations of Use: 
DALIRESP is not a bronchodilator and is not indicated for the relief of acute bronchospasm.",Standard,No,No,N/A,No,N/A,No,No,NA,2009-07-17,2011-02-28,591,6.3818160174060985,Mid-PDUFA
Benlysta,belimumab,Human Genome Sciences,BLA,125370,NA,NA,Injectable,Injection,NA,NA,NA,NA,6/9/2010,3/9/2011,2011,NA,"BENLYSTA (belimumab) is indicated for the treatment of adult patients with active, autoantibody-positive, systemic lupus erythematosus (SLE) who are receiving standard therapy.  
Limitations of Use:  
The efficacy of BENLYSTA has not been evaluated in patients with severe active lupus nephritis or severe active central nervous system lupus.  BENLYSTA has not been studied in combination with other biologics or intravenous cyclophosphamide. Use of BENLYSTA is not recommended in these situations.",Priority,No,No,N/A,Yes,N/A,No,No,NA,2010-06-09,2011-03-09,273,5.60947179518496,Mid-PDUFA
Gadavist,gadobutrol,Bayer HealthCare Pharmaceuticals,NDA,201277,NA,NA,Solution,Intravenous,NA,NA,NA,NA,5/14/2010,3/14/2011,2011,NA,Gadavast is a gadolinium-based contrast agent indicated for intravenous use in diagnostic magnetic resonance imaging (MRI) in adults and children (2 years of age and older) to detect and visualize areas with disrupted blood brain barrier (BBB) and/or abnormal vascularity of the central nervous system.,Standard,No,No,N/A,No,N/A,No,No,NA,2010-05-14,2011-03-14,304,5.717027701406222,Mid-PDUFA
Yervoy,ipilimumab,Bristol-Myers Squibb,BLA,125377,NA,NA,Injectable,Injection,NA,NA,NA,NA,6/25/2010,3/25/2011,2011,NA,YERVOY (ipilimumab) is indicated for the treatment of unresectable metastatic melanoma.,Priority,Yes,No,N/A,Yes,N/A,No,No,NA,2010-06-25,2011-03-25,273,5.60947179518496,Mid-PDUFA
Caprelsa,vandetanib,AstraZeneca Pharmaceuticals,NDA,22405,NA,NA,Tablet,Oral,NA,NA,NA,NA,7/7/2010,4/6/2011,2011,NA,"Vandetanib is indicated for the treatment of symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease.  
Use of vandetanib in patients with indolent, asymptomatic or slowly progressing disease should be carefully considered because of the treatment related risks of vandetanib.",Priority,Yes,No,N/A,Yes,N/A,No,No,NA,2010-07-07,2011-04-06,273,5.60947179518496,Mid-PDUFA
Horizant,gabapentin enacarbil,GlaxoSmithKline,NDA,22399,NA,NA,"Tablet, Extended Release",Oral,NA,NA,NA,NA,1/9/2009,4/6/2011,2011,NA,"HORIZANT (gabapentin enacarbil) Extended-Release Tablets are indicated for the treatment of moderate-to-severe primary Restless Legs Syndrome (RLS) in adults.  
HORIZANT is not recommended for patients who are required to sleep during the daytime and remain awake at night.",Standard,No,No,N/A,No,N/A,No,No,NA,2009-01-09,2011-04-06,817,6.705639094860003,Mid-PDUFA
Zytiga,abiraterone acetate,Ortho Biotech Oncology Research and Development,NDA,202379,NA,NA,Tablet,Oral,NA,NA,NA,NA,12/20/2010,4/28/2011,2011,NA,ZYTIGA in combination with prednisone is indicated for the treatment of patients with metastatic castration-resistant prostate cancer (CRPC) who have received prior chemotherapy containing docetaxel.,Priority,No,No,N/A,No,N/A,No,No,NA,2010-12-20,2011-04-28,129,4.859812404361672,Mid-PDUFA
Tradjenta,linagliptin,Boehringer Ingelheim Pharmaceuticals,NDA,201280,NA,NA,Tablet,Oral,NA,NA,NA,NA,7/2/2010,5/2/2011,2011,NA,"Monotherapy and Combination Therapy:
TRADJENTA tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. 
Important Limitations of Use:
TRADJENTA should not be used in patients with type 1 diabetes for the treatment of diabetic ketoacidosis, as it would not be effective in these settings.
TRADJENTA has not been studied in combination with insulin.",Standard,No,No,N/A,No,N/A,No,No,NA,2010-07-02,2011-05-02,304,5.717027701406222,Mid-PDUFA
Victrelis,boceprevir,Schering,NDA,202258,NA,NA,Capsule,Oral,NA,NA,NA,NA,11/15/2010,5/13/2011,2011,NA,"VICTRELIS (boceprevir) is indicated for the treatment of chronic hepatitis C genotype 1 infection, in combination with peginterferon alfa and ribavirin, in adult patients (18 years and older) with compensated liver disease, including cirrhosis, who are previously untreated or who have failed previous interferon and ribavirin therapy.  
The following points should be considered when initiating VICTRELIS for treatment of chronic hepatitis C infection:  
- VICTRELIS must not be used as monotherapy and should only be used in combination with peginterferon alfa and ribavirin.  
- VICTRELIS efficacy has not been studied in patients who have previously failed therapy with a treatment regimen that includes VICTRELIS or other HCV NS3/4A protease inhibitors.  
- VICTRELIS in combination with peginterferon alfa and ribavirin has not been studied in patients documented to be historical null responders (less than a 2-log10 HCV-RNA decline by treatment week 12) during prior therapy with peginterferon alfa and ribavirin. The clinical studies included subjects who were poorly interferon responsive. Subjects with less than 0.5-log10 HCV-RNA decline in viral load at Treatment Week 4 with peginterferon alfa plus ribavirin alone are predicted to have a null response (less than 2-log10 viral load decline at Treatment Week 12) to peginterferon alfa and ribavirin therapy.  
- Poorly interferon responsive patients who were treated with VICTRELIS in combination with peginterferon alfa and ribavirin have a lower likelihood of achieving a sustained virologic response (SVR), and a higher rate of detection of resistance-associated substitutions upon treatment failure, compared to patients with a greater response to peginterferon alfa and ribavirin.",Priority,No,No,N/A,Yes,N/A,No,No,NA,2010-11-15,2011-05-13,179,5.187385805840755,Mid-PDUFA
Edurant,rilpivirine,Tibotec,NDA,202022,NA,NA,Tablet,Oral,NA,NA,NA,NA,7/23/2010,5/20/2011,2011,NA,"EDURANT, in combination with other antiretroviral agents, is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in antiretroviral treatment-naïve adult patients.  
This indication is based on Week 48 safety and efficacy analyses from 2 randomized, double-blind, active controlled, Phase 3 trials in treatment-naïve subjects and Week 96 safety and efficacy analyses from a Phase 2b trial in treatment-naïve subjects.  
The following points should be considered when initiating therapy with EDURANT:  
- More EDURANT treated subjects with HIV-1 RNA greater than 100,000 copies/mL at the start of therapy experienced virologic failure compared to subjects with HIV-1 RNA less than 100,000 copies/mL at the start of therapy.  
- The observed virologic failure rate in EDURANT treated subjects conferred a higher rate of overall treatment resistance and cross-resistance to the NNRTI class compared to efavirenze.  
- More subjects treated with EDURANT developed lamivudine/emtricitabine associated resistance compared to efavirenz.",Standard,No,No,N/A,No,N/A,No,No,NA,2010-07-23,2011-05-20,301,5.707110264748875,Mid-PDUFA
Incivek,telaprevir,Vertex Pharmaceuticals,NDA,201917,NA,NA,Tablet,Oral,NA,NA,NA,NA,11/23/2010,5/23/2011,2011,NA,"INCIVEK (telaprevir), in combination with peginterferon alfa and ribavirin, is indicated for the treatment of genotype 1 chronic hepatitis C in adult patients with compensated liver disease, including cirrhosis, who are treatment-naïve or who have previously been treated with interferon-based treatment, including prior null responders, partial responders, and relapsers.  
The following points should be considered when initiating treatment with INCIVEK: 
- INCIVEK must not be administered as monotherapy and must only be prescribed with both peginterferon alfa and ribavirin.  
- A high proportion of previous null responders (particularly those with cirrhosis) did not achieve a Sustained Virologic Response (SVR) and had telaprevir resistance-associated substitutions emerge on treatment with INCIVEK combination treatment. 
- INCIVEK efficacy has not been established for patients who have previously failed therapy with a treatment regimen that includes INCIVEK or other HCV NS3/4A protease inhibitors.",Priority,No,No,N/A,Yes,N/A,No,No,NA,2010-11-23,2011-05-23,181,5.198497031265826,Mid-PDUFA
Dificid,fidaxomicin,Optimer Pharmaceuticals,NDA,201699,NA,NA,Tablet,Oral,NA,NA,NA,NA,11/30/2010,5/27/2011,2011,NA,"To reduce the development of drug-resistant bacteria and maintain the effectiveness of DIFICID and other antibacterial drugs, DIFICID should be used only to treat infections that are proven or strongly suspected to be caused by Clostridium difficile.  
DIFICID is a macrolide antibacterial drug indicated in adults (>=18 years of age) for treatment of Clostridium difficile-associated diarrhea (CDAD).",Priority,No,No,N/A,Yes,N/A,No,No,NA,2010-11-30,2011-05-27,178,5.181783550292085,Mid-PDUFA
Potiga,ezogabine,Valeant Pharmaceuticals,NDA,22345,NA,NA,Tablet,Oral,NA,NA,NA,NA,10/30/2009,6/10/2011,2011,NA,POTIGA is indicated as adjunctive treatment of partial-onset seizures in patients aged 18 years and older.,Standard,No,No,N/A,No,N/A,No,No,NA,2009-10-30,2011-06-10,588,6.376726947898627,Mid-PDUFA
Nulojix,belatacept,Bristol-Myers Squibb,BLA,125288,NA,NA,Injectable,Injection,NA,NA,NA,NA,7/1/2009,6/15/2011,2011,NA,"NULOJIX (belatacept) is indicated for prophylaxis of organ rejection in adult patients receiving a kidney transplant.  NULOJIX is to be used in combination with basiliximab induction, mycophenolate mofetil, and corticosteroids.  
Limitations of use:  
Use NULOJIX only in patients who are EBV seropositive.  
Use of NULOJIX for the prophylaxis of organ rejection in transplanted organs other than kidney has not been established.",Standard,Yes,No,N/A,Yes,N/A,No,No,NA,2009-07-01,2011-06-15,714,6.570882962339584,Mid-PDUFA
Arcapta Neohaler,indacaterol,Novartis Pharmaceuticals,NDA,22383,NA,NA,Powder,Inhalation,NA,NA,NA,NA,12/18/2008,7/1/2011,2011,NA,"ARCAPTA NEOHALER is a long-acting beta2-agonist indicated for long-term, once-daily maintenance bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. 
Important Limitations of Use:  
ARCAPTA NEOHALER is not indicated to treat acute deteriorations of chronic obstructive pulmonary disease.  
ARCAPTA NEOHALER is not indicated to treat asthma.  The safety and effectiveness of ARCAPTA NEOHALER in asthma have not been established.",Standard,No,No,N/A,No,N/A,No,No,NA,2008-12-18,2011-07-01,925,6.829793737512425,Mid-PDUFA
Xarelto,rivaroxaban,Johnson & Johnson,NDA,22406,NA,NA,Tablet,Oral,NA,NA,NA,NA,7/28/2008,7/1/2011,2011,NA,"XARELTO (rivaroxaban) Tablets are indicated for the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE) in patients undergoing knee or hip replacement surgery.",Standard,No,No,N/A,No,N/A,No,No,NA,2008-07-28,2011-07-01,1068,6.97354301952014,Mid-PDUFA
Brilinta,ticagrelor,AstraZeneca Pharmaceuticals,NDA,22433,NA,NA,Tablet,Oral,NA,NA,NA,NA,11/16/2009,7/20/2011,2011,NA,"BRILINTA is a P2Y12 platelet inhibitor indicated to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS) (unstable angina, non-ST elevation myocardial infarction, or ST elevation myocardial infarction). BRILINTA has been shown to reduce the rate of a combined endpoint of cardiovascular death, myocardial infarction or stroke compared to clopidogrel. The difference between treatments was driven by CV death and MI with no difference in stroke. In patients treated with PCI, it also reduces the rate of stent thrombosis.  
BRILINTA has been studied in ACS in combination with aspirin.  Maintenance doses of aspirin above 100 mg decreased the effectiveness of BRILINTA.  Avoid maintenance doses of aspirin above 100 mg daily.",Standard,No,No,N/A,No,N/A,No,No,NA,2009-11-16,2011-07-20,611,6.415096959171596,Mid-PDUFA
Zelboraf,vemurafenib,Hoffmann-La Roche,NDA,202429,NA,NA,Tablet,Oral,NA,NA,NA,NA,4/28/2011,8/17/2011,2011,NA,"ZELBORAF is indicated for the treatment of patients with unresectable or metastatic melanoma with BRAFV600E mutation as detected by an FDA-approved test.  
Limitation of Use:  ZELBORAF is not recommended for use in patients with wild-type BRAF melanoma.",Priority,Yes,No,N/A,Yes,N/A,No,No,NA,2011-04-28,2011-08-17,111,4.709530201312334,Mid-PDUFA
Adcetris,brentuximab vedotin,Seattle Genetics,BLA,125388,NA,NA,Injectable,Injection,NA,NA,NA,NA,2/28/2011,8/19/2011,2011,NA,"These indications are based on response rate.  There are no data available demonstrating improvement in patient reported outcomes or survival with ADCETRIS. 
[A] ADCETRIS (brentuximab vedotin) is indicated for treatment of patients with Hodgkin lymphoma (HL) after failure of autologous stem cell transplant (ASCT) or after failure of at least two prior multi-agent chemotherapy regimens in patients who are not ASCT candidates.  
[B] ADCETRIS is indicated for the treatment of patients with systemic anaplastic large cell lymphoma (sALCL) after failure of at least one prior multi-agent chemotherapy regimen.",Priority,Yes,Yes,N/A,Yes (indication [A] only),N/A,No,No,NA,2011-02-28,2011-08-19,172,5.147494476813453,Mid-PDUFA
Firazyr,icatibant,Shire Orphan Therapies,NDA,22150,NA,NA,Injectable,Subcutaneous,NA,NA,NA,NA,10/26/2007,8/25/2011,2011,NA,FIRAZYR (icatibant) is indicated for the treatment of acute attacts of hereditary angioedema (HAE) in adults 18 years of age and older.,Priority,Yes,No,N/A,Yes,N/A,No,No,NA,2007-10-26,2011-08-25,1399,7.243512974665482,Mid-PDUFA
Xalkori,crizotinib,Pfizer,NDA,202570,NA,NA,Capsule,Oral,NA,NA,NA,NA,3/30/2011,8/26/2011,2011,NA,"XALKORI is indicated for the treatment of patients with locally advanced metastatic non-small cell lung cancer (NSCLC) that is anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test.  
This indication is based on response rate.  There are no data available demonstrating improvement in patient reported outcomes or survival with XALKORI.",Priority,Yes,Yes,N/A,Yes,N/A,No,No,NA,2011-03-30,2011-08-26,149,5.003946305945459,Mid-PDUFA
Ferriprox,deferiprone,ApoPharma,NDA,21825,NA,NA,Tablet,Oral,NA,NA,NA,NA,1/30/2009,10/14/2011,2011,NA,"FERRIPROX (deferiprone) is indicated for the treatment of patients with transfusional iron overload due to thalassemia syndromes when current chelation therapy is inadequate. 
Approval is based on a reduction in serum ferritin levels.  There are no controlled trials demonstrating a direct treatment benefit, such as improvement in disease-related symptoms, functioning, or increased survival.  
Limitation of Use:  
- Safety and effectiveness have not been established for the treatment of transfusional iron overload in patients with other chronic anemias.",Standard,Yes,Yes,N/A,Yes,N/A,No,No,NA,2009-01-30,2011-10-14,987,6.894670039433482,Mid-PDUFA
Onfi,clobazam,Lundbeck,NDA,202067,NA,NA,Tablet,Oral,NA,NA,NA,NA,12/23/2010,10/21/2011,2011,NA,ONFI (clobazam) is indicated for the adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients 2 years of age or older.,Standard,Yes,No,N/A,No,N/A,No,No,NA,2010-12-23,2011-10-21,302,5.71042701737487,Mid-PDUFA
Jakafi,ruxolitinib,Incyte,NDA,202192,NA,NA,Tablet,Oral,NA,NA,NA,NA,6/3/2011,11/16/2011,2011,NA,"Jakafi is indicated for treatment of patients with intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis.",Priority,Yes,No,N/A,Yes,N/A,No,No,NA,2011-06-03,2011-11-16,166,5.111987788356544,Mid-PDUFA
Erwinaze,asparaginase Erwinia chrysanthemi,EUSA Pharma,BLA,125359,NA,NA,Injectable,Injection,NA,NA,NA,NA,11/1/2010,11/18/2011,2011,NA,ERWINAZE (asparaginase Erwinia chrysanthemi) is indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of patients with acute lymphoblastic leukemia (ALL) who have developed hypersensitivity to E. coli-derived asparaginase.,Priority,Yes,No,N/A,Yes,N/A,No,No,NA,2010-11-01,2011-11-18,382,5.945420608606575,Mid-PDUFA
Eylea,aflibercept,Regeneron Pharmaceuticals,BLA,125387,NA,NA,Injectable,Injection,NA,NA,NA,NA,2/18/2011,11/18/2011,2011,NA,EYLEA is indicated for the treatment of patients with Neovascular (Wet) Age-Related Macular Degeneration (AMD).,Priority,No,No,N/A,No,N/A,No,No,NA,2011-02-18,2011-11-18,273,5.60947179518496,Mid-PDUFA
Voraxaze,glucarpidase,BTG International,BLA,125327,NA,NA,Injectable,Injection,NA,NA,NA,NA,7/18/2011,1/17/2012,2012,NA,"VORAXAZE (glucarpidase) is indicated for the treatment of toxic plasma methotrexate concentrations (>1 micromole per liter) in patients with delayed methotrexate clearance due to impaired renal function.  
Limitation of Use:
VORAXAZE is not indicated for use in patients who exhibit the expected clearance of methotrexate (plasma methotrexate concentrations within 2 standard deviations of the mean methotrexate excretion curve specific for the dose of methotrexate administered) or those with normal or mildly impaired renal function because of the potential risk of subtherapeutic exposure to methotrexate.",Priority,Yes,No,N/A,Yes,N/A,No,No,NA,2011-07-18,2012-01-17,183,5.209486152841421,Mid-PDUFA
Picato,ingenol mebutate,Leo Pharma,NDA,202833,NA,NA,Gel,Topical,NA,NA,NA,NA,3/25/2011,1/23/2012,2012,NA,Picato gel is indicated for the topical treatment of actinic keratosis.,Standard,No,No,N/A,No,N/A,No,No,NA,2011-03-25,2012-01-23,304,5.717027701406222,Mid-PDUFA
Inlyta,axitinib,Pfizer,NDA,202324,NA,NA,Tablet,Oral,NA,NA,NA,NA,4/14/2011,1/27/2012,2012,NA,INLYTA is indicated for the treatment of advanced renal cell carcinoma (RCC) after failure of one prior systemic therapy.,Standard,No,No,N/A,Yes,N/A,No,No,NA,2011-04-14,2012-01-27,288,5.662960480135946,Mid-PDUFA
Erivedge,vismodegib,Genentech,NDA,203388,NA,NA,Capsule,Oral,NA,NA,NA,NA,9/8/2011,1/30/2012,2012,NA,"ERIVEDGE capsule is indicated for the treatment of adults with metastatic basal cell carcinoma, or with locally advanced basal cell carcinoma that has recurred following surgery or who are not candidates for surgery, and who are not candidates for radiation.",Priority,No,No,N/A,No,N/A,No,No,NA,2011-09-08,2012-01-30,144,4.969813299576001,Mid-PDUFA
Kalydeco,ivacaftor,Vertex Pharmaceuticals,NDA,203188,NA,NA,Tablet,Oral,NA,NA,NA,NA,10/18/2011,1/31/2012,2012,NA,"KALYDECO is classified as a cystic fibrosis transmembrane conductance regulator (CFTR) potentiator. KALYDECO is indicated for the treatment of cystic fibrosis (CF) in patients age 6 years and older who have a G551D mutation in the CFTR gene. If the patient’s genotype is unknown, an FDA-cleared CF mutation test should be used to detect the presence of the G551D mutation.
Limitations of Use:
KALYDECO is not effective in patients with CF who are homozygous for the F508del mutation in the CFTR gene and has not been studied in other populations of patients with CF.",Priority,Yes,No,N/A,Yes,N/A,No,No,NA,2011-10-18,2012-01-31,105,4.653960350157523,Mid-PDUFA
Zioptan,tafluprost,Merck,NDA,202514,NA,NA,Solution/Drops,Ophthalmic,NA,NA,NA,NA,1/7/2011,2/10/2012,2012,NA,ZIOPTAN (tafluprost ophthalmic solution) 0.0015% is indicated for reducing elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.,Standard,No,No,N/A,No,N/A,No,No,NA,2011-01-07,2012-02-10,399,5.988961416889864,Mid-PDUFA
Surfaxin,lucinactant,Discovery Laboratories,NDA,21746,NA,NA,Suspension,Intratracheal,NA,NA,NA,NA,4/13/2004,3/6/2012,2012,NA,SURFAXIN (lucinactant) Intratracheal Suspension is indicated for the prevention of respiratory distress syndrome (RDS) in premature infants at high risk for RDS.  SURFAXIN reduces the incidence of RDS at 24 hours and mortality due to RDS.,Standard,No,No,N/A,Yes,N/A,No,No,NA,2004-04-13,2012-03-06,2884,7.96693349840484,Mid-PDUFA
Omontys,peginesatide,Affymax,NDA,202799,NA,NA,Solution,"Intravenous, Subcutaneous",NA,NA,NA,NA,5/27/2011,3/27/2012,2012,NA,"OMONTYS is indicated for the treatment of anemia due to chronic kidney disease (CKD) in adult patients on dialysis.  
Limitations of Use:
OMONTYS is not indicated and is not recommended for use: 
- In patients with CKD not on dialysis because of safety concerns in this population.  
- In patients receiving treatment for cancer and whose anemia is not due to CKD, because ESAs have shown harm in some settings and the benefit-risk factors for OMONTYS in this setting have not been evaluated.  
- As a substitute for RBC transfusions in patients who require immediate correction of anemia.  
- OMONTYS has not been shown to improve symptoms, physical functioning or health-related quality of life.",Standard,No,No,N/A,No,N/A,No,No,NA,2011-05-27,2012-03-27,305,5.720311776607412,Mid-PDUFA
Amyvid,florbetapir F 18,Avid Radiopharmaceuticals,NDA,202008,NA,NA,Solution,Intravenous,NA,NA,NA,NA,9/17/2010,4/6/2012,2012,NA,"Amyvid is indicated for Positron Emission Tomography (PET) imaging of the brain to estimate beta-amyloid neuritic plaque density in adult patients with cognitive impairment who are being evaluated for Alzheimer’s Disease (AD) and other causes of cognitive decline. A negative Amyvid scan indicates sparse to no neuritic plaques and is inconsistent with a neuropathological diagnosis of AD at the time of image acquisition; a negative scan result reduces the likelihood that a patient’s cognitive impairment is due to AD. A positive Amyvid scan indicates moderate to frequent amyloid neuritic plaques; neuropathological examination has shown this amount of amyloid neuritic plaque is present in patients with AD, but may also be present in patients with other types of neurologic conditions as well as older people with normal cognition. Amyvid is an adjunct to other diagnostic evaluations.
Limitations of Use:
- A positive Amyvid scan does not establish a diagnosis of AD or other cognitive disorder. 
- Safety and effectiveness of Amyvid have not been established for: 
-- predicting development of dementia or other neurologic condition; 
-- monitoring responses to therapies.",Priority,No,No,N/A,No,N/A,No,No,NA,2010-09-17,2012-04-06,567,6.340359303727752,Mid-PDUFA
Stendra,avanafil,Vivus,NDA,202276,NA,NA,Tablet,Oral,NA,NA,NA,NA,6/29/2011,4/27/2012,2012,NA,STENDRA is a phosphodieasterase 5 (PDE5) inhibitor indicated for the treatment of erectile dysfunction.,Standard,No,No,N/A,No,N/A,No,No,NA,2011-06-29,2012-04-27,303,5.713732805509369,Mid-PDUFA
Elelyso,taliglucerase alfa,Protalix,BLA,22458,NA,NA,Powder,Intravenous,NA,NA,NA,NA,4/26/2010,5/1/2012,2012,NA,ELELYSO (taliglucerase alfa) for injection is a hydrolytic lysosomal glucocerebroside-specific enzyme indicated for long-term enzyme replacement therapy (ERT) for adults with a confirmed diagnosis of Type 1 Gaucher disease.,Standard,Yes,No,N/A,Yes,N/A,No,No,Transition Product from NDA to BLA due to BPCI : Please see page 2 of data dictionary for more information.,2010-04-26,2012-05-01,736,6.601230118728877,Mid-PDUFA
Perjeta,pertuzumab,Genentech,BLA,125409,NA,NA,Injectable,Injection,NA,NA,NA,NA,12/8/2011,6/8/2012,2012,NA,PERJETA is indicated for use in combination with trastuzumab and docetaxel for the treatment of patients with HER2-positive metastatic breast cancer who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease.,Priority,No,No,N/A,No,N/A,No,No,NA,2011-12-08,2012-06-08,183,5.209486152841421,Mid-PDUFA
Belviq,lorcaserin hydrochloride,Arena Pharmacueticals,NDA,22529,NA,NA,Tablet,Oral,NA,NA,NA,NA,12/22/2009,6/27/2012,2012,NA,"BELVIQ is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index (BMI) of: 
- 30 kg/m2 or greater (obese), or 
- 27 kg/m2 or greater (overweight) in the presence of at least one weight related comorbid condition (e.g., hypertension, dyslipidemia, type 2 diabetes)  
Limitations of Use: 
- The safety and efficacy of coadministration of BELVIQ with other products intended for weight loss including prescription drugs (e.g., phentermine), over-the-counter drugs, and herbal preparations have not been established  
- The effect of BELVIQ on cardiovascular morbidity and mortality has not been established",Standard,No,No,N/A,No,N/A,No,No,NA,2009-12-22,2012-06-27,918,6.822197390620491,Mid-PDUFA
Myrbetriq,mirabegron,Astellas Pharma,NDA,202611,NA,NA,"Tablet, Extended Release",Oral,NA,NA,NA,NA,8/29/2011,6/28/2012,2012,NA,"Myrbetriq is a beta-3 adrenergic agonist indicated for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency.",Standard,No,No,N/A,No,N/A,No,No,NA,2011-08-29,2012-06-28,304,5.717027701406222,Mid-PDUFA
Prepopik,"sodium picosulfate, magnesium oxide, citric acid",Ferring Pharmaceuticals,NDA,202535,NA,NA,For Solution,Oral,NA,NA,NA,NA,9/16/2011,7/16/2012,2012,NA,"PREPOPIK (sodium picosulfate, magnesium oxide and anhydrous citric acid) for oral solution is indicated for cleansing of the colon as a preparation for colonoscopy in adults.",Standard,No,No,No,No,No,No,No,NA,2011-09-16,2012-07-16,304,5.717027701406222,Mid-PDUFA
Kyprolis,carfilzomib,Onyx Pharmaceuticals,NDA,202714,NA,NA,Powder,Intravenous,NA,NA,NA,NA,9/27/2011,7/20/2012,2012,NA,"KYPROLIS is indicated for the treatment of patients with multiple myeloma who have received at least two prior therapies including bortezomib and an immunomodulatory agent and have demonstrated disease progression on or within 60 days of completion of the last therapy.  Approval is based on response rate.  Clinical benefit, such as improvement in survival or symptoms, has not been verified.",Standard,Yes,Yes,No,Yes,No,No,No,NA,2011-09-27,2012-07-20,297,5.6937321388027,Mid-PDUFA
Tudorza Pressair,aclidinium bromide,Forest Laboratories,NDA,202450,NA,NA,"Powder, Metered",Inhalation,NA,NA,NA,NA,6/23/2011,7/23/2012,2012,NA,"TUDORZA Pressair (aclidinium bromide inhalation powder) is indicated for the long-term, maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.",Standard,No,No,No,No,No,No,No,NA,2011-06-23,2012-07-23,396,5.981414211254481,Mid-PDUFA
Zaltrap,ziv-aflibercept,Sanofi-Aventis,BLA,125418,NA,NA,Injectable,Injection,NA,NA,NA,NA,2/3/2012,8/3/2012,2012,NA,"ZALTRAP, in combination with 5-fluorouracil, leucovorin, irinotecan-(FOLFIRI), is indicated for patients with metastatic colorectal cancer (mCRC) that is resistant to or has progressed following an oxaliplatin-containing regimen.",Priority,No,No,No,No,N/A,No,No,NA,2012-02-03,2012-08-03,182,5.204006687076795,Mid-PDUFA
Stribild,"elvitegravir, cobicistat, emtricitabine, tenofovir disoproxil fumarate",Gilead Sciences,NDA,203100,NA,NA,Tablet,Oral,NA,NA,NA,NA,10/27/2011,8/27/2012,2012,NA,STRIBILD is indicated as a complete regimen for the treatment of HIV-1 infection in adults who are antiretroviral treatment-naïve.,Standard,No,No,No,Yes,No,No,No,NA,2011-10-27,2012-08-27,305,5.720311776607412,Mid-PDUFA
Granix,tbo-filgrastim,Sicor Biotech,BLA,125294,NA,NA,Injectable,Injection,NA,NA,NA,NA,11/30/2009,8/29/2012,2012,NA,Tbo-filgrastim is indicated to reduce the duration of severe neutropenia in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.,Standard,No,No,No,No,N/A,No,No,NA,2009-11-30,2012-08-29,1003,6.910750787961936,Mid-PDUFA
Linzess,linaclotide,Forest Laboratories,NDA,202811,NA,NA,Capsule,Oral,NA,NA,NA,NA,8/9/2011,8/30/2012,2012,NA,"LINZESS (linaclotide) is indicated in adults for the treatment of irritable bowel syndrome with constipation (IBS-C).  
LINZESS is indicated in adults for the treatment of chronic idiopathic constipation (CIC).",Standard,No,No,No,No,No,No,No,NA,2011-08-09,2012-08-30,387,5.958424693029782,Mid-PDUFA
Xtandi,enzalutamide,Medivation,NDA,203415,NA,NA,Capsule,Oral,NA,NA,NA,NA,5/22/2012,8/31/2012,2012,NA,XTANDI is indicated for the treatment of patients with metastatic castration-resistant prostate cancer who have previously received docetaxel.,Priority,No,No,No,Yes,No,No,No,NA,2012-05-22,2012-08-31,101,4.61512051684126,Mid-PDUFA
Bosulif,bosutinib,Wyeth Pharmaceuticals,NDA,203341,NA,NA,Tablet,Oral,NA,NA,NA,NA,11/17/2011,9/4/2012,2012,NA,"BOSULIF is indicated for the treatment of adult patients with chronic, accelerated, or blast phase Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) with resistance or intolerance to prior therapy.",Standard,Yes,No,No,No,No,No,No,NA,2011-11-17,2012-09-04,292,5.676753802268282,Mid-PDUFA
[drug marketed without a proprietary name],choline C 11,Mayo Clinic,NDA,203155,NA,NA,Injectable,Intravenous,NA,NA,NA,NA,12/12/2011,9/12/2012,2012,NA,"Choline C 11 Injection is indicated for positron emission tomography (PET) imaging of patients with suspected prostate cancer recurrence and non-informative bone scintigraphy, computerized tomography (CT) or magnetic resonance imaging (MRI).  In these patients, 11C-choline PET imaging may help identify potential sites of prostate cancer recurrence for subsequent histologic confirmation.  Suspected prostate recurrence is based upon elevated blood prostate specific antigen (PSA) levels following initial therapy.  In clinical studies, images were produced with PET/CT coregistration. 
Limitation of Use: 11C-choline PET imaging is not a replacement for histologic verification of recurrent prostate cancer.",Priority,No,No,No,No,No,No,No,NA,2011-12-12,2012-09-12,275,5.616771097666572,Mid-PDUFA
Aubagio,teriflunomide,Sanofi-Aventis,NDA,202992,NA,NA,Tablet,Oral,NA,NA,NA,NA,8/12/2011,9/12/2012,2012,NA,AUBAGIO is indicated for the treatment of patients with relapsing forms of multiple sclerosis.,Standard,No,No,No,No,No,No,No,NA,2011-08-12,2012-09-12,397,5.983936280687191,Mid-PDUFA
Stivarga,regorafenib,Bayer HealthCare Pharmaceuticals,NDA,203085,NA,NA,Tablet,Oral,NA,NA,NA,NA,4/27/2012,9/27/2012,2012,NA,"Stivarga is indicated for the treatment of patients with metastatic colorectal cancer (CRC) who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, and anti-VEGF therapy, and, if KRAS wild type, and anti-EGFR therapy.",Priority,No,No,No,Yes,No,No,No,NA,2012-04-27,2012-09-27,153,5.030437921392435,Mid-PDUFA
Jetrea,ocriplasmin,ThromboGenics,BLA,125422,NA,NA,Injectable,Injection,NA,NA,NA,NA,4/17/2012,10/17/2012,2012,NA,JETREA is a proteolytic enzyme indicated for the treatment of symptomatic vitreomacular adhesion.,Priority,No,No,No,No,N/A,No,No,NA,2012-04-17,2012-10-17,183,5.209486152841421,Mid-PDUFA
Fycompa,perampanel,Eisai,NDA,202834,NA,NA,Tablet,Oral,NA,NA,NA,NA,12/22/2011,10/22/2012,2012,NA,FYCOMPA (perampanel) is indicated as adjunctive therapy for the treatment of partial-onset seizures with or without secondarily generalized seizures in patients with epilepsy aged 12 years and older.,Standard,No,No,No,No,No,No,No,NA,2011-12-22,2012-10-22,305,5.720311776607412,Mid-PDUFA
Synribo,omacetaxine mepesuccinate,Ivax International GmbH,NDA,203585,NA,NA,Powder,Subcutaneous,NA,NA,NA,NA,3/30/2012,10/26/2012,2012,NA,SYNRIBO is indicated for the treatment of adult patients with chronic or accelerated phase chronic myeloid leukemia (CML) with resistance and/or intolerance to two or more tyrosine kinase inhibitors (TKI).  This indication is based upon response rate.  There are no trials verifying an improvement in disease-related symptoms or increased survival with SYNRIBO.,Standard,Yes,Yes,No,Yes,No,No,No,NA,2012-03-30,2012-10-26,210,5.3471075307174685,Mid-PDUFA
Xeljanz,tofacitinib,Pfizer,NDA,203214,NA,NA,Tablet,Oral,NA,NA,NA,NA,10/21/2011,11/6/2012,2012,NA,"XELJANZ (tofacitinib) is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate.  It may be used as monotherapy or in combination with methotrexate or other nonbiologic disease-modifying antirheumatic drugs (DMARDs).
XELJANZ should not be used in combination with biologic DMARDs or with potent immunosuppressants such as azathioprine and cyclosporine.",Standard,No,No,No,No,No,No,No,NA,2011-10-21,2012-11-06,382,5.945420608606575,Mid-PDUFA
Cometriq,cabozantinib,Exelixis,NDA,203756,NA,NA,Capsule,Oral,NA,NA,NA,NA,5/29/2012,11/29/2012,2012,NA,"COMETRIQ is indicated for the treatment of patients with progressive, metastatic medullary thyroid cancer (MTC).",Priority,Yes,No,No,Yes,No,No,No,NA,2012-05-29,2012-11-29,184,5.214935757608986,Mid-PDUFA
[drug marketed without a proprietary name],raxibacumab,Human Genome Sciences,BLA,125349,NA,NA,Injectable,Injection,NA,NA,NA,NA,5/14/2009,12/14/2012,2012,NA,"Raxibacumab is indicated for the treatment of adult and pediatric patients with inhalational anthrax due to Bacillus anthracis in combination with appropriate antibacterial drugs.  Raxibacumab is also indicated for prophylaxis of inhalational anthrax when alternative therapies are not available or are not appropriate.  
Limitations of Use:
The effectiveness of raxibacumab is based solely on efficacy studies in animal models of inhalational anthrax.  It is not ethical or feasible to conduct controlled clinical trials with intentional exposure of humans to anthrax.  
Safety and pharmacokinetics (PK) of raxibacumab have been studied in healthy volunteers.  There have been no studies of safety or PK of raxibacumab in the pediatric population.  A population PK approach was used to derive dosing regimens that are predicted to provide pediatric patients with exposure comparable to the observed exposure in adults. 
Raxibacumab binds to the protective antigen (PA) of B. anthracis; it does not have direct antibacterial activity.  Raxibacumab does not cross the blood-brain barrier and does not prevent or treat meningitis.  Raxibacumab should be used in combination with appropriate antibacterial drugs.",Priority,Yes,No,No,Yes,N/A,No,No,NA,2009-05-14,2012-12-14,1310,7.177782416195197,Mid-PDUFA
Signifor,pasireotide,Novartis Pharmaceuticals,NDA,200677,NA,NA,Solution,Subcutaneous,NA,NA,NA,NA,2/17/2012,12/14/2012,2012,NA,SIGNIFOR is indicated for the treatment of adult patients with Cushing’s disease for whom pituitary surgery is not an option or has not been curative.,Standard,Yes,No,No,No,No,No,No,NA,2012-02-17,2012-12-14,301,5.707110264748875,Mid-PDUFA
Iclusig,ponatinib,Ariad Pharmaceuticals,NDA,203469,NA,NA,Tablet,Oral,NA,NA,NA,NA,9/27/2012,12/14/2012,2012,NA,"Iclusig (ponatinib) is indicated for the treatment of adult patients with chronic phase, accelerated phase, or blast phase chronic myeloid leukemia (CML) that is resistant to prior tyrosine kinase inhibitor therapy or Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ALL) that is resistant or intolerant to prior tyrosine kinase inhibitor therapy. 
This indication is based upon response rate.  There are no trials verifying an improvement in disease-related symptoms or increased survival with Iclusig.",Priority,Yes,Yes,No,Yes,No,No,No,NA,2012-09-27,2012-12-14,78,4.356708826689592,Mid-PDUFA
Juxtapid,lomitapide,Aegerion Pharmaceuticals,NDA,203858,NA,NA,Capsule,Oral,NA,NA,NA,NA,2/29/2012,12/21/2012,2012,NA,"JUXTAPID is indicated as an adjunct to a low-fat diet and other lipid-lowering treatments, including LDL apheresis where available, to reduce low-density lipoprotein cholesterol (LDL-C), total cholesterol (TC), apolipoprotein B (apo B), and non-high density lipoprotein cholesterol (non-HDL-C) in patients with homozygous familial hypercholesterolemia (HoFH). 
Limitations of Use: 
- The safety and effectiveness of JUXTAPID have not been established in patients with hypercholesterolemia who do not have HoFH. 
- The effect of JUXTAPID on cardiovascular morbidity and mortality has not been determined.",Standard,Yes,No,No,No,No,No,No,NA,2012-02-29,2012-12-21,296,5.69035945432406,Mid-PDUFA
Gattex,teduglutide (rDNA origin),NPS Pharmaceuticals,NDA,203441,NA,NA,Powder,Subcutaneous,NA,NA,NA,NA,11/30/2011,12/21/2012,2012,NA,GATTEX (teduglutide [rDNA origin]) for injection is indicated for the treatment of adult patiens with Short Bowel Syndrome (SBS) who are dependent on parenteral support.,Standard,Yes,No,No,No,No,No,No,NA,2011-11-30,2012-12-21,387,5.958424693029782,Mid-PDUFA
Eliquis,apixaban,Bristol-Myers Squibb,NDA,202155,NA,NA,Tablet,Oral,NA,NA,NA,NA,9/28/2011,12/28/2012,2012,NA,ELIQUIS (apixaban) is indicated to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation.,Priority,No,No,No,Yes,No,No,No,NA,2011-09-28,2012-12-28,457,6.124683390894205,Mid-PDUFA
Sirturo,bedaquiline,Janssen Research & Development,NDA,204384,NA,NA,Tablet,Oral,NA,NA,NA,NA,6/29/2012,12/28/2012,2012,NA,"SIRTURO is a diarylquinoline antimycobacterial drug indicated as part of combination therapy in adults (>= 18 years) with pulmonary multi-drug resistant tuberculosis (MDR-TB).  Reserve SIRTURO for use when an effective treatment regimen cannot otherwise be provided.  SIRTURO should be administered by directly observed therapy (DOT). 
This indication is based on analysis of time to sputum culture conversion from two controlled Phase 2 trials in patients with pulmonary MDR-TB. 
Limitations of Use: 
The safety and efficacy of SIRTURO for the treatment of latent infection due to Mycobacterium tuberculosis has not been established.  The safety and efficacy of SIRTURO for the treatment of drug-sensitive TB has not been established.  In addition, there are no data on the treatment with SIRTURO of extra-pulmonary TB (e.g., central nervous system).  Therefore, use of SIRTURO in these settings is not recommended.",Priority,Yes,Yes,No,Yes,No,TD,No,NA,2012-06-29,2012-12-28,182,5.204006687076795,Mid-PDUFA
Fulyzaq,crofelemer,Salix Pharmaceuticals,NDA,202292,NA,NA,"Tablet, Delayed Release",Oral,NA,NA,NA,NA,12/5/2011,12/31/2012,2012,NA,FULYZAQ is indicated for symptomatic relief of non-infectious diarrhea in patients with HIV/AIDS on anti-retroviral therapy.,Priority,No,No,No,Yes,No,No,No,NA,2011-12-05,2012-12-31,392,5.971261839790462,Mid-PDUFA
Nesina,alogliptin,Takeda Pharmaceuticals,NDA,22271,NA,NA,Tablet,Oral,NA,NA,NA,NA,12/27/2007,1/25/2013,2013,NA,"NESINA is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in multiple clinical settings.   
Limitation of Use:
NESINA should not be used in patients with type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis, as it would not be effective in these settings.",Standard,No,No,No,No,No,No,No,NA,2007-12-27,2013-01-25,1856,7.526178913346146,Post-FDASIA
Kynamro,mipomersen sodium,Genzyme,NDA,203568,NA,NA,Solution,Subcutaneous,NA,NA,NA,NA,3/29/2012,1/29/2013,2013,NA,"KYNAMRO is indicated as an adjunct to lipid-lowering medications and diet to reduce low density lipoprotein-cholesterol (LDL-C), apolipoprotein B (apo B), total cholesterol (TC), and non-high density lipoprotein-cholesterol (non-HDL-C) in patients with homozygous familial hypercholesterolemia (HoFH). 
Limitations of Use : 
- The safety and effectiveness of KYNAMRO have not been established in patients with hypercholesterolemia who do not have HoFH.  
- The effect of KYNAMRO on cardiovascular morbidity has not been determined.  
- The safety and effectiveness of KYNAMRO as an adjunct to LDL apheresis have not been established; therefore, the use of KYNAMRO as an adjunct to LDL apheresis is not recommended.",Standard,Yes,No,No,No,No,No,No,NA,2012-03-29,2013-01-29,306,5.723585101952381,Post-FDASIA
Pomalyst,pomalidomide,Celgene,NDA,204026,NA,NA,Capsule,Oral,NA,NA,NA,NA,4/10/2012,2/8/2013,2013,NA,"POMALYST is indicated for patients with multiple myeloma who have received at least two prior therapies including lenalidomide and bortezomib and have demonstrated disease progression on or within 60 days of completion of the last therapy.  Approval is based on response rate.  Clinical benefit, such as improvement in survival or symptoms, has not been verified.",Standard,Yes,Yes,No,Yes,No,No,No,NA,2012-04-10,2013-02-08,304,5.717027701406222,Post-FDASIA
Kadcyla,ado-trastuzumab emtansine,Genentech,BLA,125427,NA,NA,Injectable,Injection,NA,NA,NA,NA,8/27/2012,2/22/2013,2013,NA,"KADCYLA, as a single agent, is indicated for the treatment of patients with HER2-positive, metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination.  Patients should have either: 
- received prior therapy for metastatic disease, or, 
- developed disease recurrence during or within six months of completing adjuvant therapy.",Priority,No,No,No,Yes,N/A,No,No,NA,2012-08-27,2013-02-22,179,5.187385805840755,Post-FDASIA
Osphena,ospemifene,Shionogi,NDA,203505,NA,NA,Tablet,Oral,NA,NA,NA,NA,4/26/2012,2/26/2013,2013,NA,"OSPHENA is indicated for the treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy, due to menopause.",Standard,No,No,No,No,No,No,No,NA,2012-04-26,2013-02-26,306,5.723585101952381,Post-FDASIA
Lymphoseek,technetium Tc 99m tilmanocept,Navidea Biopharmaceuticals,NDA,202207,NA,NA,Injectable,Injection,NA,NA,NA,NA,8/10/2011,3/13/2013,2013,NA,Lymphoseek (technetium Tc 99m tilmanocept) Injection is indicated for lymphatic mapping with a handheld gamma counter to assist in the localization of lymph nodes draining a primary tumor site in patients with breast cancer or melanoma.,Standard,No,No,No,No,No,No,No,NA,2011-08-10,2013-03-13,581,6.364750756851911,Post-FDASIA
Dotarem,gadoterate meglumine,Guerbet,NDA,204781,NA,NA,Solution,Intravenous,NA,NA,NA,NA,9/20/2012,3/20/2013,2013,NA,"DOTAREM is a gadolinium-based contrast agent indicated for intravenous use with magnetic resonance imaging (MRI) in brain (intracranial), spine and associated tissues in adult and pediatric patients (2 years of age and older) to detect and visualize areas with disruption of the blood brain barrier (BBB) and/or abnormal vascularity.",Priority,No,No,No,No,No,No,No,NA,2012-09-20,2013-03-20,181,5.198497031265826,Post-FDASIA
Tecfidera,dimethyl fumarate,Biogen Idec,NDA,204063,NA,NA,"Capsule, Delayed Release",Oral,NA,NA,NA,NA,2/27/2012,3/27/2013,2013,NA,TECFIDERA is indicated for the treatment of patients with relapsing forms of multiple sclerosis.,Standard,No,No,No,No,No,No,No,NA,2012-02-27,2013-03-27,394,5.976350909297934,Post-FDASIA
Invokana,canagliflozin,Janssen Research & Development,NDA,204042,NA,NA,Tablet,Oral,NA,NA,NA,NA,5/31/2012,3/29/2013,2013,NA,"INVOKANA (canagliflozin) is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.  
Limitation of Use: 
INVOKANA is not recommended in patients with type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis.",Standard,No,No,No,No,No,No,No,NA,2012-05-31,2013-03-29,302,5.71042701737487,Post-FDASIA
Breo Ellipta,fluticasone furoate and vilanterol,GlaxoSmithKline,NDA,204275,NA,NA,Powder,Inhalation,NA,NA,NA,NA,7/12/2012,5/10/2013,2013,NA,"BREO ELLIPTA is a combination inhaled corticosteroid/long-acting beta2-adrenergic agonist (ICS/LABA) indicated for the long-term, once-daily, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.  BREO ELLIPTA is also indicated to reduce exacerbations of COPD in patients with history of exacerbations.  
BREO ELLIPTA is NOT indicated for the relief of acute bronchospasm or for the treatment of asthma.",Standard,No,No,No,No,No,No,No,NA,2012-07-12,2013-05-10,302,5.71042701737487,Post-FDASIA
Xofigo,radium Ra 223 dichloride,Bayer HealthCare Pharmaceuticals,NDA,203971,NA,NA,Solution,Intravenous,NA,NA,NA,NA,12/14/2012,5/15/2013,2013,NA,"Xofigo is indicated for the treatment of patients with castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastatic disease.",Priority,No,No,No,Yes,No,No,No,NA,2012-12-14,2013-05-15,152,5.0238805208462765,Post-FDASIA
Tafinlar,dabrafenib,GlaxoSmithKline,NDA,202806,NA,NA,Capsule,Oral,NA,NA,NA,NA,7/30/2012,5/29/2013,2013,NA,"TAFINLAR is indicated for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E mutation as detected by an FDA-approved test. 
TAFINLAR is not indicated for the treatment of patients with wild-type BRAF melanoma. 

Unresectable or metastatic melanoma with BRAF V600E mutation as detected
by an FDA-approved test. 
Limitation of use: TAFINLAR is not indicated for treatment of patients with
wild-type BRAF melanoma.",Standard,Yes,No,No,Yes,No,No,No,NA,2012-07-30,2013-05-29,303,5.713732805509369,Post-FDASIA
Mekinist,trametinib,GlaxoSmithKline,NDA,204114,NA,NA,Tablet,Oral,NA,NA,NA,NA,8/3/2012,5/29/2013,2013,NA,"MEKINIST is indicated for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations, as detected by an FDA-approved test.  
MEKINIST is not indicated for treatment of patients who have received prior BRAF-inhibitor therapy.",Standard,Yes,No,No,Yes,No,No,No,NA,2012-08-03,2013-05-29,299,5.700443573390687,Post-FDASIA
Gilotrif,afatinib,Boehringer Ingelheim Pharmaceuticals,NDA,201292,NA,NA,Tablet,Oral,NA,NA,NA,NA,11/15/2012,7/12/2013,2013,NA,"GILOTRIF is indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test.  
Limitation of Use: Safety and efficacy of GILOTRIF have not been established in patients whose tumors have other EGFR mutations.",Priority,Yes,No,No,Yes,No,No,No,NA,2012-11-15,2013-07-12,239,5.476463551931511,Post-FDASIA
Tivicay,dolutegravir,GlaxoSmithKline,NDA,204790,NA,NA,Tablet,Oral,NA,NA,NA,NA,12/17/2012,8/12/2013,2013,NA,"TIVICAY is indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults and children aged 12 years and older and weighing at least 40 kg. 
The following should be considered prior to initiating treatment with TIVICAY: 
- Poor virologic response was observed in subjects treated with TIVICAY 50 mg twice daily with an integrase strand transfer inhibitor (INSTI)-resistance Q148 substitution plus 2 or more additional INSTI-resistance substitutions, including L74I/M, E138A/D/K/T, G140A/S, Y143H/R, E157Q, G163E/K/Q/R/S, or G193E/R.",Priority,No,No,No,Yes,No,No,No,NA,2012-12-17,2013-08-12,238,5.472270673671475,Post-FDASIA
Brintellix,vortioxetine,Takeda Pharmaceuticals,NDA,204447,NA,NA,Tablet,Oral,NA,NA,NA,NA,10/2/2012,9/30/2013,2013,NA,BRINTELLIX is indicated for the treatment of major depressive disorder (MDD). The efficacy of BRINTELLIX was established in six 6 to 8 week studies (including one study in the elderly) and one maintenance study in adults.,Standard,No,No,No,No,No,No,No,NA,2012-10-02,2013-09-30,363,5.8944028342648505,Post-FDASIA
Duavee,conjugated estrogens and bazedoxifene,Wyeth Pharmaceuticals,NDA,22247,NA,NA,Tablet,Oral,NA,NA,NA,NA,10/3/2012,10/3/2013,2013,NA,"DUAVEE is indicated in women with a uterus for: 
Treatment of Moderate to Severe Vasomotor Symptoms Associated with Menopause  
Prevention of Postmenopausal Osteoporosis  
Important Limitations of Use: 
- Use DUAVEE for the shortest duration consistent with treatment goals and risks for the individual woman.  Postmenopausal women should be re-evaluated periodically as clinically appropriate to determine if treatment is still necessary.  
- When prescribing solely for the prevention of postmenopausal osteoporosis, therapy should only be considered for women at significant risk of osteoporosis and non-estrogen medication should be carefully considered.",Standard,No,No,No,No,No,No,No,NA,2012-10-03,2013-10-03,365,5.8998973535824915,Post-FDASIA
Adempas,riociguat,Bayer HealthCare Pharmaceuticals,NDA,204819,NA,NA,Tablet,Oral,NA,NA,NA,NA,2/8/2013,10/8/2013,2013,NA,"Adempas is indicated for the treatment of adults with persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH), (WHO Group 4) after surgical treatment, or inoperable CTEPH, to improve exercise capacity and WHO functional class. 
Adempas is indicated for the treatment of adults with pulmonary arterial hypertension (PAH), (WHO Group 1), to improve exercise capacity, WHO functional class and to delay clinical worsening. 
Efficacy was shown in patients on Adempas monotherapy or in combination with endothelin receptor antagonists or prostanoids.  Studies establishing effectiveness including predominantly patients with WHO functional class II-III and etiologies of idiopathic or heritable PAH (61%) or PAH associated with connective tissue disease (25%).",Priority,Yes,No,No,No,No,No,No,NA,2013-02-08,2013-10-08,242,5.488937726156687,Post-FDASIA
Opsumit,macitentan,Actelion Pharmaceuticals,NDA,204410,NA,NA,Tablet,Oral,NA,NA,NA,NA,10/19/2012,10/18/2013,2013,NA,"OPSUMIT is an endothelin receptor antagonist (ERA) indicated for the treatment of pulmonary arterial hypertension (PAH, WHO Group I) to delay disease progression.  Disease progression included: death, initiation of intravenous (IV) or subcutaneous prostanoids, or clinical worsening or PAH (decreased 6-minute walk distance, worsened PAH symptoms and need for additional PAH treatment).  OPSUMIT also reduced hospitalization for PAH. 
Effectiveness was established in a long-term study in PAH patients with predominantly WHO Functional Class II-III symptoms treated for an average of 2 years.  Patients were treated with OPSUMIT monotherapy or in combination with phosphodieasterase-5 inhibitors or inhaled prostanoids.  Patients had idiopathic and heritable PAH (57%), PAH caused by connective tissue disorders (31%), and PAH caused by congenital heart disease with repaired shunts (8%).",Standard,Yes,No,No,No,No,No,No,NA,2012-10-19,2013-10-18,364,5.8971538676367405,Post-FDASIA
Vizamyl,flutemetamol F 18,GE Healthcare,NDA,203137,NA,NA,Injectable,Intravenous,NA,NA,NA,NA,10/26/2012,10/25/2013,2013,NA,"Vizamyl is indicated for Positron Emission Tomography (PET) imaging of the brain to estimate beta amyloid neuritic plaque density in adult patients with cognitive impairment who are being evaluated for Alzheimer’s Disease (AD) and other causes of cognitive decline. 
A negative Vizamyl scan indicates sparse to no neuritic plaques and is inconsistent with a neuropathological diagnosis of AD at the time of image acquisition; a negative scan result reduces the likelihood that a patient’s cognitive impairment is due to AD.  A positive Vizamyl scan indicates moderate to frequent amyloid neuritic plaques; neuropathological examination has shown this amount of amyloid neuritic plaque is present in patients with AD, but may also be present in patients with other types of neurologic conditions as well as in older people with normal cognition.  Vizamyl is an adjunct to other diagnostic evaluations.  
Limitations of Use: 
- A positive Vizamyl scan does not establish diagnosis of AD or other cognitive disorder.  
- Safety and effectiveness of Vizamyl have not been established for: 
-- Predicting development of dementia or other neurologic condition. 
--Monitoring responses to therapies.",Standard,No,No,No,No,No,No,No,NA,2012-10-26,2013-10-25,364,5.8971538676367405,Post-FDASIA
Gazyva,obinutuzumab,Genentech,BLA,125486,NA,NA,Injectable,Injection,NA,NA,NA,NA,4/22/2013,11/1/2013,2013,NA,"GAZYVA, in combination with chlorambucil, is indicated for the treatment of patients with previously untreated chronic lymphocytic leukemia (CLL).",Priority,Yes,No,Yes,No,N/A,No,No,NA,2013-04-22,2013-11-01,193,5.262690188904886,Post-FDASIA
Aptiom,eslicarbazepine acetate,Sunovion Pharmaceuticals,NDA,22416,NA,NA,Tablet,Oral,NA,NA,NA,NA,3/30/2009,11/8/2013,2013,NA,APTIOM (eslicarbazepine acetate) is indicated as adjunctive treatment of partial-onset seizures.,Standard,No,No,No,No,No,No,No,NA,2009-03-30,2013-11-08,1684,7.428927194802272,Post-FDASIA
Imbruvica,ibrutinib,Pharmacyclics,NDA,205552,NA,NA,Capsule,Oral,NA,NA,NA,NA,6/28/2013,11/13/2013,2013,NA,IMBRUVICA is indicated for the treatment of patients with mantel cell lymphoma (MCL) who have received at least one prior therapy.  This indication is based on overall response rate.  An improvement in survival or disease-related symptoms has not been established.,Priority,Yes,Yes,Yes,Yes,No,No,No,NA,2013-06-28,2013-11-13,138,4.927253685157205,Post-FDASIA
Luzu,luliconazole,Medicis Pharmaceutical,NDA,204153,NA,NA,Cream,Topical,NA,NA,NA,NA,12/11/2012,11/14/2013,2013,NA,"LUZU (luliconazole) Cream, 1% is indicated for the topical treatment of interdigital tinea pedis, tinea cruris, and tinea corporis caused by the organisms Trichophyton rubrum and Epidermophyton floccosum, in patients 18 years of age and older.",Standard,No,No,No,No,No,No,No,NA,2012-12-11,2013-11-14,338,5.823045895483019,Post-FDASIA
Olysio,simeprevir,Janssen Research & Development,NDA,205123,NA,NA,Capsule,Oral,NA,NA,NA,NA,3/28/2013,11/22/2013,2013,NA,"OLYSIO is a hepatitis C virus (HCV) NS3/4A protease inhibitor indicated for the treatment of chronic hepatitis C (CHC) infection as a component of a combination antiviral treatment regimen.  
- OLYSIO efficacy has been established in combination with peginterferon alfa and ribavirin, in HCV genotype 1 infected subjects with compensated liver disease (including cirrhosis). 
The following points should be considered when initiating OLYSIO for treatment of chronic hepatitis C infection: 
- OLYSIO must not be used as monotherapy. -OLYSIO efficacy in combination with peginterferon alfa and ribavirin is influenced by baseline host and viral factors. 
- OLYSIO efficacy in combination with peginterferon alfa and ribavirin is substantially reduced in patients infected with hepatitis C virus (HCV) genotype 1a without the Q80K polymorphism.  Screening patients with HCV genotype 1a infection for the presence of virus with the NS3 Q80K polymorphism at baseline is strongly recommended.  Alternative therapy should be considered for patients infected with HCV genotype 1a containing the Q80K polymorphism. 
- OLYSIO efficacy has not been studied in patients who have previously failed therapy with a treatment regimen that includes OLYSIO or other HCV protease inhibitors.",Priority,No,No,No,Yes,No,No,No,NA,2013-03-28,2013-11-22,239,5.476463551931511,Post-FDASIA
Sovaldi,sofosbuvir,Gilead Sciences,NDA,204671,NA,NA,Tablet,Oral,NA,NA,NA,NA,4/8/2013,12/6/2013,2013,NA,"SOVALDI is a hepatitis C virus (HCV) nucleotide analog NS5B polymerase inhibitor indicated for the treatment of chronic hepatitis C (CHC) infection as a component of a combination antiviral treatment regimen. 
- SOVALDI efficacy has been established in subjects with HCV genotype 1, 2, 3, or 4 infection, including those with hepatocellular carcinoma meeting Milan criteria (awaiting liver transplantation) and those with HCV/HIV-1 co-infection.  
The following points should be considered when initiating treatment with SOVALDI: 
- Monotherapy of SOVALDI is not recommended for treatment of CHC. 
- Treatment regimen and duration are dependent on both viral genotype and patient population.  
- Treatment response varies based on baseline host and viral factors.",Priority,No,No,Yes,Yes,No,No,No,NA,2013-04-08,2013-12-06,242,5.488937726156687,Post-FDASIA
Anoro Ellipta,"umeclidinium, vilanterol",GlaxoSmithKline,NDA,203975,NA,NA,Powder,Inhalation,NA,NA,NA,NA,12/18/2012,12/18/2013,2013,NA,"ANORO ELLIPTA is a combination anticholinergic/long-acting beta2-adrenergic agonist (anticholinergic/LABA) indicated for the long-term, once-daily, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. 
Important Limitations of Use: ANORO ELLIPTA is NOT indicated for the relief of acute bronchospasm or for the treatment of asthma.",Standard,No,No,No,No,No,No,No,NA,2012-12-18,2013-12-18,365,5.8998973535824915,Post-FDASIA
Farxiga,dapagliflozin,Bristol-Myers Squibb,NDA,202293,NA,NA,Tablet,Oral,NA,NA,NA,NA,12/28/2010,1/8/2014,2014,NA,FARXIGA is a sodium-glucose cotransporter 2 (SGLT2) inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Limitation of use: Not for treatment of type 1 diabetes mellitus or diabetic ketoacidosis.,Standard,No,No,No,No,No,No,No,NA,2010-12-28,2014-01-08,1107,7.009408932708637,Post-FDASIA
Hetlioz,tasimelteon,Vanda Pharmaceuticals,NDA,205677,NA,NA,Capsule,Oral,NA,NA,NA,NA,5/31/2013,1/31/2014,2014,NA,HETLIOZ is indicated for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24).,Priority,Yes,No,No,No,No,No,No,NA,2013-05-31,2014-01-31,245,5.501258210544727,Post-FDASIA
Vimizim,elosulfase alfa,BioMarin Pharmaceutical,BLA,125460,NA,NA,Injectable,Injection,NA,NA,NA,NA,3/29/2013,2/14/2014,2014,NA,Vimizim (elosulfase alfa) is indicated for patients with Mucopolysaccharidosis type IVA (MPS IVA; Morquio A syndrome).,Priority,Yes,No,No,Yes,N/A,RPD,No,NA,2013-03-29,2014-02-14,322,5.7745515455444085,Post-FDASIA
Northera,droxidopa,Chelsea Therapeutics,NDA,203202,NA,NA,Capsule,Oral,NA,NA,NA,NA,9/28/2011,2/18/2014,2014,NA,"NORTHERA is indicated for the treatment of orthostatic dizziness, lightheadedness, or the “feeling that you are about to black out” in adult patients with symptomatic neurogenic orthostatic hypotension (NOH) caused by primary autonomic failure [Parkinson's disease (PD), multiple system atrophy and pure autonomic failure], dopamine beta-hydroxylase deficiency, and non-diabetic autonomic neuropathy. Effectiveness beyond 2 weeks of treatment has not been established. The continued effectiveness of NORTHERA should be assessed periodically.",Priority,Yes,Yes,No,Yes,No,No,No,NA,2011-09-28,2014-02-18,874,6.773080375655535,Post-FDASIA
Myalept,metreleptin,Amylin Pharmaceuticals,BLA,125390,NA,NA,Injectable,Injection,NA,NA,NA,NA,3/27/2013,2/24/2014,2014,NA,"MYALEPT (metreleptin for injection) is indicated as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy.  
Limitations of Use: 
- The safety and effectiveness of MYALEPT for the treatment of complications of partial lipodystrophy have not been established.  
- The safety and effectiveness of MYALEPT for the treatment of liver disease, including nonalcoholic steatohepatitis (NASH), have not been established.  
- MYALEPT is not indicated for use in patients with HIV-related lipodystrphy.  
- MYALEPT is not indicated for use in patients with metabolic disease, including diabetes mellitus and hypertriglyceridemia, without concurrent evidence of congenital or acquired generalized lipodystrophy.",Priority,Yes,No,No,Yes,N/A,No,No,NA,2013-03-27,2014-02-24,334,5.811140992976701,Post-FDASIA
Impavido,miltefosine,Paladin Therapeutics,NDA,204684,NA,NA,Capsule,Oral,NA,NA,NA,NA,4/19/2013,3/19/2014,2014,NA,"IMPAVIDO (miltefosine) capsules are indicated in adults and adolescents >= 12 years of age weighing  >= 30 kg for the treatment of: 
- Visceral leishmaniasis caused by Leishmania donovani. 
- Cutaneous leishmaniasis caused by Leishmania braziliensis, Leishmania guyanensis, and Leishmania panamensis. 
- Mucosal leishmaniasis caused by Leishmania braziliensis. 
Limitations of Use: 
- Leishmania species studied in clinical trials evaluating IMPAVIDO were based on epidemiologic data. 
- There may be geographic variation in clinical response of the same Leishmania species to IMPAVIDO. 
- The efficacy of IMPAVIDO in the treatment of other Leishmania species has not been evaluated.",Priority,Yes,No,No,Yes,No,TD,No,NA,2013-04-19,2014-03-19,334,5.811140992976701,Post-FDASIA
Neuraceq,florbetaben F 18,Piramal Imaging,NDA,204677,NA,NA,Solution,Intravenous,NA,NA,NA,NA,12/21/2012,3/19/2014,2014,NA,"Neuraceq is indicated for Positron Emission Tomography (PET) imaging of the brain to estimate ß-amyloid neuritic plaque density in adult patients with cognitive impairment who are being evaluated for Alzheimer's Disease (AD) and other causes of cognitive decline.  
A negative Neuraceq scan indicates sparse to no amyloid neuritic plaques and is inconsistent with a neropathological diagnosis of AD at the time of image acquisition; a negative scan result reduces the likelihood that a patient's cognitive impairment is due to AD. A positive Neuraceq scan indicates moderate to frequent amyloid neuritic plaques; neuropathological examination has shown this amount of amyloid neuritic plaque is present in patients with AD, but may also be present in patients with other types of neurologic conditions as well as older people with normal cognition.  Neuraceq is an adjunct to other diagnostic evaluations.   
Limitations of Use: 
- A positive Neuraceq scan does not establish the diagnosis of AD or any other cognative disorder.  
- Safety and effectiveness of Neuraceq have not been established for: 
-- Predicting development of dementia or other neurologic conditions; 
-- Monitoring responses to therapies.",Standard,No,No,No,No,No,No,No,NA,2012-12-21,2014-03-19,453,6.115892125483034,Post-FDASIA
Otezla,apremilast,Celgene,NDA,205437,NA,NA,Tablet,Oral,NA,NA,NA,NA,3/21/2013,3/21/2014,2014,NA,OTEZLA is indicated for the treatment of adult patients with active psoriatic arthritis.,Standard,No,No,No,No,No,No,No,NA,2013-03-21,2014-03-21,365,5.8998973535824915,Post-FDASIA
Tanzeum,albiglutide,GlaxoSmithKline,BLA,125431,NA,NA,Injectable,Injection,NA,NA,NA,NA,1/14/2013,4/15/2014,2014,NA,"Tanzeum is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.  
Limitations of Use: 
- Tanzeum is not recommended as first-line therapy for patients inadequately controlled on diet and exercise.  
- Tanzeum has not been studied in patients with a history of pancreatitis. Consider other antidiabetic therapies in patients with a history of pancreatitis. 
- Tanzeum is not indicated in the treatment of patients with type 1 diabetes mellitus or for the treatment of patients with diabetic ketoacidosis. 
- Tanzeum has not been studied in patients with severe gastrointestinal disease, including severe gastroparesis. The use of Tanzeum is not recommended in patients with pre-existing severe gastrointestinal disease. 
- Tanzeum has not been studied in combination with prandial insulin.",Standard,No,No,No,No,N/A,No,No,NA,2013-01-14,2014-04-15,456,6.1224928095143865,Post-FDASIA
Cyramza,ramucirumab,Eli Lilly,BLA,125477,NA,NA,Injectable,Injection,NA,NA,NA,NA,8/23/2013,4/21/2014,2014,NA,"Cyramza as a single-agent is indicated for the treatment of patients with advanced or metastatic, gastric or gastro-esophageal junction adenocarcinoma with disease progression on or after prior fluoropyrimidine- or platinum- containing chemotherapy.",Priority,Yes,No,No,Yes,N/A,No,No,NA,2013-08-23,2014-04-21,241,5.484796933490655,Post-FDASIA
Sylvant,siltuximab,Janssen Biotech,BLA,125496,NA,NA,Injectable,Injection,NA,NA,NA,NA,8/30/2013,4/23/2014,2014,NA,"SYLVANT is indicated for the treatment of patients with multicentric Castleman’s disease (MCD) who are human immunodeficiency virus (HIV) negative and human herpesvirus-8 (HHV-8) negative. 
Limitation of Use: 
SYLVANT was not studied in patients with MCD who are HIV positive or HHV-8 positive because SYLVANT did not bind to virally produced IL-6 in a nonclinical study.",Priority,Yes,No,No,No,N/A,No,No,NA,2013-08-30,2014-04-23,236,5.4638318050256105,Post-FDASIA
Zykadia,ceritinib,Novartis Pharmaceuticals,NDA,205755,NA,NA,Capsule,Oral,NA,NA,NA,NA,12/24/2013,4/29/2014,2014,NA,ZYKADIA is indicated for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib. This indication is approved under accelerated approval based on tumor response rate and duration of response. An improvement in survival or disease-related symptoms has not been established. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.,Priority,Yes,Yes,Yes,No,No,No,No,NA,2013-12-24,2014-04-29,126,4.836281906951478,Post-FDASIA
Zontivity,vorapaxar,Merck Sharp & Dohme,NDA,204886,NA,NA,Tablet,Oral,NA,NA,NA,NA,5/10/2013,5/8/2014,2014,NA,"ZONTIVITY is indicated for the reduction of thrombotic cardiovascular events in patients with a history of myocardial infarction (MI) or with peripheral arterial disease (PAD). ZONTIVITY has been shown to reduce the rate of a combined endpoint of cardiovascular death, MI, stroke, and urgent coronary revascularization (UCR).",Standard,No,No,No,Yes,No,No,No,NA,2013-05-10,2014-05-08,363,5.8944028342648505,Post-FDASIA
Entyvio,vedolizumab,Takeda Pharmaceuticals,BLA,125476,NA,NA,Injectable,Injection,NA,NA,NA,NA,6/20/2013,5/20/2014,2014,NA,"Entyvio (vedolizumab) is indicated for: -inducing and maintaining clinical response, 
- inducing and maintaining clinical remission, 
- improving the endoscopic appearance of the mucosa, and 
- achieving corticosteroid-free remission 
in adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to a tumor necrosis factor (TNF) blocker or immunomodulator; or had an inadequate response with, were intolerant to, or demonstrated dependence on corticosteroids. 
Entyvio (vedolizumab) is indicated for: 
- achieving clinical response, 
- achieving clinical remission, and 
- achieving corticosteroid-free remission 
in adult patients with moderately to severely active Crohn’s disease who have had an inadequate response with, lost response to, or were intolerant to a tumor necrosis factor (TNF) blocker or immunomodulator; or had an inadequate response with, were intolerant to, or demonstrated dependence on corticosteroids.",Priority,No,No,No,Yes,N/A,No,No,NA,2013-06-20,2014-05-20,334,5.811140992976701,Post-FDASIA
Dalvance,dalbavancin,Durata Therapeutics International,NDA,21883,NA,NA,Powder,Intravenous,NA,NA,NA,NA,12/21/2004,5/23/2014,2014,NA,"DALVANCE (dalbavancin) for injection is indicated for the treatment of adult patients with acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible isolates of the following Gram-positive microorganisms: Staphylococcus aureus (including methicillin-susceptible and methicillin-resistant strains), Streptococcus pyogenes, Streptococcus agalactiae and Streptococcus anginosus group (including S. anginosus, S. intermedius, S. constellatus). Usage: To reduce the development of drug-resistant bacteria and maintain the effectiveness of DALVANCE and other antibacterial agents, DALVANCE should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.",Priority,No,No,No,Yes,Yes,No,No,NA,2004-12-21,2014-05-23,3440,8.143226750367445,Post-FDASIA
Jublia,efinaconazole,Dow Pharmaceutical Sciences,NDA,203567,NA,NA,Solution,Topical,NA,NA,NA,NA,7/26/2012,6/6/2014,2014,NA,"Jublia (efinaconazole) topical solution, 10% is an azole antifungal indicated for the topical treatment of onychomycosis of the toenail(s) due to Trichophyton rubrum and Trichophyton mentagrophytes.",Standard,No,No,No,No,No,No,No,NA,2012-07-26,2014-06-06,680,6.522092798170152,Post-FDASIA
Sivextro,tedizolid phosphate,Cubist Pharmaceuticals,NDA,205435,205436,NA,Tablet,Oral,Injectable,Injection,NA,NA,10/21/2013,6/20/2014,2014,NA,"SIVEXTRO is an oxazolidinone-class antibacterial indicated for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible isolates of the following Gram-positive microorganisms: Staphylococcus aureus (including methicillin-resistant [MRSA] and methicillin-susceptible [MSSA] isolates), Streptococcus pyogenes, Streptococcus agalactiae, Streptococcus anginosus Group (including Streptococcus anginosus, Streptococcus intermedius, and Streptococcus constellatus), and Enterococcus faecalis. 
Usage: 
To reduce the development of drug-resistant bacteria and maintain the effectiveness of SIVEXTRO and other antibacterial drugs, SIVEXTRO should be used only to treat ABSSSI that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.",Priority,No,No,No,No,Yes,No,No,NA,2013-10-21,2014-06-20,242,5.488937726156687,Post-FDASIA
Beleodaq,belinostat,Spectrum Pharmaceuticals,NDA,206256,NA,NA,Powder,Intravenous,NA,NA,NA,NA,12/9/2013,7/3/2014,2014,NA,"Beleodaq is indicated for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). 
This indication is approved under accelerated approval based on tumor response rate and duration of response.  An improvement in survival or disease-related symptoms has not been established. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trial.",Priority,Yes,Yes,No,Yes,No,No,No,NA,2013-12-09,2014-07-03,206,5.327876168789581,Post-FDASIA
Kerydin,tavaborole,Anacor Pharmaceuticals,NDA,204427,NA,NA,Solution,Topical,NA,NA,NA,NA,7/29/2013,7/7/2014,2014,NA,"KERYDIN (tavaborole) topical solution, 5% is an oxaborole antifungal indicated for the treatment of onychomycosis of the toenails due to Trichophyton rubrum or Trichophyton mentagrophytes.",Standard,No,No,No,No,No,No,No,NA,2013-07-29,2014-07-07,343,5.8377304471659395,Post-FDASIA
Zydelig,idelalisib,Gilead Sciences,NDA,206545,205858,NA,Tablet,Oral,Tablet,Oral,NA,NA,9/11/2013,7/23/2014,2014,NA,"[A] Zydelig is indicated, in combination with rituximab, for the treatment of patients with relapsed chronic lymphocytic leukemia (CLL) for whom rituximab alone would be considered appropriate therapy due to other co-morbidities
[B] Zydelig is indicated for the treatment of patients with relapsed follicular B-cell non-Hodgkin lymphoma (FL) who have received at least two prior systemic therapies. Accelerated approval was granted for this indication based on Overall Response Rate.  An improvement in patient survival or disease related symptoms has not been established. Continues approval for this indication may be contingent upon verification of clinical benefit in confirmatory trials. 
[C] Zydelig is indicated for the treatment of patients with relapsed small lymphocytic lymphoma (SLL) who have received at least two prior systemic therapies.  Accelerated approval was granted for this indication based on Overall Response Rate. An improvement in patient survival or disease related symptoms has not been established. Continued approval for this indication may be contingent upon verification of clinical benefit in confirmatory trials.",Priority (indication [A] only),Yes,Yes (indications [B] and [C] only),Yes (indication [A] only),Yes (indication [A] only),No,No,No,NA,2013-09-11,2014-07-23,315,5.752572638825633,Post-FDASIA
Striverdi Respimat,olodaterol,Boehringer Ingelheim Pharmaceuticals,NDA,203108,NA,NA,"Spray, Metered",Inhalation,NA,NA,NA,NA,5/14/2012,7/31/2014,2014,NA,"STRIVERDI RESPIMAT is a long-acting beta2-agonist indicated for long-term, once-daily maintenance bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. 
STRIVERDI RESPIMAT is not indicated to treat acute deteriorations of COPD.
STRIVERDI RESPIMAT is not indicated to treat asthma. The safety and effectiveness of STRIVERDI RESPIMAT in asthma have not been established.",Standard,No,No,No,No,No,No,No,NA,2012-05-14,2014-07-31,808,6.694562058521095,Post-FDASIA
Jardiance,empagliflozin,Boehringer Ingelheim Pharmaceuticals,NDA,204629,NA,NA,Tablet,Oral,NA,NA,NA,NA,3/5/2013,8/1/2014,2014,NA,Jardiance is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Limitations of Use: Jardiance is not recommended for patients with type 1 diabetes or for the treatment of diabetic ketoacidosis.,Standard,No,No,No,No,No,No,No,NA,2013-03-05,2014-08-01,514,6.2422232654551655,Post-FDASIA
Orbactiv,oritavancin diphosphate,The Medicines Company,NDA,206334,NA,NA,Powder,Intravenous,NA,NA,NA,NA,12/6/2013,8/6/2014,2014,NA,"ORBACTIV (Oritavancin) for injection is indicated for the treatment of adult patients with acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible isolates of the following Gram-positive microorganisms: Staphylococcus aureus (including methicillin-susceptible and methicillin-resistant isolates), Streptococcus pyogenes, Streptococcus agalactiae, Streptococcus dysgalactiae, Streptococcus anginosus group (includes S. anginosus, S. intermedius, and S. constellatus), and Enterococcus faecalis (vancomycin-susceptible isolates only). 
Usage: 
To reduce the development of drug-resistant bacteria and maintain the effectiveness of ORBACTIV and other antibacterial drugs, ORBACTIV should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria.  When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy.  In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.",Priority,No,No,No,No,Yes,No,No,NA,2013-12-06,2014-08-06,243,5.493061443340548,Post-FDASIA
Belsomra,suvorexant,Merck,NDA,204569,NA,NA,Tablet,Oral,NA,NA,NA,NA,8/30/2012,8/13/2014,2014,NA,BELSOMRA (surovexant) is indicated for the treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance.,Standard,No,No,No,No,No,No,No,NA,2012-08-30,2014-08-13,713,6.569481420414296,Post-FDASIA
Plegridy,peginterferon beta-1a,Biogen Idec,BLA,125499,NA,NA,Injectable,Injection,NA,NA,NA,NA,5/16/2013,8/15/2014,2014,NA,PLEGRIDY (peginterferon beta-1a) is indicated for the treatment of patients with relapsing forms of multiple sclerosis.,Standard,No,No,No,No,N/A,No,No,NA,2013-05-16,2014-08-15,456,6.1224928095143865,Post-FDASIA
Cerdelga,eliglustat,Genzyme,NDA,205494,NA,NA,Capsule,Oral,NA,NA,NA,NA,9/20/2013,8/19/2014,2014,NA,"CERDELGA is indicated for the long-term treatment of adult patients with Gaucher disease type 1 (GD1) who are CYP2D6 extensive metabolizers (EMs), intermediate metabolizers (IMs), or poor metabolizers (PMs) as detected by an FDA-cleared test. 
Limitations of Use: 
- Patients who are CYP2D6 ultra-rapid metabolizers (URMs) may not achieve adequate concentrations of CERDELGA to achieve a therapeutic effect.  
- A specific dosage cannot be recommended for those patients whose CYP2D6 genotype cannot be determined (indeterminate metabolizers).",Priority,Yes,No,No,No,No,No,No,NA,2013-09-20,2014-08-19,333,5.808142489980444,Post-FDASIA
Keytruda,pembrolizumab,Merck Sharp & Dohme,BLA,125514,NA,NA,Injectable,Injection,NA,NA,NA,NA,2/27/2014,9/4/2014,2014,NA,"KEYTRUDA (pembrolizumab) is indicated for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor. 
This indication is approved under accelerated approval based on tumor response rate and durability of response. An improvement in survival or disease-related symptoms has not yet been established. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.",Priority,Yes,Yes,Yes,No,N/A,No,No,NA,2014-02-27,2014-09-04,189,5.241747015059643,Post-FDASIA
Movantik,naloxegol,AstraZeneca Pharmaceuticals,NDA,204760,NA,NA,Tablet,Oral,NA,NA,NA,NA,9/16/2013,9/16/2014,2014,NA,MOVANTIK (naloxegol) is indicated for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain.,Standard,No,No,No,No,No,No,No,NA,2013-09-16,2014-09-16,365,5.8998973535824915,Post-FDASIA
Trulicity,dulaglutide,Eli Lilly,BLA,125469,NA,NA,Injectable,Injection,NA,NA,NA,NA,9/18/2013,9/18/2014,2014,NA,"TRULICITY is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. 
Limitations of Use: 
- TRULICITY is not recommended as a first-line therapy for patients who have inadequate glycemic control on diet and exercise. 
- TRULICITY has not been studied in patients with a history of pancreatitis. Consider other antidiabetic therapies in patients with a history of pancreatitis. 
- TRULICITY should not be used in patients with type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis. TRULICITY is not a substitute for insulin. 
- TRULICITY has not been studied in patients with severe gastrointestinal disease, including severe gastroparesis. The use of TRULICITY is not recommended in patients with pre-existing severe gastrointestinal disease. 
- The concurrent use of TRULICITY and basal insulin has not been studied.",Standard,No,No,No,No,N/A,No,No,NA,2013-09-18,2014-09-18,365,5.8998973535824915,Post-FDASIA
Akynzeo,"netupitant, palonosetron",Helsinn Healthcare,NDA,205718,NA,NA,Capsule,Oral,NA,NA,NA,NA,9/27/2013,10/10/2014,2014,NA,"AKYNZEO is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy. AKYNZEO is an oral fixed combination of palonosetron and netupitant: palonosetron prevents nausea and vomiting during the acute phase and netupitant prevents nausea and vomiting during both the acute and delayed phase after cancer chemotherapy.",Standard,No,No,No,No,No,No,No,NA,2013-09-27,2014-10-10,378,5.934894195619588,Post-FDASIA
Lumason,sulfur hexafluoride lipid-type A microspheres,Bracco Diagnostics,NDA,203684,NA,NA,For Suspension,Intravenous,NA,NA,NA,NA,12/21/2011,10/10/2014,2014,NA,Lumason is indicated for use in patients with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border.,Standard,No,No,No,No,No,No,No,NA,2011-12-21,2014-10-10,1024,6.931471805599453,Post-FDASIA
Harvoni,"ledipasvir, sofosbuvir",Gilead Sciences,NDA,205834,NA,NA,Tablet,Oral,NA,NA,NA,NA,2/10/2014,10/10/2014,2014,NA,HARVONI is indicated for the treatment of chronic hepatitis C (CHC) genotype 1 infection in adults.,Priority,No,No,Yes,Yes,No,No,No,NA,2014-02-10,2014-10-10,242,5.488937726156687,Post-FDASIA
Esbriet,pirfenidone,Intermune,NDA,22535,NA,NA,Capsule,Oral,NA,NA,NA,NA,11/4/2009,10/15/2014,2014,NA,ESBRIET is indicated for the treatment of idiopathic pulmonary fibrosis (IPF),Priority,Yes,No,Yes,Yes,No,No,No,NA,2009-11-04,2014-10-15,1806,7.498869733976931,Post-FDASIA
Ofev,nintedanib,Boehringer Ingelheim Pharmaceuticals,NDA,205832,NA,NA,Capsule,Oral,NA,NA,NA,NA,5/2/2014,10/15/2014,2014,NA,OFEV is indicated for the treatment of idiopathic pulmonary fibrosis (IPF).,Priority,Yes,No,Yes,Yes,No,No,No,NA,2014-05-02,2014-10-15,166,5.111987788356544,Post-FDASIA
Blincyto,blinatumomab,Amgen,BLA,125557,NA,NA,Injectable,Injection,NA,NA,NA,NA,9/19/2014,12/3/2014,2014,NA,"BLINCYTO is indicated for the treatment of Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). 
This indication is approved under accelerated approval.  Continued approval for this indication may be contingent upon verification of clinical benefit in subsequent trials.",Priority,Yes,Yes,Yes,No,N/A,No,No,NA,2014-09-19,2014-12-03,75,4.31748811353631,Post-FDASIA
Xtoro,finafloxacin,Alcon Research,NDA,206307,NA,NA,Suspension/Drops,Otic,NA,NA,NA,NA,4/25/2014,12/17/2014,2014,NA,"XTORO (finafloxacin otic suspension), 0.3% is indicated for the treatment of acute otitis externa (AOE) with or without an otowick, caused by susceptible strains of Pseudomonas aeruginosa and Staphylococcus aureus inpatients age 1 year and older.",Priority,No,No,No,No,No,No,No,NA,2014-04-25,2014-12-17,236,5.4638318050256105,Post-FDASIA
Lynparza,olaparib,AstraZeneca Pharmaceuticals,NDA,206162,NA,NA,Capsule,Oral,NA,NA,NA,NA,2/3/2014,12/19/2014,2014,NA,"Lynparza is indicated as monotherapy in patients with deleterious or suspected deleterious germline BRCA mutated (as detected by an FDA-approved test) advanced ovarian cancer who have been treated with three or more prior lines of chemotherapy. 
The indication is approved under accelerated approval based on objective response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.",Priority,Yes,Yes,No,No,No,No,No,NA,2014-02-03,2014-12-19,319,5.765191102784844,Post-FDASIA
Zerbaxa,"ceftolozane, tazobactam",Cubist Pharmaceuticals,NDA,206829,NA,NA,Powder,Intravenous,NA,NA,NA,NA,4/21/2014,12/19/2014,2014,NA,"ZERBAXA (ceftolozane/tazobactam) for Injection is indicated for the treatment of patients 18 years or older with the following infections caused by designated susceptible microorganisms. 
ZERBAXA used in combination with metronidazole is indicated for the treatment of complicated intra-abdominal infections (cIAI) caused by the following Gram-negative and Gram-positive microorganisms: Enterobacter cloacae, Escherichia coli, Klebsiella oxytoca, Klebsiella pneumonia, Proteus mirabilis, Pseudomonas aeruginosa, Bacteroides fragilis, Streptococcus anginosus, Streptococcus constellatus, and Streptococcus salivarius. 
ZERBAXA is indicated for the treatment of complicated urinary tract infections (cUTI), including pyelonephritis, caused by the following Gram-negative microorganisms: Escherichia coli, Klebsiella pneumonia, Proteus mirabilis, and Pseudomonas aeruginosa. 
Usage: 
To reduce the development of drug-resistant bacteria and maintain the effectiveness of ZERBAXA and other antibacterial drugs, ZERBAXA should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy.  In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.",Priority,No,No,No,Yes,Yes,No,No,NA,2014-04-21,2014-12-19,242,5.488937726156687,Post-FDASIA
Rapivab,peramivir,BioCryst Pharmaceuticals,NDA,206426,NA,NA,Solution,Intravenous,NA,NA,NA,NA,12/23/2013,12/19/2014,2014,NA,"RAPIVAB is indicated for the treatment of acute uncomplicated influenza in patients 18 years and older who have been symptomatic for no more than 2 days. 
Limitations of Use: 
- Efficacy of RAPIVAB is based on clinical trials of naturally occurring influenza in which the predominant influenza infections were influenza A virus; a limited number of subjects infected with influenza B virus were enrolled. 
- Influenza viruses change over time. Emergence of resistance substitutions could decrease drug effectiveness.  Other factors (for example, change in viral virulence) might also diminish clinical benefit of antiviral drugs. Prescribers should consider available information on influenza drug susceptibility patters and treatment effects when deciding whether to use RAPIVAB.  
- The efficacy of RAPIVAB could not be established in patients with serious influenza requiring hospitalization.",Standard,No,No,No,Yes,No,No,No,NA,2013-12-23,2014-12-19,361,5.8888779583328805,Post-FDASIA
Viekira Pak,"ombitasvir, paritaprevir, ritonavir; dasabuvir (co-packaged)",AbbVie,NDA,206619,NA,NA,"Tablet, Tablet",Oral,NA,NA,NA,NA,4/21/2014,12/19/2014,2014,NA,"VIEKIRA PAK with or without ribavirin is indicated for the treatment of patients with genotype 1 chronic hepatitis C virus (HCV) infection including those with compensated cirrhosis.  
Limitation of Use:  
VIEKIRA PAK is not recommended for use in patients with decompensated liver disease.",Priority,No,No,Yes,Yes,No,No,No,NA,2014-04-21,2014-12-19,242,5.488937726156687,Post-FDASIA
Opdivo,nivolumab,Bristol-Myers Squibb,BLA,125554,NA,NA,Injectable,Injection,NA,NA,NA,NA,7/30/2014,12/22/2014,2014,NA,"OPDIVO (nivolumab) is indicated for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor. 
This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.",Priority,Yes,Yes,Yes,Yes,N/A,No,No,NA,2014-07-30,2014-12-22,145,4.976733742420574,Post-FDASIA
Savaysa,edoxaban tosylate,Daiichi Sankyo,NDA,206316,NA,NA,Tablet,Oral,NA,NA,NA,NA,1/8/2014,1/8/2015,2015,NA,"SAVAYSA is indicated to reduce the risk of stroke and systemic embolism (SE) in patients with nonvalvular atrial fibrillation (NVAF). 
Limitation of Use for NVAF: 
SAVAYSA should not be used in patients with CrCL > 95 mL/min because of an increased risk of ischemic stroke compared to warfarin. SAVAYSA is indicated for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) following 5 to 10 days of initial therapy with a parenteral anticoagulant.",Standard,No,No,No,No,No,No,No,NA,2014-01-08,2015-01-08,365,5.8998973535824915,Post-FDASIA
Cosentyx,secukinumab,Novartis Pharmaceuticals,BLA,125504,NA,NA,Injectable,Injection,NA,NA,NA,NA,10/24/2013,1/21/2015,2015,NA,COSENTYX is indicated for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy.,Standard,No,No,No,No,N/A,No,No,NA,2013-10-24,2015-01-21,454,6.118097198041348,Post-FDASIA
Natpara,parathyroid hormone,NPS Pharmaceuticals,BLA,125511,NA,NA,Injectable,Injection,NA,NA,NA,NA,10/24/2013,1/23/2015,2015,NA,"NATPARA is a parathyroid hormone indicated as an adjunct to calcium and vitamin D to control hypocalcemia in patients with hypoparathyroidism.  
Limitations of use: 
- Because of the potential risk of osteosarcoma, NATPARA is recommended only for patients who cannot be well-controlled on calcium supplements and active forms of vitamin D alone. 
- NATPARA was not studied in patients with hypoparathyroidism caused by calcium-sensing receptor mutations.  
- NATPARA was not studied in patients with acute post-surgical hypoparathyroidism.",Standard,Yes,No,No,No,N/A,No,No,NA,2013-10-24,2015-01-23,456,6.1224928095143865,Post-FDASIA
Ibrance,palbociclib,Pfizer,NDA,207103,NA,NA,Capsule,Oral,NA,NA,NA,NA,8/13/2014,2/3/2015,2015,NA,"IBRANCE is indicated in combination with letrozole for the treatment of postmenopausal women with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer as initial endocrine-based therapy for their metastatic disease. 
This indication is approved under accelerated approval based on progression-free survival (PFS). Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.",Priority,No,Yes,Yes,No,No,No,No,NA,2014-08-13,2015-02-03,174,5.159055299214529,Post-FDASIA
Lenvima,lenvatinib,Eisai,NDA,206947,NA,NA,Capsule,Oral,NA,NA,NA,NA,8/14/2014,2/13/2015,2015,NA,"LENVIMA is indicated for the treatment of patients with locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer (DTC).",Priority,Yes,No,No,No,No,No,No,NA,2014-08-14,2015-02-13,183,5.209486152841421,Post-FDASIA
Farydak,panobinostat,Novartis Pharmaceuticals,NDA,205353,NA,NA,Capsule,Oral,NA,NA,NA,NA,3/24/2014,2/23/2015,2015,NA,"FARYDAK, a histone deacetylase inhibitor, in combination with bortezomin and dexamethasone, is indicated for the treatment of patients with multiple myeloma who have received at least 2 prior regimens, including bortezomib and an immunomodulatory agent.  This indication is approved under accelerated approval based on progression free survival.  Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.",Priority,Yes,Yes,No,No,No,No,No,NA,2014-03-24,2015-02-23,336,5.817111159963204,Post-FDASIA
Avycaz,ceftazidime and avibactam,Forest Research Institute,NDA,206494,NA,NA,Powder,Iv (Infusion),NA,NA,NA,NA,6/25/2014,2/25/2015,2015,NA,"AVYCAZ (ceftazidime-avibactam), in combination with metronidazole, is indicated for the treatment of complicated intra-abdominal infections (cIAI) caused by the following susceptible microorganisms: Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Providencia stuartii, Enterobacter cloacae, Klebsiella oxytoca, and Pseudomonas aeruginosa in patients 18 years or older. 
As only limited clinical safety and efficacy data for AVYCAZ are currently available, reserve AVYCAZ for use in patients who have limited or no alternative treatment options. 
AVYCAZ (ceftazidime-avibactam) is indicated for the treatment of complicated urinary tract infections (cUTI) including pyelonephritis caused by the following susceptible microorganisms: Escherichia coli, Klebsiella pneumoniae, Citrobacter koseri, Enterobacter aerogenes, Enterobacter cloacae, Citrobacter freundii, Proteus spp., and Pseudomonas aeruginosa in patients 18 years or older. 
As only limited clinical safety and efficacy data for AVYCAZ are currently available, reserve AVYCAZ for use in patients who have limited or no alternative treatment options. 
Usage: 
To reduce the development of drug-resistant bacteria and maintain the effectiveness of AVYCAZ and other antibacterial drugs, AVYCAZ should be used to treat only indicated infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.",Priority,No,No,No,Yes,Yes,No,No,NA,2014-06-25,2015-02-25,245,5.501258210544727,Post-FDASIA
Cresemba,isavuconazonium sulfate,Astellas Pharma,NDA,207500,207501,NA,Capsule,Oral,Injectable,Injection,NA,NA,7/8/2014,3/6/2015,2015,NA,"CRESEMBA is an azole antifungal indicated for patients 18 years of age and older for the treatment of invasive aspergillosis.
CRESEMBA is an azole antifungal indicated for patients 18 years of age and older for the treatment of invasive mucormycosis.
Usage:
Specimens for fungal culture and other relevant laboratory studies (including histopathology) to isolate and identify causative organism(s) should be obtained prior to initiating antifungal therapy. Therapy may be instituted before the results of the cultures and other laboratory studies are known. However, once these results become available, antifungal therapy should be adjusted accordingly.",Priority,Yes,No,No,No,Yes,No,No,NA,2014-07-08,2015-03-06,241,5.484796933490655,Post-FDASIA
Unituxin,dinutuximab,United Therapeutics,BLA,125516,NA,NA,Injectable,Injection,NA,NA,NA,NA,4/11/2014,3/10/2015,2015,NA,"Unituxin (dinutuximab) is indicated, in combination with granulocyte-macrophage colonystimulating factor (GM-CSF), interleukin-2 (IL-2) and 13-cis-retinoic acid (RA), for the treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to prior first-line multiagent, multimodality therapy.",Priority,Yes,No,No,No,N/A,RPD,No,NA,2014-04-11,2015-03-10,333,5.808142489980444,Post-FDASIA
Cholbam,cholic acid,Asklepion Pharmaceuticals,NDA,205750,NA,NA,Capsule,Oral,NA,NA,NA,NA,11/21/2013,3/17/2015,2015,NA,"CHOLBAM is indicated for the treatment of bile acid synthesis disorders due to single enzyme defects (SEDs). 
CHOLBAM is indicated for adjunctive treatment of peroxisomal disorders (PDs) including Zellweger spectrum disorders in patients who exhibit manifestations of liver disease, steatorrhea or complications from decreased fat soluble vitamin absorption. 
The safety and effectiveness of CHOLBAM on extrahepatic manifestations of bile acid synthesis disorders due to SEDs or PDs including Zellweger spectrum disorders have not been established.",Priority,Yes,No,No,No,No,RPD,No,NA,2013-11-21,2015-03-17,481,6.175867270105761,Post-FDASIA
Corlanor,ivabradine,Amgen,NDA,206143,NA,NA,Tablet,Oral,NA,NA,NA,NA,6/27/2014,4/15/2015,2015,NA,"Corlanor is indicated to reduce the risk of hospitalization for worsening heart failure in patients with stable, symptomatic chronic heart failure with left ventricular ejection fraction <= 35%, who are in sinus rhythm with resting heart rate >= 70 beats per minute and either are on maximally tolerated doses of betablockers or have a contraindication to beta-blocker use.",Priority,No,No,No,Yes,No,No,No,NA,2014-06-27,2015-04-15,292,5.676753802268282,Post-FDASIA
Kybella,deoxycholic acid,Kythera Biopharmaceuticals,NDA,206333,NA,NA,Solution,Subcutaneous,NA,NA,NA,NA,5/13/2014,4/29/2015,2015,NA,"KYBELLA (deoxycholic acid) injection is indicated for improvement in the appearance of moderate to severe convexity or fullness associated with submental fat in adults. 
Limitation of use:
The safe and effective use of KYBELLA for the treatment of subcutaneous fat outside the submental region has not been established and is not recommended.",Standard,No,No,No,No,No,No,No,NA,2014-05-13,2015-04-29,351,5.860786223465865,Post-FDASIA
Viberzi,eluxadoline,Furiex Pharmaceuticals,NDA,206940,NA,NA,Tablet,Oral,NA,NA,NA,NA,6/27/2014,5/27/2015,2015,NA,VIBERZI is indicated in adults for the treatment of irritable bowel syndrome with diarrhea (IBS-D).,Priority,No,No,No,Yes,No,No,No,NA,2014-06-27,2015-05-27,334,5.811140992976701,Post-FDASIA
Kengreal,cangrelor,The Medicines Company,NDA,204958,NA,NA,Powder,Intravenous,NA,NA,NA,NA,4/30/2013,6/22/2015,2015,NA,"KENGREAL is indicated as an adjunct to percutaneous coronary intervention (PCI) to reduce the risk of periprocedural myocardial infarction (MI), repeat coronary revascularization, and stent thrombosis (ST) in patients who have not been treated with a P2Y12 platelet inhibitor and are not being given a glycoprotein IIb/IIIa inhibitor.",Standard,No,No,No,No,No,No,No,NA,2013-04-30,2015-06-22,783,6.663132695990803,Post-FDASIA
Orkambi,"lumacaftor, ivacaftor",Vertex Pharmaceuticals,NDA,206038,NA,NA,Tablet,Oral,NA,NA,NA,NA,11/5/2014,7/2/2015,2015,NA,"ORKAMBI is a combination of lumacaftor and ivacaftor indicated for the treatment of cystic fibrosis (CF) in patients age 12 years and older who are homozygous for the F508del mutation in the CFTR gene. If the patient’s genotype is unknown, an FDA-cleared CF mutation test should be used to detect the presence of the F508del mutation on both alleles of the CFTR gene.
Limitations of Use:
The efficacy and safety of ORKAMBI have not been established in patients with CF other than those homozygous for the F508del mutation.",Priority,Yes,No,Yes,Yes,No,No,No,NA,2014-11-05,2015-07-02,239,5.476463551931511,Post-FDASIA
Entresto,"sacubitril, valsartan",Novartis Pharmaceuticals,NDA,207620,NA,NA,Tablet,Oral,NA,NA,NA,NA,12/17/2014,7/7/2015,2015,NA,"ENTRESTO is indicated to reduce the risk of cardiovascular death and hospitalization for heart failure in patients with chronic heart failure (NYHA Class II-IV) and reduced ejection fraction.
ENTRESTO is usually administered in conjunction with other heart failure therapies, in place of an ACE inhibitor or other ARB.",Priority,No,No,No,Yes,No,No,No,NA,2014-12-17,2015-07-07,202,5.308267697401205,Post-FDASIA
Rexulti,brexpiprazole,Otsuka Pharmaceutical,NDA,205422,NA,NA,Tablet,Oral,NA,NA,NA,NA,7/11/2014,7/10/2015,2015,NA,"REXULTI is indicated for:
- Adjunctive treatment of major depressive disorder (MDD).
- Treatment of schizophrenia.",Standard,No,No,No,No,No,No,No,NA,2014-07-11,2015-07-10,364,5.8971538676367405,Post-FDASIA
Odomzo,sonidegib,Novartis Pharmaceuticals,NDA,205266,NA,NA,Capsule,Oral,NA,NA,NA,NA,9/26/2014,7/24/2015,2015,NA,"ODOMZO (sonidegib) is indicated for the treatment of adult patients with locally advanced basal cell carcinoma (BCC) that has recurred following surgery or radiation therapy, or those who are not candidates for surgery or radiation therapy.",Standard,No,No,No,No,No,No,No,NA,2014-09-26,2015-07-24,301,5.707110264748875,Post-FDASIA
Praluent,alirocumab,Sanofi-Aventis,BLA,125559,NA,NA,Injectable,Injection,NA,NA,NA,NA,11/24/2014,7/24/2015,2015,NA,"PRALUENT is indicated as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease, who require additional lowering of LDL-C.
Limitations of Use:
The effect of PRALUENT on cardiovascular morbidity and mortality has not been determined.",Priority (used priority review voucher),No,No,No,No,N/A,No,Yes,NA,2014-11-24,2015-07-24,242,5.488937726156687,Post-FDASIA
Daklinza,daclatasvir,Bristol-Myers Squibb,NDA,206843,NA,NA,Tablet,Oral,NA,NA,NA,NA,3/31/2014,7/24/2015,2015,NA,"DAKLINZA is indicated for use with sofosbuvir for the treatment of patients with chronic hepatitis C virus (HCV) genotype 3 infection.
Limitations of Use:
- Sustained virologic response (SVR) rates are reduced in HCV genotype 3-infected patients with cirrhosis receiving DAKLINZA in combination with sofosbuvir for 12 weeks.",Priority,No,No,No,Yes,No,No,No,NA,2014-03-31,2015-07-24,480,6.173786103901937,Post-FDASIA
Addyi,flibanserin,Sprout Pharmaceuticals,NDA,22526,NA,NA,Tablet,Oral,NA,NA,NA,NA,10/27/2009,8/18/2015,2015,NA,"ADDYI is indicated for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD), as characterized by low sexual desire that causes marked distress or interpersonal difficulty and is NOT due to: 
- A co-existing medical or psychiatric condition, 
- Problems within the relationship, or 
- The effects of a medication or other drug substance. 
Acquired HSDD refers to HSDD that develops in a patient who previously had no problems with sexual desire. Generalized HSDD refers to HSDD that occurs regardless of the type of stimulation, situation or partner. 
Limitations of Use:
- ADDYI is not indicated for the treatment of HSDD in postmenopausal women or in men. 
- ADDYI is not indicated to enhance sexual performance.",Standard,No,No,No,No,No,No,No,NA,2009-10-27,2015-08-18,2121,7.659642954564682,Post-FDASIA
Repatha,evolocumab,Amgen,BLA,125522,NA,NA,Injectable,Injection,NA,NA,NA,NA,8/27/2014,8/27/2015,2015,NA,"[A] REPATHA is indicated as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia (HeFH) or clinical atherosclerotic cardiovascular disease (CVD), who require additional lowering of low density lipoprotein cholesterol (LDL-C). 
[B] REPATHA is indicated as an adjunct to diet and other LDL-lowering therapies (e.g., statins, ezetimibe, LDL apheresis) for the treatment of patients with homozygous familial hypercholesterolemia (HoFH) who require additional lowering of LDL-C.
Limitations of Use: 
The effect of REPATHA on cardiovascular morbidity and mortality has not been determined.",Standard,Yes (indication [B] only),No,No,No,N/A,No,No,NA,2014-08-27,2015-08-27,365,5.8998973535824915,Post-FDASIA
Varubi,rolapitant,Tesaro,NDA,206500,NA,NA,Tablet,Oral,NA,NA,NA,NA,9/5/2014,9/1/2015,2015,NA,"VARUBI is indicated in combination with other antiemetic agents in adults for the prevention of delayed nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy.",Standard,No,No,No,No,No,No,No,NA,2014-09-05,2015-09-01,361,5.8888779583328805,Post-FDASIA
Xuriden,uridine triacetate,Wellstat Therapeutics,NDA,208169,NA,NA,Granule,Oral,NA,NA,NA,NA,1/8/2015,9/4/2015,2015,NA,XURIDEN is indicated for the treatment of hereditary orotic aciduria.,Priority,Yes,No,Yes,No,No,RPD,No,NA,2015-01-08,2015-09-04,239,5.476463551931511,Post-FDASIA
Vraylar,cariprazine,Forest Laboratories,NDA,204370,NA,NA,Capsule,Oral,NA,NA,NA,NA,11/19/2012,9/17/2015,2015,NA,"VRAYLAR is indicated for the: 
- Treatment of schizophrenia.
- Acute treatment of manic or mixed episodes associated with bipolar I disorder.",Standard,No,No,No,No,No,No,No,NA,2012-11-19,2015-09-17,1032,6.939253946041508,Post-FDASIA
Lonsurf,trifluridine and tipiracil,Taiho Oncology,NDA,207981,NA,NA,Tablet,Oral,NA,NA,NA,NA,12/19/2014,9/22/2015,2015,NA,"LONSURF is indicated for the treatment of patients with metastatic colorectal cancer who have been previously treated with fluoropyrimidine-, oxaliplatin-and irinotecan-based chemotherapy, an anti-VEGF biological therapy, and if RAS wild-type, an anti-EGFR therapy.",Standard,No,No,No,Yes,No,No,No,NA,2014-12-19,2015-09-22,277,5.6240175061873385,Post-FDASIA
Tresiba,insulin degludec,Novo Nordisk,BLA,203314,NA,NA,Solution,Subcutaneous,NA,NA,NA,NA,9/29/2011,9/25/2015,2015,NA,"TRESIBA is indicated to improve glycemic control in adults with diabetes mellitus. 
Limitations of Use:
TRESIBA is not recommended for the treatment of diabetic ketoacidosis.",Standard,No,No,No,No,N/A,No,No,Transition Product from NDA to BLA due to BPCI : Please see page 2 of data dictionary for more information.,2011-09-29,2015-09-25,1457,7.284134806195205,Post-FDASIA
Aristada,aripiprazole lauroxil,Alkermes,NDA,207533,NA,NA,"Suspension, Extended Release",Intramuscular,NA,NA,NA,NA,8/22/2014,10/5/2015,2015,NA,ARISTADA is indicated for treatment of schizophrenia.,Standard,No,No,No,No,No,No,No,NA,2014-08-22,2015-10-05,409,6.013715156042802,Post-FDASIA
Praxbind,idarucizumab,Boehringer Ingelheim Pharmaceuticals,BLA,761025,NA,NA,Injectable,Injection,NA,NA,NA,NA,2/19/2015,10/16/2015,2015,NA,"PRAXBIND is indicated in patients treated with Pradaxa when reversal of the anticoagulant effects of dabigatran is needed: 
- For emergency surgery/urgent procedures
- In life-threatening or uncontrolled bleeding
This indication is approved under accelerated approval based on a reduction in unbound dabigatran and normalization of coagulation parameters in healthy volunteers. Continued approval for this indication may be contingent upon the results of an ongoing cohort case series study.",Priority,Yes,Yes,Yes,No,N/A,No,No,NA,2015-02-19,2015-10-16,239,5.476463551931511,Post-FDASIA
Veltassa,patiromer,Relypsa,NDA,205739,NA,NA,Powder,Oral,NA,NA,NA,NA,10/21/2014,10/21/2015,2015,NA,"Veltassa is indicated for the treatment of hyperkalemia.
Limitation of Use: Veltassa should not be used as an emergency treatment for life-threatening hyperkalemia because of its delayed onset of action.",Standard,No,No,No,No,No,No,No,NA,2014-10-21,2015-10-21,365,5.8998973535824915,Post-FDASIA
Strensiq,asfotase alfa,Alexion Pharmaceuticals,BLA,125513,NA,NA,Injectable,Injection,NA,NA,NA,NA,12/23/2014,10/23/2015,2015,NA,Strensiq is indicated for the treatment of patients with perinatal/infantile- and juvenile-onset hypophosphatasia (HPP).,Priority,Yes,No,Yes,Yes,N/A,RPD,No,NA,2014-12-23,2015-10-23,304,5.717027701406222,Post-FDASIA
Yondelis,trabectedin,Janssen Products,NDA,207953,NA,NA,Powder,Intravenous,NA,NA,NA,NA,11/24/2014,10/23/2015,2015,NA,YONDELIS is indicated for the treatment of patients with unresectable or metastatic liposarcoma or leiomyosarcoma who received a prior anthracycline-containing regimen.,Priority,Yes,No,No,No,No,No,No,NA,2014-11-24,2015-10-23,333,5.808142489980444,Post-FDASIA
Nucala,mepolizumab,GlaxoSmithKline,BLA,125526,NA,NA,Injectable,Injection,NA,NA,NA,NA,11/4/2014,11/4/2015,2015,NA,"NUCALA is indicated for the add-on maintenance treatment of patients with severe asthma aged 12 years and older, and with an eosinophilic phenotype.
Limitations of Use:
- NUCALA is not indicated for treatment of other eosinophilic conditions. 
- NUCALA is not indicated for the relief of acute bronchospasm or status asthmaticus.",Standard,No,No,No,No,N/A,No,No,NA,2014-11-04,2015-11-04,365,5.8998973535824915,Post-FDASIA
Genvoya,"elvitegravir, cobicistat, emtricitabine, tenofovir alafenamide",Gilead Sciences,NDA,207561,NA,NA,Tablet,Oral,NA,NA,NA,NA,11/5/2014,11/5/2015,2015,NA,GENVOYA is indicated as a complete regimen for the treatment of HIV-1 infection in adults and pediatric patients 12 years of age and older who have no antiretroviral treatment history or to replace the current antiretroviral regimen in those who are virologically-suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen for at least 6 months with no history of treatment failure and no known substitutions associated with resistance to the individual components of GENVOYA.,Standard,No,No,No,Yes,No,No,No,NA,2014-11-05,2015-11-05,365,5.8998973535824915,Post-FDASIA
Cotellic,cobimetinib,Genentech,NDA,206192,NA,NA,Tablet,Oral,NA,NA,NA,NA,12/11/2014,11/10/2015,2015,NA,"COTELLIC is indicated for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, in combination with vemurafenib. 
Limitation of Use: COTELLIC is not indicated for treatment of patients with wild-type BRAF melanoma.",Priority,Yes,No,No,Yes,No,No,No,NA,2014-12-11,2015-11-10,334,5.811140992976701,Post-FDASIA
Tagrisso,osimertinib,AstraZeneca Pharmaceuticals,NDA,208065,NA,NA,Tablet,Oral,NA,NA,NA,NA,6/5/2015,11/13/2015,2015,NA,"TAGRISSO is indicated for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC), as detected by an FDA-approved test, who have progressed on or after EGFR tyrosine kinase inhibitor (TKI) therapy. 
This indication is approved under accelerated approval based on tumor response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.",Priority,Yes,Yes,Yes,Yes,No,No,No,NA,2015-06-05,2015-11-13,161,5.081404364984463,Post-FDASIA
Darzalex,daratumumab,Janssen Biotech,BLA,761036,NA,NA,Injectable,Injection,NA,NA,NA,NA,7/9/2015,11/16/2015,2015,NA,"DARZALEX is indicated for the treatment of patients with multiple myeloma who have received at least three prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory agent or who are double-refractory to a PI and an immunomodulatory agent.
This indication is approved under accelerated approval based on response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.",Priority,Yes,Yes,Yes,Yes,N/A,No,No,NA,2015-07-09,2015-11-16,130,4.867534450455582,Post-FDASIA
Ninlaro,ixazomib,Millennium Pharmaceuticals,NDA,208462,NA,NA,Capsule,Oral,NA,NA,NA,NA,7/10/2015,11/20/2015,2015,NA,NINLARO is indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy.,Priority,Yes,No,No,No,No,No,No,NA,2015-07-10,2015-11-20,133,4.890349128221754,Post-FDASIA
Portrazza,necitumumab,Eli Lilly,BLA,125547,NA,NA,Injectable,Injection,NA,NA,NA,NA,12/2/2014,11/24/2015,2015,NA,"PORTRAZZA is indicated, in combination with gemcitabine and cisplatin, for first-line treatment of patients with metastatic squamous non-small cell lung cancer. 
Limitation of Use:
PORTRAZZA is not indicated for treatment of non-squamous non-small cell lung cancer.",Standard,Yes,No,No,Yes,N/A,No,No,NA,2014-12-02,2015-11-24,357,5.877735781779639,Post-FDASIA
Empliciti,elotuzumab,Bristol-Myers Squibb,BLA,761035,NA,NA,Injectable,Injection,NA,NA,NA,NA,6/29/2015,11/30/2015,2015,NA,EMPLICITI is indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received one to three prior therapies.,Priority,Yes,No,Yes,No,N/A,No,No,NA,2015-06-29,2015-11-30,154,5.0369526024136295,Post-FDASIA
Kanuma,sebelipase alfa,Alexion Pharmaceuticals,BLA,125561,NA,NA,Injectable,Injection,NA,NA,NA,NA,1/8/2015,12/8/2015,2015,NA,KANUMA is indicated for the treatment of patients with a diagnosis of Lysosomal Acid Lipase (LAL) deficiency.,Priority,Yes,No,Yes,Yes,N/A,RPD,No,NA,2015-01-08,2015-12-08,334,5.811140992976701,Post-FDASIA
Alecensa,alectinib,Hoffmann-La Roche,NDA,208434,NA,NA,Capsule,Oral,NA,NA,NA,NA,7/6/2015,12/11/2015,2015,NA,"ALECENSA is indicated for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive, metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib.
This indication is approved under accelerated approval based on tumor response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.",Priority,Yes,Yes,Yes,No,No,No,No,NA,2015-07-06,2015-12-11,158,5.062595033026967,Post-FDASIA
Bridion,sugammadex,Merck,NDA,22225,NA,NA,Solution,Intravenous,NA,NA,NA,NA,10/31/2007,12/15/2015,2015,NA,BRIDION is indicated for the reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide in adults undergoing surgery.,Priority,No,No,No,No,No,No,No,NA,2007-10-31,2015-12-15,2967,7.995306620290822,Post-FDASIA
Uptravi,selexipag,Actelion Pharmaceuticals,NDA,207947,NA,NA,Tablet,Oral,NA,NA,NA,NA,12/22/2014,12/21/2015,2015,NA,"UPTRAVI is indicated for the treatment of pulmonary arterial hypertension (PAH, WHO Group I) to delay disease progression and reduce the risk of hospitalization for PAH.
Effectiveness was established in a long-term study in PAH patients with WHO Functional Class II-III symptoms.
Patients had idiopathic and heritable PAH (58%), PAH associated with connective tissue disease (29%), PAH associated with congenital heart disease with repaired shunts (10%).",Standard,Yes,No,No,No,No,No,No,NA,2014-12-22,2015-12-21,364,5.8971538676367405,Post-FDASIA
Zurampic,lesinurad,Ardea Biosciences,NDA,207988,NA,NA,Tablet,Oral,NA,NA,NA,NA,12/29/2014,12/22/2015,2015,NA,"ZURAMPIC is indicated in combination with a xanthine oxidase inhibitor for the treatment of hyperuricemia associated with gout in patients who have not achieved target serum uric acid levels with a xanthine oxidase inhibitor alone.
Limitations of Use:
ZURAMPIC is not recommended for the treatment of asymptomatic hyperuricemia. 
ZURAMPIC should not be used as monotherapy.",Standard,No,No,No,No,No,No,No,NA,2014-12-29,2015-12-22,358,5.8805329864007,Post-FDASIA
Zepatier,elbasvir and grazoprevir,Merck,NDA,208261,NA,NA,Tablet,Oral,NA,NA,NA,NA,5/28/2015,1/28/2016,2016,NA,ZEPATIER is indicated with or without ribavirin for the treatment of chronic hepatitis C virus (HCV) genotypes 1 or 4 infection in adults.,Priority,No,No,Yes,No,No,No,No,NA,2015-05-28,2016-01-28,245,5.501258210544727,Post-FDASIA
Briviact,brivaracetam,UCB,NDA,205836,205837,205838,Tablet,Oral,Injectable,Injection,Solution,Oral,11/24/2014,2/18/2016,2016,NA,BRIVIACT is indicated as adjunctive therapy in the treatment of partial-onset seizures in patients 16 years of age and older with epilepsy.,Standard,No,No,No,No,No,No,No,NA,2014-11-24,2016-02-18,451,6.111467339502679,Post-FDASIA
Anthim,obiltoxaximab,Elusys Therapeutics,BLA,125509,NA,NA,Injectable,Injection,NA,NA,NA,NA,3/20/2015,3/18/2016,2016,NA,"ANTHIM is indicated in adult and pediatric patients for the treatment of inhalational anthrax due to Bacillus anthracis in combination with appropriate antibacterial drugs. 
ANTHIM is indicated for prophylaxis of inhalational anthrax due to B. anthracis when alternative therapies are not available or not appropriate. 
Limitations of Use:
ANTHIM should only be used for prophylaxis when its benefit for prevention of inhalational anthrax outweighs the risk of hypersensitivity and anaphylaxis.
The effectiveness of ANTHIM is based solely on efficacy studies in animal models of inhalational anthrax. It is not ethical or feasible to conduct controlled clinical trials with intentional exposure of humans to anthrax.
Safety and PK of ANTHIM have been studied in adult healthy volunteers. There have been no studies of safety or PK of ANTHIM in the pediatric population. A population PK approach was used to derive intravenous infusion dosing regimens that are predicted to provide pediatric patients with exposure comparable to the observed exposure in adults.
ANTHIM binds to the protective antigen (PA) component of B. anthracis toxin; it does not have direct antibacterial activity. ANTHIM is not expected to cross the blood-brain barrier and does not prevent or treat meningitis. ANTHIM should be used in combination with appropriate antibacterial drugs.",Standard,Yes,No,No,Yes,N/A,No,No,NA,2015-03-20,2016-03-18,364,5.8971538676367405,Post-FDASIA
Taltz,ixekizumab,Eli Lilly,BLA,125521,NA,NA,Injectable,Injection,NA,NA,NA,NA,3/23/2015,3/22/2016,2016,NA,TALTZ is indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.,Standard,No,No,No,No,N/A,No,No,NA,2015-03-23,2016-03-22,365,5.8998973535824915,Post-FDASIA
Cinqair,reslizumab,Teva Respiratory,BLA,761033,NA,NA,Injectable,Injection,NA,NA,NA,NA,3/30/2015,3/23/2016,2016,NA,"CINQAIR is indicated for the add-on maintenance treatment of patients with severe asthma aged 18 years and older with an eosinophilic phenotype.
Limitation of Use:
- CINQAIR is not indicated for treatment of other eosinophilic conditions.
- CINQAIR is not indicated for the relief of acute bronchospasm or status asthmaticus.",Standard,No,No,No,No,N/A,No,No,NA,2015-03-30,2016-03-23,359,5.883322388488279,Post-FDASIA
Defitelio,defibrotide sodium,Jazz Pharmaceuticals,NDA,208114,NA,NA,Solution,Intravenous,NA,NA,NA,NA,7/31/2015,3/30/2016,2016,NA,"DEFITELIO is indicated for the treatment of adult and pediatric patients with hepatic veno-occlusive disease (VOD), also known as sinusoidal obstruction syndrome (SOS), with renal or pulmonary dysfunction following hematopoietic stem-cell transplantation (HSCT).",Priority,Yes,No,No,Yes,No,No,No,NA,2015-07-31,2016-03-30,243,5.493061443340548,Post-FDASIA
Venclexta,venetoclax,AbbVie,NDA,208573,NA,NA,Tablet,Oral,NA,NA,NA,NA,10/29/2015,4/11/2016,2016,NA,"VENCLEXTA is indicated for the treatment of patients with chronic lymphocytic leukemia (CLL) with 17p deletion, as detected by an FDA approved test, who have received at least one prior therapy.
This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.",Priority,Yes,Yes,Yes,No,No,No,No,NA,2015-10-29,2016-04-11,165,5.10594547390058,Post-FDASIA
Nuplazid,pimavanserin,Acadia Pharmaceuticals,NDA,207318,NA,NA,Tablet,Oral,NA,NA,NA,NA,9/1/2015,4/29/2016,2016,NA,NUPLAZID is indicated for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis.,Priority,No,No,Yes,No,No,No,No,NA,2015-09-01,2016-04-29,241,5.484796933490655,Post-FDASIA
Tecentriq,atezolizumab,Genentech,BLA,761034,NA,NA,Injectable,Injection,NA,NA,NA,NA,1/12/2016,5/18/2016,2016,NA,"TECENTRIQ (atezolizumab) is indicated for the treatment of patients with locally advanced or metastatic urothelial carcinoma who:
- Have disease progression during or following platinum-containing chemotherapy
- Have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy
This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.",Priority,No,Yes,Yes,No,N/A,No,No,NA,2016-01-12,2016-05-18,127,4.844187086458591,Post-FDASIA
Zinbryta,daclizumab,Biogen,BLA,761029,NA,NA,Injectable,Injection,NA,NA,NA,NA,2/27/2015,5/27/2016,2016,NA,"ZINBRYTA is indicated for the treatment of adult patients with relapsing forms of multiple sclerosis (MS). Because of its safety profile, the use of ZINBRYTA should generally be reserved for patients who have had an inadequate response to two or more drugs indicated for the treatment of MS.",Standard,No,No,No,No,N/A,No,No,NA,2015-02-27,2016-05-27,455,6.12029741895095,Post-FDASIA
Axumin,fluciclovine F 18,Blue Earth Diagnostics,NDA,208054,NA,NA,Solution,Intravenous,NA,NA,NA,NA,9/28/2015,5/27/2016,2016,NA,Axumin is indicated for positron emission tomography (PET) in men with suspected prostate cancer recurrence based on elevated blood prostate specific antigen (PSA) levels following prior treatment.,Priority,No,No,No,No,No,No,No,NA,2015-09-28,2016-05-27,242,5.488937726156687,Post-FDASIA
Ocaliva,obeticholic acid,Intercept Pharmaceuticals,NDA,207999,NA,NA,Tablet,Oral,NA,NA,NA,NA,6/29/2015,5/27/2016,2016,NA,"OCALIVA is indicated for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA, or as monotherapy in adults unable to tolerate UDCA.
This indication is approved under accelerated approval based on a reduction in alkaline phosphatase (ALP). An improvement in survival or disease-related symptoms has not been established. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.",Priority,Yes,Yes,No,Yes,No,No,No,NA,2015-06-29,2016-05-27,333,5.808142489980444,Post-FDASIA
Netspot,gallium Ga 68 dotatate,Advanced Accelerator Applications,NDA,208547,NA,NA,Powder,Intravenous,NA,NA,NA,NA,7/1/2015,6/1/2016,2016,NA,"NETSPOT, after radiolabeling with Ga 68, is indicated for use with positron emission tomography (PET) for localization of somatostatin receptor positive neuroendocrine tumors (NETs) in adult and pediatric patients.",Priority,Yes,No,No,No,No,No,No,NA,2015-07-01,2016-06-01,336,5.817111159963204,Post-FDASIA
Epclusa,sofosbuvir and velpatasvir,Gilead Sciences,NDA,208341,NA,NA,Tablet,Oral,NA,NA,NA,NA,10/28/2015,6/28/2016,2016,NA,"EPCLUSA is indicated for the treatment of adult patients with chronic hepatitis C virus (HCV) genotype 1, 2, 3, 4, 5 or 6 infection:
- without cirrhosis or with compensated cirrhosis
- with decompensated cirrhosis for use in combination with ribavirin",Priority,No,No,Yes,Yes,No,No,No,NA,2015-10-28,2016-06-28,244,5.497168225293202,Post-FDASIA
Xiidra,lifitegrast,Shire Development,NDA,208073,NA,NA,Solution/Drops,Ophthalmic,NA,NA,NA,NA,2/25/2015,7/11/2016,2016,NA,Xiidra (lifitegrast ophthalmic solution) 5% is indicated for the treatment of the signs and symptoms of dry eye disease (DED).,Priority,No,No,No,No,No,No,No,NA,2015-02-25,2016-07-11,502,6.218600119691729,Post-FDASIA
Adlyxin,lixisenatide,Sanofi,BLA,208471,NA,NA,Solution,Subcutaneous,NA,NA,NA,NA,7/27/2015,7/27/2016,2016,NA,"ADLYXIN is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Limitations of Use:
- ADLYXIN has not been studied in patients with chronic pancreatitis or a history of unexplained pancreatitis. Consider other antidiabetic therapies in patients with a history of pancreatitis.
- ADLYXIN is not a substitute for insulin. ADLYXIN is not indicated for use in patients with type 1 diabetes mellitus or for treatment of diabetic ketoacidosis.
- The concurrent use of ADLYXIN with short acting insulin has not been studied and is not recommended.
- ADLYXIN has not been studied in patients with gastroparesis and is not recommended in patients with gastroparesis.",Standard,No,No,No,No,N/A,No,No,Transition Product from NDA to BLA due to BPCI : Please see page 2 of data dictionary for more information.,2015-07-27,2016-07-27,366,5.902633333401366,Post-FDASIA
Exondys 51,eteplirsen,Sarepta Therapeutics,NDA,206488,NA,NA,Solution,Intravenous,NA,NA,NA,NA,6/26/2015,9/19/2016,2016,NA,EXONDYS 51 is indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping. This indication is approved under accelerated approval based on an increase in dystrophin in skeletal muscle observed in some patients treated with EXONDYS 51. A clinical benefit of EXONDYS 51 has not been established. Continued approval for this indication may be contingent upon verification of a clinical benefit in confirmatory trials.,Priority,Yes,Yes,No,Yes,No,RPD,No,NA,2015-06-26,2016-09-19,451,6.111467339502679,Post-FDASIA
Lartruvo,olaratumab,Eli Lilly,BLA,761038,NA,NA,Injectable,Injection,NA,NA,NA,NA,2/24/2016,10/19/2016,2016,NA,"LARTRUVO is indicated, in combination with doxorubicin, for the treatment of adult patients with soft tissue sarcoma (STS) with a histologic subtype for which an anthracycline-containing regimen is appropriate and which is not amenable to curative treatment with radiotherapy or surgery.
This indication is approved under accelerated approval. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trial.",Priority,Yes,Yes,Yes,Yes,N/A,No,No,NA,2016-02-24,2016-10-19,238,5.472270673671475,Post-FDASIA
Zinplava,bezlotoxumab,Merck,BLA,761046,NA,NA,Injectable,Injection,NA,NA,NA,NA,11/23/2015,10/21/2016,2016,NA,"ZINPLAVA is indicated to reduce recurrence of Clostridium difficile infection (CDI) in patients 18 years of age or older who are receiving antibacterial drug treatment of CDI and are at a high risk for CDI recurrence.
Limitation of Use:
ZINPLAVA is not indicated for the treatment of CDI. ZINPLAVA is not an antibacterial drug. ZINPLAVA should only be used in conjunction with antibacterial drug treatment of CDI.",Priority,No,No,No,Yes,N/A,No,No,NA,2015-11-23,2016-10-21,333,5.808142489980444,Post-FDASIA
Eucrisa,crisaborole,Anacor Pharmacueticals,NDA,207695,NA,NA,Ointment,Topical,NA,NA,NA,NA,1/7/2016,12/14/2016,2016,NA,EUCRISA is indicated for topical treatment of mild to moderate atopic dermatitis in patients 2 years of age and older.,Standard,No,No,No,No,No,No,No,NA,2016-01-07,2016-12-14,342,5.834810737062605,Post-FDASIA
Rubraca,rucaparib,Clovis Oncology,NDA,209115,NA,NA,Tablet,Oral,NA,NA,NA,NA,6/23/2016,12/19/2016,2016,NA,"Rubraca is indicated as monotherapy for the treatment of patients with deleterious BRCA mutation (germline and/or somatic) associated advanced ovarian cancer who have been treated with two or more chemotherapies. Select patients for therapy based on an FDA-approved companion diagnostic for Rubraca.
This indication is approved under accelerated approval based on objective response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.",Priority,Yes,Yes,Yes,No,No,No,No,NA,2016-06-23,2016-12-19,179,5.187385805840755,Post-FDASIA
Spinraza,nusinersen,Biogen,NDA,209531,NA,NA,Solution,Intrathecal,NA,NA,NA,NA,9/23/2016,12/23/2016,2016,NA,SPINRAZA is indicated for the treatment of spinal muscular atrophy (SMA) in pediatric and adult patients.,Priority,Yes,No,No,Yes,No,RPD,No,NA,2016-09-23,2016-12-23,91,4.51085950651685,Post-FDASIA
Trulance,plecanatide,Synergy Pharmaceuticals,NDA,208745,NA,NA,Tablet,Oral,NA,NA,NA,NA,1/29/2016,1/19/2017,2017,NA,TRULANCE is indicated in adults for the treatment of chronic idiopathic constipation (CIC).,Standard,No,No,No,No,No,No,No,NA,2016-01-29,2017-01-19,356,5.87493073085203,Post-FDASIA
Parsabiv,etelcalcetide,Amgen,NDA,208325,NA,NA,Solution,Intravenous,NA,NA,NA,NA,8/24/2015,2/7/2017,2017,NA,"PARSABIV is indicated for the treatment of secondary hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD) on hemodialysis.
Limitations of Use:
PARSABIV has not been studied in adult patients with parathyroid carcinoma, primary hyperparathyroidism, or with chronic kidney disease who are not on hemodialysis and is not recommended for use in these populations.",Standard,No,No,No,No,No,No,No,NA,2015-08-24,2017-02-07,533,6.278521424165844,Post-FDASIA
Emflaza,deflazacort,Marathon Pharmaceuticals,NDA,208684,208685,NA,Tablet,Oral,Solution,Oral,NA,NA,6/9/2016,2/9/2017,2017,NA,EMFLAZA is indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients 5 years of age and older.,Priority,Yes,No,No,Yes,No,RPD,No,NA,2016-06-09,2017-02-09,245,5.501258210544727,Post-FDASIA
Siliq,brodalumab,Valeant Pharmaceuticals,BLA,761032,NA,NA,Injectable,Injection,NA,NA,NA,NA,11/16/2015,2/15/2017,2017,NA,SILIQ is indicated for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy and have failed to respond or have lost response to other systemic therapies.,Standard,No,No,No,No,N/A,No,No,NA,2015-11-16,2017-02-15,457,6.124683390894205,Post-FDASIA
Xermelo,telotristat ethyl,Lexicon Pharmaceuticals,NDA,208794,NA,NA,Tablet,Oral,NA,NA,NA,NA,3/30/2016,2/28/2017,2017,NA,Xermelo is indicated for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog (SSA) therapy in adults inadequately controlled by SSA therapy.,Priority,Yes,No,No,Yes,No,No,No,NA,2016-03-30,2017-02-28,335,5.814130531825066,Post-FDASIA
Kisqali,ribociclib,Novartis Pharmaceuticals,NDA,209092,NA,NA,Tablet,Oral,NA,NA,NA,NA,8/29/2016,3/13/2017,2017,NA,"KISQALI is indicated in combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)- negative advanced or metastatic breast cancer.",Priority,No,No,Yes,No,No,No,No,NA,2016-08-29,2017-03-13,196,5.278114659230517,Post-FDASIA
Xadago,safinamide,Newron Pharmaceuticals,NDA,207145,NA,NA,Tablet,Oral,NA,NA,NA,NA,12/29/2014,3/21/2017,2017,NA,"XADAGO is indicated as adjunctive treatment to levodopa/carbidopa in patients with Parkinson’s disease (PD) experiencing “off” episodes.
Limitations of Use:
XADAGO has not been shown to be effective as monotherapy for the treatment of PD.",Standard,No,No,No,No,No,No,No,NA,2014-12-29,2017-03-21,813,6.70073110954781,Post-FDASIA
Bavencio,avelumab,EMD Serono,BLA,761049,NA,NA,Injectable,Injection,NA,NA,NA,NA,9/23/2016,3/23/2017,2017,NA,"BAVENCIO is indicated for the treatment of adults and pediatric patients 12 years and older with metastatic Merkel cell carcinoma (MCC).
This indication is approved under accelerated approval based on tumor response and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.",Priority,Yes,Yes,Yes,Yes,N/A,No,No,NA,2016-09-23,2017-03-23,181,5.198497031265826,Post-FDASIA
Symproic,naldemedine,Shionogi,NDA,208854,NA,NA,Tablet,Oral,NA,NA,NA,NA,3/23/2016,3/23/2017,2017,NA,Symproic is indicated for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain.,Standard,No,No,No,No,No,No,No,NA,2016-03-23,2017-03-23,365,5.8998973535824915,Post-FDASIA
Zejula,niraparib,Tesaro,NDA,208447,NA,NA,Capsule,Oral,NA,NA,NA,NA,10/31/2016,3/27/2017,2017,NA,"ZEJULA is indicated for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.",Priority,Yes,No,Yes,Yes,No,No,No,NA,2016-10-31,2017-03-27,147,4.990432586778736,Post-FDASIA
Ocrevus,ocrelizumab,Genentech,BLA,761053,NA,NA,Injectable,Injection,NA,NA,NA,NA,4/28/2016,3/28/2017,2017,NA,OCREVUS is indicated for the treatment of adult patients with relapsing or primary progressive forms of multiple sclerosis.,Priority,No,No,Yes,Yes,N/A,No,No,NA,2016-04-28,2017-03-28,334,5.811140992976701,Post-FDASIA
Dupixent,dupilumab,Regeneron Pharmaceuticals,BLA,761055,NA,NA,Injectable,Injection,NA,NA,NA,NA,7/29/2016,3/28/2017,2017,NA,DUPIXENT is indicated for the treatment of adult patients with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. DUPIXENT can be used with or without topical corticosteroids.,Priority,No,No,Yes,No,N/A,No,No,NA,2016-07-29,2017-03-28,242,5.488937726156687,Post-FDASIA
Austedo,deutetrabenazine,Teva Pharmaceuticals,NDA,208082,NA,NA,Tablet,Oral,NA,NA,NA,NA,5/29/2015,4/3/2017,2017,NA,AUSTEDO is indicated for the treatment of chorea associated with Huntington’s disease.,Standard,Yes,No,No,No,No,No,No,NA,2015-05-29,2017-04-03,675,6.51471269087253,Post-FDASIA
Ingrezza,valbenazine,Neurocrine Biosciences,NDA,209241,NA,NA,Capsule,Oral,NA,NA,NA,NA,8/11/2016,4/11/2017,2017,NA,INGREZZA is indicated for the treatment of adults with tardive dyskinesia.,Priority,No,No,Yes,Yes,No,No,No,NA,2016-08-11,2017-04-11,243,5.493061443340548,Post-FDASIA
Brineura,cerliponase alfa,BioMarin Pharmaceutical,BLA,761052,NA,NA,Injectable,Injection,NA,NA,NA,NA,5/27/2016,4/27/2017,2017,NA,"Brineura is indicated to slow the loss of ambulation in symptomatic pediatric patients 3 years of age and older with late infantile neuronal ceroid lipofuscinosis type 2 (CLN2), also known as tripeptidyl peptidase 1 (TPP1) deficiency.",Priority,Yes,No,Yes,No,N/A,RPD,No,NA,2016-05-27,2017-04-27,335,5.814130531825066,Post-FDASIA
Rydapt,midostaurin,Novartis Pharmaceuticals,NDA,207997,NA,NA,Capsule,Oral,NA,NA,NA,NA,8/29/2016,4/28/2017,2017,NA,"[A] RYDAPT is indicated, in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation chemotherapy, for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) who are FLT3 mutation-positive, as detected by a FDA approved test.
Limitations of Use:  RYDAPT is not indicated as a single-agent induction therapy for the treatment of patients with AML.
[B] RYDAPT is indicated for the treatment of adult patients with aggressive systemic mastocytosis (ASM), systemic mastocytosis with associated hematological neoplasm (SM-AHN), or mast cell leukemia (MCL).",Priority,Yes,No,Yes (indication [A] only),Yes (indication [B] only),No,No,No,NA,2016-08-29,2017-04-28,242,5.488937726156687,Post-FDASIA
Tymlos,abaloparatide,Radius Health,NDA,208743,NA,NA,Solution,Subcutaneous,NA,NA,NA,NA,3/30/2016,4/28/2017,2017,NA,"TYMLOS is indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture defined as a history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy. In postmenopausal women with osteoporosis, TYMLOS reduces the risk of vertebral fractures and nonvertebral fractures.
Limitations of Use:
Because of the unknown relevance of the rodent osteosarcoma findings to humans, cumulative use of TYMLOS and parathyroid hormone analogs (e.g., teriparatide) for more than 2 years during a patient’s lifetime is not recommended.",Standard,No,No,No,No,No,No,No,NA,2016-03-30,2017-04-28,394,5.976350909297934,Post-FDASIA
Alunbrig,brigatinib,Ariad Pharmaceuticals,NDA,208772,NA,NA,Tablet,Oral,NA,NA,NA,NA,8/29/2016,4/28/2017,2017,NA,"ALUNBRIG is indicated for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib.
This indication is approved under accelerated approval based on tumor response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.",Priority,Yes,Yes,Yes,No,No,No,No,NA,2016-08-29,2017-04-28,242,5.488937726156687,Post-FDASIA
Imfinzi,durvalumab,AstraZeneca UK Limited,BLA,761069,NA,NA,Injectable,Injection,NA,NA,NA,NA,10/13/2016,5/1/2017,2017,NA,"IMFINZI is indicated for the treatment of patients with locally advanced or metastatic urothelial carcinoma who:
- have disease progression during or following platinum-containing chemotherapy.
- have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.
This indication is approved under accelerated approval based on tumor response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.",Priority,No,Yes,Yes,No,N/A,No,No,NA,2016-10-13,2017-05-01,200,5.298317366548036,Post-FDASIA
Radicava,edaravone,Mitsubishi Tanabe Pharma Development,NDA,209176,NA,NA,Solution,Intravenous,NA,NA,NA,NA,6/16/2016,5/5/2017,2017,NA,RADICAVA is indicated for the treatment of amyotrophic lateral sclerosis (ALS).,Standard,Yes,No,No,No,No,No,No,NA,2016-06-16,2017-05-05,323,5.777652323222656,Post-FDASIA
Kevzara,sarilumab,Sanofi,BLA,761037,NA,NA,Injectable,Injection,NA,NA,NA,NA,10/30/2015,5/22/2017,2017,NA,KEVZARA is indicated for treatment of adult patients with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response or intolerance to one or more disease-modifying antirheumatic drugs (DMARDs).,Standard,No,No,No,No,N/A,No,No,NA,2015-10-30,2017-05-22,570,6.345636360828596,Post-FDASIA
Baxdela,delafloxacin,Melinta Therapeutics,NDA,208610,208611,NA,Tablet,Oral,Injectable,Injection,NA,NA,10/19/2016,6/19/2017,2017,NA,"BAXDELA is indicated in adults for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible isolates of the following:
Gram-positive organisms: Staphylococcus aureus (including methicillin-resistant [MRSA] and methicillinsusceptible [MSSA] isolates), Staphylococcus haemolyticus, Staphylococcus lugdunensis, Streptococcus agalactiae, Streptococcus anginosus Group (including Streptococcus anginosus, Streptococcus intermedius, and Streptococcus constellatus), Streptococcus pyogenes, and Enterococcus faecalis.
Gram-negative organisms: Escherichia coli, Enterobacter cloacae, Klebsiella pneumoniae, and Pseudomonas aeruginosa.
Usage:
To reduce the development of drug-resistant bacteria and maintain the effectiveness of BAXDELA and other antibacterial drugs, BAXDELA should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.",Priority,No,No,No,Yes,Yes,No,No,NA,2016-10-19,2017-06-19,243,5.493061443340548,Post-FDASIA
Bevyxxa,betrixaban,Portola Pharmaceuticals,NDA,208383,NA,NA,Capsule,Oral,NA,NA,NA,NA,10/24/2016,6/23/2017,2017,NA,"BEVYXXA is indicated for the prophylaxis of venous thromboembolism (VTE) in adult patients hospitalized for an acute medical illness who are at risk for thromboembolic complications due to moderate or severe restricted mobility and other risk factors for VTE.
Limitations of Use:
The safety and effectiveness of BEVYXXA have not been established in patients with prosthetic heart valves because this population has not been studied.",Priority,No,No,No,Yes,No,No,No,NA,2016-10-24,2017-06-23,242,5.488937726156687,Post-FDASIA
Tremfya,guselkumab,Janssen Biotech,BLA,761061,NA,NA,Injectable,Injection,NA,NA,NA,NA,11/16/2016,7/13/2017,2017,NA,TREMFYA is indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.,Priority (used priority review voucher),No,No,No,No,N/A,No,Yes,NA,2016-11-16,2017-07-13,239,5.476463551931511,Post-FDASIA
Nerlynx,neratinib,Puma Biotechnology,NDA,208051,NA,NA,Tablet,Oral,NA,NA,NA,NA,7/19/2016,7/17/2017,2017,NA,"NERLYNX is indicated for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, to follow adjuvant trastuzumab based therapy.",Standard,No,No,No,No,No,No,No,NA,2016-07-19,2017-07-17,363,5.8944028342648505,Post-FDASIA
Vosevi,"sofosbuvir, velpatasvir, voxilaprevir",Gilead Sciences,NDA,209195,NA,NA,Tablet,Oral,NA,NA,NA,NA,12/8/2016,7/18/2017,2017,NA,"VOSEVI is indicated for the treatment of adult patients with chronic hepatitis C virus (HCV) infection without cirrhosis or with compensated cirrhosis (Child-Pugh A) who have: 
- genotype 1, 2, 3, 4, 5, or 6 infection and have previously been treated with an HCV regimen containing an NS5A inhibitor. 
- genotype 1a or 3 infection and have previously been treated with an HCV regimen containing sofosbuvir without an NS5A inhibitor.
-- Additional benefit of VOSEVI over sofosbuvir/velpatasvir was not shown in adults with genotype 1b, 2, 4, 5, or 6 infection previously treated with sofosbuvir without an NS5A inhibitor.",Priority,No,No,No,No,No,No,No,NA,2016-12-08,2017-07-18,222,5.402677381872279,Post-FDASIA
Idhifa,enasidenib,Celgene,NDA,209606,NA,NA,Tablet,Oral,NA,NA,NA,NA,12/30/2016,8/1/2017,2017,NA,IDHIFA is indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA-approved test.,Priority,Yes,No,No,Yes,No,No,No,NA,2016-12-30,2017-08-01,214,5.365976015021851,Post-FDASIA
Mavyret,"glecaprevir, pibrentasvir",AbbVie,NDA,209394,NA,NA,Tablet,Oral,NA,NA,NA,NA,12/14/2016,8/3/2017,2017,NA,"MAVYRET is indicated for the treatment of adult patients with chronic hepatitis C virus (HCV) genotype 1, 2, 3, 4, 5 or 6 infection without cirrhosis or with compensated cirrhosis (Child-Pugh A). MAVYRET is also indicated for the treatment of adult patients with HCV genotype 1 infection, who previously have been treated with a regimen containing an HCV NS5A inhibitor or an NS3/4A protease inhibitor (PI), but not both.",Priority,No,No,Yes,Yes,No,No,No,NA,2016-12-14,2017-08-03,232,5.44673737166631,Post-FDASIA
Besponsa,inotuzumab ozogamicin,Pfizer,BLA,761040,NA,NA,Injectable,Injection,NA,NA,NA,NA,12/20/2016,8/17/2017,2017,NA,BESPONSA is indicated for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).,Priority,Yes,No,Yes,No,N/A,No,No,NA,2016-12-20,2017-08-17,240,5.480638923341991,Post-FDASIA
Vabomere,meropenem and vaborbactam,The Medicines Company,NDA,209776,NA,NA,Powder,Intravenous,NA,NA,NA,NA,12/29/2016,8/29/2017,2017,NA,"VABOMERE is indicated for the treatment of patients 18 years of age and older with complicated urinary tract infections (cUTI) including pyelonephritis caused by the following susceptible microorganisms: Escherichia coli, Klebsiella pneumoniae, and Enterobacter cloacae species complex.
Usage:
To reduce the development of drug-resistant bacteria and maintain the effectiveness of VABOMERE and other antibacterial drugs, VABOMERE should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.",Priority,No,No,No,Yes,Yes,No,No,NA,2016-12-29,2017-08-29,243,5.493061443340548,Post-FDASIA
[drug marketed without a proprietary name],benznidazole,"Chemo Research, S.L.",NDA,209570,NA,NA,Tablet,Oral,NA,NA,NA,NA,12/29/2016,8/29/2017,2017,NA,"Benznidazole Tablets are indicated in pediatric patients 2 to 12 years of age for the treatment of Chagas disease (American trypanosomiasis) caused by Trypanosoma cruzi.
This indication is approved under accelerated approval based on the number of treated patients who became Immunoglobulin G (IgG) antibody negative against the recombinant antigens of T. cruzi. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.",Priority,Yes,Yes,No,No,No,TD,No,NA,2016-12-29,2017-08-29,243,5.493061443340548,Post-FDASIA
Aliqopa,copanlisib,Bayer HealthCare Pharmaceuticals,NDA,209936,NA,NA,Powder,Intravenous,NA,NA,NA,NA,3/16/2017,9/14/2017,2017,NA,"ALIQOPA is indicated for the treatment of adult patients with relapsed follicular lymphoma (FL) who have received at least two prior systemic therapies. 
Accelerated approval was granted for this indication based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.",Priority,Yes,Yes,No,Yes,No,No,No,NA,2017-03-16,2017-09-14,182,5.204006687076795,Post-FDASIA
Solosec,secnidazole,Symbiomix Therapeutics,NDA,209363,NA,NA,Granule,Oral,NA,NA,NA,NA,1/17/2017,9/15/2017,2017,NA,"SOLOSEC is indicated for the treatment of bacterial vaginosis in adult women.
Usage:
To reduce the development of drug-resistant bacteria and maintain the effectiveness of SOLOSEC and other antibacterial drugs, SOLOSEC should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.",Priority,No,No,No,Yes,Yes,No,No,NA,2017-01-17,2017-09-15,241,5.484796933490655,Post-FDASIA
Verzenio,abemaciclib,Eli Lilly,NDA,208716,NA,NA,Tablet,Oral,NA,NA,NA,NA,5/5/2017,9/28/2017,2017,NA,"VERZENIO (abemaciclib) is indicated:
- in combination with fulvestrant for the treatment of women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer with disease progression following endocrine therapy.
- as monotherapy for the treatment of adult patients with HR-positive, HER2-negative advanced or metastatic breast cancer with disease progression following endocrine therapy and prior chemotherapy in the metastatic setting.",Priority,No,No,Yes,Yes,No,No,No,NA,2017-05-05,2017-09-28,146,4.983606621708336,Post-FDASIA
Calquence,acalabrutinib,Acerta Pharma B.V.,NDA,210259,NA,NA,Capsule,Oral,NA,NA,NA,NA,6/13/2017,10/31/2017,2017,NA,"CALQUENCE is indicated for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.
This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.",Priority,Yes,Yes,Yes,No,No,No,No,NA,2017-06-13,2017-10-31,140,4.941642422609304,Post-FDASIA
Vyzulta,latanoprostene bunod,Bausch & Lomb,NDA,207795,NA,NA,Solution/Drops,Ophthalmic,NA,NA,NA,NA,7/21/2015,11/2/2017,2017,NA,VYZULTA (latanoprostene bunod ophthalmic solution) 0.024% is indicated for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.,Standard,No,No,No,No,No,No,No,NA,2015-07-21,2017-11-02,835,6.727431724850855,Post-FDASIA
Prevymis,letermovir,Merck,NDA,209939,209940,NA,Tablet,Oral,Injectable,Injection,NA,NA,3/8/2017,11/8/2017,2017,NA,PREVYMIS is indicated for prophylaxis of cytomegalovirus (CMV) infection and disease in adult CMV-seropositive recipients [R+] of an allogeneic hematopoietic stem cell transplant (HSCT).,Priority,Yes,No,Yes,Yes,No,No,No,NA,2017-03-08,2017-11-08,245,5.501258210544727,Post-FDASIA
Fasenra,benralizumab,AstraZeneca Pharmaceuticals,BLA,761070,NA,NA,Injectable,Injection,NA,NA,NA,NA,11/16/2016,11/14/2017,2017,NA,"FASENRA is indicated for the add-on maintenance treatment of patients with severe asthma aged 12 years and older, and with an eosinophilic phenotype.
Limitations of use:
- FASENRA is not indicated for treatment of other eosinophilic conditions.
- FASENRA is not indicated for the relief of acute bronchospasm or status asthmaticus.",Standard,No,No,No,No,N/A,No,No,NA,2016-11-16,2017-11-14,363,5.8944028342648505,Post-FDASIA
Mepsevii,vestronidase alfa-vjbk,Ultragenyx Pharmaceutical,BLA,761047,NA,NA,Injectable,Injection,NA,NA,NA,NA,3/16/2017,11/15/2017,2017,NA,"MEPSEVII is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII (MPS VII, Sly syndrome).
Limitations of Use:
The effect of MEPSEVII on the central nervous system manifestations of MPS VII has not been determined.",Priority,Yes,No,No,Yes,N/A,RPD,No,NA,2017-03-16,2017-11-15,244,5.497168225293202,Post-FDASIA
Hemlibra,emicizumab-kxwh,Genentech,BLA,761083,NA,NA,Injectable,Injection,NA,NA,NA,NA,6/23/2017,11/16/2017,2017,NA,HEMLIBRA is indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients with hemophilia A (congenital factor VIII deficiency) with factor VIII inhibitors.,Priority,Yes,No,Yes,No,N/A,No,No,NA,2017-06-23,2017-11-16,146,4.983606621708336,Post-FDASIA
Ozempic,semaglutide,Novo Nordisk,NDA,209637,NA,NA,Solution,Subcutaneous,NA,NA,NA,NA,12/5/2016,12/5/2017,2017,NA,"OZEMPIC is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Limitations of Use:
- OZEMPIC is not recommended as a first-line therapy for patients who have inadequate glycemic control on diet and exercise because of the uncertain relevance of rodent C-cell tumor findings to humans.
- OZEMPIC has not been studied in patients with a history of pancreatitis. Consider other antidiabetic therapies in patients with a history of pancreatitis.
- OZEMPIC is not a substitute for insulin. OZEMPIC is not indicated for use in patients with type 1 diabetes mellitus or for the treatment of patients with diabetic ketoacidosis, as it would not be effective in these settings.",Standard,No,No,No,No,No,No,No,NA,2016-12-05,2017-12-05,365,5.8998973535824915,Post-FDASIA
Xepi,ozenoxacin,Ferrer Internacional S.A.,NDA,208945,NA,NA,Cream,Topical,NA,NA,NA,NA,6/23/2016,12/11/2017,2017,NA,XEPI is indicated for the topical treatment of impetigo due to Staphylococcus aureus or Streptococcus pyogenes in adult and pediatric patients 2 months of age and older.,Standard,No,No,No,No,No,No,No,NA,2016-06-23,2017-12-11,536,6.284134161070802,Post-FDASIA
Rhopressa,netarsudil,Aerie Pharmaceuticals,NDA,208254,NA,NA,Solution/Drops,Ophthalmic,NA,NA,NA,NA,2/28/2017,12/18/2017,2017,NA,RHOPRESSA (netarsudil ophthalmic solution) 0.02% is indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.,Standard,No,No,No,No,No,No,No,NA,2017-02-28,2017-12-18,293,5.680172609017068,Post-FDASIA
Steglatro,ertugliflozin,Merck Sharp & Dohme,NDA,209803,NA,NA,Tablet,Oral,NA,NA,NA,NA,12/19/2016,12/19/2017,2017,NA,"STEGLATRO is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Limitations of Use:
- STEGLATRO is not recommended in patients with type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis.",Standard,No,No,No,No,No,No,No,NA,2016-12-19,2017-12-19,365,5.8998973535824915,Post-FDASIA
Macrilen,macimorelin,Aeterna Zentaris GmBH,NDA,205598,NA,NA,For Solution,Oral,NA,NA,NA,NA,11/5/2013,12/20/2017,2017,NA,"MACRILEN is indicated for the diagnosis of adult growth hormone deficiency (AGHD).
Limitations of Use:
The safety and diagnostic performance of MACRILEN have not been established for subjects with a body mass index (BMI) > 40 kg/m2.",Standard,Yes,No,No,No,No,No,No,NA,2013-11-05,2017-12-20,1506,7.317212408359839,Post-FDASIA
Giapreza,angiotensin II,La Jolla Pharmaceuticals,NDA,209360,NA,NA,Solution,Intravenous,NA,NA,NA,NA,6/29/2017,12/21/2017,2017,NA,GIAPREZA increases blood pressure in adults with septic or other distributive shock.,Priority,No,No,No,No,No,No,No,NA,2017-06-29,2017-12-21,175,5.1647859739235145,Post-FDASIA
Lutathera,lutetium Lu 177 dotatate,Advanced Accelerator Applications,NDA,208700,NA,NA,Solution,Intravenous,NA,NA,NA,NA,4/28/2016,1/26/2018,2018,NA,"LUTATHERA is indicated for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut, and hindgut neuroendocrine tumors in adults.",Priority,Yes,No,No,Yes,No,No,No,NA,2016-04-28,2018-01-26,638,6.45833828334479,Post-FDASIA
Biktarvy,"bictegravir, emtricitabine, tenofovir alafenamide",Gilead Sciences,NDA,210251,NA,NA,Tablet,Oral,NA,NA,NA,NA,6/12/2017,2/7/2018,2018,NA,BIKTARVY is indicated as a complete regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults who have no antiretroviral treatment history or to replace the current antiretroviral regimen in those who are virologically-suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen for at least 3 months with no history of treatment failure and no known substitutions associated with resistance to the individual components of BIKTARVY.,Priority (used priority review voucher),No,No,No,No,No,No,Yes,NA,2017-06-12,2018-02-07,240,5.480638923341991,Post-FDASIA
Symdeko,"tezacaftor, ivacaftor; ivacaftor (co-packaged)",Vertex Pharmaceuticals,NDA,210491,NA,NA,"Tablet, Tablet",Oral,NA,NA,NA,NA,6/28/2017,2/12/2018,2018,NA,"SYMDEKO is indicated for the treatment of patients with cystic fibrosis (CF) aged 12 years and older who are homozygous for the F508del mutation or who have at least one mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that is responsive to tezacaftor/ivacaftor based on in vitro data and/or clinical evidence.
If the patient’s genotype is unknown, an FDA-cleared CF mutation test should be used to detect the presence of a CFTR mutation followed by verification with bi-directional sequencing when recommended by the mutation test instructions for use.",Priority,Yes,No,Yes,Yes,No,RPD,No,NA,2017-06-28,2018-02-12,229,5.43372200355424,Post-FDASIA
Erleada,apalutamide,Janssen Biotech,NDA,210951,NA,NA,Tablet,Oral,NA,NA,NA,NA,10/10/2017,2/14/2018,2018,NA,"ERLEADA is indicated for the treatment of patients with non-metastatic, castration-resistant prostate cancer (NM-CRPC).",Priority,No,No,No,Yes,No,No,No,NA,2017-10-10,2018-02-14,127,4.844187086458591,Post-FDASIA
Trogarzo,ibalizumab-uiyk,TaiMed Biologics,BLA,761065,NA,NA,Injectable,Injection,NA,NA,NA,NA,5/3/2017,3/6/2018,2018,NA,"TROGARZO, in combination with other antiretroviral(s), is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in heavily treatment-experienced adults with multidrug resistant HIV-1 infection failing their current antiretroviral regimen.",Priority,Yes,No,Yes,Yes,N/A,No,No,NA,2017-05-03,2018-03-06,307,5.726847747587197,Post-FDASIA
Ilumya,tildrakizumab-asmn,Merck Sharp & Dohme,BLA,761067,NA,NA,Injectable,Injection,NA,NA,NA,NA,3/23/2017,3/20/2018,2018,NA,ILUMYA is indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.,Standard,No,No,No,No,N/A,No,No,NA,2017-03-23,2018-03-20,362,5.8916442118257715,Post-FDASIA
Crysvita,burosumab-twza,Ultragenyx Pharmaceutical,BLA,761068,NA,NA,Injectable,Injection,NA,NA,NA,NA,8/17/2017,4/17/2018,2018,NA,CRYSVITA is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older.,Priority,Yes,No,Yes,Yes,N/A,RPD,No,NA,2017-08-17,2018-04-17,243,5.493061443340548,Post-FDASIA
Tavalisse,fostamatinib disodium hexahydrate,Rigel Pharmaceuticals,NDA,209299,NA,NA,Tablet,Oral,NA,NA,NA,NA,4/17/2017,4/17/2018,2018,NA,TAVALISSE is indicated for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment.,Standard,Yes,No,No,No,No,No,No,NA,2017-04-17,2018-04-17,365,5.8998973535824915,Post-FDASIA
Akynzeo,fosnetupitant and palonosetron,Helsinn Healthcare,NDA,210493,NA,NA,Powder,Intravenous,NA,NA,NA,NA,4/20/2017,4/19/2018,2018,NA,"AKYNZEO capsules is indicated in combination with dexamethasone in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy. AKYNZEO capsules is a combination of palonosetron and netupitant: palonosetron prevents nausea and vomiting during the acute phase and netupitant prevents nausea and vomiting during both the acute and delayed phase after cancer chemotherapy.
AKYNZEO for injection is indicated in combination with dexamethasone in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy. AKYNZEO for injection is a combination of palonosetron and fosnetupitant, a prodrug of netupitant: palonosetron prevents nausea and vomiting during the acute phase and fosnetupitant prevents nausea and vomiting during both the acute and delayed phase after cancer chemotherapy.
Limitations of Use:
AKYNZEO for injection has not been studied for the prevention of nausea and vomiting associated with anthracycline plus cyclophosphamide chemotherapy.",Standard,No,No,No,No,No,No,No,NA,2017-04-20,2018-04-19,364,5.8971538676367405,Post-FDASIA
Lucemyra,lofexidine,US World Meds,NDA,209229,NA,NA,Tablet,Oral,NA,NA,NA,NA,9/26/2017,5/16/2018,2018,NA,LUCEMYRA is indicated for mitigation of opioid withdrawal symptoms to facilitate abrupt opioid discontinuation in adults.,Priority,No,No,No,Yes,No,No,No,NA,2017-09-26,2018-05-16,232,5.44673737166631,Post-FDASIA
Aimovig,erenumab-aooe,Amgen,BLA,761077,NA,NA,Injectable,Injection,NA,NA,NA,NA,5/17/2017,5/17/2018,2018,NA,AIMOVIG is indicated for the preventive treatment of migraine in adults.,Standard,No,No,No,No,N/A,No,No,NA,2017-05-17,2018-05-17,365,5.8998973535824915,Post-FDASIA
Lokelma,sodium zirconium cyclosilicate,AstraZeneca Pharmaceuticals,NDA,207078,NA,NA,For Suspension,Oral,NA,NA,NA,NA,5/26/2015,5/18/2018,2018,NA,"LOKELMA is indicated for the treatment of hyperkalemia in adults.
Limitation of Use:
LOKELMA should not be used as an emergency treatment for life-threatening hyperkalemia because of its delayed onset of action.",Standard,No,No,No,No,No,No,No,NA,2015-05-26,2018-05-18,1088,6.992096427415888,Post-FDASIA
Doptelet,avatrombopag,Dova Pharmaceuticals,NDA,210238,NA,NA,Tablet,Oral,NA,NA,NA,NA,9/21/2017,5/21/2018,2018,NA,DOPTELET (avatrombopag) is indicated for the treatment of thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo a procedure.,Priority,No,No,No,No,No,No,No,NA,2017-09-21,2018-05-21,242,5.488937726156687,Post-FDASIA
Palynziq,pegvaliase-pqpz,BioMarin Pharmaceutical,BLA,761079,NA,NA,Injectable,Injection,NA,NA,NA,NA,6/30/2017,5/24/2018,2018,NA,Palynziq is indicated to reduce blood phenylalanine concentrations in adult patients with phenylketonuria (PKU) who have uncontrolled blood phenylalanine concentrations greater than 600 micromol/L on existing management.,Priority,Yes,No,No,Yes,N/A,No,No,NA,2017-06-30,2018-05-24,328,5.793013608384144,Post-FDASIA
Olumiant,baricitinib,Eli Lilly,NDA,207924,NA,NA,Tablet,Oral,NA,NA,NA,NA,1/15/2016,5/31/2018,2018,NA,"OLUMIANT (baricitinib) is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more tumor necrosis factor (TNF) antagonist therapies.
Limitation of Use: Use of OLUMIANT in combination with other JAK inhibitors, biologic disease-modifying antirheumatic drugs (DMARDs), or with potent immunosuppressants such as azathioprine and cyclosporine is not recommended.",Standard,No,No,No,No,No,No,No,NA,2016-01-15,2018-05-31,867,6.7650389767805414,Post-FDASIA
[drug marketed without a proprietary name],moxidectin,Medicines Development For Global Health,NDA,210867,NA,NA,Tablet,Oral,NA,NA,NA,NA,10/13/2017,6/13/2018,2018,NA,"Moxidectin Tablets are indicated for the treatment of onchocerciasis due to Onchocerca volvulus in patients aged 12 years and older.
Limitations of Use:
Moxidectin Tablets do not kill adult O. volvulus. Follow-up evaluation is advised.
The safety and efficacy of repeat administration of Moxidectin Tablets in patients with O. volvulus has not been studied.",Priority,Yes,No,No,No,No,TD,No,NA,2017-10-13,2018-06-13,243,5.493061443340548,Post-FDASIA
Zemdri,plazomicin,Achaogen,NDA,210303,NA,NA,Solution,Intravenous,NA,NA,NA,NA,10/25/2017,6/25/2018,2018,NA,"ZEMDRI is indicated in patients 18 years of age or older for the treatment of complicated urinary tract infections (cUTI), including pyelonephritis caused by the following susceptible microorganism(s): Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, and Enterobacter cloacae.
As only limited clinical safety and efficacy data for ZEMDRI are currently available, reserve ZEMDRI for use in cUTI patients who have limited or no alternative treatment options.
Usage:
To reduce the development of drug resistant bacteria and maintain the effectiveness of ZEMDRI and other antibacterial drugs, ZEMDRI should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.",Priority,No,No,No,No,Yes,No,No,NA,2017-10-25,2018-06-25,243,5.493061443340548,Post-FDASIA
Epidiolex,cannabidiol,GW Pharmaceuticals,NDA,210365,NA,NA,Solution,Oral,NA,NA,NA,NA,10/27/2017,6/25/2018,2018,NA,EPIDIOLEX is indicated for the treatment of seizures associated with [A] Lennox-Gastaut syndrome (LGS) or [B] Dravet syndrome (DS) in patients 2 years of age and older.,Priority,Yes,No,No,Yes (indication [B] only),No,RPD,No,NA,2017-10-27,2018-06-25,241,5.484796933490655,Post-FDASIA
Braftovi,encorafenib,Array Biopharma,NDA,210496,NA,NA,Capsule,Oral,NA,NA,NA,NA,6/30/2017,6/27/2018,2018,NA,"BRAFTOVI is indicated, in combination with binimetinib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test.
Limitations of Use: BRAFTOVI is not indicated for treatment of patients with wild-type BRAF melanoma.",Standard,Yes,No,No,No,No,No,No,NA,2017-06-30,2018-06-27,362,5.8916442118257715,Post-FDASIA
Mektovi,binimetinib,Array Biopharma,NDA,210498,NA,NA,Tablet,Oral,NA,NA,NA,NA,6/30/2017,6/27/2018,2018,NA,"MEKTOVI is indicated, in combination with encorafenib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test.",Standard,Yes,No,No,No,No,No,No,NA,2017-06-30,2018-06-27,362,5.8916442118257715,Post-FDASIA
Tpoxx,tecovirimat,SIGA Technologies,NDA,208627,NA,NA,Capsule,Oral,NA,NA,NA,NA,12/8/2017,7/13/2018,2018,NA,"TPOXX is indicated for the treatment of human smallpox disease caused by variola virus in adults and pediatric patients weighing at least 13 kg.
Limitations of Use:
The effectiveness of TPOXX for treatment of smallpox disease has not been determined in humans because adequate and well-controlled field trials have not been feasible, and inducing smallpox disease in humans to study the drug’s efficacy is not ethical.
TPOXX efficacy may be reduced in immunocompromised patients based on studies demonstrating reduced efficacy in immunocompromised animal models.",Priority,Yes,No,No,Yes,No,MTMC,No,NA,2017-12-08,2018-07-13,217,5.37989735354046,Post-FDASIA
Krintafel,tafenoquine,GlaxoSmithKline,NDA,210795,NA,NA,Tablet,Oral,NA,NA,NA,NA,11/22/2017,7/20/2018,2018,NA,"KRINTAFEL is indicated for the radical cure (prevention of relapse) of Plasmodium vivax malaria in patients aged 16 years and older who are receiving appropriate antimalarial therapy for acute P. vivax infection.
Limitation of Use:
KRINTAFEL is NOT indicated for the treatment of acute P. vivax malaria.",Priority,Yes,No,Yes,No,No,TD,No,NA,2017-11-22,2018-07-20,240,5.480638923341991,Post-FDASIA
Tibsovo,ivosidenib,Agios Pharmaceuticals,NDA,211192,NA,NA,Tablet,Oral,NA,NA,NA,NA,12/21/2017,7/20/2018,2018,NA,TIBSOVO is indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test.,Priority,Yes,No,No,Yes,No,No,No,NA,2017-12-21,2018-07-20,211,5.351858133476067,Post-FDASIA
Orilissa,elagolix,AbbVie,NDA,210450,NA,NA,Tablet,Oral,NA,NA,NA,NA,8/23/2017,7/23/2018,2018,NA,ORILISSA is indicated for the management of moderate to severe pain associated with endometriosis.,Priority,No,No,No,No,No,No,No,NA,2017-08-23,2018-07-23,334,5.811140992976701,Post-FDASIA
Omegaven,fish oil triglycerides,Fresenius Kabi,NDA,210589,NA,NA,Emulsion,Intravenous,NA,NA,NA,NA,12/1/2017,7/27/2018,2018,NA,"Omegaven is indicated as a source of calories and fatty acids in pediatric patients with parenteral nutrition-associated cholestasis (PNAC).
Limitations of Use:
- Omegaven is not indicated for the prevention of PNAC. It has not been demonstrated that Omegaven prevents PNAC in parenteral nutrition (PN)-dependent patients.
- It has not been demonstrated that the clinical outcomes observed in patients treated with Omegaven are a result of the omega-6:omega-3 fatty acid ratio of the product.",Priority,Yes,No,No,Yes,No,No,No,NA,2017-12-01,2018-07-27,238,5.472270673671475,Post-FDASIA
Mulpleta,lusutrombopag,Shionogi,NDA,210923,NA,NA,Tablet,Oral,NA,NA,NA,NA,12/26/2017,7/31/2018,2018,NA,MULPLETA is indicated for the treatment of thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo a procedure.,Priority,No,No,No,Yes,No,No,No,NA,2017-12-26,2018-07-31,217,5.37989735354046,Post-FDASIA
Poteligeo,mogamulizumab-kpkc,Kyowa Kirin Pharmaceutical Development,BLA,761051,NA,NA,Injectable,Injection,NA,NA,NA,NA,10/4/2017,8/8/2018,2018,NA,POTELIGEO is indicated for the treatment of adult patients with relapsed or refractory mycosis fungoides (MF) or Sezary syndrome (SS) after at least one prior systemic therapy.,Priority,Yes,No,Yes,No,N/A,No,No,NA,2017-10-04,2018-08-08,308,5.730099782973574,Post-FDASIA
Galafold,migalastat,Amicus Therapeutics,NDA,208623,NA,NA,Capsule,Oral,NA,NA,NA,NA,12/13/2017,8/10/2018,2018,NA,"GALAFOLD is indicated for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene (GLA) variant based on in vitro assay data.
This indication is approved under accelerated approval based on reduction in kidney interstitial capillary cell globotriaosylceramide (KIC GL-3) substrate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.",Priority,Yes,Yes,No,Yes,No,No,No,NA,2017-12-13,2018-08-10,240,5.480638923341991,Post-FDASIA
Annovera,"segesterone acetate, ethinyl estradiol",The Population Council,NDA,209627,NA,NA,Ring,Vaginal,NA,NA,NA,NA,8/17/2017,8/10/2018,2018,NA,"ANNOVERA is indicated for use by females of reproductive potential to prevent pregnancy.
Limitation of Use:
ANNOVERA has not been adequately studied in females with a BMI >29 kg/m2.",Standard,No,No,No,No,No,No,No,NA,2017-08-17,2018-08-10,358,5.8805329864007,Post-FDASIA
Onpattro,patisiran,Alnylam Pharmaceuticals,NDA,210922,NA,NA,Solution,Intravenous,NA,NA,NA,NA,12/11/2017,8/10/2018,2018,NA,ONPATTRO is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.,Priority,Yes,No,Yes,Yes,No,No,No,NA,2017-12-11,2018-08-10,242,5.488937726156687,Post-FDASIA
Diacomit,stiripentol,Biocodex SA,NDA,206709,207223,NA,Capsule,Oral,Suspension,Oral,NA,NA,12/20/2017,8/20/2018,2018,NA,DIACOMIT is indicated for the treatment of seizures associated with Dravet syndrome (DS) in patients 2 years of age and older taking clobazam. There are no clinical data to support the use of DIACOMIT as monotherapy in Dravet syndrome.,Priority,Yes,No,No,No,No,No,No,NA,2017-12-20,2018-08-20,243,5.493061443340548,Post-FDASIA
Oxervate,cenegermin-bkbj,Dompé farmaceutici S.p.A.,BLA,761094,NA,NA,Solution/Drops,Ophthalmic,NA,NA,NA,NA,12/22/2017,8/22/2018,2018,NA,OXERVATE (cenegermin-bkbj) ophthalmic solution 0.002% is indicated for the treatment of neurotrophic keratitis.,Priority,Yes,No,Yes,Yes,N/A,No,No,NA,2017-12-22,2018-08-22,243,5.493061443340548,Post-FDASIA
Takhzyro,lanadelumab-flyo,Dyax Corporation,BLA,761090,NA,NA,Injectable,Injection,NA,NA,NA,NA,12/26/2017,8/23/2018,2018,NA,TAKHZYRO is indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in patients 12 years and older.,Priority,Yes,No,Yes,Yes,N/A,No,No,NA,2017-12-26,2018-08-23,240,5.480638923341991,Post-FDASIA
Xerava,eravacycline,Tetraphase Pharmaceuticals,NDA,211109,NA,NA,Powder,Intravenous,NA,NA,NA,NA,12/28/2017,8/27/2018,2018,NA,"XERAVA is indicated for the treatment of complicated intra-abdominal infections (cIAI) caused by susceptible microorganisms: Escherichia coli, Klebsiella pneumoniae, Citrobacter freundii, Enterobacter cloacae, Klebsiella oxytoca, Enterococcus faecalis, Enterococcus faecium, Staphylococcus aureus, Streptococcus anginosus group, Clostridium perfringens, Bacteroides species, and Parabacteroides distasonis in patients 18 years or older.
Limitations of Use:
XERAVA is not indicated for the treatment of complicated urinary tract infections (cUTI).
Usage:
To reduce the development of drug-resistant bacteria and maintain the effectiveness of XERAVA and other antibacterial drugs, XERAVA should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.",Priority,No,No,No,Yes,Yes,No,No,NA,2017-12-28,2018-08-27,242,5.488937726156687,Post-FDASIA
Pifeltro,doravirine,Merck Sharp & Dohme,NDA,210806,NA,NA,Tablet,Oral,NA,NA,NA,NA,10/23/2017,8/30/2018,2018,NA,PIFELTRO is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in adult patients with no prior antiretroviral treatment history.,Standard,No,No,No,No,No,No,No,NA,2017-10-23,2018-08-30,311,5.739792912179234,Post-FDASIA
Lumoxiti,moxetumomab pasudotox-tdfk,AstraZeneca Pharmaceuticals,BLA,761104,NA,NA,Injectable,Injection,NA,NA,NA,NA,1/29/2018,9/13/2018,2018,NA,"LUMOXITI is indicated for the treatment of adult patients with relapsed or refractory hairy cell leukemia (HCL) who received at least two prior systemic therapies, including treatment with a purine nucleoside analog (PNA).
Limitations of Use:
LUMOXITI is not recommended in patients with severe renal impairment (CrCl = 29 mL/min).",Priority,Yes,No,No,Yes,N/A,No,No,NA,2018-01-29,2018-09-13,227,5.424950017481403,Post-FDASIA
Ajovy,fremanezumab-vfrm,Teva Pharmaceuticals,BLA,761089,NA,NA,Injectable,Injection,NA,NA,NA,NA,10/16/2017,9/14/2018,2018,NA,AJOVY is indicated for the preventive treatment of migraine in adults.,Priority (used priority review voucher),No,No,No,No,N/A,No,Yes,NA,2017-10-16,2018-09-14,333,5.808142489980444,Post-FDASIA
Copiktra,duvelisib,Verastem,NDA,211155,NA,NA,Capsule,Oral,NA,NA,NA,NA,2/5/2018,9/24/2018,2018,NA,"[A] COPIKTRA is indicated for the treatment of adult patients with relapsed or refractory CLL or SLL after at least two prior therapies.
[B] COPIKTRA is indicated for the treatment of adult patients with relapsed or refractory FL after at least two prior systemic therapies.
This indication is approved under accelerated approval based on overall response rate (ORR); continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.",Priority,Yes,Yes (indication [B] only),No,Yes,No,No,No,NA,2018-02-05,2018-09-24,231,5.442417710521793,Post-FDASIA
Emgality,galcanezumab-gnlm,Eli Lilly,BLA,761063,NA,NA,Injectable,Injection,NA,NA,NA,NA,9/27/2017,9/27/2018,2018,NA,EMGALITY is indicated for the preventive treatment of migraine in adults.,Standard,No,No,No,No,N/A,No,No,NA,2017-09-27,2018-09-27,365,5.8998973535824915,Post-FDASIA
Vizimpro,dacomitinib,Pfizer,NDA,211288,NA,NA,Tablet,Oral,NA,NA,NA,NA,1/31/2018,9/27/2018,2018,NA,VIZIMPRO is indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution mutations as detected by an FDA-approved test.,Priority,Yes,No,No,No,No,No,No,NA,2018-01-31,2018-09-27,239,5.476463551931511,Post-FDASIA
Libtayo,cemiplimab-rwlc,Regeneron Pharmaceuticals,BLA,761097,NA,NA,Injectable,Injection,NA,NA,NA,NA,2/28/2018,9/28/2018,2018,NA,LIBTAYO is indicated for the treatment of patients with metastatic cutaneous squamous cell carcinoma (CSCC) or locally advanced CSCC who are not candidates for curative surgery or curative radiation.,Priority,No,No,Yes,No,N/A,No,No,NA,2018-02-28,2018-09-28,212,5.356586274672012,Post-FDASIA
Seysara,sarecycline,Allergan,NDA,209521,NA,NA,Tablet,Oral,NA,NA,NA,NA,10/20/2017,10/1/2018,2018,NA,"SEYSARA (sarecycline) tablet, is indicated for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients 9 years of age and older.
Limitations of Use:
Efficacy of SEYSARA beyond 12 weeks and safety beyond 12 months have not been established. SEYSARA has not been evaluated in the treatment of infections.
To reduce the development of drug-resistant bacteria as well as to maintain the effectiveness of other antibacterial drugs, SEYSARA should be used only as indicated.",Standard,No,No,No,No,No,No,No,NA,2017-10-20,2018-10-01,346,5.846438775057725,Post-FDASIA
Nuzyra,omadacycline,Paratek Pharmacueticals,NDA,209816,209817,NA,Tablet,Oral,Injectable,Injection,NA,NA,2/2/2018,10/2/2018,2018,NA,"NUZYRA is indicated for the treatment of adult patients with community-acquired bacterial pneumonia (CABP) caused by the following susceptible microorganisms: Streptococcus pneumoniae, Staphylococcus aureus (methicillin-susceptible isolates), Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, Legionella pneumophila, Mycoplasma pneumoniae, and Chlamydophila pneumoniae.
NUZYRA is indicated for the treatment of adult patients with acute bacterial skin and skin structure infections (ABSSSI) caused by the following susceptible microorganisms: Staphylococcus aureus (methicillin-susceptible and -resistant isolates), Staphylococcus lugdunensis, Streptococcus pyogenes, Streptococcus anginosus grp. (includes S. anginosus, S. intermedius, and S. constellatus), Enterococcus faecalis, Enterobacter cloacae, and Klebsiella pneumoniae.
Usage:
To reduce the development of drug-resistant bacteria and maintain the effectiveness of NUZYRA and other antibacterial drugs, NUZYRA should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.",Priority,No,No,No,Yes,Yes,No,No,NA,2018-02-02,2018-10-02,242,5.488937726156687,Post-FDASIA
Revcovi,elapegademase-lvlr,Leadiant Biosciences,BLA,761092,NA,NA,Injectable,Injection,NA,NA,NA,NA,10/24/2017,10/5/2018,2018,NA,REVCOVI is indicated for the treatment of adenosine deaminase severe combined immune deficiency (ADA-SCID) in pediatric and adult patients.,Priority,Yes,No,No,Yes,N/A,RPD,No,NA,2017-10-24,2018-10-05,346,5.846438775057725,Post-FDASIA
Tegsedi,inotersen,Ionis Pharmaceuticals,NDA,211172,NA,NA,Solution,Subcutaneous,NA,NA,NA,NA,11/6/2017,10/5/2018,2018,NA,TEGSEDI is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.,Priority,Yes,No,No,Yes,No,No,No,NA,2017-11-06,2018-10-05,333,5.808142489980444,Post-FDASIA
Talzenna,talazoparib,Pfizer,NDA,211651,NA,NA,Capsule,Oral,NA,NA,NA,NA,4/6/2018,10/16/2018,2018,NA,TALZENNA is indicated for the treatment of adult patients with deleterious or suspected deleterious germline breast cancer susceptibility gene (BRCA)-mutated (gBRCAm) human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer. Select patients for therapy based on an FDA-approved companion diagnostic for TALZENNA.,Priority,No,No,No,No,No,No,No,NA,2018-04-06,2018-10-16,193,5.262690188904886,Post-FDASIA
Xofluza,baloxavir marboxil,Shionogi,NDA,210854,NA,NA,Tablet,Oral,NA,NA,NA,NA,4/24/2018,10/24/2018,2018,NA,"XOFLUZA is indicated for the treatment of acute uncomplicated influenza in patients 12 years of age and older who have been symptomatic for no more than 48 hours.
Limitations of Use:
Influenza viruses change over time, and factors such as the virus type or subtype, emergence of resistance, or changes in viral virulence could diminish the clinical benefit of antiviral drugs. Consider available information on drug susceptibility patterns for circulating influenza virus strains when deciding whether to use XOFLUZA.",Priority,No,No,No,No,No,No,No,NA,2018-04-24,2018-10-24,183,5.209486152841421,Post-FDASIA
Lorbrena,lorlatinib,Pfizer,NDA,210868,NA,NA,Tablet,Oral,NA,NA,NA,NA,12/5/2017,11/2/2018,2018,NA,"LORBRENA is indicated for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) whose disease has progressed on
- crizotinib and at least one other ALK inhibitor for metastatic disease; or
- alectinib as the first ALK inhibitor therapy for metastatic disease; or
- ceritinib as the first ALK inhibitor therapy for metastatic disease.
This indication is approved under accelerated approval based on tumor response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.",Priority,Yes,Yes,Yes,No,No,No,No,NA,2017-12-05,2018-11-02,332,5.805134968916488,Post-FDASIA
Yupelri,revefenacin,Theravance Biopharma,NDA,210598,NA,NA,Solution,Inhalation,NA,NA,NA,NA,11/13/2017,11/9/2018,2018,NA,YUPELRI (revefenacin) inhalation solution is indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).,Standard,No,No,No,No,No,No,No,NA,2017-11-13,2018-11-09,361,5.8888779583328805,Post-FDASIA
Aemcolo,rifamycin,Cosmo Technologies,NDA,210910,NA,NA,"Tablet, Delayed Release",Oral,NA,NA,NA,NA,3/16/2018,11/16/2018,2018,NA,"AEMCOLO is indicated for the treatment of travelers’ diarrhea (TD) caused by non-invasive strains of Escherichia coli in adults.
Limitations of Use:
AEMCOLO is not indicated in patients with diarrhea complicated by fever or bloody stool or due to pathogens other than noninvasive strains of Escherichia coli.
Usage:
To reduce the development of drug-resistant bacteria and maintain the effectiveness of AEMCOLO and other antibacterial drugs, AEMCOLO should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.",Priority,No,No,No,Yes,Yes,No,No,NA,2018-03-16,2018-11-16,245,5.501258210544727,Post-FDASIA
Gamifant,emapalumab-lzsg,Novimmune S.A.,BLA,761107,NA,NA,Injectable,Injection,NA,NA,NA,NA,3/20/2018,11/20/2018,2018,NA,"GAMIFANT is indicated for the treatment of adult and pediatric (newborn and older) patients with primary hemophagocytic lymphohistiocytosis (HLH) with refractory, recurrent or progressive disease or intolerance with conventional HLH therapy.",Priority,Yes,No,Yes,No,N/A,RPD,No,NA,2018-03-20,2018-11-20,245,5.501258210544727,Post-FDASIA
Daurismo,glasdegib,Pfizer,NDA,210656,NA,NA,Tablet,Oral,NA,NA,NA,NA,4/27/2018,11/21/2018,2018,NA,"DAURISMO is indicated, in combination with low-dose cytarabine, for the treatment of newly-diagnosed acute myeloid leukemia (AML) in adult patients who are >75 years old or who have comorbidities that preclude use of intensive induction chemotherapy.
Limitation of Use: DAURISMO has not been studied in patients with the comorbidities of severe renal impairment or moderate-to-severe hepatic impairment.",Priority,Yes,No,No,No,No,No,No,NA,2018-04-27,2018-11-21,208,5.337538079701318,Post-FDASIA
Vitrakvi,larotrectinib,Loxo Oncology,NDA,210861,211710,NA,Capsule,Oral,Solution,Oral,NA,NA,3/26/2018,11/26/2018,2018,NA,"VITRAKVI is indicated for the treatment of adult and pediatric patients with solid tumors that:
- have a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a known acquired resistance mutation,
- are metastatic or where surgical resection is likely to result in severe morbidity, and
- have no satisfactory alternative treatments or that have progressed following treatment.
This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.",Priority,Yes,Yes,Yes,No,No,No,No,NA,2018-03-26,2018-11-26,245,5.501258210544727,Post-FDASIA
Firdapse,amifampridine,Catalyst Pharmaceuticals,NDA,208078,NA,NA,Tablet,Oral,NA,NA,NA,NA,3/28/2018,11/28/2018,2018,NA,FIRDAPSE is indicated for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in adults.,Priority,Yes,No,Yes,No,No,No,No,NA,2018-03-28,2018-11-28,245,5.501258210544727,Post-FDASIA
Xospata,gilteritinib,Astellas Pharma,NDA,211349,NA,NA,Tablet,Oral,NA,NA,NA,NA,3/29/2018,11/28/2018,2018,NA,XOSPATA is indicated for the treatment of adult patients who have relapsed or refractory acute myeloid leukemia (AML) with a FMS-like tyrosine kinase 3 (FLT3) mutation as detected by an FDA-approved test.,Priority,Yes,No,No,Yes,No,No,No,NA,2018-03-29,2018-11-28,244,5.497168225293202,Post-FDASIA
Motegrity,prucalopride,Shire Development,NDA,210166,NA,NA,Tablet,Oral,NA,NA,NA,NA,12/21/2017,12/14/2018,2018,NA,MOTEGRITY is indicated for the treatment of chronic idiopathic constipation (CIC) in adults.,Standard,No,No,No,No,No,No,No,NA,2017-12-21,2018-12-14,358,5.8805329864007,Post-FDASIA
Asparlas,calaspargase pegol-mknl,Servier Pharmaceuticals,BLA,761102,NA,NA,Injectable,Injection,NA,NA,NA,NA,12/22/2017,12/20/2018,2018,NA,ASPARLAS is indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia in pediatric and young adult patients age 1 month to 21 years.,Standard,Yes,No,No,No,N/A,No,No,NA,2017-12-22,2018-12-20,363,5.8944028342648505,Post-FDASIA
Ultomiris,ravulizumab-cwvz,Alexion Pharmaceuticals,BLA,761108,NA,NA,Injectable,Injection,NA,NA,NA,NA,6/18/2018,12/21/2018,2018,NA,ULTOMIRIS is indicated for the treatment of adult patients with paroxysmal nocturnal hemoglobinuria (PNH).,Priority (used priority review voucher),Yes,No,No,No,N/A,No,Yes,NA,2018-06-18,2018-12-21,186,5.225746673713202,Post-FDASIA
Elzonris,tagraxofusp-erzs,Stemline Therapeutics,BLA,761116,NA,NA,Injectable,Injection,NA,NA,NA,NA,6/21/2018,12/21/2018,2018,NA,ELZONRIS is a CD123-directed cytotoxin for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in adults and in pediatric patients 2 years and older.,Priority,Yes,No,Yes,No,N/A,No,No,NA,2018-06-21,2018-12-21,183,5.209486152841421,Post-FDASIA
Jeuveau,prabotulinumtoxinA-xvfs,Evolus,BLA,761085,NA,NA,Injectable,Injection,NA,NA,NA,NA,5/15/2017,2/1/2019,2019,NA,JEUVEAU is indicated for the temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adult patients.,Standard,No,No,No,No,N/A,No,No,NA,2017-05-15,2019-02-01,627,6.440946540632921,Post-FDASIA
Cablivi,caplacizumab-yhdp,Ablynx NV,BLA,761112,NA,NA,Injectable,Injection,NA,NA,NA,NA,6/6/2018,2/6/2019,2019,NA,"CABLIVI is indicated for the treatment of adult patients with acquired thrombotic thrombocytopenic purpura (aTTP), in combination with plasma exchange and immunosuppressive therapy.",Priority,Yes,No,No,Yes,N/A,No,No,NA,2018-06-06,2019-02-06,245,5.501258210544727,Post-FDASIA
Egaten,triclabendazole,Novartis Pharmaceuticals,NDA,208711,NA,NA,Tablet,Oral,NA,NA,NA,NA,6/14/2018,2/13/2019,2019,NA,EGATEN is indicated for the treatment of fascioliasis in patients 6 years of age and older.,Priority,Yes,No,No,Yes,No,TD,No,NA,2018-06-14,2019-02-13,244,5.497168225293202,Post-FDASIA
Zulresso,brexanolone,Sage Therapeutics,NDA,211371,NA,NA,Solution,Intravenous,NA,NA,NA,NA,4/19/2018,3/19/2019,2019,NA,ZULRESSO is indicated for the treatment of postpartum depression (PPD) in adults.,Priority,No,No,Yes,No,No,No,No,NA,2018-04-19,2019-03-19,334,5.811140992976701,Post-FDASIA
Sunosi,solriamfetol,Jazz Pharmaceuticals,NDA,211230,NA,NA,Tablet,Oral,NA,NA,NA,NA,12/20/2017,3/20/2019,2019,NA,"SUNOSI is indicated to improve wakefulness in adult patients with excessive daytime sleepiness associated with [A] narcolepsy or [B] obstructive sleep apnea (OSA).
Limitations of use:
SUNOSI is not indicated to treat the underlying airway obstruction in OSA. Ensure that the underlying airway obstruction is treated (e.g., with continuous positive airway pressure (CPAP)) for at least one month prior to initiating SUNOSI for excessive daytime sleepiness. Modalities to treat the underlying airway obstruction should be continued during treatment with SUNOSI.
SUNOSI is not a substitute for these modalities.",Standard,Yes (indication [A] only),No,No,No,No,No,No,NA,2017-12-20,2019-03-20,455,6.12029741895095,Post-FDASIA
Mayzent,siponimod,Novartis Pharmaceuticals,NDA,209884,NA,NA,Tablet,Oral,NA,NA,NA,NA,7/26/2018,3/26/2019,2019,NA,"MAYZENT is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.",Priority (used priority review voucher),No,No,No,No,No,No,Yes,NA,2018-07-26,2019-03-26,243,5.493061443340548,Post-FDASIA
Evenity,romosozumab-aqqg,Amgen,BLA,761062,NA,NA,Injectable,Injection,NA,NA,NA,NA,7/19/2016,4/9/2019,2019,NA,"EVENITY is indicated for the treatment of osteoporosis in postmenopausal women at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy.
Limitations of Use:
The anabolic effect of EVENITY wanes after 12 monthly doses of therapy. Therefore, the duration of EVENITY use should be limited to 12 monthly doses. If osteoporosis therapy remains warranted, continued therapy with an anti-resorptive agent should be considered.",Standard,No,No,No,No,N/A,No,No,NA,2016-07-19,2019-04-09,994,6.901737206656574,Post-FDASIA
Balversa,erdafitinib,Janssen Biotech,NDA,212018,NA,NA,Tablet,Oral,NA,NA,NA,NA,9/18/2018,4/12/2019,2019,NA,"BALVERSA is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (mUC), that has:
- susceptible FGFR3 or FGFR2 genetic alterations, and
- progressed during or following at least one line of prior platinum-containing chemotherapy, including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy.
Select patients for therapy based on an FDA-approved companion diagnostic for BALVERSA. 
This indication is approved under accelerated approval based on tumor response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.",Priority,No,Yes,Yes,No,No,No,No,NA,2018-09-18,2019-04-12,206,5.327876168789581,Post-FDASIA
Skyrizi,risankizumab-rzaa,AbbVie,BLA,761105,NA,NA,Injectable,Injection,NA,NA,NA,NA,4/23/2018,4/23/2019,2019,NA,SKYRIZI is indicated for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.,Standard,No,No,No,No,N/A,No,No,NA,2018-04-23,2019-04-23,365,5.8998973535824915,Post-FDASIA
Vyndaqel,tafamidis meglumine,Pfizer,NDA,211996,NA,NA,Capsule,Oral,NA,NA,NA,NA,11/2/2018,5/3/2019,2019,NA,VYNDAQEL is indicated for the treatment of the cardiomyopathy of wild type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular mortality and cardiovascular-related hospitalization.,Priority,Yes,No,Yes,Yes,No,No,No,NA,2018-11-02,2019-05-03,182,5.204006687076795,Post-FDASIA
Piqray,alpelisib,Novartis Pharmaceuticals,NDA,212526,NA,NA,Tablet,Oral,NA,NA,NA,NA,12/18/2018,5/24/2019,2019,NA,"PIQRAY is indicated in combination with fulvestrant for the treatment of postmenopausal women, and men, with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer as detected by an FDA-approved test following progression on or after an endocrine-based regimen.",Priority,No,No,No,No,No,No,No,NA,2018-12-18,2019-05-24,157,5.056245805348308,Post-FDASIA
Polivy,polatuzumab vedotin-piiq,Genentech,BLA,761121,NA,NA,Injectable,Injection,NA,NA,NA,NA,12/19/2018,6/10/2019,2019,NA,"POLIVY in combination with bendamustine and a rituximab product is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, after at least two prior therapies.
Accelerated approval was granted for this indication based on complete response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.",Priority,Yes,Yes,Yes,No,N/A,No,No,NA,2018-12-19,2019-06-10,173,5.153291594497779,Post-FDASIA
Vyleesi,bremelanotide,AMAG Pharmaceuticals,NDA,210557,NA,NA,Solution,Subcutaneous,NA,NA,NA,NA,3/23/2018,6/21/2019,2019,NA,"VYLEESI is indicated for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD), as characterized by low sexual desire that causes marked distress or interpersonal difficulty and is NOT due to:
- A co-existing medical or psychiatric condition,
- Problems with the relationship, or
- The effects of a medication or drug substance.
Acquired HSDD refers to HSDD that develops in a patient who previously had no problems with sexual desire.
Generalized HSDD refers to HSDD that occurs regardless of the type of stimulation, situation or partner.
Limitations of Use:
- VYLEESI is not indicated for the treatment of HSDD in postmenopausal women or in men.
- VYLEESI is not indicated to enhance sexual performance.",Standard,No,No,No,No,No,No,No,NA,2018-03-23,2019-06-21,455,6.12029741895095,Post-FDASIA
Xpovio,selinexor,Karyopharm Therapeutics,NDA,212306,NA,NA,Tablet,Oral,NA,NA,NA,NA,8/6/2018,7/3/2019,2019,NA,"XPOVIO is indicated in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma (RRMM) who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti-CD38 monoclonal antibody.
This indication is approved under accelerated approval based on response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.",Priority,Yes,Yes,No,Yes,No,No,No,NA,2018-08-06,2019-07-03,331,5.802118375377063,Post-FDASIA
Recarbrio,"imipenem, cilastatin, and relebactam",Merck Sharp & Dohme,NDA,212819,NA,NA,Powder,Intravenous,NA,NA,NA,NA,11/16/2018,7/16/2019,2019,NA,"RECARBRIO is indicated in patients 18 years of age and older who have limited or no alternative treatment options, for the treatment of complicated urinary tract infections (cUTI), including pyelonephritis,caused by the following susceptible gram-negative microorganisms: Enterobacter cloacae, Escherichia coli, Klebsiella aerogenes, Klebsiella pneumoniae, and Pseudomonas aeruginosa.
Approval of this indication is based on limited clinical safety and efficacy data for RECARBRIO. 
RECARBRIO is indicated in patients 18 years of age and older who have limited or no alternative treatment options for the treatment of complicated intra-abdominal infections (cIAI) caused by the following susceptible gram-negative microorganisms: Bacteroides caccae, Bacteroides fragilis, Bacteroides ovatus, Bacteroides stercoris, Bacteroides thetaiotaomicron, Bacteroides uniformis, Bacteroides vulgatus, Citrobacter freundii, Enterobacter cloacae, Escherichia coli, Fusobacterium nucleatum, Klebsiella aerogenes, Klebsiella oxytoca, Klebsiella pneumoniae, Parabacteroides distasonis, and Pseudomonas aeruginosa.
Approval of this indication is based on limited clinical safety and efficacy data for RECARBRIO.
Usage:
To reduce the development of drug-resistant bacteria and maintain the effectiveness of RECARBRIO and other antibacterial drugs, RECARBRIO should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.",Priority,No,No,No,Yes,Yes,No,No,NA,2018-11-16,2019-07-16,242,5.488937726156687,Post-FDASIA
Accrufer,ferric maltol,Sheild Therapeutics,NDA,212320,NA,NA,Capsule,Oral,NA,NA,NA,NA,9/27/2018,7/25/2019,2019,NA,ACCRUFER is indicated for the treatment of iron deficiency in adults.,Standard,No,No,No,No,No,No,No,NA,2018-09-27,2019-07-25,301,5.707110264748875,Post-FDASIA
Nubeqa,darolutamide,Bayer HealthCare Pharmaceuticals,NDA,212099,NA,NA,Tablet,Oral,NA,NA,NA,NA,2/26/2019,7/30/2019,2019,NA,NUBEQA is indicated for the treatment of patients with non-metastatic castration resistant prostate cancer (nmCRPC).,Priority,No,No,No,Yes,No,No,No,NA,2019-02-26,2019-07-30,154,5.0369526024136295,Post-FDASIA
Turalio,pexidartinib,Daiichi Sankyo,NDA,211810,NA,NA,Capsule,Oral,NA,NA,NA,NA,12/3/2018,8/2/2019,2019,NA,TURALIO is indicated for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) associated with severe morbidity or functional limitations and not amenable to improvement with surgery.,Priority,Yes,No,Yes,No,No,No,No,NA,2018-12-03,2019-08-02,242,5.488937726156687,Post-FDASIA
Wakix,pitolisant,Bioprojet Pharma,NDA,211150,NA,NA,Tablet,Oral,NA,NA,NA,NA,12/14/2018,8/14/2019,2019,NA,WAKIX is indicated for the treatment of excessive daytime sleepiness (EDS) in adult patients with narcolepsy.,Priority,Yes,No,No,Yes,No,No,No,NA,2018-12-14,2019-08-14,243,5.493061443340548,Post-FDASIA
[drug marketed without a proprietary name],pretomanid,Global Alliance for TB Drug Development,NDA,212862,NA,NA,Tablet,Oral,NA,NA,NA,NA,12/14/2018,8/14/2019,2019,NA,"Limited Population: Pretomanid Tablet is indicated, as part of a combination regimen with bedaquiline and linezolid for the treatment of adults with pulmonary extensively drug resistant (XDR) or treatment-intolerant or nonresponsive multidrug-resistant (MDR) tuberculosis (TB). Approval of this indication is based on limited clinical safety and efficacy data. This drug is indicated for use in a limited and specific population of patients. Limitations of Use:
- Pretomanid Tablets are not indicated in patients with the following conditions:
-- Drug-sensitive (DS) tuberculosis
-- Latent infection due to Mycobacterium tuberculosis.
-- Extra-pulmonary infection due to Mycobacterium tuberculosis.
-- MDR-TB that is not treatment-intolerant or nonresponsive to standard therapy.
- Safety and effectiveness of Pretomanid Tablets have not been established for its use in combination with drugs other than bedaquiline and linezolid as part of the recommended dosing regimen.",Priority,Yes,No,No,Yes,Yes,TD,No,NA,2018-12-14,2019-08-14,243,5.493061443340548,Post-FDASIA
Rozlytrek,entrectinib,Genentech,NDA,212725,212726,NA,Capsule,Oral,Capsule,Oral,NA,NA,12/18/2018,8/15/2019,2019,NA,"[A] ROZLYTREK is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are ROS1-positive.
[B] ROZLYTREK is indicated for the treatment of adult and pediatric patients 12 years of age and older with solid tumors that:
- have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known acquired resistance mutation,
- are metastatic or where surgical resection is likely to result in severe morbidity, and
- have either progressed following treatment or have no satisfactory alternative therapy.
This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.",Priority,Yes,Yes (indication [B] only),Yes (indication [B] only),No,No,No,No,NA,2018-12-18,2019-08-15,240,5.480638923341991,Post-FDASIA
Inrebic,fedratinib,Celgene,NDA,212327,NA,NA,Capsule,Oral,NA,NA,NA,NA,1/3/2019,8/16/2019,2019,NA,INREBIC is indicated for the treatment of adult patients with intermediate-2 or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis (MF).,Priority,Yes,No,No,No,No,No,No,NA,2019-01-03,2019-08-16,225,5.41610040220442,Post-FDASIA
Rinvoq,upadacitinib,Abbvie,NDA,211675,NA,NA,"Tablet, Extended Release",Oral,NA,NA,NA,NA,12/18/2018,8/16/2019,2019,NA,"RINVOQ (upadacitinib) is indicated for the treatment of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate.
Limitation of Use: Use of RINVOQ in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine, is not recommended.",Priority (used priority review voucher),No,No,No,No,No,No,Yes,NA,2018-12-18,2019-08-16,241,5.484796933490655,Post-FDASIA
Xenleta,lefamulin,Nabriva Therapeutics,NDA,211672,211673,NA,Tablet,Oral,Injectable,Injection,NA,NA,12/19/2018,8/19/2019,2019,NA,"XENLETA is indicated for the treatment of adults with community-acquired bacterial pneumonia (CABP) caused by the following susceptible microorganisms: Streptococcus pneumoniae, Staphylococcus aureus (methicillin-susceptible isolates), Haemophilus influenzae, Legionella pneumophila, Mycoplasma pneumoniae, and Chlamydophila pneumoniae.
Usage:
To reduce the development of drug-resistant bacteria and maintain the effectiveness of XENLETA and other antibacterial drugs, XENLETA should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.",Priority,No,No,No,Yes,Yes,No,No,NA,2018-12-19,2019-08-19,243,5.493061443340548,Post-FDASIA
[drug marketed without a proprietary name],Ga 68 DOTATOC,University of Iowa Health Care,NDA,210828,NA,NA,Solution,Intravenous,NA,NA,NA,NA,5/23/2018,8/21/2019,2019,NA,Ga 68 DOTATOC Injection is indicated for use with positron emission tomography (PET) for the localization of somatostatin receptor positive neuroendocrine tumors (NETs) in adult and pediatric patients.,Standard,Yes,No,No,No,No,No,No,NA,2018-05-23,2019-08-21,455,6.12029741895095,Post-FDASIA
Ibsrela,tenapanor,Ardelyx,NDA,211801,NA,NA,Tablet,Oral,NA,NA,NA,NA,9/12/2018,9/12/2019,2019,NA,IBSRELA is indicated for treatment of irritable bowel syndrome with constipation (IBS-C) in adults.,Standard,No,No,No,No,No,No,No,NA,2018-09-12,2019-09-12,365,5.8998973535824915,Post-FDASIA
Aklief,trifarotene,Galderma Research and Development,NDA,211527,NA,NA,Cream,Topical,NA,NA,NA,NA,10/4/2018,10/4/2019,2019,NA,AKLIEF Cream is a retinoid indicated for the topical treatment of acne vulgaris in patients 9 years of age and older.,Standard,No,No,No,No,No,No,No,NA,2018-10-04,2019-10-04,365,5.8998973535824915,Post-FDASIA
Beovu,brolucizumab-dbll,Novartis Pharmaceuticals,BLA,761125,NA,NA,Injectable,Injection,NA,NA,NA,NA,2/7/2019,10/7/2019,2019,NA,BEOVU is indicated for the treatment of Neovascular (Wet) Age-related Macular Degeneration (AMD).,Priority (used priority review voucher),No,No,No,No,N/A,No,Yes,NA,2019-02-07,2019-10-07,242,5.488937726156687,Post-FDASIA
Scenesse,afamelanotide,Clinuvel,NDA,210797,NA,NA,Implant,Subcutaneous,NA,NA,NA,NA,11/8/2018,10/8/2019,2019,NA,SCENESSE is indicated to increase pain free light exposure in adult patients with a history of phototoxic reactions from erythropoietic protoporphyria (EPP).,Priority,Yes,No,No,Yes,No,No,No,NA,2018-11-08,2019-10-08,334,5.811140992976701,Post-FDASIA
[drug marketed without a proprietary name],fluorodopa F 18,Feinstein Institute,NDA,200655,NA,NA,Solution,Intravenous,NA,NA,NA,NA,10/22/2012,10/10/2019,2019,NA,Fluorodopa F 18 Injection is indicated for use in positron emission tomography (PET) to visualize dopaminergic nerve terminals in the striatum for the evaluation of adult patients with suspected Parkinsonian syndromes (PS). Fluorodopa F 18 PET is an adjunct to other diagnostic evaluations.,Standard,No,No,No,No,No,No,No,NA,2012-10-22,2019-10-10,2544,7.841492924460013,Post-FDASIA
Reyvow,lasmiditan,Eli Lilly,NDA,211280,NA,NA,Tablet,Oral,NA,NA,NA,NA,10/11/2018,10/11/2019,2019,NA,"REYVOW is indicated for the acute treatment of migraine with or without aura in adults.
Limitations of Use:
REYVOW is not indicated for the preventive treatment of migraine.",Standard,No,No,No,No,No,No,No,NA,2018-10-11,2019-10-11,365,5.8998973535824915,Post-FDASIA
Trikafta,"elexacaftor, ivacaftor, tezacaftor; ivacaftor (co-packaged)",Vertex Pharmaceuticals,NDA,212273,NA,NA,"Tablet, Tablet",Oral,NA,NA,NA,NA,7/19/2019,10/21/2019,2019,NA,"TRIKAFTA is indicated for the treatment of cystic fibrosis (CF) in patients aged 12 years and older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. 
If the patient’s genotype is unknown, an FDA-cleared CF mutation test should be used to confirm the presence of at least one F508del mutation.",Priority,Yes,No,Yes,Yes,No,RPD,No,NA,2019-07-19,2019-10-21,94,4.543294782270004,Post-FDASIA
ExEm Foam,air polymer-type A,Giskit B.V.,NDA,212279,NA,NA,Foam,Intrauterine,NA,NA,NA,NA,10/9/2018,11/7/2019,2019,NA,ExEm Foam is indicated for sonohysterosalpingography to assess fallopian tube patency in women with known or suspected infertility.,Standard,No,No,No,No,No,No,No,NA,2018-10-09,2019-11-07,394,5.976350909297934,Post-FDASIA
Reblozyl,luspatercept-aamt,Celgene,BLA,761136,NA,NA,Injectable,Injection,NA,NA,NA,NA,4/4/2019,11/8/2019,2019,NA,"REBLOZYL is indicated for the treatment of anemia in adult patients with beta thalassemia who require regular red blood cell (RBC) transfusions.
Limitations of Use:
REBLOZYL is not indicated for use as a substitute for RBC transfusions in patients who require immediate correction of anemia.",Priority,Yes,No,No,Yes,N/A,No,No,NA,2019-04-04,2019-11-08,218,5.384495062789089,Post-FDASIA
Brukinsa,zanubrutinib,BeiGene USA,NDA,213217,NA,NA,Capsule,Oral,NA,NA,NA,NA,6/27/2019,11/14/2019,2019,NA,"BRUKINSA is indicated for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.
This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.",Priority,Yes,Yes,Yes,No,No,No,No,NA,2019-06-27,2019-11-14,140,4.941642422609304,Post-FDASIA
Fetroja,cefiderocol,Shionogi,NDA,209445,NA,NA,Powder,Intravenous,NA,NA,NA,NA,12/14/2018,11/14/2019,2019,NA,"FETROJA is indicated in patients 18 years of age or older who have limited or no alternative treatment options for the treatment of complicated urinary tract infections (cUTIs), including pyelonephritis caused by the following susceptible Gram-negative microorganisms: Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa, and Enterobacter cloacae complex.
Approval of this indication is based on limited clinical safety and efficacy data for FETROJA.
Usage:
To reduce the development of drug-resistant bacteria and maintain the effectiveness of FETROJA and other antibacterial drugs, FETROJA should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.",Priority,No,No,No,Yes,Yes,No,No,NA,2018-12-14,2019-11-14,335,5.814130531825066,Post-FDASIA
Adakveo,crizanlizumab-tmca,Novartis Pharmaceuticals,BLA,761128,NA,NA,Injectable,Injection,NA,NA,NA,NA,5/16/2019,11/15/2019,2019,NA,ADAKVEO is indicated to reduce the frequency of vasoocclusive crises (VOCs) in adults and pediatric patients aged 16 years and older with sickle cell disease.,Priority,Yes,No,Yes,No,N/A,No,No,NA,2019-05-16,2019-11-15,183,5.209486152841421,Post-FDASIA
Givlaari,givosiran,Alnylam Pharmaceuticals,NDA,212194,NA,NA,Solution,Subcutaneous,NA,NA,NA,NA,6/4/2019,11/20/2019,2019,NA,GIVLAARI is indicated for the treatment of adults with acute hepatic porphyria (AHP).,Priority,Yes,No,Yes,No,No,No,No,NA,2019-06-04,2019-11-20,169,5.1298987149230735,Post-FDASIA
Xcopri,cenobamate,SK Life Science,NDA,212839,NA,NA,Tablet,Oral,NA,NA,NA,NA,11/21/2018,11/21/2019,2019,NA,XCOPRI is indicated for the treatment of partial-onset seizures in adult patients.,Standard,No,No,No,No,No,No,No,NA,2018-11-21,2019-11-21,365,5.8998973535824915,Post-FDASIA
Oxbryta,voxelotor,Global Blood Therapeutics,NDA,213137,NA,NA,Tablet,Oral,NA,NA,NA,NA,6/26/2019,11/25/2019,2019,NA,"OXBRYTA is indicated for the treatment of sickle cell disease (SCD) in adults and pediatric patients 12 years of age and older.
This indication is approved under accelerated approval based on increase in hemoglobin (Hb). Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s).",Priority,Yes,Yes,Yes,Yes,No,No,No,NA,2019-06-26,2019-11-25,152,5.0238805208462765,Post-FDASIA
Vyondys 53,golodirsen,Sarepta Therapeutics,NDA,211970,NA,NA,Solution,Intravenous,NA,NA,NA,NA,12/19/2018,12/12/2019,2019,NA,VYONDYS 53 is indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping. This indication is approved under accelerated approval based on an increase in dystrophin production in skeletal muscle observed in patients treated with VYONDYS 53. Continued approval for this indication may be contingent upon verification of a clinical benefit in confirmatory trials.,Priority,Yes,Yes,No,Yes,No,RPD,No,NA,2018-12-19,2019-12-12,358,5.8805329864007,Post-FDASIA
Padcev,enfortumab vedotin-ejfv,Astellas Pharma,BLA,761137,NA,NA,Powder,Intravenous,NA,NA,NA,NA,7/15/2019,12/18/2019,2019,NA,"PADCEV is indicated for the treatment of adult patients with locally advanced or metastatic urothelial cancer (mUC) who have previously received a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor, and a platinum-containing chemotherapy in the neoadjuvant/adjuvant, locally advanced or metastatic setting.
This indication is approved under accelerated approval based on tumor response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.",Priority,No,Yes,Yes,No,N/A,No,No,NA,2019-07-15,2019-12-18,156,5.049856007249537,Post-FDASIA
Caplyta,lumateperone,Intra-Cellular Therapies,NDA,209500,NA,NA,Capsule,Oral,NA,NA,NA,NA,9/27/2018,12/20/2019,2019,NA,CAPLYTA is indicated for the treatment of schizophrenia in adults.,Standard,No,No,No,Yes,No,No,No,NA,2018-09-27,2019-12-20,449,6.1070228877422545,Post-FDASIA
Enhertu,fam-trastuzumab deruxtecan-nxki,Daiichi Sankyo,BLA,761139,NA,NA,Powder,Intravenous,NA,NA,NA,NA,8/29/2019,12/20/2019,2019,NA,"ENHERTU is indicated for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting.
This indication is approved under accelerated approval based on tumor response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.",Priority,No,Yes,Yes,Yes,N/A,No,No,NA,2019-08-29,2019-12-20,113,4.727387818712341,Post-FDASIA
TissueBlue,Brilliant Blue G,D.O.R.C International b.v,NDA,209569,NA,NA,Solution,Ophthalmic,NA,NA,NA,NA,4/29/2019,12/20/2019,2019,NA,TissueBlue (Brilliant Blue G Ophthalmic Solution) 0.025% is indicated to selectively stain the internal limiting membrane (ILM).,Priority,Yes,No,No,No,No,No,No,NA,2019-04-29,2019-12-20,235,5.459585514144159,Post-FDASIA
Dayvigo,lemborexant,Eisai,NDA,212028,NA,NA,Tablet,Oral,NA,NA,NA,NA,12/27/2018,12/20/2019,2019,NA,"DAYVIGO is indicated for the treatment of adult patients with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance.",Standard,No,No,No,No,No,No,No,NA,2018-12-27,2019-12-20,358,5.8805329864007,Post-FDASIA
Ubrelvy,ubrogepant,Allergan,NDA,211765,NA,NA,Tablet,Oral,NA,NA,NA,NA,12/26/2018,12/23/2019,2019,NA,"UBRELVY is indicated for the acute treatment of migraine with or without aura in adults.
Limitations of Use:
UBRELVY is not indicated for the preventive treatment of migraine.",Standard,No,No,No,No,No,No,No,NA,2018-12-26,2019-12-23,362,5.8916442118257715,Post-FDASIA
Ayvakit,avapritinib,Blueprint Medicines Corporation,NDA,212608,NA,NA,Tablet,Oral,NA,NA,NA,NA,6/14/2019,1/9/2020,2020,NA,"Ayvakit is indicated for the treatment of adults with unresectable or metastatic gastrointestinal stromal tumor (GIST) harboring a platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutation, including PDGFRA D842V mutations",Priority,Yes,No,Yes,Yes,No,No,No,NA,2019-06-14,2020-01-09,209,5.342334251964811,Post-FDASIA
Tepezza,teprotumumab-trbw,Horizon Therapeutics Ireland DAC,BLA,761143,NA,NA,Injectable,Injection,NA,NA,NA,NA,7/8/2019,1/21/2020,2020,NA,Tepezza is indicated for the treatment of thyroid eye disease,Priority,Yes,No,Yes,Yes,N/A,No,No,NA,2019-07-08,2020-01-21,197,5.2832037287379885,Post-FDASIA
Tazverik,tazemetostat,"Epizyme, Inc.",NDA,211723,NA,NA,Tablet,Oral,NA,NA,NA,NA,5/23/2019,1/23/2020,2020,NA,Tazverik is indicated for the treatment of adults and pediatric patients aged 16 years and older with metastatic or locally advanced epithelioid sarcoma not eligible for complete resection,Priority,Yes,Yes,No,No,No,No,No,NA,2019-05-23,2020-01-23,245,5.501258210544727,Post-FDASIA
Pizensy,lactitol,"Braintree Laboratories, Inc.",NDA,211281,NA,NA,Powder,Oral,NA,NA,NA,NA,11/21/2018,2/12/2020,2020,NA,Pizensy is indicated for the treatment of chronic idiopathic constipation (CIC) in adults,Standard,No,No,No,No,No,No,No,NA,2018-11-21,2020-02-12,448,6.104793232414985,Post-FDASIA
Nexletol,bempedoic acid,"Esperion Therapeutics, Inc.",NDA,211616,NA,NA,Tablet,Oral,NA,NA,NA,NA,2/21/2019,2/21/2020,2020,NA,Nexletol is indicated as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease who require additional lowering of LDL-C,Standard,No,No,No,No,No,No,No,NA,2019-02-21,2020-02-21,365,5.8998973535824915,Post-FDASIA
Vyepti,eptinezumab-jjmr,"Lundbeck Seattle BioPharmaceuticals, Inc.",BLA,761119,NA,NA,Injectable,Injection,NA,NA,NA,NA,2/21/2019,2/21/2020,2020,NA,Vyepti is indicated for the preventive treatment of migraine in adults,Standard,No,No,No,No,N/A,No,No,NA,2019-02-21,2020-02-21,365,5.8998973535824915,Post-FDASIA
Barhemsys,amisulpride,Acacia Pharma Ltd.,NDA,209510,NA,NA,Injectable,Injection,NA,NA,NA,NA,10/5/2017,2/26/2020,2020,NA,"Barhemsys is indicated for the treatment of PONV in patients who have received antiemetic prophylaxis with an agent of a different class or who have not received prophylaxis . Is indicated for prevention of postoperative nausea and vomiting (PONV), either alone or in combination with an antiemetic of a different class",Standard,No,No,No,No,No,No,No,NA,2017-10-05,2020-02-26,874,6.773080375655535,Post-FDASIA
Nurtec ODT,rimegepant,Biohaven Pharmaceuticals,NDA,212728,NA,NA,Tablet,Oral,NA,NA,NA,NA,6/27/2019,2/27/2020,2020,NA,Nurtec ODT is indicated for the acute treatment of migraine with or without aura in adults,Priority (used priority review voucher),No,No,No,No,No,No,Yes,NA,2019-06-27,2020-02-27,245,5.501258210544727,Post-FDASIA
Sarclisa,isatuximab-irfc,Sanofi Aventis US LLC,BLA,761113,NA,NA,Injectable,Injection,NA,NA,NA,NA,4/30/2019,3/2/2020,2020,NA,"Sarclisa is indicated in combination with pomalidomide and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor",Standard,Yes,No,No,No,N/A,No,No,NA,2019-04-30,2020-03-02,307,5.726847747587197,Post-FDASIA
Isturisa,osilodrostat,Novartis Pharmaceuticals Corporation,NDA,212801,NA,NA,Tablet,Oral,NA,NA,NA,NA,3/7/2019,3/6/2020,2020,NA,Isturisa is indicated for the treatment of adult patients with Cushing's disease for whom pituitary surgery is not an option or has not been curative,Standard,Yes,No,No,No,No,No,No,NA,2019-03-07,2020-03-06,365,5.8998973535824915,Post-FDASIA
Zeposia,ozanimod,Celgene Corporation,NDA,209899,NA,NA,Capsule,Oral,NA,NA,NA,NA,3/25/2019,3/25/2020,2020,NA,"Zeposia is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults",Standard,No,No,No,No,No,No,No,NA,2019-03-25,2020-03-25,366,5.902633333401366,Post-FDASIA
Koselugo,selumetinib,AstraZeneca Pharmaceuticals LP,NDA,213756,NA,NA,Capsule,Oral,NA,NA,NA,NA,9/13/2019,4/10/2020,2020,NA,"Koselugo is indicated for the treatment of pediatric patients 2 years of age and older with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PN)",Priority,Yes,No,Yes,No,No,RPD,No,NA,2019-09-13,2020-04-10,210,5.3471075307174685,Post-FDASIA
Pemazyre,pemigatinib,Incyte Corporation,NDA,213736,NA,NA,Tablet,Oral,NA,NA,NA,NA,9/30/2019,4/17/2020,2020,NA,"Pemazyre is indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected by an FDA-approved test",Priority,Yes,Yes,Yes,No,No,No,No,NA,2019-09-30,2020-04-17,200,5.298317366548036,Post-FDASIA
Tukysa,tucatinib,"Seattle Genetics, Inc.",NDA,213411,NA,NA,Tablet,Oral,NA,NA,NA,NA,12/20/2019,4/17/2020,2020,NA,"Tukysa is indicated in combination with trastuzumab and capecitabine for treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received one or more prior anti-HER2-based regimens in the metastatic setting",Priority,Yes,No,Yes,Yes,No,No,No,NA,2019-12-20,2020-04-17,119,4.77912349311153,Post-FDASIA
Trodelvy,sacituzumab govitecan-hziy,"Immunomedics, Inc",BLA,761115,NA,NA,Powder,Intravenous,NA,NA,NA,NA,5/18/2018,4/22/2020,2020,NA,Trodelvy is indicated for the treatment of adult patients with metastatic triple-negative breast cancer (mTNBC) who have received at least two prior therapies for metastatic disease,Priority,No,Yes,Yes,Yes,N/A,No,No,NA,2018-05-18,2020-04-22,705,6.558197802812269,Post-FDASIA
Ongentys,opicapone,"Neurocrine Biosciences, Inc.",NDA,212489,NA,NA,Capsule,Oral,NA,NA,NA,NA,4/26/2019,4/24/2020,2020,NA,"Ongentys is indicated for the adjunctive treatment to levodopa/carbidopa in patients with Parkinson's disease (PD) experiencing ""off"" episodes",Standard,No,No,No,No,No,No,No,NA,2019-04-26,2020-04-24,364,5.8971538676367405,Post-FDASIA
Tabrecta,capmatinib,Novartis Pharmaceuticals Corporation,NDA,213591,NA,NA,Tablet,Oral,NA,NA,NA,NA,12/10/2019,5/6/2020,2020,NA,Tabrecta is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping as detected by an FDA-approved test,Priority,Yes,Yes,Yes,No,No,No,No,NA,2019-12-10,2020-05-06,148,4.997212273764115,Post-FDASIA
Retevmo,selpercatinib,"Loxo Oncology, Inc.",NDA,213246,NA,NA,Capsule,Oral,NA,NA,NA,NA,12/4/2019,5/8/2020,2020,NA,Retevmo is indicated for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET-mutant medullary thyroid cancer (MTC) who require systemic therapy. Is indicated for the treatment of adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate) .Is indicated for the treatment of adult patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC),Priority,Yes,Yes,Yes,No,No,No,No,NA,2019-12-04,2020-05-08,156,5.049856007249537,Post-FDASIA
Qinlock,ripretinib,"Deciphera Pharmaceuticals, LLC",NDA,213973,NA,NA,Tablet,Oral,NA,NA,NA,NA,12/13/2019,5/15/2020,2020,NA,"Qinlock is indicated for the treatment of adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with 3 or more kinase inhibitors, including imatinib",Priority,Yes,No,Yes,Yes,No,No,No,NA,2019-12-13,2020-05-15,154,5.0369526024136295,Post-FDASIA
Cerianna,fluoroestradiol F 18,Zionexa-US Corporation,NDA,212155,NA,NA,Injectable,Injection,NA,NA,NA,NA,2/27/2019,5/20/2020,2020,NA,Cerianna is indicated for positron emission tomography (PET) imaging for detection of estrogen receptor (ER)-positive lesions as an adjunct to biopsy in patients with recurrent or metastatic breast cancer,Standard,No,No,No,No,No,No,No,NA,2019-02-27,2020-05-20,448,6.104793232414985,Post-FDASIA
[drug marketed without a proprietary name],artesunate,"Amivas, LLC",NDA,213036,NA,NA,Injectable,Injection,NA,NA,NA,NA,9/26/2019,5/26/2020,2020,NA,Artesunate is indicated for the initial treatment of severe malaria in adult and pediatric patients,Priority,Yes,No,Yes,Yes,No,No,No,NA,2019-09-26,2020-05-26,243,5.493061443340548,Post-FDASIA
Tauvid,flortaucipir F 18,"Avid Radiopharmaceuticals, Inc.",NDA,212123,NA,NA,Injectable,Injection,NA,NA,NA,NA,9/30/2019,5/28/2020,2020,NA,Tauvid is indicated for positron emission tomography (PET) imaging of the brain to estimate the density and distribution of aggregated tau neurofibrillary tangles (NFTs) in adult patients with cognitive impairment who are being evaluated for Alzheimer’s disease (AD),Priority,No,No,No,No,No,No,No,NA,2019-09-30,2020-05-28,241,5.484796933490655,Post-FDASIA
Uplizna,inebilizumab-cdon,"Viela Bio, Inc.",BLA,761142,NA,NA,Injectable,Injection,NA,NA,NA,NA,6/11/2019,6/11/2020,2020,NA,Uplizna is indicated for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive,Standard,Yes,No,Yes,No,N/A,No,No,NA,2019-06-11,2020-06-11,366,5.902633333401366,Post-FDASIA
Zepzelca,lurbinectedin,"Pharma Mar USA, Inc.",NDA,213702,NA,NA,Injectable,Injection,NA,NA,NA,NA,12/16/2019,6/15/2020,2020,NA,Zepzelca is indicated for the treatment of adult patients with metastatic small cell lung cancer (SCLC) with disease progression on or after prior platinum-based chemotherapy,Priority,Yes,Yes,No,No,No,No,No,NA,2019-12-16,2020-06-15,182,5.204006687076795,Post-FDASIA
Dojolvi,triheptanoin,Ultragenyx Pharmaceutical Inc.,NDA,213687,NA,NA,Liquid,Oral,NA,NA,NA,NA,7/31/2019,6/30/2020,2020,NA,Dojolvi is indicated for the treatment of pediatric and adult patients with molecularly confirmed long-chain fatty acid oxidation disorders (LC-FAOD),Standard,Yes,No,No,Yes,No,No,No,NA,2019-07-31,2020-06-30,335,5.814130531825066,Post-FDASIA
Byfavo,remimazolam,"Cosmo Technologies, Ltd.",NDA,212295,NA,NA,Injectable,Injection,NA,NA,NA,NA,4/5/2019,7/2/2020,2020,NA,Byfavo is indicated for induction and maintenance of procedural sedation in adults undergoing procedures lasting 30 minutes or less,Standard,No,No,No,No,No,No,No,NA,2019-04-05,2020-07-02,454,6.118097198041348,Post-FDASIA
Rukobia,fostemsavir,ViiV Healthcare Company,NDA,212950,NA,NA,Tablet,Oral,NA,NA,NA,NA,12/4/2019,7/2/2020,2020,NA,"Rukobia is indicated for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen due to resistance, intolerance, or safety considerations",Priority,No,No,Yes,Yes,No,No,No,NA,2019-12-04,2020-07-02,211,5.351858133476067,Post-FDASIA
Inqovi,decitabine and cedazuridine,"Astex Pharmaceuticals, Inc.",NDA,212576,NA,NA,Tablet,Oral,NA,NA,NA,NA,12/11/2019,7/7/2020,2020,NA,"Inqovi is indicated for the treatment of adult patients with myelodysplastic syndromes (MDS), including previously treated and untreated, de novo and secondary MDS with the following French-American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, and chronic myelomonocytic leukemia [CMML]) and intermediate-1, intermediate-2, and high-risk International Prognostic Scoring System groups",Priority,Yes,No,No,No,No,No,No,NA,2019-12-11,2020-07-07,209,5.342334251964811,Post-FDASIA
Xeglyze,abametapir,Dr. Reddy’s Laboratories,NDA,206966,NA,NA,Lotion,Topical,NA,NA,NA,NA,9/14/2015,7/24/2020,2020,NA,Xeglyze is indicated for the treatment of head lice infestation in patients 6 months of age and older,Standard,No,No,No,No,No,No,No,NA,2015-09-14,2020-07-24,1775,7.4815557019095165,Post-FDASIA
Monjuvi,tafasitamab-cxix,"MorphoSys US, Inc.",BLA,761163,NA,NA,Injectable,Injection,NA,NA,NA,NA,12/30/2019,7/31/2020,2020,NA,"Monjuvi is indicated in combination with lenalidomide for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, including DLBCL arising from low grade lymphoma, and who are not eligible for autologous stem cell transplant (ASCT)",Priority,Yes,Yes,Yes,Yes,N/A,No,No,NA,2019-12-30,2020-07-31,214,5.365976015021851,Post-FDASIA
Blenrep,belantamab mafodotin-blmf,GlaxoSmithKline Intellectual Property Development Ltd. England,BLA,761158,NA,NA,Injectable,Injection,NA,NA,NA,NA,12/5/2019,8/5/2020,2020,NA,"Blenrep is indicated for the treatment of adults with relapsed or refractory multiple myeloma who have received at least four prior therapies including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent",Priority,Yes,Yes,Yes,No,N/A,No,No,NA,2019-12-05,2020-08-05,244,5.497168225293202,Post-FDASIA
Lampit,nifurtimox,"Bayer HealthCare Pharmaceuticals, Inc.",NDA,213464,NA,NA,Tablet,Oral,NA,NA,NA,NA,12/6/2019,8/6/2020,2020,NA,Lampit is indicated for the treatment of Chagas disease in pediatric patients birth to less than 18 years of age and weighing at least 2.5 kg,Priority,Yes,Yes,No,No,No,TD,No,NA,2019-12-06,2020-08-06,244,5.497168225293202,Post-FDASIA
Evrysdi,risdiplam,"Genentech, Inc.",NDA,213535,NA,NA,Powder,Oral,NA,NA,NA,NA,9/24/2019,8/7/2020,2020,NA,Evrysdi is indicated for the treatment of later-onset spinal muscular atrophy (SMA) in patients 2 months of age and older. Is indicated for the treatment of infantile-onset spinal muscular atrophy (SMA) in patients 2 months of age and older,Priority,Yes,No,No,Yes,No,RPD,No,NA,2019-09-24,2020-08-07,318,5.762051382780177,Post-FDASIA
Olinvyk,oliceridine,"Trevena, Inc.",NDA,210730,NA,NA,Injectable,Injection,NA,NA,NA,NA,11/2/2017,8/7/2020,2020,NA,Olinvyk is indicated for the management of acute pain severe enough to require an intravenous opioid analgesic and for whom alternative treatments are inadequate in adults,Standard,No,No,No,Yes,No,No,No,NA,2017-11-02,2020-08-07,1009,6.9167150203536085,Post-FDASIA
Viltepso,viltolarsen,"Nippon Shinyaku Co., Ltd.",NDA,212154,NA,NA,Injectable,Injection,NA,NA,NA,NA,12/12/2019,8/12/2020,2020,NA,Viltepso is indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping,Priority,Yes,Yes,No,Yes,No,RPD,No,NA,2019-12-12,2020-08-12,244,5.497168225293202,Post-FDASIA
Enspryng,satralizumab-mwge,"Genentech, Inc.",BLA,761149,NA,NA,Injectable,Injection,NA,NA,NA,NA,8/15/2019,8/14/2020,2020,NA,Enspryng is indicated for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive,Standard,Yes,No,Yes,Yes,N/A,No,No,NA,2019-08-15,2020-08-14,365,5.8998973535824915,Post-FDASIA
Winlevi,clascoterone,Cassiopea SpA,NDA,213433,NA,NA,Cream,Topical,NA,NA,NA,NA,8/27/2019,8/26/2020,2020,NA,Winlevi is indicated for the topical treatment of acne vulgaris in patients 12 years of age and older,Standard,No,No,No,No,No,No,No,NA,2019-08-27,2020-08-26,365,5.8998973535824915,Post-FDASIA
Sogroya,somapacitan-beco,"Novo Nordisk, Inc.",BLA,761156,NA,NA,Injectable,Injection,NA,NA,NA,NA,8/28/2019,8/28/2020,2020,NA,Sogroya is indicated for the replacement of endogenous growth hormone in adults with growth hormone deficiency,Standard,No,No,No,No,N/A,No,No,NA,2019-08-28,2020-08-28,366,5.902633333401366,Post-FDASIA
Detectnet,copper Cu 64 dotatate,"RadioMedix, Inc.",NDA,213227,NA,NA,Injectable,Injection,NA,NA,NA,NA,1/3/2020,9/3/2020,2020,NA,Detectnet is indicated for positron emission tomography (PET) for localization of somatostatin receptor positive neuroendocrine tumors (NETs) in adults,Priority,Yes,No,No,Yes,No,No,No,NA,2020-01-03,2020-09-03,244,5.497168225293202,Post-FDASIA
Gavreto,pralsetinib,Blueprint Medicines Corporation,NDA,213721,NA,NA,Capsule,Oral,NA,NA,NA,NA,3/23/2020,9/4/2020,2020,NA,Gavreto is indicated for the treatment of adult patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC) as detected by an FDA approved test,Priority,Yes,Yes,Yes,No,No,No,No,NA,2020-03-23,2020-09-04,165,5.10594547390058,Post-FDASIA
Inmazeb,"atoltivimab, maftivimab, and odesivimab-ebgn","Regeneron Pharmaceuticals, Inc.",BLA,761169,NA,NA,Injectable,Injection,NA,NA,NA,NA,2/25/2020,10/14/2020,2020,NA,"Inmazeb is indicated for the treatment of infection caused by Zaire ebolavirus in adult and pediatric patients, including neonates born to a mother who is RT-PCR positive for Zaire ebolavirus infection",Priority,Yes,No,Yes,No,N/A,MTMC,No,NA,2020-02-25,2020-10-14,232,5.44673737166631,Post-FDASIA
Veklury,remdesivir,"Gilead Sciences, Inc.",NDA,214787,NA,NA,Injectable,Injection,NA,NA,NA,NA,8/7/2020,10/22/2020,2020,NA,Veklury is indicated for the treatment of coronavirus disease 2019 (COVID-19) requiring hospitalization in adults and pediatric patients (12 years of age and older and weighing at least 40 kg),Priority,No,No,No,Yes,No,MTMC,No,NA,2020-08-07,2020-10-22,76,4.330733340286331,Post-FDASIA
Zokinvy,lonafarnib,"Eiger BioPharmaceuticals, Inc.",NDA,213969,NA,NA,Capsule,Oral,NA,NA,NA,NA,3/20/2020,11/20/2020,2020,NA,Zokinvy is indicated for the treatment of processing-deficient Progeroid Laminopathies with either heterozygous LMNA mutation with progerin-like protein accumulation or homozygous or compound heterozygous ZMPSTE24 mutations in patients 12 months of age and older. Is indicated to reduce the risk of mortality in Hutchinson-Gilford Progeria Syndrome (HGPS),Priority,Yes,No,Yes,No,No,RPD,No,NA,2020-03-20,2020-11-20,245,5.501258210544727,Post-FDASIA
Oxlumo,lumasiran,"Alnylam Pharmaceuticals, Inc.",NDA,214103,NA,NA,Injectable,Injection,NA,NA,NA,NA,4/3/2020,11/23/2020,2020,NA,Oxlumo is indicated for the treatment of primary hyperoxaluria type 1 (PH1) to lower urinary oxalate levels in pediatric and adult patients,Priority,Yes,No,Yes,No,No,RPD,No,NA,2020-04-03,2020-11-23,234,5.455321115357702,Post-FDASIA
Imcivree,setmelanotide,"Rhythm Pharmaceuticals, Inc.",NDA,213793,NA,NA,Injectable,Injection,NA,NA,NA,NA,3/27/2020,11/25/2020,2020,NA,"Imcivree is indicated for chronic weight management in adult and pediatric patients 6 years of age and older with obesity due to proopiomelanocortin (POMC) or proprotein convertase subtilisin/kexin type 1 (PCSK1) deficiency confirmed by genetic testing demonstrating variants in POMC or PCSK1 genes that are interpreted as pathogenic, likely pathogenic, or of uncertain significance (VUS). Is indicated for chronic weight management in adult and pediatric patients 6 years of age and older with obesity due to leptin receptor (LEPR) deficiency confirmed by genetic testing demonstrating variants in LEPR genes that are interpreted as pathogenic, likely pathogenic, or of uncertain significance (VUS)",Priority,Yes,No,Yes,No,No,RPD,No,NA,2020-03-27,2020-11-25,243,5.493061443340548,Post-FDASIA
Danyelza,naxitamab-gqgk,"Y-mAbs Therapeutics, Inc.",BLA,761171,NA,NA,Injectable,Injection,NA,NA,NA,NA,3/31/2020,11/25/2020,2020,NA,"Danyelza is indicated in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), for the treatment of pediatric patients 1 year of age and older and adult patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow who have demonstrated a partial response, minor response, or stable disease to prior therapy",Priority,Yes,Yes,Yes,No,N/A,RPD,No,NA,2020-03-31,2020-11-25,239,5.476463551931511,Post-FDASIA
[drug marketed without a proprietary name],gallium Ga 68 PSMA-11,University of California Los Angeles,NDA,212642,NA,NA,Injectable,Injection,NA,NA,NA,NA,9/6/2019,12/1/2020,2020,NA,gallium Ga 68 PSMA-11 Is indicated for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) positive lesions in men with suspected recurrence based on elevated serum prostate-specific antigen (PSA) level. Positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer with suspected metastasis who are candidates for initial definitive therapy,Standard,No,No,No,No,No,No,No,NA,2019-09-06,2020-12-01,452,6.113682179832232,Post-FDASIA
Orladeyo,berotralstat,"BioCryst Pharmaceuticals, Inc.",NDA,214094,NA,NA,Capsule,Oral,NA,NA,NA,NA,12/3/2019,12/3/2020,2020,NA,Orladeyo is indicated as prophylaxis to prevent attacks of hereditary angioedema (HAE) in adults and pediatric patients 12 years and older,Standard,Yes,No,No,Yes,No,No,No,NA,2019-12-03,2020-12-03,366,5.902633333401366,Post-FDASIA
Klisyri,tirbanibulin,"Athenex, Inc.",NDA,213189,NA,NA,Ointment,Topical,NA,NA,NA,NA,12/30/2019,12/14/2020,2020,NA,Klisyri is indicated for the topical treatment of actinic keratosis of the face or scalp,Standard,No,No,No,No,No,No,No,NA,2019-12-30,2020-12-14,350,5.857933154483459,Post-FDASIA
Margenza,margetuximab-cmkb,"MacroGenics, Inc.",BLA,761150,NA,NA,Injectable,Injection,NA,NA,NA,NA,12/18/2019,12/16/2020,2020,NA,"Margenza is indicated in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease",Standard,No,No,No,Yes,N/A,No,No,NA,2019-12-18,2020-12-16,364,5.8971538676367405,Post-FDASIA
Orgovyx,relugolix,Myovant Sciences GmbH,NDA,214621,NA,NA,Tablet,Oral,NA,NA,NA,NA,4/20/2020,12/18/2020,2020,NA,Orgovyx is indicated for the treatment of adult patients with advanced prostate cancer,Priority,No,No,No,No,No,No,No,NA,2020-04-20,2020-12-18,242,5.488937726156687,Post-FDASIA
Ebanga,ansuvimab-zykl,"Ridgeback Biotherapeutics, LP",BLA,761172,NA,NA,Injectable,Injection,NA,NA,NA,NA,5/29/2020,12/21/2020,2020,NA,"Ebanga is indicated for the treatment of infection caused by Zaire ebolavirus in adult and pediatric patients, including neonates born to a mother who is RT-PCR positive for Zaire ebolavirus infection",Priority,Yes,No,Yes,No,N/A,MTMC,No,NA,2020-05-29,2020-12-21,206,5.327876168789581,Post-FDASIA
Gemtesa,vibegron,Urovant Sciences GmbH,NDA,213006,NA,NA,Tablet,Oral,NA,NA,NA,NA,12/26/2019,12/23/2020,2020,NA,"Gemtesa is indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency in adults",Standard,No,No,No,No,No,No,No,NA,2019-12-26,2020-12-23,363,5.8944028342648505,Post-FDASIA
Verquvo,vericiguat,Merck Sharp and Dohme Corp.,NDA,214377,NA,NA,Tablet,Oral,NA,NA,NA,NA,5/20/2020,1/19/2021,2021,NA,"VERQUVO is indicated to reduce the risk of cardiovascular death and heart failure (HF) hospitalization following a hospitalization for heart failure or need for outpatient IV diuretics, in adults with symptomatic chronic HF and ejection fraction less than 45%.",Priority,No,No,No,Yes,No,No,No,NA,2020-05-20,2021-01-19,244,5.497168225293202,Post-FDASIA
Cabenuva,cabotegravir; rilpivirine (co-packaged),ViiV Healthcare Company,NDA,212888,NA,NA,Injectable,Injection,NA,NA,NA,NA,4/29/2019,1/21/2021,2021,NA,CABENUVA is indicated as a complete regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults to replace the current antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen with no history of treatment failure and with no known or suspected resistance to either cabotegravir or rilpivirine.,Priority,No,No,No,Yes,No,No,No,NA,2019-04-29,2021-01-21,633,6.450470422144176,Post-FDASIA
Lupkynis,voclosporin,"Aurinia Pharmaceuticals, Inc.",NDA,213716,NA,NA,Capsule,Oral,NA,NA,NA,NA,5/22/2020,1/22/2021,2021,NA,"LUPKYNIS is indicated in combination with a background immunosuppressive therapy regimen for the treatment of adult patients with active lupus nephritis (LN).
Limitations of Use: Safety and efficacy of LUPKYNIS have not been established in combination with cyclophosphamide. Use of LUPKYNIS is not recommended in this situation.",Priority,No,No,No,Yes,No,No,No,NA,2020-05-22,2021-01-22,245,5.501258210544727,Post-FDASIA
Tepmetko,tepotinib,"EMD Serono, Inc.",NDA,214096,NA,NA,Tablet,Oral,NA,NA,NA,NA,6/29/2020,2/3/2021,2021,NA,"TEPMETKO is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) harboring mesenchymal-epithelial transition (MET) exon 14 skipping alterations.
This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s).",Priority,Yes,Yes,No,No,No,No,No,NA,2020-06-29,2021-02-03,219,5.389071729816501,Post-FDASIA
Ukoniq,umbralisib,"TG Therapeutics, Inc.",NDA,213176,NA,NA,Tablet,Oral,NA,NA,NA,NA,6/15/2020,2/5/2021,2021,NA,"[A] UKONIQ is indicated for the treatment of adult patients with relapsed or refractory marginal zone lymphoma (MZL) who have received at least one prior anti-CD20-based regimen.
This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).
[B] UKONIQ is indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) who have received at least three prior lines of systemic therapy.
This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).",Priority (indication [A] only),Yes,Yes,Yes (indication [A] only),No,No,No,No,NA,2020-06-15,2021-02-05,235,5.459585514144159,Post-FDASIA
Evkeeza,evinacumab-dgnb,"Regeneron Pharmaceuticals, Inc.",BLA,761181,NA,NA,Injectable,Injection,NA,NA,NA,NA,6/11/2020,2/11/2021,2021,NA,"EVKEEZA is indicated as an adjunct to other low-density lipoprotein-cholesterol (LDL-C) lowering therapies for the treatment of adult and pediatric patients, aged 12 years and older, with homozygous familial hypercholesterolemia (HoFH).
Limitations of Use:
- The safety and effectiveness of EVKEEZA have not been established in patients with other causes of hypercholesterolemia, including those with heterozygous familial hypercholesterolemia (HeFH).
- The effects of EVKEEZA on cardiovascular morbidity and mortality have not been determined.",Priority,Yes,No,Yes,No,N/A,No,No,NA,2020-06-11,2021-02-11,245,5.501258210544727,Post-FDASIA
Cosela,trilaciclib,"G1 Therapeutics, Inc.",NDA,214200,NA,NA,Injectable,Injection,NA,NA,NA,NA,6/15/2020,2/12/2021,2021,NA,COSELA is indicated to decrease the incidence of chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive-stage small cell lung cancer (ES-SCLC).,Priority,No,No,Yes,No,No,No,No,NA,2020-06-15,2021-02-12,242,5.488937726156687,Post-FDASIA
Amondys 45,casimersen,"Sarepta Therapeutics, Inc.",NDA,213026,NA,NA,Injectable,Injection,NA,NA,NA,NA,6/25/2020,2/25/2021,2021,NA,AMONDYS 45 is indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 45 skipping. This indication is approved under accelerated approval based on an increase in dystrophin production in skeletal muscle observed in patients treated with AMONDYS 45. Continued approval for this indication may be contingent upon verification of a clinical benefit in confirmatory trials.,Priority,Yes,Yes,No,Yes,No,RPD,No,NA,2020-06-25,2021-02-25,245,5.501258210544727,Post-FDASIA
Nulibry,fosdenopterin,"Origin Biosciences, Inc.",NDA,214018,NA,NA,Injectable,Injection,NA,NA,NA,NA,6/29/2020,2/26/2021,2021,NA,NULIBRY is indicated to reduce the risk of mortality in patients with molybdenum cofactor deficiency (MoCD) Type A.,Priority,Yes,No,Yes,No,No,RPD,No,NA,2020-06-29,2021-02-26,242,5.488937726156687,Post-FDASIA
Pepaxto,melphalan flufenamide,Oncopeptides AB,NDA,214383,NA,NA,Injectable,Injection,NA,NA,NA,NA,6/30/2020,2/26/2021,2021,NA,"PEPAXTO is indicated in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy and whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one CD38-directed monoclonal antibody.
This indication is approved under accelerated approval based on response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s).
Limitations of Use:
PEPAXTO is not indicated and is not recommended for use as a conditioning regimen for transplant outside of controlled clinical trials.",Priority,Yes,Yes,No,No,No,No,No,NA,2020-06-30,2021-02-26,241,5.484796933490655,Post-FDASIA
Azstarys,serdexmethylphenidate and dexmethylphenidate,Commave Therapeutics SA,NDA,212994,NA,NA,Capsule,Oral,NA,NA,NA,NA,3/2/2020,3/2/2021,2021,NA,Azstarys is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in patients 6 years of age and older.,Standard,No,No,No,No,No,No,No,NA,2020-03-02,2021-03-02,365,5.8998973535824915,Post-FDASIA
Fotivda,tivozanib,"Aveo Pharmaceuticals, Inc.",NDA,212904,NA,NA,Capsule,Oral,NA,NA,NA,NA,3/31/2020,3/10/2021,2021,NA,FOTIVDA is indicated for the treatment of adult patients with relapsed or refractory advanced renal cell carcinoma (RCC) following two or more prior systemic therapies.,Standard,No,No,No,No,No,No,No,NA,2020-03-31,2021-03-10,344,5.840641657373398,Post-FDASIA
Ponvory,ponesimod,"Janssen Pharmaceuticals, Inc.",NDA,213498,NA,NA,Tablet,Oral,NA,NA,NA,NA,3/18/2020,3/18/2021,2021,NA,"PONVORY is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.",Standard,No,No,No,No,No,No,No,NA,2020-03-18,2021-03-18,365,5.8998973535824915,Post-FDASIA
Zegalogue,dasiglucagon,Zealand Pharma A/S,NDA,214231,NA,NA,Injectable,Injection,NA,NA,NA,NA,3/27/2020,3/22/2021,2021,NA,ZEGALOGUE is indicated for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes aged 6 years and above.,Standard,No,No,No,No,No,No,No,NA,2020-03-27,2021-03-22,360,5.886104031450156,Post-FDASIA
Qelbree,viloxazine,"Supernus Pharmaceuticals, Inc.",NDA,211964,NA,NA,Capsule,Oral,NA,NA,NA,NA,11/8/2019,4/2/2021,2021,NA,Qelbree is indicated for the treatment of Attention-Deficit Hyperactivity Disorder (ADHD) in pediatric patients 6 to 17 years of age.,Standard,No,No,No,No,No,No,No,NA,2019-11-08,2021-04-02,511,6.236369590203704,Post-FDASIA
Nextstellis,drospirenone and estetrol,"Mayne Pharma, LLC",NDA,214154,NA,NA,Tablet,Oral,NA,NA,NA,NA,4/15/2020,4/15/2021,2021,NA,"NEXTSTELLIS is indicated for use by females of reproductive potential to prevent pregnancy.
Limitations of Use:
NEXTSTELLIS may be less effective in females with a BMI >= 30 kg/m2. In females with BMI >= 30 kg/m2, decreasing effectiveness may be associated with increasing BMI.",Standard,No,No,No,No,No,No,No,NA,2020-04-15,2021-04-15,365,5.8998973535824915,Post-FDASIA
Jemperli,dostarlimab-gxly,"GlaxoSmithKline, LLC",BLA,761174,NA,NA,Injectable,Injection,NA,NA,NA,NA,12/19/2019,4/22/2021,2021,NA,"JEMPERLI is indicated for the treatment of adult patients with mismatch repair deficient (dMMR) recurrent or advanced endometrial cancer (EC), as determined by an FDA-approved test, that has progressed on or following prior treatment with a platinum-containing regimen.
This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).",Priority,No,Yes,Yes,No,N/A,No,No,NA,2019-12-19,2021-04-22,490,6.194405391104672,Post-FDASIA
Zynlonta,loncastuximab tesirine-lpyl,ADC Therapeutics S.A.,BLA,761196,NA,NA,Injectable,Injection,NA,NA,NA,NA,9/21/2020,4/23/2021,2021,NA,"ZYNLONTA is indicated for the treatment of adult patients with relapsed or refractory large B cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, DLBCL arising from low grade lymphoma, and high-grade B-cell lymphoma.
This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).",Priority,Yes,Yes,No,No,N/A,No,No,NA,2020-09-21,2021-04-23,214,5.365976015021851,Post-FDASIA
Empaveli,pegcetacoplan,"Apellis Pharmaceuticals, Inc.",NDA,215014,NA,NA,Injectable,Injection,NA,NA,NA,NA,9/14/2020,5/14/2021,2021,NA,EMPAVELI is indicated for the treatment of adult patients with paroxysmal nocturnal hemoglobinuria (PNH).,Priority,Yes,No,No,Yes,No,No,No,NA,2020-09-14,2021-05-14,242,5.488937726156687,Post-FDASIA
Rybrevant,amivantamab-vmjw,"Janssen Biotech, Inc.",BLA,761210,NA,NA,Injectable,Injection,NA,NA,NA,NA,11/24/2020,5/21/2021,2021,NA,"RYBREVANT is indicated for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy.
This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.",Priority,No,Yes,Yes,No,N/A,No,No,NA,2020-11-24,2021-05-21,178,5.181783550292085,Post-FDASIA
Pylarify,piflufolastat F 18,"Progenics Pharmaceuticals, Inc.",NDA,214793,NA,NA,Injectable,Injection,NA,NA,NA,NA,9/29/2020,5/26/2021,2021,NA,"PYLARIFY is indicated for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer:
- with suspected metastasis who are candidates for initial definitive therapy.
- with suspected recurrence based on elevated serum prostate-specific antigen (PSA) level.",Priority,No,No,No,No,No,No,No,NA,2020-09-29,2021-05-26,239,5.476463551931511,Post-FDASIA
Lumakras,sotorasib,"Amgen, Inc.",NDA,214665,NA,NA,Tablet,Oral,NA,NA,NA,NA,12/16/2020,5/28/2021,2021,NA,"LUMAKRAS is indicated for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), as determined by an FDA-approved test, who have received at least one prior systemic therapy.
This indication is approved under accelerated approval based on overall response rate (ORR) and duration of response (DOR). Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).",Priority,Yes,Yes,Yes,Yes,No,No,No,NA,2020-12-16,2021-05-28,163,5.093750200806762,Post-FDASIA
Lybalvi,olanzapine and samidorphan,"Alkermes, Inc.",NDA,213378,NA,NA,Tablet,Oral,NA,NA,NA,NA,11/15/2019,5/28/2021,2021,NA,"LYBALVI is indicated for treatment of:
- schizophrenia in adults
- bipolar I disorder in adults
-- Acute treatment of manic or mixed episodes as monotherapy and as adjunct to lithium or valproate
-- Maintenance monotherapy treatment",Standard,No,No,No,No,No,No,No,NA,2019-11-15,2021-05-28,560,6.327936783729195,Post-FDASIA
Truseltiq,infigratinib,"QED Therapeutics, Inc.",NDA,214622,NA,NA,Capsule,Oral,NA,NA,NA,NA,9/29/2020,5/28/2021,2021,NA,"TRUSELTIQ is indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected by an FDA-approved test.
This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).",Priority,Yes,Yes,No,Yes,No,No,No,NA,2020-09-29,2021-05-28,241,5.484796933490655,Post-FDASIA
Brexafemme,ibrexafungerp,"Scynexis, Inc.",NDA,214900,NA,NA,Tablet,Oral,NA,NA,NA,NA,10/1/2020,6/1/2021,2021,NA,BREXAFEMME is indicated for the treatment of adult and post-menarchal pediatric females with vulvovaginal candidiasis (VVC).,Priority,No,No,No,Yes,Yes,No,No,NA,2020-10-01,2021-06-01,243,5.493061443340548,Post-FDASIA
Aduhelm,aducanumab-avwa,"Biogen, Inc.",BLA,761178,NA,NA,Injectable,Injection,NA,NA,NA,NA,7/7/2020,6/7/2021,2021,NA,ADUHELM is indicated for the treatment of Alzheimer’s disease. This indication is approved under accelerated approval based on reduction in amyloid beta plaques observed in patients treated with ADUHELM. Continued approval for this indication may be contingent upon verification of clinical benefit in confirmatory trial(s).,Priority,No,Yes,No,Yes,N/A,No,No,NA,2020-07-07,2021-06-07,335,5.814130531825066,Post-FDASIA
Rylaze,asparaginase erwinia chrysanthemi (recombinant)-rywn,Jazz Pharmaceuticals Ireland Limited,BLA,761179,NA,NA,Injectable,Injection,NA,NA,NA,NA,4/30/2021,6/30/2021,2021,NA,RYLAZE is indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL) in adult and pediatric patients 1 month or older who have developed hypersensitivity to E. coli-derived asparaginase.,Standard,Yes,No,No,Yes,N/A,No,No,NA,2021-04-30,2021-06-30,61,4.110873864173311,Post-FDASIA
Kerendia,finerenone,"Bayer HealthCare Pharmaceuticals, Inc.",NDA,215341,NA,NA,Tablet,Oral,NA,NA,NA,NA,11/9/2020,7/9/2021,2021,NA,"Kerendia is indicated to reduce the risk of sustained eGFR decline, end-stage kidney disease, cardiovascular death, nonfatal myocardial infarction, and hospitalization for heart failure in adult patients with chronic kidney disease (CKD) associated with type 2 diabetes (T2D).",Priority,No,No,No,Yes,No,No,No,NA,2020-11-09,2021-07-09,242,5.488937726156687,Post-FDASIA
[drug marketed without a proprietary name],fexinidazole,Drugs for Neglected Diseases initiative,NDA,214429,NA,NA,Tablet,Oral,NA,NA,NA,NA,3/12/2020,7/16/2021,2021,NA,"Fexinidazole Tablets are indicated for the treatment of both the first-stage (hemolymphatic) and second-stage (meningoencephalitic) human African trypanosomiasis (HAT) due to Trypanosoma brucei gambiense in patients 6 years of age and older and weighing at least 20 kg.
Limitations of Use:
Due to the decreased efficacy observed in patients with severe second stage HAT (cerebrospinal fluid white blood cell count (CSF-WBC) >100 cells/?L) due to T. brucei gambiense disease, Fexinidazole Tablets should only be used in these patients if there are no other available treatment options.",Priority,Yes,No,No,No,No,TD,No,NA,2020-03-12,2021-07-16,491,6.19644412779452,Post-FDASIA
Rezurock,belumosudil,"Kadmon Pharmaceuticals, LLC",NDA,214783,NA,NA,Tablet,Oral,NA,NA,NA,NA,9/30/2020,7/16/2021,2021,NA,REZUROCK is indicated for the treatment of adult and pediatric patients 12 years and older with chronic graft-versus-host disease (chronic GVHD) after failure of at least two prior lines of systemic therapy.,Priority,Yes,No,Yes,No,No,No,No,NA,2020-09-30,2021-07-16,289,5.666426688112432,Post-FDASIA
Bylvay,odevixibat,Albireo AB,NDA,215498,NA,NA,Capsule,Oral,NA,NA,NA,NA,11/20/2020,7/20/2021,2021,NA,"BYLVAY is indicated for the treatment of pruritus in patients 3 months of age and older with progressive familial intrahepatic cholestasis (PFIC).
Limitations of Use:
-BYLVAY may not be effective in PFIC type 2 patients with ABCB11 variants resulting in nonfunctional or complete absence of bile salt export pump protein (BSEP-3).",Priority,Yes,No,No,Yes,No,RPD,No,NA,2020-11-20,2021-07-20,242,5.488937726156687,Post-FDASIA
Saphnelo,anifrolumab-fnia,AstraZeneca AB,BLA,761123,NA,NA,Injectable,Injection,NA,NA,NA,NA,7/31/2020,7/30/2021,2021,NA,"SAPHNELO (anifrolumab-fnia) is indicated for the treatment of adult patients with moderate to severe systemic lupus erythematosus (SLE), who are receiving standard therapy.
Limitations of Use: The efficacy of SAPHNELO has not been evaluated in patients with severe active lupus nephritis or severe active central nervous system lupus. Use of SAPHNELO is not recommended in these situations.",Standard,No,No,No,Yes,N/A,No,No,NA,2020-07-31,2021-07-30,364,5.8971538676367405,Post-FDASIA
Nexviazyme,avalglucosidase alfa-ngpt,Genzyme Corporation,BLA,761194,NA,NA,Injectable,Injection,NA,NA,NA,NA,9/18/2020,8/6/2021,2021,NA,NEXVIAZYME is indicated for the treatment of patients 1 year of age and older with late-onset Pompe disease (lysosomal acid alpha-glucosidase [GAA] deficiency).,Priority,Yes,No,Yes,Yes,N/A,No,No,NA,2020-09-18,2021-08-06,322,5.7745515455444085,Post-FDASIA
Welireg,belzutifan,Merck Sharp and Dohme Corp.,NDA,215383,NA,NA,Tablet,Oral,NA,NA,NA,NA,1/15/2021,8/13/2021,2021,NA,"WELIREG is indicated for treatment of adult patients with von Hippel-Lindau (VHL) disease who require therapy for associated renal cell carcinoma (RCC), central nervous system (CNS) hemangioblastomas, or pancreatic neuroendocrine tumors (pNET), not requiring immediate surgery.",Priority,Yes,No,No,No,No,No,No,NA,2021-01-15,2021-08-13,210,5.3471075307174685,Post-FDASIA
Korsuva,difelikefalin,"Cara Therapeutics, Inc.",NDA,214916,NA,NA,Injectable,Injection,NA,NA,NA,NA,12/23/2020,8/23/2021,2021,NA,"KORSUVA is indicated for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD-aP) in adults undergoing hemodialysis (HD).
Limitations of Use:
KORSUVA has not been studied in patients on peritoneal dialysis and is not recommended for use in this population.",Priority,No,No,Yes,No,No,No,No,NA,2020-12-23,2021-08-23,243,5.493061443340548,Post-FDASIA
Skytrofa,lonapegsomatropin-tcgd,Ascendis Pharma Endocrinology Division A/S,BLA,761177,NA,NA,Injectable,Injection,NA,NA,NA,NA,6/25/2020,8/25/2021,2021,NA,SKYTROFA (lonapegsomatropin-tcgd) is a human growth hormone indicated for the treatment of pediatric patients 1 year and older who weigh at least 11.5 kg and have growth failure due to inadequate secretion of endogenous growth hormone (GH).,Standard,Yes,No,No,No,N/A,No,No,NA,2020-06-25,2021-08-25,426,6.054439346269371,Post-FDASIA
Exkivity,mobocertinib,"Takeda Pharmaceuticals U.S.A., Inc.",NDA,215310,NA,NA,Capsule,Oral,NA,NA,NA,NA,2/26/2021,9/15/2021,2021,NA,"EXKIVITY is indicated for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy.
This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s).",Priority,Yes,Yes,Yes,Yes,No,No,No,NA,2021-02-26,2021-09-15,201,5.303304908059076,Post-FDASIA
Tivdak,tisotumab vedotin-tftv,"Seagen, Inc.",BLA,761208,NA,NA,Injectable,Injection,NA,NA,NA,NA,2/10/2021,9/20/2021,2021,NA,"TIVDAK is indicated for the treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy.
This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.",Priority,No,Yes,No,No,N/A,No,No,NA,2021-02-10,2021-09-20,222,5.402677381872279,Post-FDASIA
Qulipta,atogepant,"AbbVie, Inc.",NDA,215206,NA,NA,Tablet,Oral,NA,NA,NA,NA,1/28/2021,9/28/2021,2021,NA,QULIPTA is indicated for the preventive treatment of episodic migraine in adults.,Priority (used priority review voucher),No,No,No,No,No,No,Yes,NA,2021-01-28,2021-09-28,243,5.493061443340548,Post-FDASIA
Livmarli,maralixibat,"Mirum Pharmaceuticals, Inc.",NDA,214662,NA,NA,Solution,Oral,NA,NA,NA,NA,1/29/2021,9/29/2021,2021,NA,LIVMARLI is indicated for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) 1 year of age and older.,Priority,Yes,No,Yes,No,No,RPD,No,NA,2021-01-29,2021-09-29,243,5.493061443340548,Post-FDASIA
Tavneos,avacopan,"ChemoCentryx, Inc.",NDA,214487,NA,NA,Capsule,Oral,NA,NA,NA,NA,7/7/2020,10/7/2021,2021,NA,TAVNEOS is indicated as an adjunctive treatment of adult patients with severe active antineutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (granulomatosis with polyangiitis [GPA] and microscopic polyangiitis [MPA]) in combination with standard therapy including glucocorticoids. TAVNEOS does not eliminate glucocorticoid use.,Standard,Yes,No,No,No,No,No,No,NA,2020-07-07,2021-10-07,457,6.124683390894205,Post-FDASIA
Scemblix,asciminib,Novartis Pharmaceuticals Corporation,NDA,215358,NA,NA,Tablet,Oral,NA,NA,NA,NA,6/24/2021,10/29/2021,2021,NA,"SCEMBLIX is indicated for the treatment of adult patients with:
[A]Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP), previously treated with two or more tyrosine kinase inhibitors (TKIs)
[B] Treatment of adult patients with Ph+ CML in CP with the T315I mutation.",Priority,Yes,Yes (indication [A] only),Yes,Yes,No,No,No,NA,2021-06-24,2021-10-29,127,4.844187086458591,Post-FDASIA
Besremi,ropeginterferon alfa-2b-njft,PharmaEssentia Corporation,BLA,761166,NA,NA,Injectable,Injection,NA,NA,NA,NA,3/13/2020,11/12/2021,2021,NA,BESREMi is indicated for the treatment of adults with polycythemia vera.,Standard,Yes,No,No,No,N/A,No,No,NA,2020-03-13,2021-11-12,609,6.411818267709897,Post-FDASIA
Voxzogo,vosoritide,"BioMarin Pharmaceutical, Inc.",NDA,214938,NA,NA,Injectable,Injection,NA,NA,NA,NA,8/20/2020,11/19/2021,2021,NA,VOXZOGO is indicated to increase linear growth in pediatric patients with achondroplasia who are 5 years of age and older with open epiphyses. This indication is approved under accelerated approval based on an improvement in annualized growth velocity [see Clinical Studies (14)]. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s).,Priority,Yes,Yes,No,No,No,RPD,No,NA,2020-08-20,2021-11-19,456,6.1224928095143865,Post-FDASIA
Livtencity,maribavir,"Takeda Pharmaceuticals U.S.A., Inc.",NDA,215596,NA,NA,Tablet,Oral,NA,NA,NA,NA,3/23/2021,11/23/2021,2021,NA,"LIVTENCITY is indicated for the treatment of adults and pediatric patients (12 years of age and older and weighing at least 35 kg) with post-transplant cytomegalovirus (CMV) infection/disease that is refractory to treatment (with or without genotypic resistance) with ganciclovir, valganciclovir, cidofovir or foscarnet.",Priority,Yes,No,Yes,No,No,No,No,NA,2021-03-23,2021-11-23,245,5.501258210544727,Post-FDASIA
Cytalux,pafolacianine,"On Target Laboratories, Inc.",NDA,214907,NA,NA,Injectable,Injection,NA,NA,NA,NA,12/29/2020,11/29/2021,2021,NA,CYTALUX is an optical imaging agent indicated in adult patients with ovarian cancer as an adjunct for intraoperative identification of malignant lesions.,Priority,Yes,No,No,Yes,No,No,No,NA,2020-12-29,2021-11-29,335,5.814130531825066,Post-FDASIA
Tezspire,tezepelumab-ekko,AstraZeneca AB,BLA,761224,NA,NA,Injectable,Injection,NA,NA,NA,NA,5/7/2021,12/17/2021,2021,NA,"TEZSPIRE is indicated for the add-on maintenance treatment of adult and pediatric patients aged 12 years and older with severe asthma.
Limitations of Use:
TEZSPIRE is not indicated for the relief of acute bronchospasm or status asthmaticus.",Priority,No,No,No,No,N/A,No,No,NA,2021-05-07,2021-12-17,224,5.4116460518550396,Post-FDASIA
Vyvgart,efgartigimod alfa-fcab,argenx BV,BLA,761195,NA,NA,Injectable,Injection,NA,NA,NA,NA,12/17/2020,12/17/2021,2021,NA,VYVGART is indicated for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive.,Standard,Yes,No,No,Yes,N/A,No,No,NA,2020-12-17,2021-12-17,365,5.8998973535824915,Post-FDASIA
Leqvio,inclisiran,Novartis Pharmaceuticals Corporation,NDA,214012,NA,NA,Injectable,Injection,NA,NA,NA,NA,12/23/2019,12/22/2021,2021,NA,"LEQVIO is indicated as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia (HeFH) or clinical atherosclerotic cardiovascular disease (ASCVD), who require additional lowering of low-density lipoprotein cholesterol (LDL-C).
Limitations of Use:
The effect of LEQVIO on cardiovascular morbidity and mortality has not been determined.",Standard,No,No,No,No,No,No,No,NA,2019-12-23,2021-12-22,730,6.593044534142437,Post-FDASIA
Adbry,tralokinumab-ldrm,LEO Pharma A/S,BLA,761180,NA,NA,Injectable,Injection,NA,NA,NA,NA,4/27/2020,12/27/2021,2021,NA,ADBRY is indicated for the treatment of moderate-to-severe atopic dermatitis in adult patients whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. ADBRY can be used with or without topical corticosteroids.,Standard,No,No,No,No,N/A,No,No,NA,2020-04-27,2021-12-27,609,6.411818267709897,Post-FDASIA
Quviviq,daridorexant,Idorsia Pharmaceuticals Ltd.,NDA,214985,NA,NA,Tablet,Oral,NA,NA,NA,NA,1/8/2021,1/7/2022,2022,NA,"QUVIVIQ is indicated for the treatment of adult patients with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance.",Standard,No,No,No,No,No,No,No,NA,2021-01-08,2022-01-07,364,5.8971538676367405,Post-FDASIA
Cibinqo,abrocitinib,"Pfizer, Inc.",NDA,213871,NA,NA,Tablet,Oral,NA,NA,NA,NA,8/25/2020,1/14/2022,2022,NA,"CIBINQO is indicated for the treatment of adults with refractory, moderate-to-severe atopic dermatitis whose disease is not adequately controlled with other systemic drug products, including biologics, or when use of those therapies is inadvisable.
Limitations of Use:
CIBINQO is not recommended for use in combination with other JAK inhibitors, biologic immunomodulators, or with other immunosuppressants.",Priority,No,No,Yes,No,No,No,No,NA,2020-08-25,2022-01-14,507,6.2285110035911835,Post-FDASIA
Kimmtrak,tebentafusp-tebn,Immunocore Limited,BLA,761228,NA,NA,Injectable,Injection,NA,NA,NA,NA,6/23/2021,1/25/2022,2022,NA,KIMMTRAK is indicated for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma.,Priority,Yes,No,Yes,No,N/A,No,No,NA,2021-06-23,2022-01-25,216,5.375278407684165,Post-FDASIA
Vabysmo,faricimab-svoa,"Genentech, Inc.",BLA,761235,NA,NA,Injectable,Intravitreal,NA,NA,NA,NA,5/28/2021,1/28/2022,2022,NA,"VABYSMO is a vascular endothelial growth factor (VEGF) and angiopoietin 2 (Ang-2) inhibitor indicated for the treatment of patients with:
- Neovascular (wet) Age-Related Macular Degeneration (nAMD)
- Diabetic Macular Edema (DME)",Priority (used priority review voucher),No,No,No,No,N/A,No,Yes,NA,2021-05-28,2022-01-28,245,5.501258210544727,Post-FDASIA
Enjaymo,sutimlimab-jome,"Bioverativ USA, Inc.",BLA,761164,NA,NA,Injectable,Injection,NA,NA,NA,NA,3/13/2020,2/4/2022,2022,NA,ENJAYMO (sutimlimab-jome) is indicated to decrease the need for red blood cell (RBC) transfusion due to hemolysis in adults with cold agglutinin disease (CAD),Priority,Yes,No,Yes,No,N/A,No,No,NA,2020-03-13,2022-02-04,693,6.541029999189903,Post-FDASIA
Pyrukynd,mitapivat,"Agios Pharmaceuticals, Inc.",NDA,216196,NA,NA,Tablet,Oral,NA,NA,NA,NA,6/17/2021,2/17/2022,2022,NA,PYRUKYND is indicated for the treatment of hemolytic anemia in adults with pyruvate kinase (PK) deficiency.,Priority,Yes,No,No,Yes,No,No,No,NA,2021-06-17,2022-02-17,245,5.501258210544727,Post-FDASIA
Vonjo,pacritinib,CTI BioPharma Corporation,NDA,208712,NA,NA,Capsule,Oral,NA,NA,NA,NA,3/30/2021,2/28/2022,2022,NA,VONJO is indicated for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis (MF) with a platelet count below 50 × 10^9/L. This indication is approved under accelerated approval based on spleen volume reduction. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).,Priority,Yes,Yes,No,Yes,No,No,No,NA,2021-03-30,2022-02-28,335,5.814130531825066,Post-FDASIA
Opdualag,nivolumab and relatlimab-rmbw,Bristol-Myers Squibb Company,BLA,761234,NA,NA,Solution,Intravenous,NA,NA,NA,NA,7/19/2021,3/18/2022,2022,NA,OPDUALAG is indicated for the treatment of adult and pediatric patients 12 years of age or older with unresectable or metastatic melanoma.,Priority,Yes,No,No,Yes,N/A,No,No,NA,2021-07-19,2022-03-18,242,5.488937726156687,Post-FDASIA
Ztalmy,ganaxolone,"Marinus Pharmaceuticals, Inc.",NDA,215904,NA,NA,Suspension,Oral,NA,NA,NA,NA,7/20/2021,3/18/2022,2022,NA,ZTALMY is indicated for the treatment of seizures associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD) in patients 2 years of age and older.,Priority,Yes,No,No,No,No,RPD,No,NA,2021-07-20,2022-03-18,241,5.484796933490655,Post-FDASIA
Pluvicto,lutetium Lu 177 vipivotide tetraxetan,"Advanced Accelerator Applications USA, Inc.",NDA,215833,NA,NA,Solution,Intravenous,NA,NA,NA,NA,7/29/2021,3/23/2022,2022,NA,PLUVICTO is indicated for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor (AR) pathway inhibition and taxane-based chemotherapy.,Priority,No,No,Yes,No,No,No,No,NA,2021-07-29,2022-03-23,237,5.4680601411351315,Post-FDASIA
Vivjoa,oteseconazole,"Mycovia Pharmaceuticals, Inc.",NDA,215888,NA,NA,Capsule,Oral,NA,NA,NA,NA,5/27/2021,4/26/2022,2022,NA,"VIVJOA is indicated to reduce the incidence of recurrent vulvovaginal candidiasis (RVVC) in females with a history of RVVC who are NOT of reproductive potential.
If specimens for fungal culture are obtained prior to therapy, antifungal therapy may be instituted before the results of the cultures are known. However, once these results become available, antifungal therapy should be adjusted accordingly.",Priority,No,No,No,Yes,Yes,No,No,NA,2021-05-27,2022-04-26,334,5.811140992976701,Post-FDASIA
Camzyos,mavacamten,"MyoKardia, Inc.",NDA,214998,NA,NA,Capsule,Oral,NA,NA,NA,NA,1/28/2021,4/28/2022,2022,NA,CAMZYOS is indicated for the treatment of adults with symptomatic New York Heart Association (NYHA) class II-III obstructive hypertrophic cardiomyopathy (HCM) to improve functional capacity and symptoms.,Standard,Yes,No,Yes,No,No,No,No,NA,2021-01-28,2022-04-28,455,6.12029741895095,Post-FDASIA
Voquezna Triple Pak,vonoprazan; amoxicillin; clarithromycin (co-packaged),"Phathom Pharmaceuticals, Inc.",NDA,215152,NA,NA,"Capsule, Tablet, Tablet",Oral,NA,NA,NA,NA,9/3/2021,5/3/2022,2022,NA,"VOQUEZNA TRIPLE PAK or VOQUEZNA DUAL PAK are indicated for the treatment of Helicobacter pylori (H. pylori) infection in adults. 
To reduce the development of drug-resistant bacteria and maintain the effectiveness of VOQUEZNA TRIPLE PAK, VOQUEZNA DUAL PAK and other antibacterial drugs, VOQUEZNA TRIPLE PAK and VOQUEZNA DUAL PAK should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.",Priority,No,No,No,Yes,Yes,No,No,NA,2021-09-03,2022-05-03,242,5.488937726156687,Post-FDASIA
Mounjaro,tirzepatide,Eli Lilly and Company,NDA,215866,NA,NA,Solution,Subcutaneous,NA,NA,NA,NA,9/15/2021,5/13/2022,2022,NA,"MOUNJARO is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes
mellitus.
Limitations of Use:
MOUNJARO has not been studied in patients with a history of pancreatitis.
MOUNJARO is not indicated for use in patients with type 1 diabetes mellitus.",Priority (used priority review voucher),No,No,No,No,No,No,Yes,NA,2021-09-15,2022-05-13,240,5.480638923341991,Post-FDASIA
Vtama,tapinarof,"Dermavant Sciences, Inc.",NDA,215272,NA,NA,Cream,Topical,NA,NA,NA,NA,5/26/2021,5/23/2022,2022,NA,"VTAMA (tapinarof) cream, 1% is an aryl hydrocarbon receptor agonist indicated for the topical treatment of plaque psoriasis in adults.",Standard,No,No,No,No,No,No,No,NA,2021-05-26,2022-05-23,362,5.8916442118257715,Post-FDASIA
Amvuttra,vutrisiran,"Alnylam Pharmaceuticals, Inc.",NDA,215515,NA,NA,Solution,Subcutaneous,NA,NA,NA,NA,4/14/2021,6/13/2022,2022,NA,AMVUTTRA is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.,Standard,Yes,No,No,Yes,No,No,No,NA,2021-04-14,2022-06-13,425,6.052089168924417,Post-FDASIA
Xenpozyme,olipudase alfa-rpcp,Genzyme Corporation,BLA,761261,NA,NA,Injectable,Injection,NA,NA,NA,NA,11/3/2021,8/31/2022,2022,NA,XENPOZYME is indicated for treatment of non–central nervous system manifestations of acid sphingomyelinase deficiency (ASMD) in adult and pediatric patients.,Priority,Yes,No,Yes,Yes,N/A,RPD,No,NA,2021-11-03,2022-08-31,301,5.707110264748875,Post-FDASIA
Spevigo,spesolimab-sbzo,"Boehringer Ingelheim Pharmaceuticals, Inc.",BLA,761244,NA,NA,Injectable,Intravenous,NA,NA,NA,NA,10/1/2021,9/1/2022,2022,NA,SPEVIGO is indicated for the treatment of generalized pustular psoriasis (GPP) flares in adults.,Priority,Yes,No,Yes,No,N/A,No,No,NA,2021-10-01,2022-09-01,335,5.814130531825066,Post-FDASIA
Daxxify,daxibotulinumtoxinA-lanm,"Revance Therapeutics, Inc.",BLA,761127,NA,NA,Injectable,"Intramuscular, Subcutaneous",NA,NA,NA,NA,11/25/2019,9/7/2022,2022,NA,DAXXIFY (daxibotulinumtoxinA-lanm) is indicated for the temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adult patients.,Standard,No,No,No,No,N/A,No,No,NA,2019-11-25,2022-09-07,1017,6.92461239604856,Post-FDASIA
Rolvedon,eflapegrastim-xnst,"Spectrum Pharmaceuticals, Inc.",BLA,761148,NA,NA,Injectable,Subcutaneous,NA,NA,NA,NA,10/24/2019,9/9/2022,2022,NA,"ROLVEDON is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in adult patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with clinically significant incidence of febrile neutropenia.
Limitations of Use:
Rolvedon is not indicated for the mobilization of peripheral blood progenitor cells for hematopoietic stem cell transplantation.",Standard,No,No,No,No,N/A,No,No,NA,2019-10-24,2022-09-09,1051,6.957497370876951,Post-FDASIA
Sotyktu,deucravacitinib,Bristol-Myers Squibb Company,NDA,214958,NA,NA,Tablet,Oral,NA,NA,NA,NA,9/10/2021,9/9/2022,2022,NA,"SOTYKTU is indicated for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.
Limitations of Use:
SOTYKTU is not recommended for use in combination with other potent immunosuppressants.",Standard,No,No,No,No,No,No,No,NA,2021-09-10,2022-09-09,364,5.8971538676367405,Post-FDASIA
Elucirem,gadopiclenol,"Guerbet, LLC",NDA,216986,NA,NA,Solution,Intravenous,NA,NA,NA,NA,1/21/2022,9/21/2022,2022,NA,"ELUCIREM is indicated in adult and pediatric patients aged 2 years and older for use with magnetic resonance imaging (MRI) to detect and visualize lesions with abnormal vascularity in:
- the central nervous system (brain, spine, and associated tissues),
- the body (head and neck, thorax, abdomen, pelvis, and musculoskeletal system).",Priority,No,No,No,No,No,No,No,NA,2022-01-21,2022-09-21,243,5.493061443340548,Post-FDASIA
Omlonti,omidenepag isopropyl,"Santen, Inc.",NDA,215092,NA,NA,Solution,Ophthalmic,NA,NA,NA,NA,11/19/2020,9/22/2022,2022,NA,"OMLONTI (omidenepag isopropyl ophthalmic solution) 0.002%, is indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.",Standard,No,No,No,No,No,No,No,NA,2020-11-19,2022-09-22,672,6.5102583405231496,Post-FDASIA
Relyvrio,sodium phenylbutyrate and taurursodiol,"Amylyx Pharmaceuticals, Inc.",NDA,216660,NA,NA,For Suspension,Oral,NA,NA,NA,NA,10/29/2021,9/29/2022,2022,NA,RELYVRIO is indicated for the treatment of amyotrophic lateral sclerosis (ALS) in adults.,Priority,Yes,No,No,No,No,No,No,NA,2021-10-29,2022-09-29,335,5.814130531825066,Post-FDASIA
Lytgobi,futibatinib,"Taiho Oncology, Inc.",NDA,214801,NA,NA,Tablet,Oral,NA,NA,NA,NA,1/31/2022,9/30/2022,2022,NA,"LYTGOBI is indicated for the treatment of adult patients with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma harboring fibroblast growth factor receptor 2 (FGFR2) gene fusions or other rearrangements.
This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).",Priority,Yes,Yes,Yes,Yes,No,No,No,NA,2022-01-31,2022-09-30,242,5.488937726156687,Post-FDASIA
Imjudo,tremelimumab-actl,AstraZeneca AB,BLA,761289,NA,NA,Injectable,Intravenous,NA,NA,NA,NA,2/23/2022,10/21/2022,2022,NA,IMJUDO in combination with durvalumab is indicated for the treatment of adult patients with unresectable hepatocellular carcinoma (uHCC).,Priority (used priority review voucher),Yes,No,No,No,N/A,No,Yes,NA,2022-02-23,2022-10-21,240,5.480638923341991,Post-FDASIA
Tecvayli,teclistamab-cqyv,"Janssen Biotech, Inc.",BLA,761291,NA,NA,Injectable,Injection,NA,NA,NA,NA,12/28/2021,10/25/2022,2022,NA,"TECVAYLI is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody.
This indication is approved under accelerated approval based on response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s).",Priority,Yes,Yes,Yes,No,N/A,No,No,NA,2021-12-28,2022-10-25,301,5.707110264748875,Post-FDASIA
Elahere,mirvetuximab soravtansine-gynx,"ImmunoGen, Inc.",BLA,761310,NA,NA,Injectable,Injection,NA,NA,NA,NA,3/28/2022,11/14/2022,2022,NA,"ELAHERE is indicated for the treatment of adult patients with folate receptor-alpha (FRalpha) positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received one to three prior systemic treatment regimens. Select patients for therapy based on an FDA-approved test.
This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.",Priority,Yes,Yes,No,Yes,N/A,No,No,NA,2022-03-28,2022-11-14,231,5.442417710521793,Post-FDASIA
Tzield,teplizumab-mzwv,"Provention Bio, Inc.",BLA,761183,NA,NA,Injectable,Injection,NA,NA,NA,NA,11/2/2020,11/17/2022,2022,NA,TZIELD is indicated to delay the onset of Stage 3 type 1 diabetes in adults and pediatric patients 8 years of age and older with Stage 2 type 1 diabetes.,Priority,No,No,Yes,No,N/A,No,No,NA,2020-11-02,2022-11-17,745,6.61338421837956,Post-FDASIA
Rezlidhia,olutasidenib,"Forma Therapeutics, Inc.",NDA,215814,NA,NA,Capsule,Oral,NA,NA,NA,NA,2/15/2022,12/1/2022,2022,NA,REZLIDHIA is indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test.,Standard,Yes,No,No,No,No,No,No,NA,2022-02-15,2022-12-01,289,5.666426688112432,Post-FDASIA
Krazati,adagrasib,"Mirati Therapeutics, Inc.",NDA,216340,NA,NA,Tablet,Oral,NA,NA,NA,NA,12/14/2021,12/12/2022,2022,NA,"KRAZATI is indicated for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), as determined by an FDA-approved test, who have received at least one prior systemic therapy.
This indication is approved under accelerated approval based on objective response rate (ORR) and duration of response (DOR). Continued approval for this indication may be contingent upon verification and description of a clinical benefit in a confirmatory trial(s).",Standard,Yes,Yes,Yes,Yes,No,No,No,NA,2021-12-14,2022-12-12,363,5.8944028342648505,Post-FDASIA
Lunsumio,mosunetuzumab-axgb,"Genentech, Inc.",BLA,761263,NA,NA,Injectable,Injection,NA,NA,NA,NA,4/29/2022,12/22/2022,2022,NA,"LUNSUMIO is indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy.
This indication is approved under accelerated approval based on response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).",Priority,Yes,Yes,Yes,No,N/A,No,No,NA,2022-04-29,2022-12-22,237,5.4680601411351315,Post-FDASIA
Sunlenca,lenacapavir,"Gilead Sciences, Inc.",NDA,215973,NA,NA,Solution,Subcutaneous,NA,NA,NA,NA,6/28/2021,12/22/2022,2022,NA,"SUNLENCA, in combination with other antiretroviral(s), is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in heavily treatment-experienced adults with multidrug resistant HIV-1 infection failing their current antiretroviral regimen due to resistance, intolerance, or safety considerations.",Priority,No,No,Yes,Yes,No,No,No,NA,2021-06-28,2022-12-22,542,6.295266001439646,Post-FDASIA
Xenoview,xenon Xe 129 hyperpolarized,"Polarean, Inc.",NDA,214375,NA,NA,Gas,Inhalation,NA,NA,NA,NA,10/5/2020,12/23/2022,2022,NA,"XENOVIEW, prepared from the Xenon Xe 129 Gas Blend, is indicated for use with magnetic resonance imaging (MRI) for evaluation of lung ventilation in adults and pediatric patients aged 12 years and older.
Limitations of Use:
XENOVIEW has not been evaluated for use with lung perfusion imaging.",Standard,No,No,No,No,No,No,No,NA,2020-10-05,2022-12-23,809,6.695798917058491,Post-FDASIA
Briumvi,ublituximab-xiiy,"TG Therapeutics, Inc.",BLA,761238,NA,NA,Injectable,Intravenous,NA,NA,NA,NA,9/28/2021,12/28/2022,2022,NA,"BRIUMVI is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.",Standard,No,No,No,No,N/A,No,No,NA,2021-09-28,2022-12-28,456,6.1224928095143865,Post-FDASIA
NexoBrid,anacaulase-bcdb,"MediWound, Ltd.",BLA,761192,NA,NA,Gel,Topical,NA,NA,NA,NA,6/29/2020,12/28/2022,2022,NA,"NEXOBRID is indicated for eschar removal in adults with deep partial thickness (DPT) and/or full thickness (FT) thermal burns. 
Limitations of Use:
The safety and effectiveness of NEXOBRID have not been established for treatment of:
-Chemical or electrical burns
-Burns on the face, perineum, or genitalia
-Burns on the feet of patients with diabetes mellitus or on the feet of patients with occlusive vascular disease
-Circumferential burns
-Burns in patients with significant cardiopulmonary disease, including inhalation injury
NEXOBRID is not recommended for wounds contaminated with radioactive and other hazardous substances to avoid unforeseeable reactions with the product and an increased risk of spreading the noxious substance.",Standard,Yes,No,No,No,N/A,No,No,NA,2020-06-29,2022-12-28,912,6.815639990074331,Post-FDASIA
Leqembi,lecanemab-irmb,"Eisai, Inc.",BLA,761269,NA,NA,Injectable,Injection,NA,NA,NA,NA,5/6/2022,1/6/2023,2023,NA,"LEQEMBI is indicated for the treatment of Alzheimer’s disease. Treatment with LEQEMBI should be initiated in patients with mild cognitive impairment or mild dementia stage of disease, the population in which treatment was initiated in clinical trials. There are no safety or effectiveness data on initiating treatment at earlier or later stages of the disease than were studied. This indication is approved under accelerated approval based on reduction in amyloid beta plaques observed in patients treated with LEQEMBI . Continued approval for this indication may be contingent upon verification of clinical benefit in a confirmatory trial.",Priority,No,Yes,Yes,Yes,N/A,No,No,NA,2022-05-06,2023-01-06,245,5.501258210544727,Post-FDASIA
Brenzavvy,bexagliflozin,"TheracosBio, LLC.",NDA,214373,NA,NA,Tablet,Oral,NA,NA,NA,NA,10/22/2021,1/20/2023,2023,NA,"BRENZAVVY is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Limitations of Use:
BRENZAVVY is not recommended in patients with type 1 diabetes mellitus. It may increase the risk of diabetic ketoacidosis in these patients.",Standard,No,No,No,No,No,No,No,NA,2021-10-22,2023-01-20,455,6.12029741895095,Post-FDASIA
Jaypirca,pirtobrutinib,"Loxo Oncology, Inc.",NDA,216059,NA,NA,Tablet,Oral,NA,NA,NA,NA,5/27/2022,1/27/2023,2023,NA,"JAYPIRCA is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy, including a BTK inhibitor.
This indication is approved under accelerated approval based on response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.",Priority,Yes,Yes,No,Yes,No,No,No,NA,2022-05-27,2023-01-27,245,5.501258210544727,Post-FDASIA
Orserdu,elacestrant,"Stemline Therapeutics, Inc.",NDA,217639,NA,NA,Tablet,Oral,NA,NA,NA,NA,6/17/2022,1/27/2023,2023,NA,"ORSERDU is indicated for the treatment of postmenopausal women or adult men with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, ESR1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy.",Priority,No,No,No,Yes,No,No,No,NA,2022-06-17,2023-01-27,224,5.4116460518550396,Post-FDASIA
Jesduvroq,daprodustat,GlaxoSmithKline Intellectual Property (No. 2) Limited England,NDA,216951,NA,NA,Tablet,Oral,NA,NA,NA,NA,2/1/2022,2/1/2023,2023,NA,"JESDUVROQ is indicated for the treatment of anemia due to chronic kidney disease (CKD) in adults who have been receiving dialysis for at least four months.
Limitations of Use:
JESDUVROQ has not been shown to improve quality of life, fatigue, or patient well-being.
JESDUVROQ is not indicated for use:
-As a substitute for red blood cell transfusions in patients who require immediate
correction of anemia.
-For treatment of anemia of chronic kidney disease in patients who are not on dialysis.",Standard,No,No,No,No,No,No,No,NA,2022-02-01,2023-02-01,365,5.8998973535824915,Post-FDASIA
Lamzede,velmanase alfa-tycv,Chiesi Farmaceutici SpA,BLA,761278,NA,NA,Injectable,Injection,NA,NA,NA,NA,6/17/2022,2/16/2023,2023,NA,LAMZEDE is indicated for the treatment of non-central nervous system manifestations of alpha-mannosidosis in adult and pediatric patients.,Priority,Yes,No,No,Yes,N/A,RPD,No,NA,2022-06-17,2023-02-16,244,5.497168225293202,Post-FDASIA
Filspari,sparsentan,"Travere Therapeutics, Inc.",NDA,216403,NA,NA,Tablet,Oral,NA,NA,NA,NA,3/17/2022,2/17/2023,2023,NA,"FILSPARI is indicated to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid disease progression, generally a urine protein-to-creatinine ratio (UPCR) >=1.5 g/g.
This indication is approved under accelerated approval based on a reduction of proteinuria. It has not been established whether FILSPARI slows kidney function decline in patients with IgAN. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory clinical trial.",Priority,Yes,Yes,No,No,No,No,No,NA,2022-03-17,2023-02-17,337,5.820082930352362,Post-FDASIA
Skyclarys,omaveloxolone,"Reata Pharmaceuticals, Inc.",NDA,216718,NA,NA,Capsule,Oral,NA,NA,NA,NA,3/30/2022,2/28/2023,2023,NA,SKYCLARYS is indicated for the treatment of Friedreich's ataxia in adults and adolescents aged 16 years and older.,Priority,Yes,No,No,Yes,No,RPD,No,NA,2022-03-30,2023-02-28,335,5.814130531825066,Post-FDASIA
Zavzpret,zavegepant,"Pfizer, Inc.",NDA,216386,NA,NA,"Spray, Metered",Nasal,NA,NA,NA,NA,3/9/2022,3/9/2023,2023,NA,"ZAVZPRET is indicated for the acute treatment of migraine with or without aura in adults.
Limitations of Use:
ZAVZPRET is not indicated for the preventive treatment of migraine.",Standard,No,No,No,No,No,No,No,NA,2022-03-09,2023-03-09,365,5.8998973535824915,Post-FDASIA
Daybue,trofinetide,"Acadia Pharmaceuticals, Inc.",NDA,217026,NA,NA,Solution,Oral,NA,NA,NA,NA,7/12/2022,3/10/2023,2023,NA,DAYBUE is indicated for the treatment of Rett syndrome in adults and pediatric patients 2 years of age and older.,Priority,Yes,No,No,Yes,No,RPD,No,NA,2022-07-12,2023-03-10,241,5.484796933490655,Post-FDASIA
Rezzayo,rezafungin,"Cidara Therapeutics, Inc.",NDA,217417,NA,NA,Injectable,Injection,NA,NA,NA,NA,7/22/2022,3/22/2023,2023,NA,"REZZAYO is indicated in patients 18 years of age or older who have limited or no alternative options for the treatment of candidemia and invasive candidiasis. Approval of this indication is based on limited clinical safety and efficacy data for REZZAYO.
Limitations of Use:
REZZAYO has not been studied in patients with endocarditis, osteomyelitis, and meningitis due to Candida.",Priority,Yes,No,No,Yes,Yes,No,No,NA,2022-07-22,2023-03-22,243,5.493061443340548,Post-FDASIA
Zynyz,retifanlimab-dlwr,Incyte Corporation,BLA,761334,NA,NA,Injectable,Injection,NA,NA,NA,NA,8/8/2022,3/22/2023,2023,NA,"ZYNYZ is indicated for the treatment of adult patients with metastatic or recurrent locally advanced Merkel cell carcinoma (MCC).
This indication is approved under accelerated approval based on tumor response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.",Priority,Yes,Yes,No,Yes,N/A,No,No,NA,2022-08-08,2023-03-22,226,5.420534999272286,Post-FDASIA
Joenja,leniolisib,Pharming Technologies B.V.,NDA,217759,NA,NA,Tablet,Oral,NA,NA,NA,NA,7/29/2022,3/24/2023,2023,NA,JOENJA is indicated for the treatment of activated phosphoinositide 3-kinase delta (PI3K-delta) syndrome (APDS) in adult and pediatric patients 12 years of age and older.,Priority,Yes,No,No,No,No,RPD,No,NA,2022-07-29,2023-03-24,238,5.472270673671475,Post-FDASIA
Qalsody,tofersen,"Biogen, Inc.",NDA,215887,NA,NA,Injectable,Injection,NA,NA,NA,NA,5/25/2022,4/25/2023,2023,NA,QALSODY is indicated for the treatment of amyotrophic lateral sclerosis (ALS) in adults who have a mutation in the superoxide dismutase 1 (SOD1) gene. This indication is approved under accelerated approval based on reduction in plasma neurofilament light chain (NfL) observed in patients treated with QALSODY. Continued approval for this indication may be contingent upon verification of clinical benefit in confirmatory trial(s).,Priority,Yes,Yes,No,Yes,No,No,No,NA,2022-05-25,2023-04-25,335,5.814130531825066,Post-FDASIA
Elfabrio,pegunigalsidase alfa-iwxj,Chiesi Farmaceutici SpA,BLA,761161,NA,NA,Injectable,Injection,NA,NA,NA,NA,5/27/2020,5/9/2023,2023,NA,ELFABRIO is indicated for the treatment of adults with confirmed Fabry disease.,Priority,No,No,No,Yes,N/A,No,No,NA,2020-05-27,2023-05-09,1077,6.981934677156389,Post-FDASIA
Veozah,fezolinetant,"Astellas Pharma US, Inc.",NDA,216578,NA,NA,Tablet,Oral,NA,NA,NA,NA,6/22/2022,5/12/2023,2023,NA,VEOZAH is indicated for the treatment of moderate to severe vasomotor symptoms due to menopause.,Priority (used priority review voucher),No,No,No,No,No,No,Yes,NA,2022-06-22,2023-05-12,324,5.780743515792329,Post-FDASIA
Miebo,perfluorohexyloctane,"Bausch and Lomb, Inc.",NDA,216675,NA,NA,Solution,Ophthalmic,NA,NA,NA,NA,6/28/2022,5/18/2023,2023,NA,MIEBO (perfluorohexyloctane ophthalmic solution) is indicated for the treatment of the signs and symptoms of dry eye disease (DED).,Standard,No,No,No,No,No,No,No,NA,2022-06-28,2023-05-18,324,5.780743515792329,Post-FDASIA
Epkinly,epcoritamab-bysp,"Genmab US, Inc.",BLA,761324,NA,NA,Injectable,Injection,NA,NA,NA,NA,9/21/2022,5/19/2023,2023,NA,"EPKINLY is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from indolent lymphoma, and high-grade B-cell lymphoma after two or more lines of systemic therapy.
This indication is approved under accelerated approval based on response rate and durability of
response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).",Priority,No,Yes,No,No,N/A,No,No,NA,2022-09-21,2023-05-19,240,5.480638923341991,Post-FDASIA
Xacduro,sulbactam; durlobactam (co-packaged),"Entasis Therapeutics, Inc.",NDA,216974,NA,NA,Injectable,Injection,NA,NA,NA,NA,9/29/2022,5/23/2023,2023,NA,"XACDURO is indicated in patients 18 years of age and older for the treatment of hospitalacquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP), caused by susceptible isolates of Acinetobacter baumannii-calcoaceticus complex.
Limitations of Use:
XACDURO is not indicated for the treatment of HABP/VABP caused by pathogens other than susceptible isolates of Acinetobacter baumannii-calcoaceticus complex.
To reduce the development of drug-resistant bacteria and maintain the effectiveness of XACDURO and other antibacterial drugs, XACDURO should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.",Priority,No,No,No,Yes,Yes,No,No,NA,2022-09-29,2023-05-23,236,5.4638318050256105,Post-FDASIA
Posluma,flotufolastat F 18,"Blue Earth Diagnostics, Ltd.",NDA,216023,NA,NA,Injectable,Injection,NA,NA,NA,NA,5/25/2022,5/25/2023,2023,NA,"POSLUMA is indicated for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer
- with suspected metastasis who are candidates for initial definitive therapy.
- with suspected recurrence based on elevated serum prostate-specific antigen (PSA) level.",Standard,No,No,No,No,No,No,No,NA,2022-05-25,2023-05-25,365,5.8998973535824915,Post-FDASIA
Paxlovid,nirmatrelvir; ritonavir (co-packaged),"Pfizer, Inc.",NDA,217188,NA,NA,Tablet,Oral,NA,NA,NA,NA,6/29/2022,5/25/2023,2023,NA,"PAXLOVID is indicated for the treatment of mild-to-moderate coronavirus disease 2019 (COVID-19) in adults who are at high risk for progression to severe COVID-19, including hospitalization or death.
Limitations of Use:
PAXLOVID is not approved for use as pre-exposure or post-exposure prophylaxis for prevention of COVID-19.",Priority,No,No,No,Yes,No,MTMC,No,NA,2022-06-29,2023-05-25,330,5.799092654460526,Post-FDASIA
Inpefa,sotagliflozin,"Lexicon Pharmaceuticals, Inc.",NDA,216203,NA,NA,Tablet,Oral,NA,NA,NA,NA,5/27/2022,5/26/2023,2023,NA,"INPEFA is indicated to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with:
- heart failure or
- type 2 diabetes mellitus, chronic kidney disease, and other cardiovascular risk factors",Standard,No,No,No,No,No,No,No,NA,2022-05-27,2023-05-26,364,5.8971538676367405,Post-FDASIA
Columvi,glofitamab-gxbm,"Genentech, Inc.",BLA,761309,NA,NA,Injectable,Injection,NA,NA,NA,NA,11/1/2022,6/15/2023,2023,NA,"COLUMVI is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma, not otherwise specified (DLBCL, NOS) or large B-cell lymphoma (LBCL) arising from follicular lymphoma, after two or more lines of systemic therapy.
This indication is approved under accelerated approval based on response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).",Priority,No,Yes,No,Yes,N/A,No,No,NA,2022-11-01,2023-06-15,226,5.420534999272286,Post-FDASIA
Litfulo,ritlecitinib,"Pfizer, Inc.",NDA,215830,NA,NA,Capsule,Oral,NA,NA,NA,NA,6/24/2022,6/23/2023,2023,NA,"LITFULO is a kinase inhibitor indicated for the treatment of severe alopecia areata in adults and adolescents 12 years and older.
Limitations of Use: Not recommended for use in combination with other JAK inhibitors, biologic immunomodulators, cyclosporine or other potent immunosuppressants.",Standard,No,No,No,No,No,No,No,NA,2022-06-24,2023-06-23,364,5.8971538676367405,Post-FDASIA
Rystiggo,rozanolixizumab-noli,"UCB, Inc.",BLA,761286,NA,NA,Injectable,Injection,NA,NA,NA,NA,10/24/2022,6/26/2023,2023,NA,RYSTIGGO is indicated for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive.,Priority,Yes,No,No,No,N/A,No,No,NA,2022-10-24,2023-06-26,245,5.501258210544727,Post-FDASIA
Ngenla,somatrogon-ghla,Pfizer Ireland Pharmaceuticals,BLA,761184,NA,NA,Injectable,Injection,NA,NA,NA,NA,10/22/2020,6/27/2023,2023,NA,NGENLA is indicated for the treatment of pediatric patients aged 3 years and older who have growth failure due to an inadequate secretion of endogenous growth hormone.,Standard,Yes,No,No,No,N/A,No,No,NA,2020-10-22,2023-06-27,978,6.885509670034818,Post-FDASIA
Beyfortus,nirsevimab-alip,AstraZeneca AB,BLA,761328,NA,NA,Injectable,Injection,NA,NA,NA,NA,9/26/2022,7/17/2023,2023,NA,"BEYFORTUS is indicated for the prevention of Respiratory Syncytial Virus (RSV) lower respiratory tract disease in:
- Neonates and infants born during or entering their first RSV season.
- Children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season.",Standard,No,No,No,Yes,N/A,No,No,NA,2022-09-26,2023-07-17,294,5.683579767338681,Post-FDASIA
Vanflyta,quizartinib,"Daiichi Sankyo, Inc.",NDA,216993,NA,NA,Tablet,Oral,NA,NA,NA,NA,8/24/2022,7/20/2023,2023,NA,"VANFLYTA is indicated in combination with standard cytarabine and anthracycline induction and cytarabine consolidation, and as maintenance monotherapy following consolidation chemotherapy, for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) that is FLT3 internal tandem duplication (ITD)-positive as detected by an FDA-approved test.
Limitations of Use:
VANFLYTA is not indicated as maintenance monotherapy following allogeneic hematopoietic stem cell transplantation (HSCT); improvement in overall survival with VANFLYTA in this setting has not been demonstrated.",Priority,Yes,No,No,Yes,No,No,No,NA,2022-08-24,2023-07-20,330,5.799092654460526,Post-FDASIA
Xdemvy,lotilaner,"Tarsus Pharmaceuticals, Inc.",NDA,217603,NA,NA,Solution,Ophthalmic,NA,NA,NA,NA,8/25/2022,7/24/2023,2023,NA,XDEMVY is indicated for the treatment of Demodex blepharitis.,Standard,No,No,No,No,No,No,No,NA,2022-08-25,2023-07-24,333,5.808142489980444,Post-FDASIA
Izervay,avacincaptad pegol,"IVERIC Bio, Inc.",NDA,217225,NA,NA,Solution,Intravitreal,NA,NA,NA,NA,12/19/2022,8/4/2023,2023,NA,IZERVAY is indicated for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD).,Priority,No,No,Yes,Yes,No,No,No,NA,2022-12-19,2023-08-04,228,5.429345628954441,Post-FDASIA
Zurzuvae,zuranolone,"Sage Therapeutics, Inc.",NDA,217369,NA,NA,Capsule,Oral,NA,NA,NA,NA,12/5/2022,8/4/2023,2023,NA,ZURZUVAE is indicated for the treatment of postpartum depression (PPD) in adults.,Priority,No,No,No,Yes,No,No,No,NA,2022-12-05,2023-08-04,242,5.488937726156687,Post-FDASIA
Talvey,talquetamab-tgvs,"Janssen Biotech, Inc.",BLA,761342,NA,NA,Injectable,Injection,NA,NA,NA,NA,12/9/2022,8/9/2023,2023,NA,"TALVEY is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody.
This indication is approved under accelerated approval based on response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).",Priority,Yes,Yes,Yes,No,N/A,No,No,NA,2022-12-09,2023-08-09,243,5.493061443340548,Post-FDASIA
Elrexfio,elranatamab-bcmm,"Pfizer, Inc.",BLA,761345,NA,NA,Injectable,Injection,NA,NA,NA,NA,12/19/2022,8/14/2023,2023,NA,"ELREXFIO is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.
This indication is approved under accelerated approval based on response rate and durability of response. Continued approval for this indication may be contingent upon verification of clinical benefit in a confirmatory trial(s).",Priority,Yes,Yes,Yes,Yes,N/A,No,No,NA,2022-12-19,2023-08-14,238,5.472270673671475,Post-FDASIA
Sohonos,palovarotene,"Ipsen Biopharmaceuticals, Inc.",NDA,215559,NA,NA,Capsule,Oral,NA,NA,NA,NA,3/31/2021,8/16/2023,2023,NA,SOHONOS is indicated for the reduction in volume of new heterotopic ossification in adults and pediatric patients aged 8 years and older for females and 10 years and older for males with fibrodysplasia ossificans progressiva (FOP).,Priority,Yes,No,No,No,No,RPD,No,NA,2021-03-31,2023-08-16,868,6.7661917146603505,Post-FDASIA
Veopoz,pozelimab-bbfg,"Regeneron Pharmaceuticals, Inc.",BLA,761339,NA,NA,Injectable,Injection,NA,NA,NA,NA,12/20/2022,8/18/2023,2023,NA,"VEOPOZ is indicated for the treatment of adult and pediatric patients 1 year of age and older with CD55-deficient protein-losing enteropathy (PLE), also known as CHAPLE disease.",Priority,Yes,No,No,Yes,N/A,RPD,No,NA,2022-12-20,2023-08-18,241,5.484796933490655,Post-FDASIA
Aphexda,motixafortide,"BioLineRx, Ltd.",NDA,217159,NA,NA,Injectable,Injection,NA,NA,NA,NA,9/9/2022,9/8/2023,2023,NA,APHEXDA is indicated in combination with filgrastim (G-CSF) to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with multiple myeloma.,Standard,Yes,No,No,No,No,No,No,NA,2022-09-09,2023-09-08,364,5.8971538676367405,Post-FDASIA
Ojjaara,momelotinib,"GlaxoSmithKline, LLC",NDA,216873,NA,NA,Tablet,Oral,NA,NA,NA,NA,6/16/2022,9/15/2023,2023,NA,"OJJAARA is indicated for the treatment of intermediate or high-risk myelofibrosis (MF), including primary MF or secondary MF [post-polycythemia vera (PV) and post-essential thrombocythemia (ET)], in adults with anemia.",Standard,Yes,No,No,No,No,No,No,NA,2022-06-16,2023-09-15,456,6.1224928095143865,Post-FDASIA
Pombiliti,cipaglucosidase alfa-atga,"Amicus Therapeutics US, LLC",BLA,761204,NA,NA,Injectable,Injection,NA,NA,NA,NA,7/29/2021,9/28/2023,2023,NA,"POMBILITI is indicated, in combination with Opfolda, for the treatment of adult patients with late-onset Pompe disease (lysosomal acid alpha-glucosidase [GAA] deficiency) weighing >=40 kg and who are not improving on their current enzyme replacement therapy (ERT).",Standard,Yes,No,Yes,No,N/A,No,No,NA,2021-07-29,2023-09-28,791,6.673297967767654,Post-FDASIA
Rivfloza,nedosiran,"Novo Nordisk, Inc.",NDA,215842,NA,NA,Injectable,Injection,NA,NA,NA,NA,9/30/2022,9/29/2023,2023,NA,"RIVFLOZA is indicated to lower urinary oxalate levels in children 9 years of age and older and adults with primary hyperoxaluria type 1 (PH1) and relatively preserved kidney function, e.g., eGFR >= 30 mL/min/1.73 m^2",Standard,Yes,No,Yes,No,No,No,No,NA,2022-09-30,2023-09-29,364,5.8971538676367405,Post-FDASIA
Velsipity,etrasimod,"Pfizer, Inc.",NDA,216956,NA,NA,Tablet,Oral,NA,NA,NA,NA,10/14/2022,10/12/2023,2023,NA,VELSIPITY is indicated for the treatment of moderately to severely active ulcerative colitis (UC) in adults.,Standard,No,No,No,No,No,No,No,NA,2022-10-14,2023-10-12,363,5.8944028342648505,Post-FDASIA
Zilbrysq,zilucoplan,"UCB, Inc.",NDA,216834,NA,NA,Injectable,Injection,NA,NA,NA,NA,8/31/2022,10/17/2023,2023,NA,ZILBRYSQ is indicated for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive.,Standard,Yes,No,No,No,No,No,No,NA,2022-08-31,2023-10-17,412,6.021023349349527,Post-FDASIA
Bimzelx,bimekizumab-bkzx,"UCB, Inc.",BLA,761151,NA,NA,Injectable,Injection,NA,NA,NA,NA,7/15/2020,10/17/2023,2023,NA,BIMZELX is indicated for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy.,Standard,No,No,No,No,N/A,No,No,NA,2020-07-15,2023-10-17,1189,7.080867896690782,Post-FDASIA
Agamree,vamorolone,Santhera Pharmaceuticals (Switzerland) Ltd.,NDA,215239,NA,NA,Suspension,Oral,NA,NA,NA,NA,10/26/2022,10/26/2023,2023,NA,AGAMREE is indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients 2 years of age and older.,Standard,Yes,No,No,Yes,No,No,No,NA,2022-10-26,2023-10-26,365,5.8998973535824915,Post-FDASIA
Omvoh,mirikizumab-mrkz,Eli Lilly and Company,BLA,761279,NA,NA,Injectable,Injection,NA,NA,NA,NA,3/30/2022,10/26/2023,2023,NA,OMVOH is indicated for the treatment of moderately to severely active ulcerative colitis in adults.,Standard,No,No,No,No,N/A,No,No,NA,2022-03-30,2023-10-26,575,6.354370040797351,Post-FDASIA
Loqtorzi,toripalimab-tpzi,"Coherus BioSciences, Inc.",BLA,761240,NA,NA,Injectable,Injection,NA,NA,NA,NA,8/31/2021,10/27/2023,2023,NA,"LOQTORZI is indicated, in combination with cisplatin and gemcitabine, for the first-line treatment of adults with metastatic or with recurrent, locally advanced nasopharyngeal carcinoma (NPC).
LOQTORZI is indicated, as a single agent, for the treatment of adults with recurrent unresectable or metastatic NPC with disease progression on or after a platinum-containing chemotherapy.",Priority,Yes,No,Yes,No,N/A,No,No,NA,2021-08-31,2023-10-27,787,6.668228248417403,Post-FDASIA
Fruzaqla,fruquintinib,"Takeda Pharmaceuticals USA, Inc.",NDA,217564,NA,NA,Capsule,Oral,NA,NA,NA,NA,3/30/2023,11/8/2023,2023,NA,"FRUZAQLA is indicated for the treatment of adult patients with metastatic colorectal cancer (mCRC) who have been previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if RAS wild-type and medically appropriate, an anti-EGFR therapy.",Priority,No,No,No,Yes,No,No,No,NA,2023-03-30,2023-11-08,223,5.407171771460119,Post-FDASIA
Defencath,taurolidine and heparin,"CorMedix, Inc.",NDA,214520,NA,NA,Catheter lock solution,Catheter Installation,NA,NA,NA,NA,6/30/2020,11/15/2023,2023,NA,"LIMITED POPULATION: DEFENCATH is indicated to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis (HD) through a central venous catheter (CVC). This drug is indicated for use in a limited and specific population of patients.
Limitations of Use:
The safety and effectiveness of DEFENCATH have not been established for use in populations other than adult patients with kidney failure receiving chronic HD through a CVC.",Priority,No,No,No,Yes,Yes,No,No,NA,2020-06-30,2023-11-15,1233,7.117205503164344,Post-FDASIA
Augtyro,repotrectinib,Bristol-Myers Squibb Company,NDA,218213,NA,NA,Capsule,Oral,NA,NA,NA,NA,3/27/2023,11/15/2023,2023,NA,AUGTYRO is indicated for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC).,Priority,Yes,No,No,No,No,No,No,NA,2023-03-27,2023-11-15,233,5.4510384535657,Post-FDASIA
Truqap,capivasertib,AstraZeneca Pharmaceuticals LP,NDA,218197,NA,NA,Tablet,Oral,NA,NA,NA,NA,3/28/2023,11/16/2023,2023,NA,"TRUQAP, in combination with fulvestrant, is indicated for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alteration as detected by an FDA-approved test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy.",Priority,No,No,No,Yes,No,No,No,NA,2023-03-28,2023-11-16,233,5.4510384535657,Post-FDASIA
Ryzneuta,efbemalenograstim alfa-vuxw,Evive Biotechnology Singapore PTE. Ltd.,BLA,761134,NA,NA,Injectable,Injection,NA,NA,NA,NA,3/30/2021,11/16/2023,2023,NA,"RYZNEUTA is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in adult patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.
Limitations of Use:
RYZNEUTA is not indicated for the mobilization of peripheral blood progenitor cells for hematopoietic stem cell transplantation.",Standard,No,No,No,No,N/A,No,No,NA,2021-03-30,2023-11-16,961,6.8679744089702925,Post-FDASIA
Ogsiveo,nirogacestat,"SpringWorks Therapeutics, Inc.",NDA,217677,NA,NA,Tablet,Oral,NA,NA,NA,NA,12/27/2022,11/27/2023,2023,NA,OGSIVEO is indicated for adult patients with progressing desmoid tumors who require systemic treatment.,Priority,Yes,No,Yes,Yes,No,No,No,NA,2022-12-27,2023-11-27,335,5.814130531825066,Post-FDASIA
Fabhalta,iptacopan,Novartis Pharmaceuticals Corporation,NDA,218276,NA,NA,Capsule,Oral,NA,NA,NA,NA,4/5/2023,12/5/2023,2023,NA,FABHALTA is indicated for the treatment of adults with paroxysmal nocturnal hemoglobinuria (PNH).,Priority (used priority review voucher),Yes,No,Yes,No,No,No,Yes,NA,2023-04-05,2023-12-05,244,5.497168225293202,Post-FDASIA
Filsuvez,birch triterpenes,Amryt Pharmaceuticals DAC,NDA,215064,NA,NA,Gel,Topical,NA,NA,NA,NA,3/30/2021,12/18/2023,2023,NA,FILSUVEZ topical gel is indicated for the treatment of wounds associated with dystrophic and junctional epidermolysis bullosa in adult and pediatric patients 6 months of age and older.,Priority,Yes,No,No,Yes,No,RPD,No,NA,2021-03-30,2023-12-18,993,6.900730664045173,Post-FDASIA
Wainua,eplontersen,"Ionis Pharmaceuticals, Inc.",NDA,217388,NA,NA,Injectable,Injection,NA,NA,NA,NA,12/22/2022,12/21/2023,2023,NA,WAINUA is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.,Standard,Yes,No,No,No,No,No,No,NA,2022-12-22,2023-12-21,364,5.8971538676367405,Post-FDASIA
Zelsuvmi,berdazimer,"LNHC, Inc.",NDA,217424,NA,NA,GEL,Topical,NA,NA,NA,NA,1/5/2023,1/5/2024,2024,NA,ZELSUVMI is indicated for the topical treatment of molluscum contagiosum (MC) in adults and pediatric patients 1 year of age and older.,Standard,No,No,No,No,No,No,No,NA,2023-01-05,2024-01-05,365,5.8998973535824915,Post-FDASIA
Exblifep,cefepime and enmetazobactam,Allecra Therapeutics SAS,NDA,216165,NA,NA,Powder,Intravenous,NA,NA,NA,NA,6/22/2023,2/22/2024,2024,NA,"EXBLIFEP is indicated for the treatment of patients 18 years of age and older with complicated urinary tract infections (cUTI) including pyelonephritis, caused by the following susceptible microorganisms: Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Proteus mirabilis, and Enterobacter cloacae complex.
To reduce the development of drug-resistant bacteria and maintain the effectiveness of EXBLIFEP and other antibacterial drugs, EXBLIFEP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.",Priority,No,No,No,Yes,Yes,No,No,NA,2023-06-22,2024-02-22,245,5.501258210544727,Post-FDASIA
Letybo,letibotulinumtoxinA-wlbg,"Hugel, Inc.",BLA,761225,NA,NA,Injectable,Intramuscular,NA,NA,NA,NA,3/31/2021,2/29/2024,2024,NA,LETYBO is indicated for the temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adult patients.,Standard,No,No,No,No,N/A,No,No,NA,2021-03-31,2024-02-29,1065,6.970730078143525,Post-FDASIA
Tevimbra,tislelizumab-jsgr,"BeiGene U.S.A., Inc.",BLA,761232,NA,NA,Injectable,Intravenous,NA,NA,NA,NA,7/12/2021,3/13/2024,2024,NA,"TEVIMBRA (tislelizumab-jsgr), as a single agent, is indicated for the treatment of adult patients with unresectable or metastatic esophageal squamous cell carcinoma after prior systemic chemotherapy that did not include a PD-(L)1 inhibitor.",Standard,Yes,No,No,No,N/A,No,No,NA,2021-07-12,2024-03-13,975,6.882437470997847,Post-FDASIA
Rezdiffra,resmetirom,"Madrigal Pharmaceuticals, Inc.",NDA,217785,NA,NA,Tablet,Oral,NA,NA,NA,NA,7/14/2023,3/14/2024,2024,NA,"REZDIFFRA is indicated in conjunction with diet and exercise for the treatment of adults with noncirrhotic nonalcoholic steatohepatitis (NASH) with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis).
This indication is approved under accelerated approval based on improvement of NASH and fibrosis. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.
Limitations of Use:
Avoid use of REZDIFFRA in patients with decompensated cirrhosis.",Priority,No,Yes,Yes,Yes,No,No,No,NA,2023-07-14,2024-03-14,244,5.497168225293202,Post-FDASIA
Tryvio,aprocitentan,Idorsia Pharmaceuticals Ltd.,NDA,217686,NA,NA,Tablet,Oral,NA,NA,NA,NA,12/19/2022,3/19/2024,2024,NA,"TRYVIO, in combination with other antihypertensive drugs, is indicated for the treatment of hypertension, to lower blood pressure (BP) in adult patients who are not adequately controlled on other drugs. Lowering BP reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes. There are no controlled trials demonstrating reduction of risk of these events with TRYVIO.
Control of high BP should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve BP goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC).
Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is BP reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly.
Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher BPs, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from BP reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower BP goal.",Standard,No,No,No,No,No,No,No,NA,2022-12-19,2024-03-19,456,6.1224928095143865,Post-FDASIA
Duvyzat,givinostat,Italfarmaco SpA,NDA,217865,NA,NA,Suspension,Oral,NA,NA,NA,NA,4/21/2023,3/21/2024,2024,NA,DUVYZAT is indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients 6 years of age and older.,Priority,Yes,No,No,Yes,No,RPD,No,NA,2023-04-21,2024-03-21,335,5.814130531825066,Post-FDASIA
Winrevair,sotatercept-csrk,"Merck Sharp and Dohme, LLC",BLA,761363,NA,NA,Injectable,Subcutaneous,NA,NA,NA,NA,7/26/2023,3/26/2024,2024,NA,"WINREVAIR is indicated for the treatment of adults with pulmonary arterial hypertension (PAH, World Health Organization [WHO] Group 1) to increase exercise capacity, improve WHO functional class (FC), and reduce the risk of clinical worsening events.",Priority,Yes,No,Yes,No,N/A,No,No,NA,2023-07-26,2024-03-26,244,5.497168225293202,Post-FDASIA
Vafseo,vadadustat,"Akebia Therapeutics, Inc.",NDA,215192,NA,NA,Tablet,Oral,NA,NA,NA,NA,3/29/2021,3/27/2024,2024,NA,"VAFSEO is indicated for the treatment of anemia due to chronic kidney disease (CKD) in adults who have been receiving dialysis for at least three months.
Limitations of Use
- VAFSEO has not been shown to improve quality of life, fatigue, or patient well-being.
- VAFSEO is not indicated for use:
-- As a substitute for red blood cell transfusions in patients who require immediate correction of anemia.
-- In patients with anemia due to CKD not on dialysis.",Standard,No,No,No,No,No,No,No,NA,2021-03-29,2024-03-27,1094,6.9975959829819265,Post-FDASIA
Voydeya,danicopan,"Alexion Pharmaceuticals, Inc.",NDA,218037,NA,NA,Tablet,Oral,NA,NA,NA,NA,3/30/2023,3/29/2024,2024,NA,"VOYDEYA is indicated as add-on therapy to ravulizumab or eculizumab for the treatment of extravascular hemolysis (EVH) in adults with paroxysmal nocturnal hemoglobinuria (PNH).
Limitations of Use:
VOYDEYA has not been shown to be effective as monotherapy and should only be prescribed as an add-on to ravulizumab or eculizumab.",Standard,Yes,No,Yes,No,No,No,No,NA,2023-03-30,2024-03-29,365,5.8998973535824915,Post-FDASIA
Zevtera,ceftobiprole medocaril sodium,"Basilea Pharmaceutica International, Ltd.",NDA,218275,NA,NA,Powder,Intravenous,NA,NA,NA,NA,8/3/2023,4/3/2024,2024,NA,"ZEVTERA is indicated for the treatment of adult patients with Staphylococcus aureus bloodstream infection (bacteremia) (SAB), including those with right-sided infective endocarditis, caused by methicillin-susceptible and methicillin-resistant isolates.
ZEVTERA is indicated for the treatment of adult patients with acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible isolates of the following gram-positive and gram-negative microorganisms: Staphylococcus aureus (methicillin-susceptible and methicillin-resistant isolates), Streptococcus pyogenes, and Klebsiella pneumoniae.
ZEVTERA is indicated for the treatment of adult and pediatric patients (3 months to less than 18 years old) with community-acquired bacterial pneumonia (CABP) caused by susceptible isolates of the following gram-positive and gram-negative microorganisms: Staphylococcus aureus methicillin-susceptible isolates), Streptococcus pneumoniae, Haemophilus influenzae, Haemophilus parainfluenzae, Escherichia coli, and Klebsiella pneumoniae.
To reduce the development of drug-resistant bacteria and maintain the effectiveness of ZEVTERA and other antibacterial drugs, ZEVTERA should be used only to treat or prevent infections that are proven, or strongly suspected, to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.",Priority,No,No,No,Yes (indication [A] only),Yes,No,No,NA,2023-08-03,2024-04-03,244,5.497168225293202,Post-FDASIA
Lumisight,pegulicianine,"Lumicell, Inc.",NDA,214511,NA,NA,Powder,Intravenous,NA,NA,NA,NA,3/17/2023,4/17/2024,2024,NA,LUMISIGHT is indicated for fluorescence imaging in adults with breast cancer as an adjunct for the intraoperative detection of cancerous tissue within the resection cavity following removal of the primary specimen during lumpectomy surgery.,Priority,No,No,No,Yes,No,No,No,NA,2023-03-17,2024-04-17,397,5.983936280687191,Post-FDASIA
Anktiva,nogapendekin alfa inbakicept-pmln,"Altor BioScience, LLC",BLA,761336,NA,NA,Solution,Intravesical,NA,NA,NA,NA,5/23/2022,4/22/2024,2024,NA,ANKTIVA in combination with Bacillus Calmette-Guérin (BCG) is indicated for the treatment of adult patients with BCG-unresponsive nonmuscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors.,Standard,No,No,Yes,Yes,N/A,No,No,NA,2022-05-23,2024-04-22,700,6.551080335043404,Post-FDASIA
Ojemda,tovorafenib,"Day One Biopharmaceuticals, Inc.",NDA,217700,218033,NA,Suspension,Oral,Tablet,Oral,NA,NA,8/31/2023,4/23/2024,2024,NA,"OJEMDA is indicated for the treatment of patients 6 months of age and older with relapsed or refractory pediatric low-grade glioma (LGG) harboring a BRAF fusion or rearrangement, or BRAF V600 mutation.
This indication is approved under accelerated approval based on response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).",Priority,Yes,Yes,Yes,No,No,RPD,No,NA,2023-08-31,2024-04-23,236,5.4638318050256105,Post-FDASIA
Xolremdi,mavorixafor,"X4 Pharmaceuticals, Inc.",NDA,218709,NA,NA,Capsule,Oral,NA,NA,NA,NA,8/31/2023,4/26/2024,2024,NA,"XOLREMDI is indicated in patients 12 years of age and older with WHIM syndrome (warts, hypogammaglobulinemia, infections and myelokathexis) to increase the number of circulating mature neutrophils and lymphocytes.",Priority,Yes,No,No,Yes,No,RPD,No,NA,2023-08-31,2024-04-26,239,5.476463551931511,Post-FDASIA
Imdelltra,tarlatamab-dlle,"Amgen, Inc.",BLA,761344,NA,NA,Injectable,Intravenous,NA,NA,NA,NA,10/12/2023,5/16/2024,2024,NA,"IMDELLTRA is indicated for the treatment of adult patients with extensive stage small cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy.
This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).",Priority,Yes,Yes,Yes,No,N/A,No,No,NA,2023-10-12,2024-05-16,217,5.37989735354046,Post-FDASIA
Rytelo,imetelstat,Geron Corporation,NDA,217779,NA,NA,Powder,Intravenous,NA,NA,NA,NA,6/16/2023,6/6/2024,2024,NA,RYTELO is indicated for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes (MDS) with transfusion-dependent anemia requiring 4 or more red blood cell units over 8 weeks who have not responded to or have lost response to or are ineligible for erythropoiesis stimulating agents (ESA).,Standard,Yes,No,No,Yes,No,No,No,NA,2023-06-16,2024-06-06,356,5.87493073085203,Post-FDASIA
Iqirvo,elafibranor,"Ipsen Biopharmaceuticals, Inc.",NDA,218860,NA,NA,Tablet,Oral,NA,NA,NA,NA,10/10/2023,6/10/2024,2024,NA,"IQIRVO is indicated for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults who have had an inadequate response to UDCA, or as monotherapy in patients unable to tolerate UDCA.
This indication is approved under accelerated approval based on reduction of alkaline phosphatase (ALP). Improvement in survival or prevention of liver decompensation events have not been demonstrated. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s).
Limitations of Use:
Use of IQIRVO is not recommended in patients who have or develop decompensated cirrhosis (e.g., ascites, variceal bleeding, hepatic encephalopathy).",Priority,Yes,Yes,Yes,No,No,No,No,NA,2023-10-10,2024-06-10,244,5.497168225293202,Post-FDASIA
Sofdra,sofpironium,"Botanix SB, Inc.",NDA,217347,NA,NA,"Gel, Metered",Topical,NA,NA,NA,NA,9/23/2022,6/18/2024,2024,NA,SOFDRA is indicated for the treatment of primary axillary hyperhidrosis in adults and pediatric patients 9 years of age and older.,Standard,No,No,No,No,No,No,No,NA,2022-09-23,2024-06-18,634,6.452048954437226,Post-FDASIA
Piasky,crovalimab-akkz,"Genentech, Inc.",BLA,761388,NA,NA,Injectable,"Intravenous, Subcutaneous",NA,NA,NA,NA,6/20/2023,6/20/2024,2024,NA,PIASKY is indicated for the treatment of adult and pediatric patients 13 years and older with paroxysmal nocturnal hemoglobinuria (PNH) and body weight of at least 40 kg.,Standard,Yes,No,No,No,N/A,No,No,NA,2023-06-20,2024-06-20,366,5.902633333401366,Post-FDASIA
Ohtuvayre,ensifentrine,"Verona Pharma, Inc.",NDA,217389,NA,NA,Suspension,Inhalation,NA,NA,NA,NA,6/26/2023,6/26/2024,2024,NA,OHTUVAYRE is indicated for the maintenance treatment of chronic obstructive pulmonary disease (COPD) in adult patients.,Standard,No,No,No,No,No,No,No,NA,2023-06-26,2024-06-26,366,5.902633333401366,Post-FDASIA
Kisunla,donanemab-azbt,Eli Lilly and Company,BLA,761248,NA,NA,Injectable,Intravenous,NA,NA,NA,NA,5/18/2022,7/2/2024,2024,NA,"KISUNLA is indicated for the treatment of Alzheimer’s disease. Treatment with KISUNLA should be initiated in patients with mild cognitive impairment or mild dementia stage of disease, the population in which treatment was initiated in the clinical trials.",Priority,No,No,Yes,Yes,N/A,No,No,NA,2022-05-18,2024-07-02,776,6.654152520183219,Post-FDASIA
Leqselvi,deuruxolitinib,"Sun Pharmaceutical Industries, Inc.",NDA,217900,NA,NA,Tablet,Oral,NA,NA,NA,NA,7/28/2023,7/25/2024,2024,NA,"LEQSELVI is indicated for the treatment of adult patients with severe alopecia areata.
Limitations of Use:
LEQSELVI is not recommended for use in combination with other JAK inhibitors, biologic immunomodulators, cyclosporine, or other potent immunosuppressants.",Standard,No,No,No,Yes,No,No,No,NA,2023-07-28,2024-07-25,363,5.8944028342648505,Post-FDASIA
Voranigo,vorasidenib,"Servier Pharmaceuticals, LLC",NDA,218784,NA,NA,Tablet,Oral,NA,NA,NA,NA,12/20/2023,8/6/2024,2024,NA,"VORANIGO is indicated for the treatment of adult and pediatric patients 12 years and older with Grade 2 astrocytoma or oligodendroglioma with a susceptible isocitrate dehydrogenase-1 (IDH1) or isocitrate dehydrogenase-2 (IDH2) mutation following surgery including biopsy, sub-total resection, or gross total resection",Priority,Yes,No,Yes,Yes,No,No,No,NA,2023-12-20,2024-08-06,230,5.438079308923196,Post-FDASIA
Yorvipath,palopegteriparatide,Ascendis Pharma Bone Diseases A/S,NDA,216490,NA,NA,Solution,Subcutaneous,NA,NA,NA,NA,8/31/2022,8/9/2024,2024,NA,"YORVIPATH is indicated for the treatment of hypoparathyroidism in adults.
Limitations of Use:
- YORVIPATH was not studied for acute post-surgical hypoparathyroidism.
- YORVIPATH’s titration scheme was only evaluated in adults who first achieved an albumin-corrected serum calcium of at least 7.8 mg/dL using calcium and active vitamin D treatment.",Priority,Yes,No,No,No,No,No,No,NA,2022-08-31,2024-08-09,709,6.5638555265321274,Post-FDASIA
Nemluvio,nemolizumab-ilto,"Galderma Laboratories, LP",BLA,761390,NA,NA,Injectable,Subcutaneous,NA,NA,NA,NA,12/12/2023,8/12/2024,2024,NA,NEMLUVIO is indicated for the treatment of adults with prurigo nodularis.,Priority,No,No,Yes,No,N/A,No,No,NA,2023-12-12,2024-08-12,244,5.497168225293202,Post-FDASIA
Livdelzi,seladelpar,"CymaBay Therapeutics, Inc.",NDA,217899,NA,NA,Capsule,Oral,NA,NA,NA,NA,12/14/2023,8/14/2024,2024,NA,"LIVDELZI is indicated for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults who have had an inadequate response to UDCA, or as monotherapy in patients unable to tolerate UDCA.
This indication is approved under accelerated approval based on a reduction of alkaline phosphatase (ALP). Improvement in survival or prevention of liver decompensation events have not been demonstrated. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s).
Limitations of Use:
Use of LIVDELZI is not recommended in patients who have or develop decompensated cirrhosis (e.g., ascites, variceal bleeding, hepatic encephalopathy).",Priority,Yes,Yes,Yes,No,No,No,No,NA,2023-12-14,2024-08-14,244,5.497168225293202,Post-FDASIA
Niktimvo,axatilimab-csfr,Incyte Corporation,BLA,761411,NA,NA,Injectable,Intravenous,NA,NA,NA,NA,12/28/2023,8/14/2024,2024,NA,NIKTIMVO is indicated for the treatment of chronic graft-versus-host disease (cGVHD) after failure of at least two prior lines of systemic therapy in adult and pediatric patients weighing at least 40 kg.,Priority,Yes,No,No,Yes,N/A,No,No,NA,2023-12-28,2024-08-14,230,5.438079308923196,Post-FDASIA
Lazcluze,lazertinib,"Janssen Biotech, Inc.",NDA,219008,NA,NA,Tablet,Oral,NA,NA,NA,NA,12/20/2023,8/19/2024,2024,NA,"LAZCLUZE, in combination with amivantamab, is indicated for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations, as detected by an FDA-approved test.",Priority,No,No,No,No,No,No,No,NA,2023-12-20,2024-08-19,243,5.493061443340548,Post-FDASIA
Ebglyss,lebrikizumab-lbkz,Eli Lilly and Company,BLA,761306,NA,NA,Injectable,Subcutaneous,NA,NA,NA,NA,9/28/2022,9/13/2024,2024,NA,EBGLYSS is indicated for the treatment of adults and pediatric patients 12 years of age and older who weigh at least 40 kg with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. EBGLYSS can be used with or without topical corticosteroids.,Standard,No,No,No,Yes,N/A,No,No,NA,2022-09-28,2024-09-13,716,6.573680166960646,Post-FDASIA
Miplyffa,arimoclomol,Zevra Denmark A/S,NDA,214927,NA,NA,Capsule,Oral,NA,NA,NA,NA,7/17/2020,9/20/2024,2024,NA,MIPLYFFA is indicated for use in combination with miglustat for the treatment of neurological manifestations of Niemann-Pick disease type C (NPC) in adult and pediatric patients 2 years of age and older.,Priority,Yes,No,Yes,Yes,No,RPD,No,NA,2020-07-17,2024-09-20,1526,7.330405211844402,Post-FDASIA
Aqneursa,levacetylleucine,"IntraBio, Inc.",NDA,219132,NA,NA,Suspension,Oral,NA,NA,NA,NA,1/24/2024,9/24/2024,2024,NA,AQNEURSA is indicated for the treatment of neurological manifestations of Niemann-Pick disease type C (NPC) in adults and pediatric patients weighing >=15 kg.,Priority,Yes,No,No,Yes,No,RPD,No,NA,2024-01-24,2024-09-24,244,5.497168225293202,Post-FDASIA
Cobenfy,xanomeline and trospium chloride,Bristol-Myers Squibb Company,NDA,216158,NA,NA,Capsule,Oral,NA,NA,NA,NA,9/26/2023,9/26/2024,2024,NA,COBENFY is indicated for the treatment of schizophrenia in adults.,Standard,No,No,No,No,No,No,No,NA,2023-09-26,2024-09-26,366,5.902633333401366,Post-FDASIA
Flyrcado,flurpiridaz F 18,"GE Healthcare, Inc.",NDA,215168,NA,NA,Solution,Intravenous,NA,NA,NA,NA,9/27/2023,9/27/2024,2024,NA,FLYRCADO is indicated for positron emission tomography (PET) myocardial perfusion imaging (MPI) under rest or stress (pharmacologic or exercise) in adult patients with known or suspected coronary artery disease (CAD) to evaluate for myocardial ischemia and infarction.,Standard,No,No,No,No,No,No,No,NA,2023-09-27,2024-09-27,366,5.902633333401366,Post-FDASIA
Itovebi,inavolisib,"Genentech, Inc.",NDA,219249,NA,NA,Tablet,Oral,NA,NA,NA,NA,3/27/2024,10/10/2024,2024,NA,"ITOVEBI, in combination with palbociclib and fulvestrant, is indicated for the treatment of adults with endocrine-resistant, PIK3CA-mutated, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer, as detected by an FDA-approved test, following recurrence on or after completing adjuvant endocrine therapy.",Priority,No,No,Yes,No,No,No,No,NA,2024-03-27,2024-10-10,197,5.2832037287379885,Post-FDASIA
Hympavzi,marstacimab-hncq,"Pfizer, Inc.",BLA,761369,NA,NA,Injectable,Subcutaneous,NA,NA,NA,NA,10/11/2023,10/11/2024,2024,NA,"HYMPAVZI is indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with:
- hemophilia A (congenital factor VIII deficiency) without factor VIII inhibitors, or
- hemophilia B (congenital factor IX deficiency) without factor IX inhibitors.",Standard,Yes,No,No,No,N/A,No,No,NA,2023-10-11,2024-10-11,366,5.902633333401366,Post-FDASIA
Vyloy,zolbetuximab-clzb,"Astellas Pharma US, Inc.",BLA,761365,NA,NA,Injectable,Intravenous,NA,NA,NA,NA,5/12/2023,10/18/2024,2024,NA,"VYLOY, in combination with fluoropyrimidine- and platinum-containing chemotherapy, is indicated for the first-line treatment of adults with locally advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors are claudin (CLDN) 18.2 positive as determined by an FDA-approved test.",Priority,Yes,No,No,Yes,N/A,No,No,NA,2023-05-12,2024-10-18,525,6.263398262591624,Post-FDASIA
Orlynvah,sulopenem etzadroxil and probenecid,Iterum Therapeutics U.S. Ltd.,NDA,213972,NA,NA,Tablet,Oral,NA,NA,NA,NA,11/25/2020,10/25/2024,2024,NA,"ORLYNVAH is indicated for the treatment of uncomplicated urinary tract infections (uUTI) caused by the designated microorganisms Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis in adult women who have limited or no alternative oral antibacterial treatment options.
Limitations of Use:
ORLYNVAH is not indicated for the treatment of:
- Complicated urinary tract infections (cUTI) or as step-down treatment after intravenous antibacterial treatment of cUTI.
- Complicated intra-abdominal infections (cIAI)) or as step-down treatment after intravenous antibacterial treatment of cIAI.",Priority,No,No,No,Yes,Yes,No,No,NA,2020-11-25,2024-10-25,1430,7.265429723253953,Post-FDASIA
Revuforj,revumenib,"Syndax Pharmaceuticals, Inc.",NDA,218944,NA,NA,Tablet,Oral,NA,NA,NA,NA,1/26/2024,11/15/2024,2024,NA,REVUFORJ is indicated for the treatment of relapsed or refractory acute leukemia with a lysine methyltransferase 2A gene (KMT2A) translocation in adult and pediatric patients 1 year and older.,Priority,Yes,No,Yes,Yes,No,No,No,NA,2024-01-26,2024-11-15,294,5.683579767338681,Post-FDASIA
Ziihera,zanidatamab-hrii,"Jazz Pharmaceuticals Ireland, Limited",BLA,761416,NA,NA,Injectable,Intravenous,NA,NA,NA,NA,3/29/2024,11/20/2024,2024,NA,"ZIIHERA is indicated for the treatment of adults with previously treated, unresectable or metastatic HER2-positive (IHC 3+) biliary tract cancer (BTC), as detected by an FDA-approved test.
This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).",Priority,Yes,Yes,Yes,Yes,N/A,No,No,NA,2024-03-29,2024-11-20,236,5.4638318050256105,Post-FDASIA
Attruby,acoramidis,"BridgeBio Pharma, Inc.",NDA,216540,NA,NA,Tablet,Oral,NA,NA,NA,NA,11/29/2023,11/22/2024,2024,NA,ATTRUBY is indicated for the treatment of the cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular death and cardiovascular-related hospitalization.,Standard,Yes,No,No,No,No,No,No,NA,2023-11-29,2024-11-22,359,5.883322388488279,Post-FDASIA
Rapiblyk,landiolol,AOP Orphan Pharmaceuticals GmbH,NDA,217202,NA,NA,Powder,Intravenous,NA,NA,NA,NA,5/31/2022,11/22/2024,2024,NA,RAPIBLYK is indicated for the short-term reduction of ventricular rate in adults with supraventricular tachycardia including atrial fibrillation and atrial flutter.,Standard,No,No,No,No,No,No,No,NA,2022-05-31,2024-11-22,906,6.80903930604298,Post-FDASIA
Iomervu,iomeprol,"Bracco Diagnostics, Inc.",NDA,216017,216016,NA,Solution,Intravenous,Solution,Intra-Arterial,NA,NA,11/30/2021,11/27/2024,2024,NA,"IOMERVU is indicated for:
- Cerebral arteriography, including intra-arterial digital subtraction angiography (IA-DSA), in adults and pediatric patients
- Visceral and peripheral arteriography and aortography, including IA-DSA, in adults and pediatric patients
- Coronary arteriography and cardiac ventriculography in adults
- Radiographic evaluation of cardiac chambers and related arteries in pediatric patients
IOMERVU is indicated for:
- Computed tomography (CT) of the head and body in adults and pediatric patients
- CT angiography of intracranial, visceral, and lower extremity arteries in adults and pediatric patients
- Coronary CT angiography in adults and pediatric patients
- CT urography in adults and pediatric patients
Specific concentrations of IOMERVU are recommended for each type of imaging procedure",Standard,No,No,No,No,No,No,No,NA,2021-11-30,2024-11-27,1093,6.996681488176539,Post-FDASIA
Bizengri,zenocutuzumab-zbco,Merus N.V.,BLA,761352,NA,NA,Injectable,Intravenous,NA,NA,NA,NA,3/4/2024,12/4/2024,2024,NA,"BIZENGRI is indicated for the treatment of adults with advanced unresectable or metastatic non-small cell lung cancer (NSCLC) harboring a neuregulin 1 (NRG1) gene fusion with disease progression on or after prior systemic therapy.
This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). 
BIZENGRI is indicated for the treatment of adults with advanced unresectable or metastatic pancreatic adenocarcinoma harboring a neuregulin 1 (NRG1) gene fusion with disease progression on or after prior systemic therapy.
This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).",Priority,Yes,Yes,Yes,Yes,N/A,No,No,NA,2024-03-04,2024-12-04,275,5.616771097666572,Post-FDASIA
Crenessity,crinecerfont,"Neurocrine Biosciences, Inc.",NDA,218808,218820,NA,Capsule,Oral,Solution,Oral,NA,NA,4/29/2024,12/13/2024,2024,NA,CRENESSITY is indicated as adjunctive treatment to glucocorticoid replacement to control androgens in adults and pediatric patients 4 years of age and older with classic congenital adrenal hyperplasia (CAH).,Priority,Yes,No,Yes,Yes,No,RPD,No,NA,2024-04-29,2024-12-13,228,5.429345628954441,Post-FDASIA
Unloxcyt,cosibelimab-ipdl,"Checkpoint Therapeutics, Inc.",BLA,761297,NA,NA,Injectable,Intravenous,NA,NA,NA,NA,1/3/2023,12/13/2024,2024,NA,UNLOXCYT is indicated for the treatment of adults with metastatic cutaneous squamous cell carcinoma (mCSCC) or locally advanced CSCC (laCSCC) who are not candidates for curative surgery or curative radiation.,Standard,No,No,No,No,N/A,No,No,NA,2023-01-03,2024-12-13,710,6.565264970035361,Post-FDASIA
Ensacove,ensartinib,"Xcovery Holdings, Inc.",NDA,218171,NA,NA,Capsule,Oral,NA,NA,NA,NA,12/28/2023,12/18/2024,2024,NA,ENSACOVE is indicated for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) who have not previously received an ALK-inhibitor.,Standard,No,No,No,No,No,No,No,NA,2023-12-28,2024-12-18,356,5.87493073085203,Post-FDASIA
Tryngolza,olezarsen,"Ionis Pharmaceuticals, Inc.",NDA,218614,NA,NA,Solution,Subcutaneous,NA,NA,NA,NA,4/19/2024,12/19/2024,2024,NA,TRYNGOLZA is indicated as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS).,Priority,Yes,No,Yes,Yes,No,No,No,NA,2024-04-19,2024-12-19,244,5.497168225293202,Post-FDASIA
Alhemo,concizumab-mtci,"Novo Nordisk, Inc.",BLA,761315,NA,NA,Injectable,Subcutaneous,NA,NA,NA,NA,8/24/2022,12/20/2024,2024,NA,"Alhemo is indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with:
- hemophilia A (congenital factor VIII deficiency) with FVIII inhibitors
- hemophilia B (congenital factor IX deficiency) with FIX inhibitors",Priority,Yes,No,No,No,N/A,RPD,No,NA,2022-08-24,2024-12-20,849,6.744059186311348,Post-FDASIA
Alyftrek,"vanzacaftor, tezacaftor and deutivacaftor","Vertex Pharmaceuticals, Inc.",NDA,218730,NA,NA,Tablet,Oral,NA,NA,NA,NA,5/2/2024,12/20/2024,2024,NA,"ALYFTREK is indicated for the treatment of cystic fibrosis (CF) in patients 6 years of age and older who have at least one F508del mutation or another responsive mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene (see Table 5).
If the patient’s genotype is unknown, an FDA-cleared CF mutation test should be used to confirm the presence of at least one indicated mutation.",Priority (used priority review voucher),Yes,No,No,No,No,No,Yes,NA,2024-05-02,2024-12-20,232,5.44673737166631,Post-FDASIA
